Page 1 UNITED STATES DISTRICT COURT 1 NORTHERN DISTRICT OF FLORIDA 2 3 CASE NO. 4:22-cv-00325-RH-MAF 4 5 AUGUST DEKKER, et al., Plaintiffs, 6 7 vs. JASON WEIDA, et al., 8 Defendants 9 10 Volume 1, Pgs. 1 - 124 11 12 VIDEOTAPED DEPOSITION OF: MATTHEW BRACKETT AT THE INSTANCE OF: 13 THE PLAINTIFFS 14 DATE: FEBRUARY 8, 2023 15 TIME: COMMENCED: 10:00 A.M. AGENCY FOR HEALTH CARE 16 LOCATION: ADMINISTRATION 17 2727 MAHAN DRIVE TALLAHASSEE, FLORIDA 32308 18 REPORTED BY: DANA W. REEVES 19 Court Reporter and Notary Public in and for State of Florida at Large 20 21 22 23 24 25

Page 2 1 **APPEARANCES:** 2 REPRESENTING THE PLAINTIFF: 3 KATY DeBRIERE, ESQ. Florida Health Justice Project 4 3900 Richmond Street Jacksonville, Florida 32205 5 SIMONE CHRISS, ESQ. CHELSEA DUNN, ESQ. 6 Southern Legal Counsel, Inc. 1229 NW 12th Avenue 7 Gainesville, Florida 32601 8 SHANI RIVAUX, ESQ. Pillsbury, Winthrop, Shaw, Pittman, LLP 9 600 Brickell Avenue, Suite 3100 Miami, Florida 33131 10 OMAR GONZALEZ-PAGAN, ESQ. 11 Lambda Legal Defense and Education 12 Fund, Inc. 120 Wall Street, 19th Floor 13 New York, NY 10005 CATHERINE MCKEE, ESQ. 14 1512 E. Franklin Street, Suite 110 Chapel Hill, NC 27514 15 16 17 REPRESENTING THE DEFENDANT: 18 MOHAMMAD O. JAZIL, ESQ. GARY V. PERKO, ESQ. 19 Holtzman, Vogel, Barantorchinsky & Josefiak 119 S. Monroe Street, Suite 500 20 Tallahassee, Florida 32301 21 22 ALSO PRESENT: 23 RL Minnich, Videographer 24 25

Case 4:22-cv-00325-RH-MAF Document 120-6 Filed 04/07/23 Page 3 of 346

		Page 3
1	INDEX TO WITNESS	
2		
3	MATTHEW BRACKETT	PAGE
4	Examination by Ms. DeBriere	5
5		
6	INDEX TO EXHIBITS	
7		
8	NO. DESCRIPTION	MARKED
9	Exhibit 1 Notice of deposition	7
	Exhibit 2 Florida Medicaid policy	16
10	Exhibit 3 Cross-Sex Hormone Therapy GAR	PMS 21
	Exhibit 4 DEF_000145170	32
11	Exhibit 5 April 19, 2022 GAPMS	57
	Exhibit 6 June 23, 2017 GAPMS	60
12	Exhibit 7 DEF_000288776	71
	Exhibit 8 Gender confirmation surgery G	SAPMS 80
13	Exhibit 9 Native document	83
	Exhibit 10 Native document	83
14	Exhibit 11 June 2, 2022 GAPMS	85
	Exhibit 12 After the fact request form u	nder 100
15	35K	
16		
17		
18		
19	*Uh-uh is a negative response	
	*Uh-huh is a positive response	
20		
21		
22		
23		
24		
25		

1	DEPOSITION
2	VIDEOGRAPHER: This is the video-recorded
3	deposition of corporate representative for Agency
4	for Healthcare Administration, in the matter of
5	August Decker, et al. vs. Jason Weida, et al. Case
6	No. 4:22-cv-00325, RH-MAF. This deposition is
7	being held at 2727 Mahan Drive in Tallahassee,
8	Florida. Today's date is February 8th, 2023 and
9	the time is 10:08 a.m. The court reporter is Dana
10	Reeves. My name is RL Minnich. I'm the
11	videographer. Would counsel please introduce
12	themselves and the court reporter please swear in
13	the witness?
14	MS. DEBRIERE: Yes, Katy DeBriere and I
15	represent the plaintiffs.
16	MS. CHRISS: Simone Chriss and I also represent
17	the plaintiffs.
18	MS. DUNN: Chelsea Dunn. I also represent the
19	plaintiffs.
20	MR. JAZIL: Mohammad Jazil for the defense.
21	MS. DEBRIERE: And we have a few people on the
22	Zoom link from the plaintiff's side. That would be
23	Catherine McKee and Omar Gonzalez-Pagan.
24	MR. PERKO: And Gary Perko on behalf of the
25	defendants on the Zoom link.

Page 5 MS. DEBRIERE: And Shani Rivaux has joined us 1 2 from the plaintiff's side as well. COURT REPORTER: All right, sir, if you would 3 raise your right hand, please. 4 Whereupon, 5 MATTHEW BRACKETT 6 7 was called as a witness, having been first duly sworn to speak the truth, the whole truth, and nothing but the 8 9 truth, was examined and testified as follows: 10 THE WITNESS: I do. COURT REPORTER: Thank you. 11 12 EXAMINATION 13 BY MS. DEBRIERE:: All right. So we're just going to mark 14 0 15 exhibits as they're discussed, if that's okay with you, 16 Matt. 17 А That's fine. 18 As we walk through those exhibits, I'm going 0 to read off the Bates numbers on the bottom of each 19 20 So those are just the -- that line of numbers I'm page. reading out loud as we discuss exhibits, and that should 21 2.2 help you track what page I'm on as we're discussing 23 So we're going to go ahead and mark the notice of them. deposition as Exhibit 1. I saw that you brought the 24 copy with you, as well, Mr. Brackett. 25

1 (Whereupon, Exhibit No. 1 was marked for 2 identification.)

MR. JAZIL: Is this the court reporter's copy?
 MS. CHRISS: The witness' copy that can become
 the court reporter's copy.

6 BY MS. DEBRIERE::

7 Okay. So just some preliminary stuff before 0 we go over this notice. I'm going to be using the 8 9 acronym GAPMS guite a bit. That stands for Generally 10 Accepted Professional Medical Standards, and is the 11 acronym that refers to the process described at Florida 12 Administrative Code Rule 59-G-1.035. When I refer to 13 the GAPMS or GAPMS process, do you understand what I 14 mean?

15

23

A Yes.

Q I will also use the term gender dysphoria, which is defined as discomfort or distress that is caused by a discrepancy between a person's gender identity and that person's sex assigned at birth and the associated gender role and/or primary and secondary sex characteristics. Can we agree that when I say gender dysphoria, that's the definition I'm using?

A Yes.

24 Q I will also be using a phrase categorical 25 exclusion of treatment for gender dysphoria, which

Page 7 refers to the exclusion in Florida Administrative Code 1 2 Rule 59-G-1.050(7). Do you understand that that phrase 3 refers to all the services in that particular portion of the rule when I say categorical exclusion? 4 Α I do. 5 And then I will also be using the term EPSDT 6 0 7 services, which stands for Early Periodic -- Early and Periodic Screening Diagnostic and Treatment Services. 8 9 When I say EPSDT, do you know what I mean? 10 Α Yes. 11 Have you ever been deposed before? Q 12 Yes, I have. Α 13 Okay. So if there's at any point that you Q don't understand my question, what I want you to do is I 14 15 want you to stop and ask me to rephrase it. I don't want you to try to attempt to ask -- answer the question 16 17 if you don't understand it. Okay? 18 Α Okay. I have a problem sometimes of speaking over 19 Q 20 someone else, I don't know if you have the same problem, but what we need to try to do is just give each other 21 2.2 space to pause in between the questions so we're not 23 speaking over each other. Okay? I'm fine with that. 24 Α Okay. Verbal answers. Sounds like, you know, 25 Q

Page 8 you speak very clearly, so we shouldn't have a problem, 1 2 but obviously -- although we do have a videographer 3 here, it's better to speak your answer out loud. Α I do understand. Articulating hand gestures, 4 the court reporter cannot get those into the 5 6 transcripts. 7 Exactly. All right, if you need to take a 0 break for any reason, totally fine, just let me know. 8 Ι 9 do ask that you answer my question before we take a 10 break. 11 А Okay. 12 And then are you on any medications or other Q 13 substances that could impact your memory today? Α No. 14 15 0 And state your name for the record. So my full name is John Matthew Brackett. 16 А 17 Okay. And it's your understanding that you're 0 representing the Florida Agency for Health Care 18 Administration in a 30(b)(6) deposition? 19 20 Α That's correct. Okay. What topics, looking at the notice, 21 Ο 2.2 which is Exhibit 1, notice of 30(b)(6) deposition, what topics were you designated for? Were they all of them 23 24 here? 25 А Yes.

Page 9 And you're prepared to testify on behalf of 1 0 2 the Agency on each of these topics? Α Yes. 3 Have you seen the 30(b)(6) deposition topics? 4 0 You mean as those listed in the -- yes, I have 5 Α 6 seen them. 7 0 And who provided them to you? Those were provided to me by our outside 8 Α 9 counsel. 10 Okay. And did you consent to acting as the 0 agency representative? 11 12 Α Yes, I did. 13 Q What did you do to -- excuse me. What did you do to prepare for today? 14 15 Α Mostly just familiarize myself with areas and topics that are on the list that are not familiar to my 16 17 current job role, and that's pretty much it. So pretty 18 much standard operating procedures here at the Agency that are -- that might fall under different divisions or 19 20 different teams, et cetera. And just kind of, like, reviewed some of our coverage policies, some of our 21 2.2 rules and some of our own materials. 23 Okay. Who did you speak to? 0 24 Α Principally, consulted with Andrew Sheeran and for any questions that involved managed care, I 25

consulted my supervisor Devona Pickle. 1 2 Q Did you gather information from anyone, anyone besides counsel? 3 I gathered a little bit of information from 4 Α Devona Pickle, since one of the questions directly 5 involved her role in the process. 6 7 Okay. I saw that you brought a document with 0 you today, it looks like maybe you reviewed that to 8 9 prepare. What is that? 10 So that is pertinent to the question. Α I can 11 provide you the exact one. Yeah, I think -- yeah, 12 question three. It was -- since that asked about the 13 process of how we looked at other states' Medicaid 14 programs, which that spreadsheet was -- Devona Pickle 15 administered that role of the GAPMS process. And since 16 that question was on there, I did ask her to provide me 17 with what she used to -- and the research methods used 18 to go through each state Medicaid program to find out what their coverage criteria is, or if they have a 19 20 statement prohibiting coverage, or if they just don't 21 have any statement whatsoever. 2.2 MS. DEBRIERE: Okay. And, Mo, do you know if 23 that was produced to us in discovery? MR. JAZIL: I don't believe it was. So we'll 24 25 make copies and get it to you.

1 BY MS. DEBRIERE::

2 Q How long did it take you to prepare for the 3 deposition today?

A Well, given that we received these questions about a week ago, I'd probably say I spent probably off and on -- I mean, in between other projects, probably I'd say three, maybe four working days.

Q Okay. A little bit about you. Describe your9 educational background.

10 So I received a -- my -- started off, I got my Α 11 AA at Tallahassee Community College. I received my 12 Bachelor of Arts in history at Florida University, 2003. 13 I graduated magna cum laude. Received my Master of Arts in History from Florida University in 2005. During my 14 15 time in graduate school, I did spend a few extra years working on a PhD, which I decided not to finish, but 16 17 during my grad school years, I presented research papers 18 on numerous topics at numerous conferences. And I also published scholarly articles in the Florida Historical 19 20 Quarterly and Southern Studies and Interdisciplinary Journal of the South. 21

22 Q The conferences, what were those about? 23 A The conferences ranged. They could -- they 24 were, I think, either conference on Florida history, 25 conferences on environmental history. I think there

were, like, graduate symposiums. So often they're also, 1 2 like, regional conferences. The topics I represented on 3 ranged from anything from environmental history to public health history. 4 And your PhD, what -- what were you attempting 5 0 6 to get it in? 7 So I was actually looking at getting my PhD in Α the history of medicine and public health. 8 And 9 actually, I was -- my dissertation topic was on 10 tuberculosis, on how during the late 19th century, how 11 kind of the infancy of public health agencies and how 12 public health was actually becoming a common concept and 13 how -- and, of course, with the emerging sciences --14 well, pretty much with the discovery of microbiology and 15 discovery of the tuberculosis bacteria, how all that was coming together to affect changes in the south in public 16 17 health, and looking at also how, since tuberculosis was 18 very common, on how that shapes southern identity. 19 Q Okay. And what's your current position at the 20 Agency for Health Care Administration? 21 А So my current position is Program Consultant. 2.2 I work on the Canadian Drug Importation Program 23 primarily. MS. DEBRIERE: And, Court Reporter, just to 24 note, we're going to refer to the Agency for Health 25

Page 13 Care Administration's throughout as either AHCA or 1 2 the Agency. BY MS. DEBRIERE:: 3 Prior to your role with the Canadian Drug 4 0 Importation Program -- did I get that right? 5 6 Α Yeah, close enough. 7 0 What was your role at the Agency? My role at the Agency, I was the Program 8 Α 9 Administrator over the Specialized Services and 10 Behavioral Health teams. Of course, we oversaw the 11 development and, of course, updating of policies, such 12 as durable medical equipment, community behavioral 13 health, non-emergency transportation, school-based services, hospice. There's actually guite a lengthy 14 list. 15 And how long did you do that for? 16 Q 17 I was in that position for three and a half Α 18 years. 19 Okay. And prior to that, were you at the Q 20 Agency? 21 Α Yes, I was. 2.2 And what was your role then? Q 23 I was a Government Analyst II. And during Α 24 that time period, that was from January 2017 to November 2017, I was -- my role specifically tasked with 25

completing the Generally Accepted Professional Medical 1 2 Standards reports. And prior to that time, were you at the 0 3 Agency? 4 А Yes. 5 And what did you do then? 6 0 7 I would -- I worked in the Office of the Α Deputy Secretary for Health Quality Assurance. 8 9 0 So your time in the Bureau of Medicaid policy 10 was from December 2017 to --11 January 2017 to November 2017. But my job --Α 12 but becoming a program administrator, I was still in the 13 same bureau. So GAPMS -- working on GAPMS was January 2017 14 0 15 to November 2017, and then you shifted to another role in Bureau and Medicaid Policy? 16 17 А Yes. 18 And that was in December of 2017 through --Q 19 November 2017 through April of 2021. Α 20 And so since May of 2021 or April 2021 you've 0 21 been with the Canadian Drug --2.2 Α April 2021. Okay. Let's look at the Florida definition of 23 0 medical necessity. And that is in the Florida Medicaid 24 Definitions Policy, which I'm sure you're intimately 25

Page 15 familiar, at Section 2.83, and it's incorporated by 1 reference into rule by Florida Administrative Code Rule 2 59-G-1.010. 3 MR. JAZIL: Simone, would you happen to have an 4 extra copy? 5 MS. CHRISS: Yes. 6 7 MR. JAZIL: I'd rather just not lean over his shoulder. 8 9 MS. DEBRIERE: You know what, Mo, you can use 10 mine. I basically have it committed to memory. 11 MR. JAZIL: Thank you. 12 MS. DEBRIERE: So we'll go ahead and mark this 13 policy as Exhibit 2. (Whereupon, Exhibit No. 2 was marked for 14 identification.) 15 16 BY MS. DEBRIERE:: 17 And, Mr. Brackett, if you want to turn to it, 0 18 it's 2.83. 19 А Okay. 20 What's the purpose of the Medical Necessity Q standard listed here? 21 2.2 Α So is -- kind of clarify -- can you clarify what's meant by purpose? 23 What does AHCA use that medical necessity 24 Q standard for? 25

So these prongs for medical necessity, as 1 А defined, these are our guidelines for determining 2 whether or not Florida Medicaid should cover a service. 3 Okay. Is it correct to say that the standard 0 4 is used to determine whether Medicaid service should be 5 prior authorized? 6 7 А I don't -- I don't -- I don't think so. 8 0 Okay. Tell me why. 9 Α Because for medical necessity, being medically 10 necessary, this is generally -- this is a criteria for whether or not Medicaid should cover a service. 11 The 12 prior authorization process is just mostly more clinical 13 review to determine whether or not delivery of that service, coverage of that service corresponds to the 14 definition of medical necessity. 15 16 Okay. So when you're doing a prior Ο 17 authorization review, you do determine whether or not the service corresponds to the definition of medical 18 necessity? 19 20 Α So since our subcontractors and our managed care plans do our prior authorizations, they do have to 21 2.2 make sure that the -- that with the service they're prior authorizing would, if subjected to the medical 23 necessity quidelines and definition, yeah, they have to 24 make sure it corresponds. 25

Okay. And that's part of the prior 1 0 2 authorization process? 3 Α That's part of the prior authorization 4 process, yes. If a Medicaid service is found to be 5 0 experimental by AHCA, would AHCA or its contractors, 6 7 subcontractors like a managed care plan, still review whether the service meets any other portion of AHCA's 8 9 medical necessity rule? 10 Α No. 11 Okay. Why not? 0 12 Because it does have to meet the five prongs Α 13 of medical necessity, and one of those prongs is it has to be in alignment with GAPMS. 14 15 0 Okay. So if it's not in alignment with GAPMS, would you analyze it under any other portion of that 16 17 definition? 18 Α No, we wouldn't. If a Medicaid service has not been determined 19 Q 20 experimental, using like GAPMS process, can a Medicaid managed care plan use the portion of the medical 21 2.2 necessity standard that reads, be consistent with Generally Accepted Professional Medical Standards? 23 Once the Agency deemed that it's not 24 Α consistent, and often these requests usually come to us 25

1 from the plans, the plan is not going to cover it.

Q Okay. Is the plan able to make an independent determination of whether those services are experimental in nature, or must that come from -- decision come from AHCA?

It does not necessarily have to come from 6 А 7 AHCA. We do grant our managed care plans a great deal of flexibility when it comes down to the services they 8 9 wish to cover, but sometimes when they get a service 10 that they're not sure about, they do often -- sometimes will ask us to do a GAPMS review of it to determine 11 12 whether or not that -- if they should cover it. So 13 sometimes we're kind of more of a reference point, but 14 the plans function pretty independently in these areas.

Q Okay. So the plan can make an independent determination as to whether or not a service is experimental or investigational?

18 A No. Whether or not to cover -- we don't allow
19 them to do -- we don't allow them to do independent
20 GAPMS reviews, if that's what you're asking.

Q What I'm asking is looking at the prong about whether this service is consistent with GAPMS, whether the plan can deny coverage of a service on that basis without AHCA's initial determination?

25

A No, they need to consult with us before

they -- they need to consult with us before they use 1 2 experimental and investigational as a basis for denial, which they will -- we do get requests from the health 3 4 plans. Okay. All right. So moving on to what's 5 0 6 Bates-stamped as defendant DEF 000126105. This is the 7 GAPMS report on cross-sex hormone therapy, which is dated --8 9 MS. CHRISS: May '22. BY MS. DEBRIERE:: 10 11 May 20th, 2022. Q 12 VIDEOGRAPHER: Counsel, can you put that mic 13 on, please? They placed it right beside you. MS. DEBRIERE: Yes. 14 Yes. 15 VIDEOGRAPHER: The one to your right. Thank 16 you. 17 MS. DEBRIERE: I should have worn my suit 18 jacket tonight. 19 THE WITNESS: It might get hot here shortly, so 20 I may be taking mine off. MS. DEBRIERE: Should I mark this as 3? 21 MS. CHRISS: Yes, the one for him. 2.2 23 MS. DEBRIERE: I think we got it split up. I'm 24 sorry. Mo, do you want to copy? MR. JAZIL: Sure. Do you really have all these 25

Page 20 committed to memory? 1 2 MS. DEBRIERE: Well, not this one, no, but somewhat. 3 MR. JAZIL: Here's the last one, Katy. 4 MS. DEBRIERE: Thanks. 5 MR. JAZIL: That's pretty impressive if you do. 6 7 MS. DEBRIERE: Well, not these, but definitely, you know, you practice Medicaid in Florida for 8 seven years, you know what the medical necessity 9 definition is. 10 11 (Whereupon, Exhibit No. 3 was marked for 12 identification.) 13 MS. DEBRIERE: All right. Not a day past seven years, either. 14 15 BY MS. DEBRIERE:: Okay. So looking at -- do you have a copy, 16 0 17 Mr. Brackett? 18 Α Yes. Okay. Looking at -- if you'll flip to what's 19 Q 20 marked as DEF 000126112, it's page eight. 21 Α Okay. Starting under coverage policy, there's some 2.2 Q discussion about federal regulations, and then moving 23 through to the Florida Medicaid section that ends on the 24 top of page 10, if you could just review that for me. 25

1	A Okay.
2	Q So is this an accurate portrayal of the
3	standard to determine Florida Medicaid coverage for
4	prescription drugs?
5	A Yes, this is.
6	Q Do all prescription drugs require prior
7	authorization to be reimbursed by Florida Medicaid?
8	A I can't speak fully to that one. I don't I
9	don't believe so, but often our managed care plans, we
10	grant them a lot more flexibility when it comes down to
11	prior authorizations, so they may require prior
12	authorization for every drug. But as far as, like,
13	every single drug, as far as the fee for service system
14	goes, I'm not a hundred percent certain, but I believe
15	that we do not require prior authorization for every
16	single drug.
17	Q Okay. Do you know if anybody at the Agency
18	would have a hard answer to that question?
19	A One of our staff pharmacists probably would.
20	Q So can you briefly describe the process a
21	Medicaid recipient undertakes in seeking prior
22	authorization for a drug?
23	A Usually, that's taken by the provider usually,
24	or in the case of pharmacy, I'm not sure who would
25	submit the prior authorization. I don't think that

1	that a manager is not initiated by the maximizet
1	that's process is not initiated by the recipient
2	themselves, it's usually initiated by the provider. Of
3	course, it goes through, like, a one-two level review
4	process. That first level is usually done by, like, a
5	nurse or an RN. They just determine whether or not it's
6	medically necessary. If it is, then that one level
7	stops. If it's a denial, it has to go I think it
8	goes to a second-level review.
9	Q Okay. And what is what is involved in that
10	review? What is being reviewed?
11	A Well, I'm not intimately familiar with it
12	because we used it a long, long time ago, prior to SM's.
13	We did that stuff in-house. That was before my time
14	with the Agency, but now that's outsourced to EQ Health
15	Solutions in the fee-for-service system. But they do
16	review the medical records, et cetera, and then, I
17	think, any other materials that are submitted by the
18	doctor, so
19	Q Do they compare it to coverage policies or
20	guidelines?
21	A Well, for children, I don't it wouldn't be
22	necessary to because of EPSDT, but for adults, I don't
23	know. That's information that we would have to ask our
24	vendors. I assume they would, but that's an assumption.
25	Q Okay. Tell me a bit more about what you mean

by coverage guidelines when it needs to be reviewed for
 children because of EPSDT.

Well, because of EPSDT, in which, since you're 3 Α familiar with all this, of course, even regardless of 4 what something says on the coverage policies -- because 5 our coverage policies and our fee schedules are very 6 7 prescriptive, they list out what services can be covered, what services can't be covered. Our fee 8 9 schedules, of course, outline the amount of money that 10 we pay for each service and our perimeter service gaps, 11 most importantly, the service gaps. So for children, if 12 it's deemed medically necessary, and usually it does 13 have to go through the prior authorization process for an EPSDT consideration, if it's determined medically 14 necessary, regardless of whether it's on a fee schedule 15 or not, or in excess of our fee schedule, or if it's not 16 17 listed in that coverage policies, because of EPSDT requirements from the feds, we do have to cover it. 18

19 Q Okay. Okay. And how do you define medical20 necessity for EPSDT?

A It's the same as listed in definitions policy. Q Okay. What would be the process for obtaining Medicaid coverage for a drug where prior authorization is not required?

25

A Well, so the thing about Medicaid coverage for

1	drugs is that we do cover all drugs that are FDA	
2	approved. So if unless it has a prior authorization	
3	requirement and if that FDA approved covered drug can be	
4	covered by Medicaid.	
5	Q Okay. What if it's not FDA approved?	
6	A If it's not FDA approved or if it's so are	
7	we talking about, like, complete non-FDA approval or are	
8	we talking about like our off-label usage?	
9	Q Actually, let's back up. So if it's FDA	
10	approved, does that mean it does not need to go through	
11	the prior authorization process for Medicaid to	
12	authorize it?	
13	A If it's not FDA approved, we I mean, we're	
14	not going to cover it if it's not FDA approved.	
15	Q Okay. If it is FDA approved, does the	
16	Medicaid recipients still have to undertake the prior	
17	authorization process to	
18	A If it's FDA approved, and it's a drug that	
19	we've required prior authorization, then, yes.	
20	Q Okay. If it's a drug that does not require	
21	prior authorization, what does that process look like	
22	for coverage?	
23	A I generally I think it just the pharmacy	
24	fills the prescription, they file a claim, agency pays	
25	the claim and the dispensing fee.	

Okay. So there's no review in medical 1 0 2 necessity under that --3 Α Providing the drug does not -- does not have prior authorization criteria, yes. 4 Okay. So if it's a drug that does not require 5 0 6 authorization, AHCA does not determine if it's being 7 prescribed for a medically necessary use; is that correct? 8 9 А Can you repeat that? 10 If a drug does not require prior Q Yep. 11 authorization, AHCA does not -- AHCA or its contractors 12 does not undertake a determination as to whether it's 13 being prescribed for a medically necessary use? 14 MR. JAZIL: Object to form. THE WITNESS: We covered -- we cover services 15 16 that are medically necessary. So if it's -- that 17 would be in violation of policy if drugs are being covered -- if drugs are being prescribed and 18 covered, when for -- when medical records and the 19 20 documentation -- when medical necessity is not being met, that is that -- no, we would not cover 21 2.2 in those circumstances. BY MS. DEBRIERE:: 23 How would you make that determination that you 24 Q would not cover if you're not doing a prior 25

1 authorization review?

A So generally when issues like that, when providers are billing Medicaid for services that are not medically necessary, that's usually when our Medicaid --Medicaid program Integrity, they start getting involved in looking at -- looking at such claims.

Q How would that rise to the surface of
triggering an investigation with Medicaid Integrity?

9 Α Well, there are lots of tip-offs. I mean, we 10 do have a -- we do have a fraud hotline. So somebody could report a provider for fraud. There -- it could be 11 12 result from an on-site survey. Our Bureau of Recipient 13 Provider Assistance does -- they often do Medicaid surveys on providers. It could also potentially result 14 15 from a -- one of our health quality assurance surveys, 16 if they're going in and looking at, like, their 17 compliance with licensure rules. So it really depends on where the fraud's detected. So there are multiple 18 19 avenues for reporting Medicaid fraud.

20 Q Does AHCA have a pharmacy coverage policy for 21 every prescription drug?

A We do have our outpatient prescribed drugs services coverage policy. And that, of course, is for our covered outpatient drug benefit.

25

Q Does that policy list every potential

prescription drug prescribed under -- prescribed to a
 Florida Medicaid recipient?

No. So -- because Florida Medicaid covers any 3 Α drug that's FDA approved, when these medical necessity 4 quidelines, that's kind of an encompassing umbrella. 5 And then, of course, we do have the preferred drug list 6 7 which is assembled by the Pharmaceutical and Therapeutics Committee. We always just call P&T, so --8 9 but because the list is so vast we don't actually 10 reproduce it in any kind of a form. So the prescribed 11 drug services policy, the way it's worded is supposed to 12 be all-encompassing, but there are exclusions in Section 13 5.2 of non-covered service -- of drugs that we won't cover under certain circumstances. 14

15 Q Okay. So it lists some drugs you won't cover, 16 but it doesn't list all the drugs you will potentially 17 cover?

A Right. But it's also -- but it's not -- it doesn't specifically state drugs, it's just -- it's more specific to conditions. Like we don't say we won't cover -- well, let me use it -- Viagra, but we say that we will not cover drugs for ED.

Q Okay. So there's some general descriptions of what you won't -- will and won't cover?

25 A

Yes.

Page 28 Is there a pharmacy -- is there an AHCA 1 0 2 pharmacy coverage policy for estradiol? And I'm happy to spell it for you if you need it. 3 Oh, are we talking about estradiol. 4 Α 0 Estradiol. Thank you. 5 No, we don't have specific coverage policies 6 А 7 for specific drugs. And by estradiol, I mean, that's an -- that's a kind of name brand estrogen. 8 9 0 Okay. And how about for medroxyprogesterone acetate, or Provera? 10 11 We don't have specific coverage policies for Α 12 those. 13 Q Okay. How about micronized progesterone? Those would all be encompassed under the 14 Α 15 prescribed drug services policy. Okay, but not specifically named? 16 0 17 We don't specifically name drugs. Α I'm just going to run down the list. Spiro --18 0 19 and you're going to correct me when I say it wrong --20 Spironolactone. Spironolactone. That one, I mean, once again, 21 Α 2.2 the previous answer applies. It's enveloped by our prescribed drug services coverage policy. We don't 23 24 have, like, an individual policy addressing that 25 specific drug.

1	Q Okay. Finasteride.	
2	A I think that's close enough. Same as before	
3	it's covered it's enveloped by the prescribed drug	
4	services coverage policy. We do not have an individual	
5	coverage policy for that drug.	
6	Q Dutasteride.	
7	A We do not have an individual coverage policy	
8	for that drug, but it is covered. It is it is	
9	addressed through the prescribed drug services coverage	
10	policy.	
11	Q Okay. Testosterone.	
12	A The same as before, we don't have an	
13	individual coverage policy for it, but it is covered	
14	through the prescribed drug services coverage policy.	
15	Q Testosterone enanthate.	
16	A Same as before, as in, we don't have a	
17	specific coverage policy, but it is covered through the	
18	prescribed drug services coverage policy.	
19	Q Okay. Two more. Testosterone undecanoate.	
20	A We do not have an individual coverage policy	
21	for that, but it is enveloped by our prescribed drug	
22	services policy.	
23	Q Gonadotropin-releasing hormone antagonists.	
24	A Gonadotropin, yeah. So, yeah, we do not have	
25	an individual coverage policy for GnRH. And that, of	

course, would be covered through the prescribed drug 1 2 services coverage policy, is how it would be addressed. Okay. You do not have a policy, a pharmacy 3 0 policy for GnRH antagonists? 4 5 Not promulgated into rule. Α 6 0 Okay. Do you have any coverage policies -- I 7 didn't realize that when I asked whether there was a coverage policy that you interpreted that to mean that 8 9 it had to be promulgated into rule. Do you have any 10 coverage policies regarding these drugs that are not 11 promulgated into rule? 12 Α As far as the policy goes, we don't really 13 have a policy so for it -- so much. There was a quideline produced, I think, in 2016 that was given to 14 15 Magellan for quidance on the prior authorization process, but as far as a policy goes, no, we don't 16 17 have -- we don't have a specific policy for these drugs. 18 Okay. So there was some quidance that AHCA Q provided to Magellan regarding GnRH antagonists. 19 20 MS. DEBRIERE: Simone, can I have that coverage 21 quidance? 2.2 MS. CHRISS: This one? MS. DEBRIERE: Yes, please. Thank you. We'll 23 mark that as Exhibit 4. You definitely need a copy 24 of this one. 25

(Whereupon, Exhibit No. 4 was marked for 1 identification.) 2 3 THE WITNESS: I've seen it enough times. BY MS. DEBRIERE:: 4 Well, so is that what you're referring to when 5 0 you said the guidance provided to Magellan? 6 7 Α Yes. That's all I needed to know. Okay. So I'm 8 0 9 sure we'll come back to that. And so you referenced FDA 10 approval in Medicaid coverage earlier. When making 11 decisions about individual claims for coverage for 12 Medicaid recipients, does AHCA or its contractor 13 determine whether the use the drug is being prescribed for is FDA approved? 14 15 Α Well, absolutely, yes. I mean -- I mean, if 16 it doesn't have FDA approval, I mean, it's still -- I 17 mean, it's either not FDA-approved, it's still going 18 through clinical trials. It's not FDA-approved, then 19 no, it's not eligible for coverage. 20 Okay. How does AHCA do that on an 0 21 individualized basis? 2.2 Α So for an individualized basis, generally this 23 is a prior authorization process, the request is put in. 24 The recipients, or health care plan enrollees, the specific condition is evaluated and determination of 25

Page 32 medical necessity is made. 1 Okay. What if the drug does not require prior 2 Q authorization, then how does AHCA determine whether the 3 use it's being prescribed for is FDA-approved? 4 Α That would normally have to involve a 5 retrospective claims review. 6 7 Okay. So at the time it'd be covered, but 0 then AHCA would go back and look to see if it should 8 9 have been covered? 10 Α That's correct. 11 And how do they do that? Q 12 How do they do that? Α 13 Q Yeah. I don't know the specifics, generally either 14 Α 15 MPI or another bureau. Often people in the field will often look at review claims, and this has happen 16 17 frequently, that if claims are found to be paid in error or paid for services that were not necessarily -- not 18 medically necessary, but the Agency does have the 19 20 ability and frequently does gather recoupments on 21 providers. 2.2 Q Okay. MPI stands for --23 Medicaid Program Integrity. А So that's like a fraud investigation? 24 Q Yes, there are two fraud investigation teams 25 Α

of the state. For MPI, they're specifically here for 1 2 Medicaid. Every Medicaid program in the country is 3 required to have a program integrity team, but we also have Medicaid Fraud Control Unit over at the Attorney 4 5 General's Office. Okay. Just turning back quickly to Exhibit 4, 6 0 7 why is this not considered a coverage policy? Because coverage policies are generally --8 Α well, first of all, it's not promulgated in a rule. 9 So 10 all of our coverage policies go through the rulemaking 11 process, which is, of course, allows for public input 12 and everything like that. This is mostly more -- these 13 are guidelines developed in-house and provided to our PBM subcontractor. 14 15 0 Okay. For use in determining whether or not 16 to prescribe GN -- strike that. 17 Are there other coverage guidelines like this 18 not promulgated into rule for other drugs? For other -- I am not aware of whether or not 19 Α 20 we have any other guidelines like this. Okay. What about for cross-sex hormone 21 Ο 2.2 therapy? 23 Α There was -- to my knowledge, there was no quidance or for cross-sex hormones. 24 Okay. So going back to the MPI post-claim 25 Q

reviews, how often does that happen? Can you quantify? 1 I don't have enough numbers of how often it 2 А 3 happens, because obviously we have thousands of Medicaid Then we do hear about cases of recoupment, 4 providers. so I couldn't tell you what the percentage of providers 5 6 that had to pay back to the Agency money, but I can 7 tell -- I can definitely tell -- like, I know -- well, for instance, I know -- like, I think Miami-Dade or 8 9 Broward County have -- like, their school district 10 actually they had -- after they had received a Federal 11 Audit from HHS, they ended up having to pay back, I 12 think, a million or so dollars in funds because they 13 were delivering services that weren't properly documented and weren't meeting that medical necessity 14 15 criteria. So as far as the larger numbers go, I don't 16 have those.

17 Q Is there somewhere publicly the public can 18 access that information, or where we can access that 19 information?

A So a public records request can always be put in. We don't have that information available on our website, but anyone can put in a public records request and find out, like, how often recoupments do occur.

24QDo you know what a drug compendium is?25AYes. Yeah, I'm aware of three.

1	Q Which three are you aware of?
2	A Drug Index is one. There are two others whose
3	names do not whose names I do not recall immediately
4	offhand. I believe they are listed. And, of course,
5	they do usually consist of, like, a very large amount of
6	information on each specific drug, and it talks about,
7	like, appropriate uses and so forth. So, for each of
8	these compendia and I they are we do utilize
9	them when evaluating whether or not we can use an
10	FDA-approved drug for an off-label purpose.
11	Q Okay. Do you know if those three compendia are
12	Drug Text Information System, United States
13	Pharmacopoeia Drug Information and American Hospital
14	Formulate Formulary Service Drug
15	A That sounds correct.
16	Q And those are the three compendia listed in
17	the Federal Medicaid Act?
18	A Yes.
19	Q Okay. So when I'm using compendium, or
20	compendia for next set of questions, I'm referring only
21	to those three listed in the Federal Medicaid Act.
22	A Okay, that's fine.
23	Q For drugs that do not require prior
24	authorization, when making decisions about individual
25	claims for coverage, does AHCA or its contractors

determine whether the use that drug is being prescribed 1 2 for is supported by citation in one of the compendia? So is this for drugs that do not require prior 3 Α authorization, or drugs that do require prior 4 5 authorization? Do not require. 6 0 7 We really don't because we don't require prior Α authorization. We're not able to check. 8 9 0 So that means where AHCA does not require 10 prior authorization for a Medicaid recipient to obtain 11 coverage of a particular drug, it covers the drug 12 without knowing in advance whether the use it's being 13 prescribed for is supported by citation in one of the compendia? 14 15 А If we're not requiring prior authorization, 16 there's no way for us to know in advance. 17 Okay. So I know you mentioned it earlier. 0 I'm just going to reference it on my computer, and that 18 is the prescription drug list. And the website link --19 20 I'll turn it so both you and counsel can see it, without spilling my drinks. That URL is 21 2.2 HTTPS://AHCA.myflorida -- Florida is spelled out --.com//Medicaid/prescribed drug/pharm -- P-H-A-R-M --23 thera -- T-H-E-R-A -- /PDF/PDL.pdf. So I'm showing you 24 what is AHCA's preferred drug list. Do you recognize 25

1 it?

2

3

- A Yes, I recognize that.
 - Q What is the PDL?

So the preferred drug list -- so even though 4 Α we have everything that's FDA-approved, our 5 Pharmaceutical and Therapeutics Committee, they do place 6 7 drugs on the preferred drug list. I don't know the -necessarily all the details. I think often it has to do 8 9 with the ability for the agency to obtain rebates and so 10 forth, so -- but they do put this together. It is 11 publicly available on our website. And, of course, it 12 does -- it does, of course, have age -- it does have 13 age, minimum age, maximum age, clinical care required.

I would like to clarify, though. I know for 14 15 our -- in our Medicaid Management Information System, 16 which we often dub as FMMIS, we do program for procedure 17 codes and so forth, corresponding diagnosis codes. So 18 if a claim does not correspond to a diagnosis code, 19 and -- that claim can be denied automatically in the 20 system. 21 0 Okay. Okay. 2.2 Α Which, I'm sorry, I forgot --23 No, no, no. It's helpful. I just want to Ο

24 make a note of it.

A And we do program our system with ICD-10

25

codes, so we do have a build in our system for claims to 1 2 deny if they don't necessarily correspond to a specific diagnosis code. 3 And that's regardless of whether the drug 4 0 requires prior authorization? 5 If it's prior authorized, the prior -- there's 6 Α 7 a different process for entering claims into the system that are prior authorized. So I think if it was prior 8 9 authorized, that would override the automatic denials, 10 but I would have to confirm that, but I believe that's 11 how the system does work. 12 So FMMIS can be programmed to deny a certain 0 13 service if it's associated with a particular diagnostic code, and that's done automatically? 14 15 Α That's automatic. Yeah. Claims can deny automatically in the system, so we do have a fail-safe 16 17 there. 18 Okay. And that's even if the drug does not 0 require prior authorization? 19 20 Α That's correct. 21 0 Okay. 2.2 Α So I know it's definitely the case for the procedure codes that I administered when I was over --23 24 when I was over specialized services. I'm going to assume that we have the same in place for NDC's, 25

Page 39 National Drug Codes. 1 2 Q Okay. Because the services you were previously working on were not prescription drugs, is 3 that correct, they were other Medicaid services? 4 No, they were a little of everything. 5 Α Do you have a diagnostic code for every drug 6 0 7 in the system? 8 Α I can't speak to that at the moment. 9 Okay. Is there some way we can find that 0 10 information out? 11 Yeah, we can -- we can find that out for you. А 12 MS. DEBRIERE: Okay. Can we flaq that as a 13 question, follow-up question? BY MS. DEBRIERE:: 14 15 0 If a drug is on the PDL, does it mean it's on 16 the fee schedule? 17 Α So we don't -- so with drugs, and this is one of the things with having worked -- working on the 18 19 Canadian Drug Importation Program is that drug pricing 20 is not a transparent process, so we don't actually list rates, we just list what we cover, or we list what's on 21 We don't actually say what we'll reimburse. 2.2 the PDL. 23 Okay, but if it's listed on the PDL, even if 0 24 the rate's not on the fee schedule, AHCA is going to 25 cover it?

1

A Yeah.

2 Q Okay. Does the PDL apply to managed care plan 3 coverage of prescription drugs?

Yes, that's actually -- well, yes, actually. 4 Α I think -- I think -- I believe it does. That we 5 wouldn't -- I would need to verify, but as far as --6 7 like, I know that's the way our pharmacy benefit works. So with pharmacy benefit managers, generally the law 8 9 ensures subcontract, that's the pharmacy benefit 10 managers, who handle both their prior authorization of 11 drugs and also negotiating rebates with manufacturers to 12 help, of course, lower expenses. And so -- but for 13 Medicaid, the SMC health plans, they have PBM's that 14 they're really only there for the prior authorization process of prescription drugs. So their PBM's do not 15 negotiate rebates. All that's done on the Agency side. 16 17 So the agencies have contracted PBM, which is another 18 branch of Magellan. They're the ones that negotiate all the rebates. 19

20 Q Okay. Just for clarity of the record, PBM 21 stands for --

A Pharmacy Benefit Manager.
Q Okay. And then SMC PBM's, they're using the
PDL to determine whether or not to authorize coverage
for a prescription drug?

Page 41 Well, since with Medicaid we'll cover anything 1 А 2 that's FDA-approved, they're going to be reviewing primarily medical necessity. 3 Okay. Are they going to match up the request 4 0 for drug coverage to the PDL? 5 I don't know if they do that or not. 6 А 7 Okay. So you don't know if Medicaid managed 0 care plans rely on the PDL to authorize coverage? 8 9 Α I don't. I can't speak to that. 10 All right. Let's look at a few specific 0 11 Say this one for me again. drugs. 12 Α Estradiol. 13 Q Estradiol. Thank you. Okay. So the PDL indicates that AHCA covers estradiol in each of these 14 15 formulations, there's many listed here, for at least one indication, but we don't know what the indication is, or 16 17 at least the PDL doesn't indicate it, correct? 18 Α That's correct. Okay, but AHCA does not cover estradiol to 19 Q 20 treat gender dysphoria? That's correct. 21 Α 2.2 For what uses or indications does AHCA Q 23 authorize coverage for estradiol? So for -- well, when estradiol needs to be 24 Α covered, generally, as I speak very generally, of 25

1	course, usually it's used for hormonal imbalances, but I
2	mean, but still we go back we defer back to the
3	medical necessity guidelines.
4	Q So what does the no let's look at the very
5	first list listed formulation of estradiol, which is
6	associated with Climara 0.025-milligrams-per-day patch.
7	And looking over at the clinical PA required, it says
8	no. What does that mean?
9	A That means if the provider wants to prescribe
10	it, that, of course, they can prescribe it without
11	having to have a clinical review process.
12	Q So that means no prior authorization is ever
13	required?
14	A Not under fee-for-service. Managed care
15	plans, however, they have the flexibility to make it go
16	through prior authorization.
17	Q Okay. So in fee-for-service, estradiol will
18	be covered without AHCA or its contractor first
19	determining for what purpose it's being used?
20	A Right, not until the claim comes in.
21	Q Okay. So that would mean that Medicaid could
22	cover this drug if it were prescribed for
23	non-FDA-approved uses?
24	A That's, of course, where our claim system
25	comes in. So our claim our claim system was

-	
1	programmed and, of course, I'm speaking generally of
2	our CPT codes, et cetera, that if it doesn't if the
3	diagnosis code doesn't align with what's in the system,
4	that can come back as a denial.
5	Q Okay. So for estradiol, let's use this as an
6	example, but not a hypothetical, in real life.
7	A Okay.
8	Q If estradiol is prescribed for treatment of
9	gender dysphoria, is FMMIS programmed to automatically
10	deny that claim?
11	A I would have to confirm with our with our
12	Medicaid fiscal agent operations to make sure to know
13	whether or not that the system has been updated for
14	to deny that.
15	Q Is it possible to program a system to do that?
16	A To program it to deny it?
17	Q Based on based on the diagnostic code
18	A From my experience, it's pretty it's a
19	pretty simple affair to update the system to when
20	we because we are uploading new and deleting
21	diagnosis codes or uploading new procedure codes, I
22	mean, it's generally a pretty straightforward process.
23	Q Okay. Can you provide us a list of those
24	diagnostic codes at some point?
25	A For estradiol?

Page 44 I think -- well the diagnostic codes would 1 0 2 be -- are you using CPT codes? What are you using? So we use ICD-10 for --А 3 ICD. Okay. 0 4 -- because it's going to be primarily -- those 5 Α are going to be like your -- well, those are your 6 7 service codes. Those aren't drug codes. Okay. So you use -- for your diagnostic 8 Q 9 codes, it's associated with ICD-10? 10 Α That's correct. 11 Okay. So, looking at testosterone, this 0 12 indicates that -- we've got to get there first, don't 13 we? So this indicates that AHCA covers testosterone, and each of these formulations listed on the PDL for at 14 15 least one indication, although based on the PDL, we 16 don't know which indications for which it covers; is 17 that correct? I mean, there's a very large number of 18 Α Yeah. FDA-approved clinical indications for testosterone. 19 20 Okay. Just for clarity, AHCA will never cover 0 21 testosterone when used to treat gender dysphoria, is 2.2 that correct? 23 А Yes. And it looks like, at least some of these 24 Q formulations, including, for example, Andrew Durham, 25

four milligrams, 24-hour patch, that there is a clinical 1 prior authorization that's required. Is that correct? 2 Yes. Yeah. Based on the PDL? Yes, there 3 Α would be a PA required. 4 For what uses or indications does AHCA provide 5 0 6 prior authorization or approve coverage? 7 So that goes back to our definition of medical А necessity. 8 9 0 Okay. Would it also be governed by AHCA's 10 drug criteria? And I'll just -- I'll pull that up. So 11 when I say AHCA's drug criteria, I'm referring to that 12 criteria listed at https://AHCA --13 A-H-C-A --.myflorida.com/Medicaid/prescribed drug/drug 14 criteria.shtml. And so would the drug criteria -- I'm looking 15 16 at the screen. It says testosterone criteria updated 17 6-16-2022. Would the indications for which testosterone will be prior authorized -- prior authorized, would it 18 be contained in this criteria? 19 It would be contained in that criteria. 20 Α 21 That's correct. 2.2 Q Okay. Is this list exhaustive of all 23 prescription drugs that AHCA will cover? I think -- I mean, I haven't seen the entire 24 А list, so -- but, I mean, for any drugs that we deem that 25

Page 46 criteria is necessary, I imagine that would be an 1 exhaustive list. 2 Q Okay. This applies in fee-for-service, 3 correct? 4 Α Those would apply for fee-for-service, yes. 5 6 0 How about for managed care? 7 Managed care plans would need to be able to --Α they would -- they would need to mirror their criteria 8 9 and align it with the agency's. 10 So it can't -- my understanding is the managed 0 11 care plan criteria cannot be more restrictive than what 12 AHCA --13 Α That's correct. So they can be less restrictive, they can't be more restrictive. 14 15 0 Okay. Would the drug criteria listed here at the link to testosterone provide all the instances in 16 17 which testosterone would be covered after prior authorization review? 18 On the criteria? 19 Α 20 Uh-huh? Q After --21 Α 2.2 Q Yes. Well, I would -- I'd have to -- I haven't 23 А 24 actually had a chance to physically look at the criteria, so -- but I would assume that what we have the 25

criteria is accurate, especially given that it was
 updated in June 2022.

Q Okay. Turning back to EPSDT briefly. If the drug was being prescribed to a child under age 21, when AHCA or its contractor was undertaking the prior authorization process, could AHCA or that contract -would AHCA or that contractor deviate from this criteria if the drug was otherwise prescribed for a medically necessary use?

10

11

15

A I have trouble following that question.

MR. JAZIL: Object to form.

12 BY MS. DEBRIERE::

13 Q So where testosterone was prescribed to a 14 child under 21.

А

Okay.

Q And EPSDT applies, then could AHCA or its contractor in its prior authorization review deviate from the criteria listed here? If medically necessary.

A As long as it meets medical necessity criteria, whether or not there's criteria involved and it meets -- if it's for an off-label use and it meets our off-label criteria, I mean, under EPSDT, I mean, yes, Florida Medicaid can cover it, but -- I mean, that would, of course, require significantly in-depth review, et cetera, but, I mean, hypothetically speaking, yes.

1	Q And one of the requirements just to circle
2	back one of the requirement under that medical
3	necessity review is that the prescribed drug cannot be
4	for an experimental or investigational use, correct?
5	A That's correct.
6	Q All right. Just turning quickly back to FMMIS
7	programming of the ICD-10 codes, what ICD-10 codes are
8	programmed into the system for estradiol?
9	A What ICD-10 codes?
10	Q Yes.
11	A We would have to check the system. I would
12	because I know pharmacy codes are set up a little
13	differently than our procedure codes. So I'm kind of
14	using the procedure code as analogous to the drug codes,
15	but we would need to speak with one of our pharmacists.
16	MS. DEBRIERE: Can we flag that as a follow-up
17	question, too? I had one more. So if you can
18	we take a break for two minutes? I just want to
19	confer or we can do longer if you need a second
20	to go to the bathroom.
21	THE WITNESS: If you need a break, you can go
22	ahead and take the break. That's fine.
23	MS. DEBRIERE: Thank you. Okay.
24	VIDEOGRAPHER: This concludes video one. The
25	time is 11:05 a.m.

1	(Brief recess.)
2	VIDEOGRAPHER: This is the beginning of video
3	two. The time is 11:08 a.m.
4	BY MS. DEBRIERE::
5	Q All right. So turning back to the preferred
6	drug list, AHCA's preferred drug list, and looking at
7	the formulation of testosterone cypionate did I say
8	that correctly?
9	A I really don't know.
10	Q The PDL indicates that AHCA covers
11	testosterone cypionate for at least one indication,
12	although it doesn't say what indication, correct?
13	A Not on the PDL, no.
14	Q Does it say it anywhere? Is there anywhere we
15	can find that information?
16	A Unless there's that criteria, unless we have a
17	criteria listed on the website, generally, no, that's
18	like one of the things I mean, we do have our claim
19	system set up, which but like all that information
20	is I mean, I suppose it could be obtained through
21	public records request. That's usually the process.
22	Q Okay. So AHCA will never cover testosterone
23	cypionate, or any formulation of testosterone for
24	treatment of gender dysphoria, is that correct?
25	A That's correct.

1	Q So looking at the formulation of testosterone
2	cypionate of testosterone CYP 1000 milligrams per 10
3	milliliters, that indicates there's no clinical prior
4	authorization required, correct?
5	A That's correct.
6	Q So that means that AHCA will cover the drug or
7	reimburse for the drug without determining for what use
8	it's being prescribed?
9	A Well, based on my understanding of how our
10	system works, through my experience is that the claim
11	would deny.
12	Q Because why?
13	A Because the diagnosis code that'd be
14	associated with that drug would trigger the system to do
15	a denial.
16	Q Okay. So you're looking not at the indication
17	of the what indication the drug's being prescribed
18	for, but instead you're looking at the diagnostic code?
19	A So that's correct. Part of the process
20	requires the procedure code, diagnostic code and place
21	of service. Of course, those are for our health
22	services, but those three all have to be programmed into
23	the system. So say you're delivering a doing a
24	checkup in a other setting, or you're doing like a
25	setting that's not approved by us, it's not in our

1 policy, that claim would deny.

Q Okay. What if it wasn't for the treatment of gender dysphoria? What if it was for a diagnostic code that was not programmed to automatically deny?

5 A If it was for -- so if it was for a diagnosis 6 code that was not programmed to deny?

7

Q Right.

A If it's programmed in the system -- we don't -- so we program the codes that it will approve. So all the other codes, it's not loaded in the system would automatically deny. So each -- so there'll be a set of ICD-10 codes that are -- that would link up with a particular service. As long as the diagnostic code corresponds to that service, the claim will pay.

Q Okay. So with the formulation of testosterone cypionate that we've been discussing that no clinical prior authorization is required, if the diagnostic code is programmed into the system, then it's going to automatically approve without looking at the indication for which the drug is prescribed?

A Provide that the claim form is -- it's a clean claim and all the pertinent information corresponds with the physician requirements, they will pay.

24QWhat is involved in a clean claim?25ANo errors.

Page 52 Errors of what? 1 0 2 Α Someone might type in the wrong code by accident. Maybe they -- human error. 3 Okay. But you're -- but in that clean claim, 4 0 there's no requirement to submit the indication for 5 which it's being prescribed or AHCA undertaking a review 6 7 of that? I mean, we do do retrospective review of 8 Α 9 claims. 10 At the time the coverage is being requested. 0 11 Okay. Can we go back a little bit? А 12 Yeah, yeah. Yeah. So looking at this 0 13 formulation of testosterone cypionate, where no clinical prior authorization is required, when the claim is 14 submitted and -- when the claim is submitted, AHCA is 15 not doing a review of whether the indication it's being 16 17 prescribed for -- sorry. Scratch that. 18 Looking at testosterone cypionate, in the formulation that we've been discussing where no clinical 19 20 prior authorization was required, when the claim is submitted, AHCA -- neither AHCA nor its contractors does 21 2.2 a review to determine for what indication the drug is 23 being prescribed for? Right, there'd be no manual clinical review 24 А process or prior authorization process, if that's what 25

1 you're asking.

2	Q And when you said AHCA will only cover drugs
3	that are FDA-approved, does that mean that AHCA never
4	covers off-label use of a drug?
5	A We do have a no, we definitely would
6	never we have a procedure for covering FDA-approved
7	drugs for non-approved clinical indications, AKA
8	off-label use. We do have a procedure for that. So we
9	wouldn't necessarily no, we would never say never.
10	That's
11	Q Okay. I thought you said earlier that AHCA
12	will only cover FDA-approved drugs?
13	A Right. But, I mean, like, let's say there's a
14	drug that okay. Let's say it's been manufactured by
15	European pharmaceutical or, you know, it's a
16	pharmaceutical and it hasn't gone through the FDA review
17	process, brand new drug. It's not FDA-approved. It's
18	really not even approved it's not even approved for
19	sale on the market. We won't cover those.
20	Q Okay. Okay. But you will cover drugs that
21	are FDA-approved for uses that in and of themselves are
22	not FDA-approved, for off-label uses?
23	A Yes, we have a procedure for that.
24	Q Okay. Do you ever program into the system the
25	use of a drug for a condition for which the drug is not

1 FDA-approved?

0

A I can't speak to a hundred percent for that, but it seems it'd be counter to the process we have in place for reviewing off-label use for drugs.

5

Okay. And what is that process?

6 А So, it's a three-prong process. Step one is 7 that there has to be a trial period for FDA-approved drugs for that clinical indication to have tried to have 8 9 been used. And, of course, if the FDA-approved drugs for that kind of indication are not successful, then 10 11 the -- then it moves to the second prong, which, you 12 know, that requires like phase-three clinical trials 13 having had to be completed on that drug. Then the third step is that the peer-review literature and one of the 14 15 three drug compendia that we mentioned earlier has to pass the list or support it. 16

Q So you're looking at when determining whether or not you'll authorize coverage for a prescribed drug, you're looking at more than just whether the indication for which it's being prescribed is listed in the compendia?

A Yes, it's a little bit more comprehensive,correct.

24 Q Yeah. And so first you look at the individual 25 Medicaid recipient and you determine whether or not they

Page 55 tried other drugs? 1 2 Α That's correct, yeah. 3 0 Okay. It would be an individualized basis. 4 Α Okay. And then the second step was what? 5 0 6 А A phase-three -- the drug had to have 7 completed phase three clinical trials. And then the third step is you look to see if 8 Q 9 the indication that's being prescribed for is listed in 10 the compendia plus --11 Plus support in the peer-reviewed literature. А 12 Okay. Let's look back at Exhibit 3. 0 13 MS. DEBRIERE: Simone, do you have that handy? That's the cross-sex hormone therapy GAPMS. 14 15 MS. CHRISS: You should still have those two versions. 16 17 MS. DEBRIERE: I might have it. I have a 18 notice of deposition and I have a cross-sex hormone 19 therapy. Here it is. 20 BY MS. DEBRIERE:: Is there anywhere on this GAPMS that describes 21 Ο the process for the criteria used? 2.2 23 Α It's on page nine, if you're referring to the off-label use. 24 Okay. And that starts with the criteria that 25 Q

utilized under the Florida Medicaid program and 1 2 authorization for drugs for off-label purposes are as follows? 3 А Uh-huh. 4 Okay. And that's what you just described to 5 0 6 me? 7 Α Yes. Okay. All right. Turning to past 8 Q Yeah. 9 GAPMS regarding gender dysphoria. 10 Α Okay. 11 We are aware, plaintiff's counsel is aware of 0 12 three pre-2022, at least draft GAPMS reports regarding 13 Medicaid coverage of the treatment for gender dysphoria. One we've already marked as Exhibit 3, and that is the 14 May 20th, 2022 version of the GAPMS for cross-sex 15 16 hormone therapy. We actually know of two other 17 versions, one dated June 23rd, 2017 and one dated April 19th, 2022. So we're going to mark the June 23rd one as 18 Exhibit 5? 19 20 MS. DUNN: Yes. 21 (Whereupon, Exhibit No. 5 was marked for 2.2 identification.) 23 THE WITNESS: Yeah. I have to apologize for 24 the auto-dating on those documents, so I can probably give you more accurate dates --25

Page 57 BY MS. DEBRIERE:: 1 2 Q Yeah, let's get the documents in front of you, and then that's exactly what we were wondering about. 3 It can get confusing. 4 Α I can give you more --5 That would be -- that's exactly what we're 6 0 7 after. We appreciate that. MR. JAZIL: They're identical except for the 8 9 date, right? 10 MS. DEBRIERE: Yes. Yeah -- well, that's not true. Yeah --11 12 THE WITNESS: Well, I have this one. I mean, 13 it's fine. There's one -- there should be one for surgeries. 14 15 MS. DEBRIERE: No, no. We're just looking at the versions of cross-sex hormone therapy right 16 17 We have three different versions, at least, now. that we've found so far. 18 19 MR. JAZIL: Thank you. 20 BY MS. DEBRIERE:: Okay. So let's first look at the one with the 21 0 2.2 June 23rd date. 23 А Okay. June 23rd, 2017. Who authored the version of 24 Q 25 this report?

So listed in our assignment writing and 1 А 2 tracking page in SharePoint, the author of this was Sarah Craiq. 3 Okay. And do we have that routing form? 4 0 MR. JAZIL: You should. 5 THE WITNESS: They should have it. We -- I did 6 7 produce it for everybody. BY MS. DEBRIERE:: 8 9 Okay. And then that was back in 2017 when she 0 authored this? 10 11 She authored it in 2016. This is actually --Δ 12 so to provide a little context. 13 Q Please. So in 2016, this was before I came to the 14 Α 15 Bureau of Medicaid Policy, there wasn't -- there wasn't a GAPMS position. Because they were accumulating a lot 16 17 of services, a lot of requests for coverage, they 18 created two GAPMS positions in the fall of 2016. They 19 were filled in January 2017. So GAPMS reports often 20 went to subject matter experts. So that's -- so in 2016 when this one was completed, the person who completed 21 22 it, their primary job was not GAPMS. Okay. What was Sarah Craig a subject matter 23 0 24 expert in? She was one of our pharmacists. 25 А

1	Q Okay. And right now, just for clarity of the
2	record, we're looking at June 23rd, 2017. That's
3	labeled Exhibit 6.
4	(Whereupon, Exhibit No. 6 was marked for
5	identification.)
6	BY MS. DEBRIERE::
7	Q Who so saying that, let's move on to the
8	April 19th, 2022, which is labeled as Exhibit 5, who
9	authored this report or made the revisions, I should
10	say, in the April 19th, 2022 version?
11	A The only person I'm aware of who worked on
12	this one was Sarah Craig. Since this was done before my
13	entrance into the Bureau, and she's the only author
14	listed in our system.
15	Q And were any changes made on the April 19th,
16	2022?
17	A No. That may have been a day when it was
18	pulled out to be printed.
19	Q Okay. Why would it have been pulled out to be
20	printed?
21	A I think because there had been some
22	questions about the history of whether the Agency had
23	previously done any work on this subject.
24	Q Okay. And why did those questions arise?
25	A Those questions had arisen as part of the

Page 60 request process for the GAPMS report we did, and that 1 2 was approved on June 2nd. 3 And that's related to the treatment of gender 0 dysphoria? 4 Α That's correct. 5 Okay. Does Sarah Craiq still work at the 6 0 7 Agency? Sarah Craig, I think, left in 2020. 8 А 9 Okay. Do you know where she went? 0 10 Α I do not. 11 Were there any changes -- looking back at 0 12 Exhibit 3, which is dated May 20th, 2022, there are some 13 revisions on this one. А 14 Okay. 15 For example, Beth Kidder is crossed out and 0 Ashley Peterson's name is put in. And the subject line 16 17 is crossed out and there's just some edits and comments. 18 And it looks like some text was added, for example, on 19 page three. 20 I was not privy to any edits or changes being А made after -- I was not privy to any changes being made 21 2.2 to that document. 23 Okay. Well, just to be clear, you're here as 0 24 the Agency representative and not in your individual capacity, so you should have some knowledge about any 25

1	revisions to these reports, based on your designation as
2	the Agency representative. Can you not speak in that
3	capacity to it?
4	A As far as the work goes during the time period
5	that we were working on the June 2nd GAPMS?
6	Q Uh-huh.
7	A That the work for the determination of the
8	transgender dysphoria in relation to consistency with
9	GAPMS, that task was specifically designated to myself,
10	and Nai Chen and Devona Pickle in supporting roles.
11	Q Okay. Right now, though, I'm just asking
12	about revisions made to the May 20th, 2022 version. You
13	do not know who made these revisions, is that correct?
14	A I do not know who made those revisions,
15	because as the Agency witness. Nobody was requiring
16	revisions to that document.
17	Q But there were revisions made based on what
18	I'm looking at.
19	A Whoever did so was doing so on their own
20	accord.
21	Q Okay. Who had access to this document?
22	A Well, given that any actually, anybody has
23	access to that document because the documents it's
24	available on our SharePoint site. It doesn't require a
25	password. Anyone in the bureau, anyone who's

knowledgeable of our repository could go through and 1 2 pull up that document. 3 0 Okay. Could it have been Ashley Peterson who made the revisions? 4 It's possible. We would have to find out from 5 А 6 our IT department. 7 Okay. I think we do need that information. 0 And then who's GS? There's some comments on the side 8 9 there on the front page, Exhibit 3. It says GS 1. 10 А Well, GS would be initials. Would usually 11 like last name first, first name second. I might --12 might occur to me later on. I can't --13 Q Would it be Sheena Grantham? It's possible. I don't know. 14 А 15 0 Okay. Can you track who has access to this 16 document? Α 17 Yeah, our IT department can track whoever had made edits to that. 18 Okay. Okay. So we can find out the answer to 19 0 20 that question? 21 А Yes. 2.2 MS. DEBRIERE: Let's flag that. BY MS. DEBRIERE:: 23 Was this report ever finalized? 24 Q To my knowledge, and I did actually do some 25 А

1	history do historical digging on this one. Since our
2	pharmacy manager at the time, and I do need to add it
3	because I forgot to add, that I did consult Arlene
4	Elliot, who was the pharmacy manager at the time that
5	this report was initially prepared, I did confer with
6	her to determine whether or not it was finalized. And
7	what I mean by finalized, it went through the review
8	process and was signed off by the deputy secretary. She
9	let me know that it had not.
10	Q Okay. Do you know why or why not? Why was it
11	never finalized?
12	A Well, generally, and this is often the case
13	with GAPMS reports, is that because it's well,
14	Medicaid is a it's very busy we're a very busy
15	division. We have lots of requests, lots of asks, lots
16	of projects, and often GAPMS reports, usually, for those
17	of us who like to be very detailed and very analytical,
18	we, you know, it's it's a craft. It's almost like
19	each one is like a seminar paper or scholarly article.
20	It takes time to read and review. And usually it's
21	and sometimes often, because unless somebody's asking
22	for it, or if it's deemed a low priority, often it
23	just it just often waits. And that may have been
24	why. That's speculation, though.
25	Q Okay.

- 25
- 800-726-7007

Page 64 But it's not surprising that a GAPMS draft is 1 А 2 out there and didn't complete the review process. Solely it's because there's just too many other projects 3 4 qoing on. And GAPMS is generally low priority? 5 0 6 Α It depends. 7 What does it depend on? 0 Depends on the situation, because often when 8 Α 9 the managed care plan requests for the GAPMS, that's 10 usually -- those usually have to be addressed quickly. 11 Okay. Let's set expedited GAPMS aside. Just Ο 12 traditional GAPMS, are they generally low priority? 13 А A traditional GAPMS? Well, like I said -like I said, it often depends on the context. 14 Ιt 15 depends on the request. Sometimes it could be -sometimes it's a stakeholder who made their voice known 16 17 downtown. Sometimes -- I mean, it really depends on the 18 context. 19 Okay. When you're referencing downtown, what Q 20 do you mean by that? 21 Α The Capitol. 2.2 Okay. So sometimes GAPMS will get bumped up Q if the Capitol is the person who's raising --23 24 Α It just depends on the situation/I just don't want to commit to an absolute answer saying that they're 25

all low priority, because not every single circumstance 1 2 or every single GAPMS means that it will be. Okay, but with the cross-sex hormone therapy 3 0 GAPMS, you're quessing that one reason why it was never 4 finalized is because it was low priority? 5 That's a guess in relation to my experience 6 А 7 when I had the role. Okay. And what was your experience when you 8 Q 9 had the role? 10 Α When I -- when I had the role, I had it for 11 about 10 months, and I think I drafted ten reports and 12 two of them made through the review process. Those two 13 I reviewed in January. They weren't finalized and signed off on until July of that year. So often, it was 14 15 more trying to -- you know, reminding supervisors at 16 different levels to review them so they can move 17 forward. And given how busy everything was, especially 18 with legislative session going on or other special projects taking precedence, often if it could be done --19 20 put on hold until the next day or later, it was. Okay. And so for the two of the ten reports 21 Ο 2.2 that were finalized, it took seven months for the reports to be finalized, reviewed and finalized? 23 24 Α Yes. Prior to its adoption, prior to AHCA's 25 Q

1	adoption of the categorical exclusion of treatment for
2	gender dysphoria, did Florida Medicaid were there any
3	instances where Florida Medicaid ever authorized
4	coverage for cross-sex hormone therapy to treat gender
5	dysphoria?
6	A Were there any circumstances? The Agency
7	didn't have a policy or criteria regarding cross-sex
8	hormones or, like, hormones for that clinical
9	indication.
10	Q So that wasn't quite my question. My question
11	is prior to the adoption of the categorical exclusion of
12	treatment for gender dysphoria, were there any
13	instances, so
14	A Under so, well
15	Q Did Florida Medicaid ever cover treatment of
16	gender use of did Florida Medicaid ever authorize
17	coverage for cross-sex hormone therapy to treat gender
18	dysphoria?
19	A So by Florida Medicaid, are you referring to
20	the Agency?
21	Q AHCA or any of its contractors, Medicaid
22	managed care plans or EQ Health or
23	A Under fee-for-service, that was no, it was
24	not an approved clinical indication. Obviously, with
25	managed care plans, since they have the flexibility to

Page 67 cover services that, you know, that are not necessarily 1 2 clarified in our coverage policies so -- I mean, it's 3 possible that we could have done that, yes. Okay. So, to be clear, in fee -- under 4 0 fee-for-service, prior to the adoption of the 5 categorical exclusion for the treatment of gender 6 7 dysphoria, there was never an instance of Florida Medicaid covering cross-sex hormone therapies to treat 8 9 qender dysphoria? 10 Α Are you referring to the fee-for-service? 11 Fee-for-service only. Q 12 We don't necessarily have that information Α 13 available. Why? 14 0 15 Α Well, not offhand. 16 0 Why? 17 Well, going -- because we want to go back Α several years. We're assessing an extensive data pull. 18 19 Or even just six months prior to August 21st, Q 20 2022. So I think we did do a data pull for the past 21 А 2.2 year. And that data pull, of course, show the results 23 of what services we were covering, had the number of recipients with the diagnosis for gender dysphoria, and 24 those who received treatment. So I'll defer to that 25

1	data.
2	Q So we don't have that data in front of us.
3	And, again, you were produced as the 30(b)(6)
4	representative, so what did that data show?
5	A That data did show that some that there
6	were a handful of recipients who were receiving the
7	services.
8	Q In fee-for-service?
9	A I think fee-for-service. I think managed
10	care.
11	Q Okay. So there were times, prior to the
12	adoption of the categorical exclusion for the treatment
13	of gender dysphoria, that Florida Medicaid covered
14	cross-sex hormone therapy for treatment of gender
15	dysphoria?
16	A Cumulatively for the whole program, yes, there
17	were.
18	Q Okay. So another previous GAPMS regarding
19	gender dysphoria is the GAPMS entitled puberty
20	suppression therapy, and that begins at DEF_ 000288776.
21	Although, for clarity of the record, I do want to say we
22	received multiple versions of this document, as well.
23	MS. DEBRIERE: Do we have the final one, by any
24	chance? I'm positive it was my mistake in terms of
25	listing exhibits.

Page 69 MS. DUNN: The one that was signed? 1 2 MS. DEBRIERE: Yeah. MS. DUNN: That's a whole different -- it has a 3 different name. 4 MS. DEBRIERE: I'm sorry, guys. That's my 5 6 fault. My fault. 7 MR. JAZIL: Counsel, do you want him to clarify that date issue? I think he mentioned it as you 8 9 were --10 MS. DEBRIERE: Oh, yeah, I thought he did. I'm sorry if -- please, go ahead and clarify the date 11 12 issue. 13 THE WITNESS: So both of these GAPMS were initiated in 2016. 14 BY MS. DEBRIERE:: 15 Okay. When you say both of these GAPMS, 16 0 17 you're referring to --18 Α Referring to the one on the cross-sex hormone 19 therapy. 20 Q Okay. 21 А And the one on the puberty suppression. 2.2 Okay. Let's not talk about the puberty Q suppression one just yet, because I want to get the 23 right exhibit into the record first. 24 25 А Okay, but as far as the date goes, these were

projects from 2016. 1 2 Q Okay. Okay. MR. JAZIL: Counsel, if you'd like me to just 3 make additional copies of that, I'm sure we can. 4 MS. DEBRIERE: So there are multiple versions 5 6 that were provided to us of this document. We are 7 looking for another version that has a signature on it, although I'm sure Mr. Brackett can speak to it 8 9 being finalized. But just to make everyone's life 10 easier in the long run, we are going to try to --11 yeah, this is great. Okay. 12 Chelsea, should we mark it? 13 MS. DUNN: Yeah. Do you want that Exhibit 7? MS. DEBRIERE: Are we on 7? 14 Okay. (Whereupon, Exhibit No. 7 was marked for 15 16 identification.) 17 BY MS. DEBRIERE:: 18 All right. We have only one copy of this, and Q 19 it's DEF 000288776, entitled puberty suppression 20 therapy, dated September 14th, 2016. And the reason we 21 were -- and that's going to be marked as Exhibit 7. The 2.2 reason we wanted that one is because if you turn to the 23 back page, it's signed by Mr. Senior. So we assume then 24 that's the final report? This would be the final report if he signed 25 Α

800-726-7007

Page 71 it. 1 2 Q Okay. So it was adopted by the Agency? The recommendations in this GAPMS were -- yes, 3 Α they would be adopted. 4 Who authored this report? 5 0 So in the --in our system, our SharePoint 6 Α 7 system, that was the individual listed for this report was Monique Johnson. 8 Okay. And who was Ms. Johnson? What was her 9 0 10 subject matter expertise? So she was a program administrator and she 11 Α 12 oversaw the primary care services team, which is 13 primarily like surgeries, inpatient -- inpatient services, dental services. Like, I think like surgical 14 procedures, things like that. Of course, child health 15 checkup procedures. Generally be like primary care and 16 17 preventive, anything that would fall into those 18 categories. 19 Why would she then look at puberty suppression Q 20 therapy? 21 Α So this was, at the time before we had the defined GAPMS individuals, so I can only speculate as to 2.2 23 why she was selected. It may have been she had bandwidth at the time to do it, but since there was no 24 one who actually did GAPMS full time, I don't -- I can't 25

Page 72 speak as to -- because I'm not that familiar with her 1 2 background, I can't -- and, of course, this was 2016, 3 but more or less, there may have been a number of reasons for why she was selected for this. 4 Okay. Why wouldn't it have gone to a 5 0 6 pharmacist? 7 Α We don't have the -- an answer for that. Was Ms. Johnson a pharmacist or pharmacy tech 8 Q 9 or had any --10 Α I think she was an RN. 11 0 Okay. 12 MR. JAZIL: Counsel, just so the record's 13 clear, this copy of Exhibit 7 has highlights on it. Did you --14 MS. DEBRIERE: It would have not been -- it 15 would have been highlighted by us. Is that right? 16 17 Yeah. So my apologies. 18 MS. DUNN: It's the only copy we have, but we 19 can potentially print a clean copy. 20 MS. DEBRIERE: And it's Bates-stamped. 21 MR. JAZIL: It's fine. I just want the record 2.2 to be clear that it's highlighted and the 23 highlights were added by counsel for plaintiffs, not the witness. 24 25 MS. DEBRIERE: Yes. Thank you for that, Mo.

Page 73 BY MS. DEBRIERE:: 1 2 Q Okay. So going back to Exhibit 4, pubertal suppression -- yep. This is the special services 3 This was developed only six days after the 4 criteria. puberty suppression therapy GAPMS report. Is that 5 6 correct? 7 You mean the criteria? А Yes. Yes. Exhibit 4. 8 0 9 Α Based -- I'm going to defer to the dates on 10 this, because it predates my time in the Bureau of 11 Medicaid Policy. So if the dates say 30 days, then that 12 would be --13 Q The dates say six days. The dates say six days? 14 Α 15 0 Yeah. I'll defer to that. 16 А 17 Okay. Are these two documents related? Q Can you provide some context on what related 18 А 19 means? 20 Is one based off another? Q 21 Α It seems -- it would appear that following the 2.2 completion and approval of the GAPMS process, that this document was completed, routed and then approved, based 23 24 on the time stamps. Okay. So was the special services criteria at 25 Q

Page 74 Exhibit 3, was it drafted based on the information 1 2 contained in the GAPMS report related to puberty 3 suppression therapy? MR. JAZIL: Exhibit 4? 4 MS. DEBRIERE: Did I say 3? I'm sorry. 5 6 Exhibit 4. Thank you, Mo. 7 THE WITNESS: It looks like it's fairly consistent. 8 9 MS. DEBRIERE: Okay. 10 THE WITNESS: Based on the EPSDT consideration 11 portion. 12 BY MS. DEBRIERE:: 13 Q So based on your understanding of office operations, then it's likely that the special services 14 15 criteria was drafted in response to the puberty suppression therapy GAPMS? 16 17 Α Yes. 18 Okay. And this is the -- this policy, Exhibit 0 4, is the criteria that AHCA used prior to its adoption 19 20 of the categorical exclusion of treatment for gender dysphoria to determine whether gonadotropin-releasing 21 2.2 hormone analog would be prior authorized for pubertal 23 suppression and treating gender dysphoria, correct? Yes, correct. 24 Α Okay. Between the time this policy was 25 Q

adopted, which was October 6th, 2016, and the time AHCA adopted the categorical exclusion of treatment for gender dysphoria in August of 2022, if an individual's condition met the criteria laid out in this policy, then Florida Medicaid would cover the cost of the drug for pubertal suppression and the treatment of gender dysphoria, is that correct?

8 A Providing that the criteria, and prior to the 9 challenge exclusion, yes.

Q Okay. Between October 6, 2016, and the time AHCA adopted its categorical exclusion of treatment for gender dysphoria, how many times did AHCA authorize the drug set forth in this policy for the treatment of gender dysphoria?

A We would have to defer at least -- at least prior to the challenge exclusion being implemented, we'd have to defer that data for that time period, but we'd have to go all the way back to 2016 as far as the data goes, at least in fee-for-service, to determine how many recipients actually received the -- actually received authorization for it.

Q Do you have any knowledge of any time period in which fee-for-service covered it, based on the criteria in this policy?

25

A So this -- so once this policy -- so once this

Page 76 criteria was released to Magellan, Magellan was our PBM 1 2 for fee-for-service. So they did the prior authorizations for fee-for-service. So Magellan would 3 review each case individually. 4 Okay. Do you know how many times Magellan 5 0 authorized it based on the criteria? 6 7 I do not have those numbers. Α Okay. Can we get those numbers? 8 0 9 Α We can try to find them. We can try to get those numbers. It's a very long time period. 10 11 But it is your understanding that in certain 0 12 instances, Magellan did authorize it? 13 А We would have to -- we would have to look at those numbers. 14 15 Okay. Because previously, when we were 0 discussing cross-sex hormone therapy, you did know that 16 17 in some instances fee-for-service had covered the drug to treat gender dysphoria, but you don't have that same 18 information for pubertal suppression? 19 20 Α That's speaking more about Medicaid, 21 cumulatively as far as the differences between fee-for-service and managed care encounters, I would 2.2 have to take a look at the data to get the exact numbers 23 24 of what was in the fee-for-service system versus the encounters for the managed care were. But we would --25

have we would have to go ahead and get this information 1 2 from Magellan going back to find out exactly how many 3 times that they get pre-authorization requests versus how many approval/how many denials. 4 Okay. Let's just look quickly at exhibit --5 0 6 it's going to take me a second to find it. 7 MS. DEBRIERE: Simone, is the list of Medicaid recipients and discussion of their 8 9 authorizations -- yeah. I don't know. Yeah, 10 that's it. Not surgery, though. There should be a 11 drug one. Maybe I'm wrong. They probably didn't 12 include it. 13 BY MS. DEBRIERE:: Mr. Brackett, while we're looking for that, 14 0 15 let's go back to the notice of deposition. In the deposition topics, we do list the number of Florida 16 17 Medicaid recipients who -- participants who have sought 18 any form of care for gender dysphoria from January 1st, 19 2015 until the enactment of the challenged exclusion. 20 And so as we're sitting here today, you're telling me you can't answer whether -- or how many times AHCA or 21

23 suppression therapy for treatment of gender dysphoria,

24 is that correct?

Α That's correct, as of now, but we can get that

one of its contractors authorized coverage of pubertal

2.2

25

1 information.

2	Q And you will provide us that information?
3	A We will obtain that information.
4	Q Okay.
5	MS. DEBRIERE: So I think that given that there
6	are a few places where we have follow-up questions
7	I do, at this point, just want to say that once
8	those questions are answered, we're going to
9	reserve some time for this deposition so that we
10	can do follow-up questions based on the information
11	that's provided to us, because right now there's
12	some holes that Mr. Brackett is not able to fill,
13	and once that information is provided to us, of
14	course, we will probably have follow-up questions.
15	So we just need to reserve some time for
16	MR. JAZIL: Okay. And just so the record's
17	clear, I think I provided objections to the last
18	set of depo topics. There may have been an
19	objection to this particular topic, going back to
20	2015, but we'll work with you. If we can gather
21	the information, we'll provide it.
22	MS. DEBRIERE: Okay.
23	BY MS. DEBRIERE::
24	Q So looking at the final GAPMS report related
25	to treatment of gender dysphoria, it's entitled gender

1 confirmation surgery.

2	MS. DEBRIERE: Oh, gosh. Do we have it from
3	the past deposition? I'm sorry. We had, like,
4	over 50 exhibits and clearly it's completely my
5	fault not putting them in the list. We can always
6	pull back around to them and print it out at lunch,
7	too. There it is. Okay. We're going to mark this
8	one as Exhibit 8, and it's entitled GAPMS gender
9	confirmation surgery, dated July 19th, 2017.
10	(Whereupon, Exhibit No. 8 was marked for
11	identification.)
12	BY MS. DEBRIERE::
13	Q And this one does have markups on it that are
14	not our markups, they're from the Agency. Who authored
15	this report?
16	A So this report is authored by Rebecca Buceo.
17	Q Okay. When?
18	A This was authored in the summer of 2017.
19	Q How do you know who was authored by?
20	A I was in the bureau at the time and was
21	present when the project was being assigned out.
22	Q Okay. Why weren't you assigned the project?
23	A I was actually being assigned I was working
24	on another project related to designated state health
25	programs and getting approval for those through the

Page 80 Centers for Medicaid -- Medicare and Medicaid Services. 1 2 So I was actually on a kind of a legislative priority 3 project. And so I was not assigned to this one. It's my understanding that there's only one 4 0 hard copy of this report, is that correct? 5 That's correct. 6 Α 7 Okay. Whose office was it found in? 0 So, I -- this report, I did -- it was in a 8 Α 9 binder with -- so this report was found in Rebecca 10 Buceo's old office. So she had an office in the bureau. 11 I know she maintained her GAPMS materials there. 12 Okay. And what else was in that binder? Q 13 Δ I think some of the research articles she 14 used. 15 0 Is that it? 16 That was it. А 17 Okay. Is Rebecca Buceo still with AHCA? Q 18 No, she's not. А When did she leave? 19 Q 20 Α I believe she left in 2019. 21 0 Okay. And what was her subject matter 22 expertise? 23 Α She had a behavioral health background. That was her -- that was her subject matter expertise. 24 Did she have any expertise in surgery? 25 Q

Page 81 Not professionally, no. 1 А 2 Q What about not professionally? In other words, she's never worked as a 3 А surgeon or anything like that. But, I mean -- but I 4 mean -- or in the formal education in that area. 5 Okay. But did she have any experience with 6 0 7 surgery that would help her inform the drafting of this GAPMS? 8 9 А I couldn't speak to that. 10 Did AHCA ever rely on the conclusions in this Q 11 report? 12 Α So this report did not get past her immediate 13 supervisor, so, no. Okay. Prior to its adoption of the 14 0 15 categorical exclusion of treatment for gender dysphoria, 16 did Florida Medicaid ever cover gender confirmation 17 surgery for the treatment of gender dysphoria? Under fee-for-service, to the best of my 18 Α 19 knowledge, we didn't. In managed care, there were a few 20 instances where the managed care plan did approve the 21 procedure. 2.2 MS. DEBRIERE: Okay. Can we look at those 23 exhibits now? The -- I forget what they're called. They're a weird name. ATTB, ATTA. It's a weird 24 It wouldn't come to me. 25 name.

1 BY MS. DEBRIERE::

2	Q Okay. So I'm handing you these were
3	natives, so they were not Bates-stamped, but I'm handing
4	you documents produced to plaintiffs in discovery. They
5	were also not labeled, and I just want to ask you some
6	questions about what they mean. We'll mark that as
7	exhibit actually, I'll take those copies. I'm sorry.
8	Well mark this as Exhibit 9 and 10. And, I'm sorry,
9	because they're natives, they don't have Bates stamps.
10	(Whereupon, Exhibit Nos. 9 - 10 were marked
11	for identification.)
12	BY MS. DEBRIERE::
13	Q So looking at Exhibit 9 first, which is two
14	pages total, front and back.
15	MS. DEBRIERE: Seems like they yeah, it
16	printed out I see. Do I put it together? What
17	do we do?
18	BY MS. DEBRIERE::
19	Q Let's look at under service type, outpatient
20	surgery. Line item status is approve. Does that mean
21	that Florida Medicaid approved outpatient surgery?
22	A Yes, that would mean it was approved.
23	Q Okay. And the product description was
24	mastectomy with a primary diagnosis code of F649?
25	A Uh-huh.

Page 83 So that means that the outpatient surgery was 1 0 2 approved for a mastectomy for a diagnosis code of F649, is that correct? 3 That's correct. 4 А Okay. And F649, what is that diagnosis code? 5 0 6 Α That's gender dysphoria. 7 Do you know if -- can you tell by this 0 document whether -- it appears that it was approved by 8 9 children's medical services under product roll-up. 10 Α So based on these two -- so based on these 11 two, I can't tell if the recipient is in managed care or 12 if they're in fee-for-service. So in Exhibit 10 --13 Q Yeah. -- this looks like this would be managed care. 14 Α 15 0 Okay. And how do you know that? Because it has, like, the member effective 16 А 17 category. Okay. If the title of both of these documents 18 0 had the term CMS on it, would that mean that it's 19 20 managed care? 21 Children's Medical Services is overseen by Α Sunshine Health. So, yes, it's managed care. 2.2 23 And looking at Exhibit 10, the Medicaid ID, 0 24 does that correspond to individual Medicaid recipients? Each Medicaid recipient has a unique Medicaid 25 Α

1 ID assigned to them. That's correct.

2 Q Okay. And these documents are indicating that 3 there were authorizations of surgeries for primary diagnosis codes of F640 and F649, is that correct? 4 Α Yeah, that's correct. 5 Okay. And F640 is a diagnostic code for what? 6 0 7 So F64, generally, there is a decimal point Α after the 4. So it was F64. The way ICD-10 codes work, 8 9 it's kind of like a taxonomy. So F64, categorically, is 10 gender dysphoria. So F64.9 would be like a -- like a 11 subcategory of that general diagnosis. 12 So these documents are showing that, at least 0

in managed care, prior to the categorical exclusion -prior to AHCA's adoption of the categorical exclusion
for the treatment of gender dysphoria, there were times
in which Florida Medicaid covered surgery to treat
gender dysphoria; is that correct?

18

A That would be correct.

19QOkay. Let's turn to the June 2022 GAPMS. We20have this exhibit. And Exhibit 11 will be the June 2nd,212022 GAPMS related to the treatment of gender dysphoria.

(Whereupon, Exhibit No. 11 was marked foridentification.)

24 BY MS. DEBRIERE::

25 Q I'm going to refer to this throughout as the

Page 85 June 2022 GAPMS. 1 2 А That's fine. When was the request to initiate this GAPMS 3 0 made? 4 So the formal request was made on April 20th. 5 А That was the date of the Secretary's letter. 6 7 Were there any informal requests prior to that 0 time? 8 There were some informal, I quess, indicators 9 Α of, you know, trying -- when they were trying to 10 11 determine whether or not we had bandwidth, you know, and 12 so there was some informal indicators that this project 13 would be coming down the pipeline because they were trying to figure out who to do it. So we were aware of 14 15 the Secretary's letter it would be coming to us. Okay. When you say they were trying to figure 16 0 17 out. Who is they? 18 Α Our Agency leadership. And who is that comprised of? 19 Q 20 So that was primarily for the Bureau of А Medicaid Policy, Ann Dalton was our bureau -- is still 21 2.2 our bureau chief at the time. 23 So Ann Dalton had knowledge of the potential 0 24 for this project coming down prior to April 20th, 2022; 25 is that correct?

Page 86 Α 1 Yes. 2 Q Okay. Who else in leadership was aware that this would be coming to AHCA prior to April 20th, 2022? 3 At the time, Secretary Weida was serving as 4 Α Assistant Deputy Secretary. He did have knowledge. 5 Okay. Anybody else? 6 0 7 Α To my --to my knowledge, those two were the ones with the knowledge of this project. 8 9 Q Okay. When did you have knowledge of the project? 10 Just probably a few days before we were given 11 Α 12 the letter. 13 Q Okay. So, like, April 17th? Something around there. Yeah, I don't 14 Α 15 remember the exact date. Okay. Who did you gain the knowledge -- who 16 0 17 did AHCA leadership gain the knowledge from? 18 Α As far as the project goes, the decision to do 19 a GAPMS to my -- so that was to do a GAPMS report, that 20 was determined by our legal as the best route to 21 evaluate the medical necessity for treatments for gender dysphoria. It was that -- it was subjected to the GAPMS 22 23 process. Okay. And which counsel was that? 24 Q 25 А Andrew Sheeran, who's now our General Counsel.

Page 87 Okay. And who contacted -- was Mr. Sheeran 1 0 the first point of contact related to what eventually 2 became the June 2022 GAPMS? 3 No, I don't think he would have been the first 4 Α point of contact. 5 Who would have been the first point of 6 0 7 contact? Generally, our first point of contact would 8 Α 9 have been our General Counsel at the time. 10 And that was? 0 11 Josephina Tamayo. Α 12 Okay. And who contacted Josephina Tamayo 0 13 about this project? So this project, about the GAPMS in 14 А particular --15 16 0 No. 17 -- or about requesting a Medicaid review? Α Requesting a Medicaid review. 18 Q So that, of course, that did come down from 19 Α 20 the Governor's office. 21 Okay. Who in the Governor's office made the 0 22 request? So that is -- so it was a multi-party meeting. 23 Α So the three staffers from the Governor's office that 24 were involved were, I think, Katie Strickland, Ryan 25

Page 88 Newman and Maureen Farino. 1 Okay. What other agencies were involved? 2 Q As far as the decision for Medicaid's review? Α 3 No, as far as that initial request coming from 4 0 the Governor's office. You said there was a multi-party 5 6 meeting. 7 А Well, between AHCA's staff and Governor's office staff. 8 9 0 I see. Okay. What other AHCA staff were 10 present at that meeting besides Ms. Tamayo? 11 I think at that meeting, I think Deputy Α 12 Secretary Weida may have been present, I think the 13 General Counsel, I think, Andrew Sheeran, may have been present as well. 14 15 0 Okay. Anybody else present at that meeting, 16 besides those people that you just named? 17 Α I can't name them with any specificity. Okay. Were they from other agencies other 18 Q than the Governor's office or AHCA? 19 20 Α So in regards specifically to this project? Are there other projects we should be aware 21 0 2.2 of? Well, I -- there were, I think, some people 23 А present from the Department of Health. 24 Regarding what project? 25 Q

Page 89 But that was regarding their review of 1 А 2 treatments for gender dysphoria. Based on actions related to the Board of 3 0 Medicine or based on CMS guidance? 4 Α What do you mean -- when you say CMS, are you 5 referring to Children's Medical Services or --6 7 Centers for Medicare. Great question. 0 No. That guidance was actually not by CMS, it was 8 Α from HHS. 9 10 Excuse me, HHS. 0 11 It was in regard to that guidance. А 12 Okay. So there was some presence of 0 13 Department of Health there, as well, but not related to Medicaid? 14 15 А Right. 16 Okay. And what was the date of that initial 0 17 meeting? I don't have -- know the date offhand. 18 Α Ι think it was like early April. 19 20 Okay. And at that meeting, it had not yet 0 been determined that AHCA would use the GAPMS process to 21 2.2 evaluate whether treatment for gender dysphoria was experimental, is that correct? 23 I think that -- yes, I believe that is 24 Α correct, based on -- based on the information we've 25

gathered, is that the decision is to route it to the 1 2 GAPMS process was done after that conversation. Okay. So what was the Governor's office 3 0 request for the meeting? 4 The Governor's office request was to -- in 5 Α 6 response to the HHS documents, the Department of Justice 7 documents, Department of Education documents regarding gender dysphoria, designing treatments for gender 8 9 dysphoria, the evidence for gender dysphoria, it was 10 that the Department of Health and AHCA both undertake 11 reviews. 12 Did the Governor's office instruct AHCA to 0 13 find -- did the Governor's office instruct AHCA to ensure that Florida Medicaid would not cover treatment 14 15 for gender dysphoria? 16 Α No. 17 Okay. Did the Governor's office make any Q specific requests about Florida Medicaid coverage as it 18 19 related to the treatment of gender dysphoria? 20 Α The Governor's office wanted the Agency to 21 undertake the review. But what type of review did it want the Agency 2.2 Q to undertake? 23 It wanted to take a look at -- a detailed look 24 Α at the available medical evidence, or at least the 25

peer-reviewed literature, and to see what it says. 1 2 Q Okay. You referenced earlier the Florida 3 Department of Health's investigation on the HHS fact sheet. What did that investigation find? 4 Α So the Department of Health's fact sheet, of 5 course, provide some cursory information, like go into 6 7 some snapshots of some literature out there, you know, stating that the evidence for support -- that was 8 9 supporting gender dysphoria treatment was too weak for 10 this to be considered a standard treatment for that 11 condition. 12 Okay. And so at the time of this initial 0 13 meeting in early April, when there was a discussion of DOH's findings, at that point there was a conclusion 14 15 that the information or evidence to support treatment of gender dysphoria was weak? 16 17 MR. JAZIL: Object to form. MS. DEBRIERE: I can strike that. 18 BY MS. DEBRIERE:: 19 20 Why did the Governor's office want AHCA to 0 21 review Medicaid coverage for treatments of gender 2.2 dysphoria? 23 Α So in response to these documents, there were questions about whether or not the evidence supported 24 what HHS, DOJ and DOE was -- at least the United States 25

Page 92 DOJ, United States DOE, the claims they were making. 1 2 They wanted to do a review to see whether or not this --3 the evidence that's supporting was -- actually sufficiently supported those claims. 4 Did the Governor have a specific position on 5 0 whether HHS' findings were accurate, prior to AHCA's 6 7 review? MR. JAZIL: Object to form. 8 9 THE WITNESS: No. 10 BY MS. DEBRIERE:: Did DOH have a position on whether HHS' 11 Q 12 findings were accurate prior to AHCA's review? 13 MR. JAZIL: Object to form. THE WITNESS: Can you rephrase that question? 14 15 BY MS. DEBRIERE:: 16 Yeah. Did DOH -- at that initial meeting, 0 17 what conclusions had DOH drawn about the HHS report? 18 Α So DOH, they didn't -- they didn't release 19 their opinions until April 20th, the day we got the 20 letter. 21 0 Okay. But had they -- at that meeting, had 2.2 they formulated those opinions? 23 Α To my -- based on the information given to me, 24 they had not yet formulated those. So why did AHCA general counsel decide that 25 Q

1 the best process to undertake the review was the GAPMS 2 process?

3 Α Because, well, I'm speaking based on our -- on how policy works is that, of course, the medical 4 necessity definition does have a prong saying that the 5 service has to be consistent with generally accepted 6 7 professional medical standards. So the best way to do a review to either -- to determine whether or not 8 9 something is consistent with GAPMS is to do that, 10 undertake that review process, and that really provides 11 the best opportunity to go through the literature on a 12 large scale and to make a conclusion.

Q Okay. To your knowledge, had there ever been a time previous where a GAPMS was used to determine the experimental nature of services previously covered by Florida Medicaid?

17

A To my knowledge, there was not.

18 Q So this is the first time the GAPMS process 19 was used to determine whether services that were already 20 being covered by Florida Medicaid were experimental?

- 21
- A To my knowledge, yes.

Q The folks at the initial early April meeting, did they reach out to HHS to get the info they relied on before conducting their own review?

25 A Are you talking about the Florida Department

	Page 94
1	of Health folks?
2	Q Or the Governor's office, anyone involved in
3	that meeting.
4	A No, we with the releases, the document
5	releases from those from those federal agencies was
6	sufficient.
7	Q So AHCA did not reach out to HHS either?
8	A No, we had their documents. We didn't we
9	didn't have any need to question them on them.
10	Q In the letter you're referring to from
11	Secretary Marstiller dated April 20th, 2022, is that
12	correct?
13	A Uh-huh.
14	Q That's the letter that directed Tom Wallace,
15	the Director I'm sorry
16	A State Medicaid Director, Deputy Secretary.
17	Q Thank you. That was the letter directing him
18	to undertake GAPMS related to treatment of gender
19	dysphoria, right?
20	A Yes.
21	Q Why did Secretary Marstiller's letter say that
22	she was making the request in response to DOH guidance
23	rather than a request from the Governor?
24	A Because the DOH guidance had just been
25	published.

Γ

Okay. But she was asking Mr. Wallace to 1 0 2 undertake that GAPMS process because it was a request from the Governor's office, correct? 3 A request for the state agencies to look at 4 Α the existing evidence and making recommendations, that 5 initially came from the Governor's office. Since I 6 7 wasn't physically -- since I personally was not present for those meetings, I can't exactly speak to the 8 sequence, but DOH would undertake its review. And, of 9 10 course, once they published their guidance, we undertook 11 ours. 12 Okay. Just to be clear, there's a few times 0 13 that you said to your knowledge, but, again, you're testifying as an Agency representative? 14 15 Α Yes. So this is to the knowledge of the Agency, 16 0 17 correct? Α To the knowledge of the Agency, yes. 18 19 When did AHCA begin work on the 2022 GAPMS? Q 20 What date? 21 А We started work on April 20th. 2.2 You didn't do anything prior to that? Q 23 I mean, I may have done, like, an article Α No. 24 search, just to see what was out there, but as far as any large-scale work goes, no, we didn't do -- we didn't 25

1 do anything like that.

2	Q Okay. And, again, just to be clear, no one at
3	the Agency, because you're in the capacity as an Agency
4	representative. So my question is not just about
5	whether you started anything related to the 2022 GAPMS.
6	A The Agency did not did not start work until
7	April 20th.
8	Q Who worked on the 2022 GAPMS at the Agency?
9	A You mean the June 2022 GAPMS?
10	Q Yes.
11	A So I was primarily the author. It was myself,
12	Devona Pickle prepared the maps of the United State
13	Medicaid programs. Nai Chen prepared the maps for the
14	internet for the European countries to classify who
15	covered what, but that was it. It was the three of us.
16	Q Okay. And I apologize. Can you just one more
17	time run through what everybody's roles were? You were
18	the primary author. Mr. Chen worked on the maps.
19	A Worked on the maps for Western Europe.
20	Q Okay. And what did Dede Pickle do?
21	A The maps for the State Medicaid programs.
22	Q Okay. And as primary author so you wrote
23	everything else except for the maps in the state
24	Medicaid coverage, then?
25	A That's correct.

Okay. And did you have any assistance? 1 0 2 Α It's -- GAPMS are a solitary project, any extensive research project is, because once you immerse 3 yourself in the literature, it's very difficult to have 4 assistance because you're trying to get up to -- you 5 6 have to transplant knowledge from yourself to them. 7 It's actually just easier to do it, to kind of sail the waters on your own. And this is coming from speaking 8 9 from experience on, like, a myriad of research projects, 10 from scholarly articles, master's theses for, like, 11 works -- other works for the Agency, previous GAPMS 12 reports. Once you under -- once you reach a certain 13 understanding of that knowledge, it comes a point where you -- it makes sense -- it's more efficient for you to 14 15 do it in a solitary fashion. Okay. So you were the only one involved in 16 0 17 outlining and reviewing the literature that became the June 2022 GAPMS? 18 19 Α Yes. 20 Okay. Was there anyone else at the Agency --0 so you didn't work with Mr. Chen on the literature or --21 2.2 Α Nai, he did -- he occasionally he'd find an article and give it to me, but other than give me the 23

24 occasional article, that was -- that was it. I went 25 through, reviewed the article, like, broke it down. As

Page 98 far as any content or analysis, he just gave me copies 1 of articles. 2 3 Okay. Okay. And so no one else at the 0 Agency -- did anybody else at the Agency take on that 4 role to where they were sending you articles or anything 5 related to that? I guess what I'm trying to determine 6 7 is whether anyone else assisted you with drafting? Nobody assisted me with the drafting. 8 Α 9 0 Inside or outside the Agency? 10 Α We did have a few consultations with some of our contracted experts --11 12 Were they a verbal consultations? Q 13 А They were verbal. Only verbal? 14 0 15 Α Yeah, but as far as drafting went, they weren't involved in that process. 16 17 Okay. So they didn't write any of the main Q report? 18 19 А They did not write any of the main report. 20 Or outline it or anything? Q 21 Α No. 2.2 Okay. Looking at -- I have another exhibit, Q the Van Mol ATF. We're going to mark this as Exhibit --23 Exhibit 12. What is wrong with me today? And it's 24 entitled Agency for Health Care Administration 25

after-the-fact request form under 35k. 1 2 (Whereupon, Exhibit No. 12 was marked for identification.) 3 BY MS. DEBRIERE:: 4 So, reason for occurrences, where I'm reading 5 0 and second sentence to the last, due to the need to 6 7 start work quickly, all of the purchase order elements were not available until May 6th. Why was there a need 8 9 to start work quickly? 10 Α Since this is -- since we did have a request, 11 and since we were writing in response to the Department 12 of Health, which had already had published their 13 findings, the Agency, of course, we considered this a priority project, and this was mostly that's -- that's 14 15 pretty much, it was a priority project. 16 I'm sorry. Why was it a priority project? 0 17 Α It was priority project because in relation to -- in relation to the Department Health guidelines, 18 which had been released, then, of course, because, you 19 20 know, as the state of Florida wanted to respond to the 21 HHS documents, which had also been released, because we 2.2 didn't want a significant amount of time, like, five or 23 six or seven months to elapse before the Agency had gotten its response out. 24 Okay. So you wanted to make sure that there 25 Q

Page 100 would be a quick response to the HHS guidance? 1 2 Α Yes. Okay. When I say a decision tree checklist 3 Q for GAPMS, do you know what I mean? 4 Α Are you referring to, like, to a checklist? 5 6 0 Yes. 7 Α Yes, I do know what you're referring to. Okay. Did AHCA do a decision tree checklist 8 Q 9 for this report? 10 Α So that decision tree checklist, that was a --11 is an internal process, and each person who does GAPMS 12 often kind of brought their own unique perspective or 13 unique approach to them, since these are research 14 projects and there's not really a formula for it, but I 15 believe -- I think Jeffrey English, I think, helped to 16 develop a checklist, which I think he used when making 17 evaluations. I kind of have my own mental checklist 18 when I did them. And also, actually, I actually wanted 19 to kind of help refine, to help cut down the number of 20 GAPMS requests we had. As we started going through requests, we started realizing, well, some of these 21 really aren't GAPMS, these are just coverage 22 determinations. 23 24 Q What -- How did you know that? Generally -- okay, well, FDA approval for the 25 Α

Case 4:22-cv-00325-RH-MAF Document 120-6 Filed 04/07/23 Page 101 of 346

	Page 101
	clinical indication.
	Q Okay.
	A If a national coverage determination's been
	released by Medicare, things like that.
	Q Okay. What about if it was already listed on
	AHCA's fee schedule?
	A Not necessarily.
	Q Why?
	A Because just because it's listed on AHCA's
	fee schedule, it does not necessarily mean that it's
	wouldn't be experimental or investigational for another
	clinical indication.
	Q So based on the checklist, if it was listed on
	the fee schedule, that one isn't going to determine
	whether or not it should go through GAPMS?
	A It shouldn't, no. And that was when I
	when I did GAPMS, that was not part of my criteria.
	Q After the checklist was developed, how many
	GAPMS did you do?
	A The checklist was developed well after I had
	left that role.
	Q Okay. So but we know you did the June 2022
	GAPMS, so at least one right?
	A Uh-huh.
	Q Okay. After the checklist was developed, for
1	

any other time that AHCA undertook a GAPMS, was a
 checklist completed?

3 Α I think there were some completed checklists that I was able to find in our PDM, but that was after 4 the fact. When I embarked on this one, I was not aware 5 a checklist even existed. Not that I didn't apply kind 6 7 of a mental checklist when I was going through it to check to see if there were certain elements in there 8 9 that would either come to the conclusion that this 10 shouldn't be that way through GAPMS or not.

11

Q What was your mental checklist?

12 FDA approval for a clinical indication, which Α 13 would mean that there was already substantiating research for it, which had been done by federal agency, 14 which would kind of render GAPMS point moot, or a 15 16 national coverage determination by Medicare. And the 17 national coverage determination is pretty much -- it's 18 like a Medicare GAPMS, and it's -- there aren't that many NCD's out there because there's a risk involved in 19 20 getting an NCD, but if -- but Medicare NCD's are backed by substantial amounts of research. So if there's an 21 2.2 NCD out there supporting a treatment and mandating coverage for a specific service, and all the research 23 they do behind it, it kind of also -- it renders doing 24 25 the GAPMS moot.

Page 103 Okay. Any other -- anything else on your 1 0 checklist? 2 3 А No, those were the two items I usually look for. 4 So that's it. And then if they didn't pass 5 0 those two tests, they went to a GAPMS? 6 7 Α Went to a GAPMS. Okay. So -- I'm sorry. I just need to find 8 Q 9 my place in the outline. When was the checklist 10 developed? Remind me. 2017? 11 No, the checklist would have been developing Α 12 in 2019. 13 Q 2019. Okay. During the 2022 -- the start of the 22 -- 2022 GAPMS, you mentioned that you were having 14 15 conversations with the Governor -- or there was an initial meeting with the Governor's office when the 16 17 request was made and DOH was also present? 18 Α Prior to the request being made. 19 After the request was made, was there any Q 20 communication with the Governor's office? 21 А No. 2.2 After the request was made, was there any Q 23 communication with the Department of Health? А 24 No. What about HHS? 25 Q

Page 104 Α No. 1 2 Q And what about Alliance Defending Freedom? No. 3 А Liberty Counsel? 4 0 Α No. 5 6 0 Okay. What consultants were used by AHCA in 7 the development of the GAPMS. So during the development, we have a few 8 Α 9 verbal conversations with Doctors Miriam Grossman and 10 Andre Van Mol. 11 Okay. And what did those conversations 0 12 entail? 13 А Well, Dr. Van Mol, he just offered suggestions for articles and research for us to look at. He did 14 15 provide us with a bibliography for our consideration, as far as -- mostly just leads on research to help save 16 17 time in finding resources. And Dr. Grossman, of course, 18 she provide us with some history of gender dysphoria treatments, and gave us more reviews of some scientific 19 20 techniques. 21 0 How did you get connected with Dr. Van Mol? So Dr. Van Mol, like all of our experts, who 2.2 Α also provide published reports, so the process for those 23 24 was that we did get a name at the very outset of the process, which was Michelle Cretella. And by contacting 25

Page 105 her, she led us to other providers -- or other 1 2 practitioners who had expertise in the fields, and that's how AHCA made contact with these individuals. 3 So Michelle was the only person who connected 4 0 AHCA to the consultants it relied on for the 20 -- June 5 6 2022 GAPMS? 7 А Yeah. Okay. And who Michelle? 8 Q 9 Α Michelle -- Dr. Michelle Cretella? 10 Uh-huh. 0 11 She's a physician. I think she has some А 12 affiliations with, like, a couple of -- I think American 13 College of Pediatrics, I think. I'm not sure what her other affiliations are. 14 15 0 How did you find her? Well, her name was passed on to us from the 16 А 17 Department of Health. 18 Q Okay. What's her relationship with to the Department of Health? 19 20 Α I -- the Agency does not know what her 21 relation to the Department of Health is. 2.2 Q Okay. So you just accepted this 23 recommendation by the Department of Health as the person who would connect you to the consultants you would use 24 to develop the 2022 GAPMS? 25

		Page 106
1	А	Yes.
2	Q	You didn't do any outside research on whether
3	you should	a seek out other consultants?
4	А	Well, we were vouching for our for the
5	consultant	s. I mean and so we did want individuals who
6	had expert	ise in their respective fields of medicine,
7	and who al	so were going to take an evidence-based
8	approach.	
9	Q	Okay. Who at Department of Health recommended
10	Dr. Cretel	la?
11	А	Don't we don't have the name of the
12	individual	- •
13	Q	Because it was sent in an anonymous email?
14	Why don't	you have the name?
15	А	We can get that information for you.
16	Q	So you don't have the name, but the Agency has
17	the name,	correct?
18	А	The Agency might have a name. We need to
19	confirm th	nat.
20	Q	And who at the Agency was this communication
21	sent to?	I mean, how was it communicated?
22	A	To my knowledge, it was verbal. It was a
23	verbal exc	change.
24	Q	Okay. So who at AHCA was part of that
25	conversati	on?

1	A So I think when it came down to, you know,
2	reaching out to experts and determining who the experts
3	we should use were, I think Andrew Sheeran and Jason
4	Weida were involved.
5	Q Okay. So it was either Andrew Sheeran or
6	Jason Weida who received that information from the
7	Department of Health related to Dr. Cretella?
8	A Yes.
9	Q Could it have been anybody else at the Agency?
10	A I don't think so. I mean
11	Q It seems like you have a name in mind.
12	A Well, I mean, there were other senior leaders.
13	The Secretary may have been given the name, or Chief of
14	Staff may have been given the name, so, but
15	Q Who was the chief of staff?
16	A Cody Farrell.
17	Q And who was the person who spoke with Dr.
18	Cretella about her recommendations?
19	A I think I think Andrew Sheeran and Jason
20	spoke about that spoke to them about the
21	recommendations.
22	Q And she recommended everyone, is that correct?
23	A Well, she from what I gathered, there was,
24	like, recommendations. She gave some names. And not
25	everyone she recommended, of course, we decided to go

	Page 108
1	with. So there were some that we did turn down.
2	Q Who did you turn down?
3	A We can get that we can get that we can
4	get those names for you.
5	Q With Dr. Cretella, was there any consideration
6	given to the associations, the medical associations of
7	which she was a member?
8	A No.
9	Q Okay. So you didn't look to see if she was
10	associated with any particular medical association?
11	A No.
12	Q You just went off the recommendation of
13	Department of Health?
14	A Yes.
15	Q Was Dr. Cretella paid for her assistance
16	with to AHCA?
17	A No.
18	Q So DOH didn't pay her or anything?
19	A Well, I don't know at DOH, that's a question
20	for the Department of Health. AHCA did not we did
21	not establish a financial arrangement with her.
22	Q Okay. Are you are you personally aware of
23	any financial arrangement between Dr. Cretella and
24	Department of Health?
25	A No.

Page 109 Okay. I'm sorry. Who did you turn down? 1 0 2 Α We would have to get those for you. Okay. And so Dr. Grossman and Dr. Van Mol 3 0 just gave you some article leads, and that's all? 4 Gave some article leads, some background 5 Α 6 information. Yeah, it was -- I mean, as far as 7 providing us with content to include in the report, they did not. 8 9 0 Why not? 10 Α Because it was an independent assessment by the Agency. 11 12 0 Okay. Did -- but they didn't write any of the 13 reports that were in the attachments to the June 2022 GAPMS either? 14 15 А Right? 16 0 Why not? 17 I think because we had experts. We already Α had a psych -- one psychologist who was writing one. We 18 already had -- we, of course, we had physicians for, 19 20 like, plastic surgery. We had a bioethicist, as well. Since those bases were covered, we felt they would best 21 22 benefit us by helping provide guide -- guidance with 23 research. 24 Q Were they ever given the option of writing a 25 report for one of the attachments?

Page 110 No, we didn't ask them to write a report. 1 Α 2 Q Okay. Did they ask if they could write a report? 3 No, they did not. 4 А How did you identify Dr. Romina 5 0 Brignardello-Petersen? 6 7 Α So through the contacts we were making, her name was passed on to us as someone at McMaster 8 9 University who had some experience in doing evidence 10 evaluation. 11 Did Dr. Cretella pass on that name? 0 12 As far as the actual contact that gave us that Α 13 name? Uh-huh. 14 0 Dr. Cretella was kind of the head of the tree 15 Α of the contacts. We would have to go back and get that 16 17 information on who gave us the exact name for Dr. 18 Brignardello-Petersen. Okay. But Dr. Cretella was the one who -- so 19 Q what -- if Dr. Cretella didn't recommend Dr. 20 Brignardello-Petersen, who would have? 21 2.2 Α We would have to get that information for you. Would it have been another physician? 23 0 Yes, it likely -- yes, it would have probably 24 А been another physician. 25

What other physicians provided recommendations 1 0 2 for consultants? 3 Α We would have to get that information. What all physicians did you talk to you prior 4 0 to -- or in the process of drafting the --5 6 А So in the process of drafting the report, we 7 really -- we talked to Doctors Grossman, Van Mol. There were a couple conference calls with the experts who 8 9 provided the reports, but those weren't about our 10 report, that was just mostly more -- that was talking to 11 them about them doing their reports. 12 Okay. So who recommended Dr. Cantor? 0 13 Α We -- that may have been Dr. Cretella who had recommended him. We would need to confirm that. 14 15 0 Okay. So, again, just pointing to topic 24 in the notice of deposition, we asked for an Agency 16 17 representative who was knowledgeable as to --18 MS. DEBRIERE: No, no. I just don't know what -- I have no idea where it is. 19 20 BY MS. DEBRIERE:: 21 So looking at topic 24, and we asked very Ο 2.2 specifically about the identification of Dr. 23 Brignardello-Petersen, Dr. Cantor, Dr. Van Meter, Dr. 24 Lappert, Dr. Donovan, in the inclusion of the written 25 assessment. So I don't know what to say. I mean, it

seems like you're not able to answer the question. 1 2 MR. JAZIL: So, counsel, the topic says the process by which AHCA prepared the memo, and I read 3 that to mean the process by which we identify these 4 experts. And so he's detailed the process. 5 It was 6 an initial consultation with one physician, and 7 then it was -- one person recommends another, recommends another. And I think he said that a lot 8 of these were oral. To the extent that we have any 9 10 written records of who specifically said, hire Dr. Romina Brignardello-Petersen, we'll supplement the 11 12 production with that. 13 MS. DEBRIERE: Other than written records, Mo, can you get us -- can you just do an investigation 14 15 of who spoke with these individuals and collected this? 16 17 MR. JAZIL: So who -- so I think he's answered that, it was General Counsel's Office, and it's now 18 19 Secretary Weida, who spoke to these individuals. 20 If the question is who specifically recommended 21 each expert --2.2 MS. DEBRIERE: Yes. 23 MR. JAZIL: -- I'll ask. And if there's a written record, it would have been turned over to 24 25 you already. If there's an oral record, beyond

Page 113 what he's talked about, well --1 2 MS. DEBRIERE: If someone knows. Because if someone knows at the Agency --3 MR. JAZIL: -- you know, Bob talked to Jill, 4 Jill talked to Jane, Jane talked to Jason and said, 5 6 hey, hire Brignardello-Petersen, I'll get that 7 information for you. MS. DEBRIERE: Thank you. 8 9 BY MS. DEBRIERE:: 10 Whose decision was it to engage with Dr. Van 0 11 I'm sorry. Who recommended Dr. Van Meter? Meter? Ι 12 apologize. 13 Δ That's information we would have to --So you don't know who recommended any of these 14 Ο 15 individuals other than Dr. Cretella? 16 Α Right. 17 Okay. When did AHCA first become aware of the Q 18 HHS fact sheet on gender-affirming care in young people? We became aware of it, since we do follow HHS 19 Α 20 publications, much of our staff in Medicaid, so forth, 21 they are actually on -- they receive automatic updates, so we became aware of them as they came out. 2.2 23 What was AHCA's independent reaction to the 0 fact sheet? 24 Well, as the Agency initially didn't -- didn't 25 А

have a reaction. There was -- we didn't -- we don't 1 2 react publicly to HHS documents. 3 Okay. So did AHCA -- you stated in your 0 declaration filed with the court on January 23rd -- are 4 you aware of what I'm talking about? I can get you a 5 6 copy, if not. 7 А I should be aware of it. I've reviewed it. Okay. That litigation was highly likely 8 Q 9 because in drafting the GAPMS report, the GAPMS 10 determination might conflict with federal standards. Do 11 you remember saying that? 12 Α Yeah. If I -- yeah, I mean, it's written and 13 signed off on, then, yes. Okay. With what federal standards, did you 14 0 15 think it might conflict? Well, it might -- it would probably conflict 16 А 17 with that guidance that was released from HHS. 18 Any other federal standards? Q 19 Α No. 20 Why did you think it would conflict with the 0 21 quidance from HHS? 2.2 Α Because the guidance from HHS, the conclusions we made -- that we made following an independent 23 assessment, conflicted with the HHS guidance. 24 The HHS 25 quidance did state that these were, like, medically

1	no so so the transforment of the transformed supportions them so
1	necessary treatments, that evidence supporting them, so
2	that they would alleviate mental health systems
3	symptoms, et cetera. Our concluded our conclusions
4	and our assessment of literature deemed otherwise, so we
5	knew that there would be a potential conflict.
6	Q At what point did you realize that there would
7	be a potential conflict?
8	A When we during the drafting process. So we
9	realized that the evidence was inadequate to support the
10	claims that HHS was making, or that that's when we
11	realized that there would be there would be a
12	conflict.
13	Q Okay. Did you anticipate that the GAPMS
14	report would conclude that the relevant services were
15	experimental?
16	A When I started working on it, I did not know
17	where the evidence would take me.
18	Q At what point did you realize that you were
19	going to conclude that the services were experimental?
20	A As the more and more I read the articles
21	that focused on the mental health benefits, the methods
22	and so forth, the more I realized that all those
23	articles left way too many unanswered questions.
24	This there was also there wasn't any evidence
25	available to answer those outstanding questions. I

1 realized that I couldn't -- that there was not going to 2 be -- that the conclusion was going to be, no, it was 3 not consistent.

Q Okay. So your analysis of those services. So I think one of your concerns related to the treatment of services for gender dysphoria that is now excluded under 59-G-1.050(7), was that the services were not supported by randomized controlled trials, is that correct?

9

А

That was one element of many elements.

10 Q Okay. Does AHCA ever require that -- does 11 every -- does AHCA require that every treatment or 12 procedure it covers be supported by randomized 13 controlled trials?

So to contextualize that question, every 14 А 15 medical service is unique. So we don't apply a uniform set of standards to every single medical service, 16 17 because every single medical service is for a specific condition, every medical service carries its own pros 18 and cons, risks versus benefits. So we don't 19 20 necessarily -- we don't have a one-size-fits-all model for evaluating each and every medical service. 21

Q You mentioned unanswered questions as you were reviewing the literature for treatment of gender dysphoria, or the services you were analyzing. What were those?

So those are iterated in the GAPMS report, but 1 А 2 generally like -- well, number one, long-term. And other unanswered questions, like a lot of these studies 3 were based on anonymous surveys. How are we supposed to 4 know whether or not these responses are credible, if we 5 6 don't have any longitudinal history of these 7 individuals? I mean, one of the things that we came up with when we were doing the literature review is the 8 9 etiology. There are lots of potential causes and 10 associations with gender dysphoria, not -- not including 11 but not limited to autism, trauma, neglect, abuse, 12 abandonment, things like that. So because there was so 13 many unanswered questions, I mean, how are we supposed 14 to know whether or not a one-time survey is going to 15 accurately capture all of that, especially if it's done -- being taken by anonymous people, or if the 16 17 survey -- or for those that weren't anonymous, the sample sizes were very, very small. So and, of course, 18 19 you're talking about one- or two-year periods. These --20 the changes prompted by these treatments are permanent. Did you adopt any of the conclusions about 21 0 treatment for gender dysphoria relied upon by the 2.2 23 American Academy of Child and Adolescent Psychiatry? The American College of -- can you repeat 24 Α 25 that?

Page 118 American Academy of Child and Adolescent 1 0 2 Psychiatry. I think it's AACAP. 3 Α No, I don't recall we -- us using their recommendations. 4 What about the American Academy of Family 5 0 Physicians? 6 7 А No, we didn't use theirs. What about the American Academy of Pediatrics? 8 Q 9 Α We did do an evaluation of theirs. 10 Did you rely on them, their conclusions? Q 11 So what do you mean by --А 12 Did you -- did you lend credence to their 0 13 conclusions? А Yeah, yeah. It was -- their conclusions 14 15 required thoughtful analysis and probing of the 16 evidence. We do take the recommendations of clinical 17 organizations very seriously, but we also do reserve the right to question those recommendations and we did 18 19 review those and we did analyze them. 20 And after you reviewed and analyzed them, did 0 21 you adopt them? No, we found that they were based on very weak 2.2 Α evidence. 23 Okay. What about the American College of 24 Q Obstetricians and Gynecologists? 25

1	A No. I mean I mean, there we didn't
2	so, aside from AAP, we did notice, like most of the
3	recommendations, guidelines, were very, very similar,
4	very straightforward, and they usually are based on
5	Endocrine Society and WPATH guidelines.
6	Q And did you adopt the recommendations from the
7	Endocrine Society and the Pediatric Endocrine Society?
8	A No, we did not. We did review those in close
9	detail, though, and analyze them.
10	Q What about I'm sorry. The other WPATH?
11	A Yes. So the World Professional Association
12	for Transgender Health, we did closely review their
13	guidelines. We did we did analyze them. And, of
14	course, we do discuss them in lengthy detail in multiple
15	areas of the GAPMS report.
16	Q And ultimately you disagreed with their
17	standards?
18	A Ultimately, yes.
19	Q What about the American Psychiatric
20	Association?
21	A I think we actually didn't make reference to
22	them in the GAPMS report.
23	Q Did you adopt their conclusions related to the
24	treatment of gender dysphoria?
25	A No, we did not.

Page 120 What about the American Psychological 1 0 Association? 2 No, we did not. 3 Α American Medical Association? 4 0 Α We did not. 5 When you say we, you mean --6 0 7 А The Agency. VIDEOGRAPHER: Excuse me, counsel. Sometime 8 9 soon, I need to take a short --10 MS. DEBRIERE: Oh, yes. VIDEOGRAPHER: -- to start the next video. 11 Do 12 you want to take a break? We could take a -- do 13 you want to take a 30-minute lunch break or --14 THE WITNESS: I'm good with that, yeah. VIDEOGRAPHER: Okay. This concludes video two. 15 16 The time is 12:42 p.m. 17 (Whereupon, the deposition resumes in Volume 2.) 18 19 20 21 2.2 23 24 25

Page 121 CERTIFICATE OF OATH 1 2 3 4 STATE OF FLORIDA) 5 COUNTY OF LEON) 6 7 8 I, the undersigned authority, certify that the 9 above-named witness personally appeared before me and 10 11 was duly sworn. 12 WITNESS my hand and official seal this 21st 13 day of February, 2023. 14 15 16 17 Jana W. Veenes 18 19 20 DANA W. REEVES NOTARY PUBLIC 21 COMMISSION #GG970595 EXPIRES MARCH 22, 2024 22 23 24 25

1	CERTIFICATE OF REPORTER
2	STATE OF FLORIDA)
	COUNTY OF LEON)
3	
4	I, DANA W. REEVES, Professional Court
5	Reporter, certify that the foregoing proceedings were
6	taken before me at the time and place therein
7	designated; that my shorthand notes were thereafter
8	translated under my supervision; and the foregoing
9	pages, numbered 5 through 120, are a true and correct
10	record of the aforesaid proceedings.
11	I further certify that I am not a relative,
12	employee, attorney or counsel of any of the parties, nor
13	am I a relative or employee of any of the parties'
14	attorney or counsel connected with the action, nor am I
15	financially interested in the action.
16	DATED this 21st day of February, 2023.
17	
18	
19	Jama W. Veenes
20	·
21	DANA W. REEVES
	NOTARY PUBLIC
22	COMMISSION #GG970595
	EXPIRES MARCH 22, 2024
23	
24	
25	

1	Gary V. Perko, Esq. gperko@holtzmanvogel.com
2	
3	February 21, 2023
4	
5	RE: August Dekker, et al. vs. Jason Weida, et al.
6	February 8, 2023/Matthew Brackett/5696545
7	
	The above-referenced transcript is available for review.
8	The witness should read the testimony to verify its
	accuracy. If there are any changes, the witness should
9	note those with the reason on the attached Errata Sheet.
	The witness should, please, date and sign the Errata
10	Sheet and email to the deposing attorney as well as to
	Veritext at Transcripts-fl@veritext.com and copies will
11	be emailed to all ordering parties. It is suggested
	that the completed errata be returned 30 days from
12	receipt of testimony, as considered reasonable under
	Federal rules*, however, there is no Florida statute to
13	this regard. If the witness fail(s) to do so, the
	transcript may be used as if signed.
14	
15	Yours,
16	Veritext Legal Solutions
17	*Federal Civil Procedure Rule 30(e)/Florida Civil
	Procedure Rule 1.310(e).
18	
19	
20	
21	
22	
23	
24	
25	

Case 4:22-cv-00325-RH-MAF Document 120-6 Filed 04/07/23 Page 124 of 346

Page 124
August Dekker, et al. vs. Jason Weida, et al.
February 8, 2023/Matthew Brackett
ERRATA SHEET
PAGE LINE CHANGE
REASON
PAGE LINE CHANGE
REASON
PAGE LINE CHANGE
REASON
PAGE LINE CHANGE
REASON
PAGE LINE CHANGE
REASON
Under penalties of perjury, I declare that I have read
the foregoing document and that the facts stated in it
are true.
Matthew Brackett DATE

[& - 3900]

Page 125

&	11:05 48:25	14:19 56:17	21st 67:19
& 2:19	11:08 49:3	57:24 58:9,19	121:13 122:16
0	12 3:14 98:24	59:2 79:9,18	22 19:9 103:14
	99:2	103:10	121:21 122:22
0.025 42:6	120 2:12 122:9	2019 80:20	23 3:11
000126105 19:6	1229 2:7	103:12,13	23rd 56:17,18
000126112	124 1:11	2020 60:8	57:22,24 59:2
20:20	12:42 120:16	2021 14:19,20	114:4
000145170 3:10	12th 2:7	14:20,22	24 45:1 111:15
000288776 3:12	14th 70:20	2022 3:11,14	111:21
68:20 70:19	1512 2:14	19:11 47:2	2727 1:17 4:7
00325 1:3 4:6	16 3:9	56:12,15,18	27514 2:15
1	17th 86:13	59:8,10,16	29229 121:18
1 1:11,11 3:9	19 3:11	60:12 61:12	122:19
5:24 6:1 8:22	19th 2:12 12:10	67:20 75:3	2nd 60:2 61:5
62:9	56:18 59:8,10	84:19,21 85:1	84:20
1.010. 15:3	59:15 79:9	85:24 86:3 87:3	3
1.035. 6:12	1st 77:18	94:11 95:19	3 3:10 19:21
1.050 7:2 116:7	2	96:5,8,9 97:18	20:11 55:12
1.310 123:17	2 3:9,14 15:13	101:22 103:13	56:14 60:12
10 3:13 20:25	15:14 120:18	103:14 105:6,25	62:9 74:1,5
37:25 44:3,9	2.83 15:1	109:13	30 8:19,22 9:4
48:7,7,9 50:2	2.83 15:18	2023 1:14 4:8	68:3 73:11
51:12 65:11		121:14 122:16	
82:8,10 83:12	20 105:5 2003 11:12	123:3,6 124:2	120:13 123:11
83:23 84:8		2024 121:21	123:17
100 3:14	2005 11:14 2015 77:19	122:22	3100 2:9
1000 50:2		20th 19:11	32 3:10
10005 2:13	78:20	56:15 60:12	32205 2:4
10:00 1:15	2016 30:14	61:12 85:5,24	32301 2:20
10:08 4:9	58:11,14,18,20	86:3 92:19	32308 1:17 32601 2:7
10.00 4.9 11 3:14 84:20,22	69:14 70:1,20 72:2 75:1 10 18	94:11 95:21	32601 2:7
110 2:14	72:2 75:1,10,18	96:7	33131 2:10
110 2:14 119 2:20	2017 3:11 13:24	21 3:10 47:4,14	35k 3:15 99:1
	13:25 14:10,11	123:3	3900 2:4
	14:11,14,15,18		

Veritext Legal Solutions

[4 - affirming]

4	80 3:12	accident 52:3	addressed 29:9
4 3:10 30:24	83 3:13,13	accord 61:20	30:2 64:10
31:1 33:6 73:2,8	85 3:14	accumulating	addressing
74:4,6,19 84:8	8th 4:8	58:16	28:24
4:22 1:3 4:6	9	accuracy 123:8	administered
5	9 3:13 82:8,10	accurate 21:2	10:15 38:23
	82:13	47:1 56:25 92:6	administration
5 3:4,11 56:19		92:12	1:16 4:4 8:19
56:21 59:8	a	accurately	12:20 98:25
122:9	a.m. 1:15 4:9	117:15	administration's
5.2 27:13	48:25 49:3	acetate 28:10	13:1
50 79:4	aa 11:11	acronym 6:9,11	administrative
500 2:20	aacap 118:2	act 35:17,21	6:12 7:1 15:2
5696545 123:6	aap 119:2	acting 9:10	administrator
57 3:11	abandonment	action 122:14	13:9 14:12
59 6:12 7:2 15:3	117:12	122:15	71:11
116:7	ability 32:20	actions 89:3	adolescent
6	37:9	actual 110:12	117:23 118:1
6 3:11 8:19,22	able 18:2 36:8	actually 12:7,9	adopt 117:21
9:4 59:3,4 68:3	46:7 78:12	12:12 13:14	118:21 119:6,23
75:10	102:4 112:1	24:9 27:9 34:10	adopted 71:2,4
6-16-2022 45:17	above 121:10	39:20,22 40:4,4	75:1,2,11
60 3:11	123:7	46:24 56:16	adoption 65:25
600 2:9	absolute 64:25	58:11 61:22	66:1,11 67:5
6th 75:1 99:8	absolutely	62:25 71:25	68:12 74:19
7	31:15	75:20,20 79:23	81:14 84:14
	abuse 117:11	80:2 82:7 89:8	adults 22:22
7 3:9,12 7:2	academy 117:23	92:3 97:7	advance 36:12
70:13,14,15,21	118:1,5,8	100:18,18	36:16
72:13 116:7	accepted 6:10	113:21 119:21	affair 43:19
71 3:12	14:1 17:23 93:6	add 63:2,3	affect 12:16
8	105:22	added 60:18	affiliations
8 1:14 3:12 79:8	access 34:18,18	72:23	105:12,14
79:10 123:6	61:21,23 62:15	additional 70:4	affirming
124:2			113:18

[aforesaid - approach]

aforesaid	30:18 31:12,20	aka 53:7	ann 85:21,23
122:10	32:3,8 35:25	al 1:5,8 4:5,5	anonymous
age 37:12,13,13	36:9 39:24	123:5,5 124:1,1	106:13 117:4,16
37:13 47:4	41:14,19,22	align 43:3 46:9	117:17
agencies 12:11	42:18 44:13,20	alignment 17:14	answer 7:16 8:3
40:17 88:2,18	45:5,12,23	17:15	8:9 21:18 28:22
94:5 95:4	46:12 47:5,6,7	alleviate 115:2	62:19 64:25
agency 1:16 4:3	47:16 49:10,22	alliance 104:2	72:7 77:21
8:18 9:2,11,18	50:6 52:6,15,21	allow 18:18,19	112:1 115:25
12:20,25 13:2,7	52:21 53:2,3,11	allows 33:11	answered 78:8
13:8,20 14:4	66:21 74:19	american 35:13	112:17
17:24 21:17	75:1,11,12	105:12 117:23	answers 7:25
22:14 24:24	77:21 80:17	117:24 118:1,5	antagonists
32:19 34:6 37:9	81:10 86:3,17	118:8,24 119:19	29:23 30:4,19
40:16 59:22	88:9,19 89:21	120:1,4	anticipate
60:7,24 61:2,15	90:10,12,13	amount 23:9	115:13
66:6,20 71:2	91:20 92:25	35:5 99:22	anybody 21:17
79:14 85:18	94:7 95:19	amounts 102:21	61:22 86:6
90:20,22 95:14	100:8 102:1	analog 74:22	88:15 98:4
95:16,18 96:3,3	104:6 105:3,5	analogous 48:14	107:9
96:6,8 97:11,20	106:24 108:16	analysis 98:1	apologies 72:17
98:4,4,9,25	108:20 112:3	116:4 118:15	apologize 56:23
99:13,23 102:14	113:17 114:3	analyst 13:23	96:16 113:12
105:20 106:16	116:10,11	analytical 63:17	appear 73:21
106:18,20 107:9	ahca's 17:8	analyze 17:16	appearances 2:1
109:11 111:16	18:24 36:25	118:19 119:9,13	appeared
113:3,25 120:7	45:9,11 49:6	analyzed 118:20	121:10
agency's 46:9	65:25 84:14	analyzing	appears 83:8
agent 43:12	88:7 92:6,12	116:24	applies 28:22
ago 11:5 22:12	101:6,9 113:23	andre 104:10	46:3 47:16
agree 6:21	ahca.myflorida	andrew 9:24	apply 40:2 46:5
ahca 13:1 15:24	36:22	44:25 86:25	102:6 116:15
17:6,6 18:5,7	ahead 5:23	88:13 107:3,5	appreciate 57:7
25:6,11,11	15:12 48:22	107:19	approach
26:20 28:1	69:11 77:1		100:13 106:8

[appropriate - autism]

appropriate	arrangement	associated 6:20	71:5 79:14,16
35:7	108:21,23	38:13 42:6 44:9	79:18,19
approval 24:7	article 63:19	50:14 108:10	authority 121:9
31:10,16 73:22	95:23 97:23,24	association	authorization
77:4 79:25	97:25 109:4,5	108:10 119:11	16:12,17 17:2,3
100:25 102:12	articles 11:19	119:20 120:2,4	21:7,12,15,22
approve 45:6	80:13 97:10	associations	21:25 23:13,23
51:9,19 81:20	98:2,5 104:14	108:6,6 117:10	24:2,11,17,19
82:20	115:20,23	assume 22:24	24:21 25:4,6,11
approved 24:2,3	articulating 8:4	38:25 46:25	26:1 30:15
24:5,6,10,13,14	arts 11:12,13	70:23	31:23 32:3
24:15,18 27:4	ashley 60:16	assumption	35:24 36:4,5,8
31:14,17,18	62:3	22:24	36:10,15 38:5
32:4 35:10 37:5	aside 64:11	assurance 14:8	38:19 40:10,14
41:2 42:23	119:2	26:15	42:12,16 45:2,6
44:19 50:25	asked 10:12	atf 98:23	46:18 47:6,17
53:3,6,7,12,17	30:7 111:16,21	atta 81:24	50:4 51:17
53:18,18,21,22	asking 18:20,21	attached 123:9	52:14,20,25
54:1,7,9 60:2	53:1 61:11	attachments	56:2 75:21 77:3
66:24 73:23	63:21 95:1	109:13,25	authorizations
82:21,22 83:2,8	asks 63:15	attb 81:24	16:21 21:11
april 3:11 14:19	assembled 27:7	attempt 7:16	76:3 77:9 84:3
14:20,22 56:17	assessing 67:18	attempting 12:5	authorize 24:12
59:8,10,15 85:5	assessment	attorney 33:4	40:24 41:8,23
85:24 86:3,13	109:10 111:25	122:12,14	54:18 66:16
89:19 91:13	114:24 115:4	123:10	75:12 76:12
92:19 93:22	assigned 6:19	audit 34:11	authorized 16:6
94:11 95:21	79:21,22,23	august 1:5 4:5	38:6,8,9 45:18
96:7	80:3 84:1	67:19 75:3	45:18 66:3
area 81:5	assignment 58:1	123:5 124:1	74:22 76:6
areas 9:15 18:14	assistance 26:13	author 58:2	77:22
119:15	97:1,5 108:15	59:13 96:11,18	authorizing
arisen 59:25	assistant 86:5	96:22	16:23
arlene 63:3	assisted 98:7,8	authored 57:24	autism 117:11
		58:10,11 59:9	

[auto - busy]

auto 56:24	79:6 82:14	behalf 4:24 9:1	70:8 77:14
automatic 38:9	110:16	behavioral	78:12 123:6
38:15 113:21	backed 102:20	13:10,12 80:23	124:2,23
automatically	background	believe 10:24	branch 40:18
37:19 38:14,16	11:9 72:2 80:23	21:9,14 35:4	brand 28:8
43:9 51:4,11,19	109:5	38:10 40:5	53:17
available 34:21	bacteria 12:15	80:20 89:24	break 8:8,10
37:11 61:24	bandwidth	100:15	48:18,21,22
67:13 90:25	71:24 85:11	benefit 26:24	120:12,13
99:8 115:25	barantorchinsky	40:7,8,9,22	brickell 2:9
123:7	2:19	109:22	brief 49:1
avenue 2:7,9	based 13:13	benefits 115:21	briefly 21:20
avenues 26:19	43:17,17 44:15	116:19	47:3
aware 33:19	45:3 50:9 61:1	best 81:18 86:20	brignardello
34:25 35:1	61:17 73:9,20	93:1,7,11	110:6,18,21
56:11,11 59:11	73:23 74:1,10	109:21	111:23 112:11
85:14 86:2	74:13 75:23	beth 60:15	113:6
88:21 102:5	76:6 78:10	better 8:3	broke 97:25
108:22 113:17	83:10,10 89:3,4	beyond 112:25	brought 5:24
113:19,22 114:5	89:25,25 92:23	bibliography	10:7 100:12
114:7	93:3 101:13	104:15	broward 34:9
b	106:7 117:4	billing 26:3	buceo 79:16
b 8:19,22 9:4	118:22 119:4	binder 80:9,12	80:17
68:3	bases 109:21	bioethicist	buceo's 80:10
bachelor 11:12	basically 15:10	109:20	build 38:1
back 24:9 31:9	basis 18:23 19:2	birth 6:19	bumped 64:22
32:8 33:6,25	31:21,22 55:4	bit 6:9 10:4 11:8	bureau 14:9,13
34:6,11 42:2,2	bates 5:19 19:6	22:25 52:11	14:16 26:12
43:4 45:7 47:3	72:20 82:3,9	54:22	32:15 58:15
48:2,6 49:5	bathroom 48:20	board 89:3	59:13 61:25
52:11 55:12	becoming 12:12	bob 113:4	73:10 79:20
58:9 60:11	14:12	bottom 5:19	80:10 85:20,21
67:17 70:23	beginning 49:2	brackett 1:12	85:22
73:2 75:18 77:2	begins 68:20	3:3 5:6,25 8:16	busy 63:14,14
77:15 78:19		15:17 20:17	65:17
//.1.5 /0.17			

[c - clinical]

c	75:2,11 81:15	123:8	circumstances
c 45:13	84:13,14	chapel 2:15	25:22 27:14
	categorically	characteristics	66:6
call 27:8	84:9	6:21	citation 36:2,13
called 5:7 81:23	categories 71:18	check 36:8	civil 123:17,17
calls 111:8	category 83:17	48:11 102:8	claim 24:24,25
canadian 12:22 13:4 14:21	catherine 2:14	checklist 100:3	33:25 37:18,19
39:19	4:23	100:5,8,10,16	42:20,24,25,25
cantor 111:12	caused 6:18	100:17 101:13	43:10 49:18
111:23	causes 117:9	101:18,20,25	50:10 51:1,14
capacity 60:25	centers 80:1	102:2,6,7,11	51:21,22,24
61:3 96:3	89:7	103:2,9,11	52:4,14,15,20
capitol 64:21,23	century 12:10	checklists 102:3	claims 26:6
capture 117:15	certain 21:14	checkup 50:24	31:11 32:6,16
care 1:16 8:18	27:14 38:12	71:16	32:17 35:25
9:25 12:20 13:1	76:11 97:12	chelsea 2:6 4:18	38:1,7,15 52:9
16:21 17:7,21	102:8	70:12	92:1,4 115:10
18:7 21:9 31:24	certificate 121:1	chen 61:10	clarified 67:2
37:13 40:2 41:8	122:1	96:13,18 97:21	clarify 15:22,22
42:14 46:6,7,11	certify 121:9	chief 85:22	37:14 69:7,11
64:9 66:22,25	122:5,11	107:13,15	clarity 40:20
68:10 71:12,16	cetera 9:20	child 47:4,14	44:20 59:1
76:22,25 77:18	22:16 43:2	71:15 117:23	68:21
81:19,20 83:11	47:25 115:3	118:1	classify 96:14
83:14,20,22	challenge 75:9	children 22:21	clean 51:21,24
84:13 98:25	75:16	23:2,11	52:4 72:19
113:18	challenged	children's 83:9	clear 60:23 67:4
carries 116:18	77:19	83:21 89:6	72:13,22 78:17
case 1:3 4:5	chance 46:24	chriss 2:5 4:16	95:12 96:2
21:24 38:22	68:24	4:16 6:4 15:6	clearly 8:1 79:4
63:12 76:4	change 124:4,7	19:9,22 30:22	climara 42:6
cases 34:4	124:10,13,16	55:15	clinical 16:12
categorical 6:24	changes 12:16	circle 48:1	31:18 37:13
7:4 66:1,11 67:6	59:15 60:11,20	circumstance	42:7,11 44:19
68:12 74:20	60:21 117:20	65:1	45:1 50:3 51:16

[clinical - considered]

52:13,19,24	comes 18:8	completed	conditions
53:7 54:8,12	21:10 42:20,25	54:13 55:7	27:20
55:7 66:8,24	97:13	58:21,21 73:23	conducting
101:1,12 102:12	coming 12:16	102:2,3 123:11	93:24
118:16	85:13,15,24	completely 79:4	confer 48:19
close 13:6 29:2	86:3 88:4 97:8	completing 14:1	63:5
119:8	commenced	completion	conference
closely 119:12	1:15	73:22	11:24 111:8
cms 83:19 89:4	comments 60:17	compliance	conferences
89:5,8	62:8	26:17	11:18,22,23,25
code 6:12 7:1	commission	comprehensive	12:2
15:2 37:18 38:3	121:21 122:22	54:22	confirm 38:10
38:14 39:6 43:3	commit 64:25	comprised	43:11 106:19
43:17 48:14	committed	85:19	111:14
50:13,18,20,20	15:10 20:1	computer 36:18	confirmation
51:3,6,13,17	committee 27:8	concept 12:12	3:12 79:1,9
52:2 82:24 83:2	37:6	concerns 116:5	81:16
83:5 84:6	common 12:12	conclude 115:14	conflict 114:10
codes 37:17,17	12:18	115:19	114:15,16,20
38:1,23 39:1	communicated	concluded	115:5,7,12
43:2,21,21,24	106:21	115:3	conflicted
44:1,2,7,7,9	communication	concludes 48:24	114:24
48:7,7,9,12,13	103:20,23	120:15	confusing 57:4
48:14 51:9,10	106:20	conclusion	connect 105:24
51:12 84:4,8	community	91:14 93:12	connected
cody 107:16	11:11 13:12	102:9 116:2	104:21 105:4
collected 112:15	compare 22:19	conclusions	122:14
college 11:11	compendia 35:8	81:10 92:17	cons 116:19
105:13 117:24	35:11,16,20	114:22 115:3	consent 9:10
118:24	36:2,14 54:15	117:21 118:10	consideration
com 36:23	54:21 55:10	118:13,14	23:14 74:10
come 17:25 18:4	compendium	119:23	104:15 108:5
18:4,6 31:9 43:4	34:24 35:19	condition 31:25	considered 33:7
81:25 87:19	complete 24:7	53:25 75:4	91:10 99:13
102:9	64:2	91:11 116:18	123:12

[consist - cover]

consist 35:5	contextualize	45:2,21 46:4,13	counter 54:3
consistency	116:14	48:4,5 49:12,24	countries 96:14
61:8	contract 47:6	49:25 50:4,5,19	country 33:2
consistent 17:22	contracted	54:23 55:2 60:5	county 34:9
17:25 18:22	40:17 98:11	61:13 73:6	121:6 122:2
74:8 93:6,9	contractor	74:23,24 75:7	couple 105:12
116:3	31:12 42:18	77:24,25 80:5,6	111:8
consult 18:25	47:5,7,17	83:3,4 84:1,4,5	course 12:13
19:1 63:3	contractors	84:17,18 85:25	13:10,11 22:3
consultant	17:6 25:11	89:23,25 94:12	23:4,9 26:23
12:21	35:25 52:21	95:3,17 96:25	27:6 30:1 33:11
consultants	66:21 77:22	106:17 107:22	35:4 37:11,12
104:6 105:5,24	control 33:4	116:8 122:9	40:12 42:1,10
106:3,5 111:2	controlled	correctly 49:8	42:24 43:1
consultation	116:8,13	correspond	47:24 50:21
112:6	conversation	37:18 38:2	54:9 67:22
consultations	90:2 106:25	83:24	71:15 72:2
98:10,12	conversations	corresponding	78:14 87:19
consulted 9:24	103:15 104:9,11	37:17	91:6 93:4 95:10
10:1	copies 10:25	corresponds	99:13,19 104:17
contact 87:2,5,7	70:4 82:7 98:1	16:14,18,25	107:25 109:19
87:8 105:3	123:10	51:14,22	117:18 119:14
110:12	copy 5:25 6:3,4	cost 75:5	court 1:1,19 4:9
contacted 87:1	6:5 15:5 19:24	counsel 2:6 4:11	4:12 5:3,11 6:3
87:12	20:16 30:24	9:9 10:3 19:12	6:5 8:5 12:24
contacting	70:18 72:13,18	36:20 56:11	114:4 122:4
104:25	72:19 80:5	69:7 70:3 72:12	cover 16:3,11
contacts 110:7	114:6	72:23 86:24,25	18:1,9,12,18
110:16	corporate 4:3	87:9 88:13	23:18 24:1,14
contained 45:19	correct 8:20	92:25 104:4	25:15,21,25
45:20 74:2	16:4 25:8 28:19	112:2 120:8	27:14,15,17,21
content 98:1	32:10 35:15	122:12,14	27:22,24 39:21
109:7	38:20 39:4	counsel's	39:25 41:1,19
context 58:12	41:17,18,21	112:18	42:22 44:20
64:14,18 73:18	44:10,17,22		45:23 47:23

[cover - debriere]

49:22 50:6 53:2	93:15,20 96:15	cross 3:10 19:7	124:23
53:12,19,20	109:21	33:21,24 55:14	dated 19:8
66:15 67:1 75:5	covering 53:6	55:18 56:15	56:17,17 60:12
81:16 90:14	67:8,23	57:16 65:3 66:4	70:20 79:9
coverage 9:21	covers 27:3	66:7,17 67:8	94:11 122:16
10:19,20 16:14	36:11 41:14	68:14 69:18	dates 56:25 73:9
18:23 20:22	44:13,16 49:10	76:16	73:11,13,14
21:3 22:19 23:1	53:4 116:12	crossed 60:15	dating 56:24
23:5,6,17,23,25	cpt 43:2 44:2	60:17	day 20:13 42:6
24:22 26:20,23	craft 63:18	cum 11:13	59:17 65:20
28:2,6,11,23	craig 58:3,23	cumulatively	92:19 121:14
29:4,5,7,9,13,14	59:12 60:6,8	68:16 76:21	122:16
29:17,18,20,25	created 58:18	current 9:17	days 11:7 73:4
30:2,6,8,10,20	credence 118:12	12:19,21	73:11,13,14
31:10,11,19	credible 117:5	cursory 91:6	86:11 123:11
33:7,8,10,17	cretella 104:25	cut 100:19	deal 18:7
35:25 36:11	105:9 106:10	cv 1:3 4:6	debriere 2:3 3:4
40:3,24 41:5,8	107:7,18 108:5	cyp 50:2	4:14,14,21 5:1
41:23 45:6	108:15,23	cypionate 49:7	5:13 6:6 10:22
52:10 54:18	110:11,15,19,20	49:11,23 50:2	11:1 12:24 13:3
56:13 58:17	111:13 113:15	51:16 52:13,18	15:9,12,16
66:4,17 67:2	criteria 10:19	d	19:10,14,17,21
77:22 90:18	16:10 25:4	d 4:1	19:23 20:2,5,7
91:21 96:24	34:15 45:10,11	dade 34:8	20:13,15 25:23
100:22 101:3	45:12,15,16,19	dalton 85:21,23	30:20,23 31:4
102:16,17,23	45:20 46:1,8,11	dana 1:18 4:9	39:12,14 47:12
covered 23:8,8	46:15,19,25	121:20 122:4,21	48:16,23 49:4
24:3,4 25:15,18	47:1,7,18,20,20	data 67:18,21	55:13,17,20
25:19 26:24	47:22 49:16,17	67:22 68:1,2,4,5	57:1,10,15,20
27:13 29:3,8,13	55:22,25 66:7	75:17,18 76:23	58:8 59:6 62:22
29:17 30:1 32:7	73:4,7,25 74:15	date 1:14 4:8	62:23 68:23
32:9 41:25	74:19 75:4,8,24	57:9,22 69:8,11	69:2,5,10,15
42:18 46:17	76:1,6 101:17	69:25 85:6	70:5,14,17
68:13 75:23	criteria.shtml.	86:15 89:16,18	72:15,20,25
76:17 84:16	45:14	95:20 123:9	73:1 74:5,9,12

[debriere - determining]

77.7 12 79.5 22	defendente 1.0	51.1 4 6 11	designated 9.22
77:7,13 78:5,22	defendants 1:9 4:25	51:1,4,6,11	designated 8:23 61:9 79:24
78:23 79:2,12		department	
81:22 82:1,12	defending 104:2	62:6,17 88:24	122:7
82:15,18 84:24	defense 2:11	89:13 90:6,7,10	designation
91:18,19 92:10	4:20	91:3,5 93:25	61:1
92:15 99:4	defer 42:2 67:25	99:11,18 103:23	designing 90:8
111:18,20	73:9,16 75:15	105:17,19,21,23	detail 119:9,14
112:13,22 113:2	75:17	106:9 107:7	detailed 63:17
113:8,9 120:10	define 23:19	108:13,20,24	90:24 112:5
december 14:10	defined 6:17	depend 64:7	details 37:8
14:18	16:2 71:22	depends 26:17	detected 26:18
decide 92:25	definitely 20:7	64:6,8,14,15,17	determination
decided 11:16	30:24 34:7	64:24	18:3,16,24
107:25	38:22 53:5	depo 78:18	25:12,24 31:25
decimal 84:7	definition 6:22	deposed 7:11	61:7 102:16,17
decision 18:4	14:23 16:15,18	deposing 123:10	114:10
86:18 88:3 90:1	16:24 17:17	deposition 1:12	determination's
100:3,8,10	20:10 45:7 93:5	3:9 4:3,6 5:24	101:3
113:10	definitions	8:19,22 9:4 11:3	determinations
decisions 31:11	14:25 23:21	55:18 77:15,16	100:23
35:24	dekker 1:5	78:9 79:3	determine 16:5
decker 4:5	123:5 124:1	111:16 120:17	16:13,17 18:11
declaration	deleting 43:20	depth 47:24	21:3 22:5 25:6
114:4	delivering 34:13	deputy 14:8	31:13 32:3 36:1
declare 124:19	50:23	63:8 86:5 88:11	40:24 52:22
dede 96:20	delivery 16:13	94:16	54:25 63:6
deem 45:25	denial 19:2 22:7	describe 11:8	74:21 75:19
deemed 17:24	43:4 50:15	21:20	85:11 93:8,14
23:12 63:22	denials 38:9	described 6:11	93:19 98:6
115:4	77:4	56:5	101:14
def 3:10,12 19:6	denied 37:19	describes 55:21	determined
20:20 68:20	dental 71:14	description 3:8	17:19 23:14
70:19	deny 18:23 38:2	82:23	86:20 89:21
defendant 2:17	38:12,15 43:10	descriptions	determining
19:6	43:14,16 50:11	27:23	16:2 33:15

[determining - drug]

42:19 50:7	digging 63:1	document 3:13	106:10 107:7,17
54:17 107:2	directed 94:14	3:13 10:7 60:22	108:5,15,23
develop 100:16	directing 94:17	61:16,21,23	109:3,3 110:5
105:25	directly 10:5	62:2,16 68:22	110:11,15,17,19
developed 33:13	director 94:15	70:6 73:23 83:8	110:20,20
73:4 101:18,20	94:16	94:4 124:19	111:12,13,22,23
101:25 103:10	disagreed	documentation	111:23,23,24
developing	119:16	25:20	112:10 113:10
103:11	discomfort 6:17	documented	113:11,15
development	discovery 10:23	34:14	draft 56:12 64:1
13:11 104:7,8	12:14,15 82:4	documents	drafted 65:11
deviate 47:7,17	discrepancy	56:24 57:2	74:1,15
devona 10:1,5	6:18	61:23 73:17	drafting 81:7
10:14 61:10	discuss 5:21	82:4 83:18 84:2	98:7,8,15 111:5
96:12	119:14	84:12 90:6,7,7	111:6 114:9
diagnosis 37:17	discussed 5:15	91:23 94:8	115:8
37:18 38:3 43:3	discussing 5:22	99:21 114:2	drawn 92:17
43:21 50:13	51:16 52:19	doe 91:25 92:1	drinks 36:21
51:5 67:24	76:16	doh 92:11,16,17	drive 1:17 4:7
82:24 83:2,5	discussion	92:18 94:22,24	drug 12:22 13:4
84:4,11	20:23 77:8	95:9 103:17	14:21 21:12,13
diagnostic 7:8	91:13	108:18,19	21:16,22 23:23
38:13 39:6	dispensing	doh's 91:14	24:3,18,20 25:3
43:17,24 44:1,8	24:25	doing 16:16	25:5,10 26:21
50:18,20 51:3	dissertation	25:25 50:23,24	26:24 27:1,4,6
51:13,17 84:6	12:9	52:16 61:19	27:11 28:15,23
differences	distress 6:17	102:24 110:9	28:25 29:3,5,8,9
76:21	district 1:1,1	111:11 117:8	29:14,18,21
different 9:19	34:9	doj 91:25 92:1	30:1 31:13 32:2
9:20 38:7 57:17	division 63:15	dollars 34:12	34:24 35:2,6,10
65:16 69:3,4	divisions 9:19	donovan 111:24	35:12,13,14
differently	doctor 22:18	downtown	36:1,11,11,19
48:13	doctors 104:9	64:17,19	36:23,25 37:4,7
difficult 97:4	111:7	dr 104:13,17,21	38:4,18 39:1,6
		104:22 105:9	39:15,19,19

[drug - error]

40:25 41:5	durham 44:25	ed 27:22	encompassing
42:22 44:7	dutasteride	edits 60:17,20	27:5,12
45:10,11,13,13	29:6	62:18	encounters
45:15 46:15	dysphoria 6:16	education 2:11	76:22,25
47:4,8 48:3,14	6:22,25 41:20	81:5 90:7	ended 34:11
49:6,6 50:6,7,14	43:9 44:21	educational	endocrine 119:5
51:20 52:22	49:24 51:3 56:9	11:9	119:7,7
53:4,14,17,25	56:13 60:4 61:8	effective 83:16	ends 20:24
53:25 54:13,15	66:2,5,12,18	efficient 97:14	engage 113:10
54:18 55:6 75:5	67:7,9,24 68:13	eight 20:20	english 100:15
75:13 76:17	68:15,19 74:21	either 11:24	enrollees 31:24
77:11	74:23 75:3,7,12	13:1 20:14	ensure 90:14
drug's 50:17	75:14 76:18	31:17 32:14	ensures 40:9
drugs 21:4,6	77:18,23 78:25	93:8 94:7 102:9	entail 104:12
24:1,1 25:17,18	81:15,17 83:6	107:5 109:14	entering 38:7
26:22 27:13,15	84:10,15,17,21	elapse 99:23	entire 45:24
27:16,19,22	86:22 89:2,22	element 116:9	entitled 68:19
28:7,17 30:10	90:8,9,9,15,19	elements 99:7	70:19 78:25
30:17 33:18	91:9,16,22	102:8 116:9	79:8 98:25
35:23 36:3,4	94:19 104:18	eligible 31:19	entrance 59:13
37:7 39:3,17	116:6,24 117:10	elliot 63:4	enveloped 28:22
40:3,11,15	117:22 119:24	email 106:13	29:3,21
41:11 45:23,25	e	123:10	environmental
53:2,7,12,20	e 2:14 4:1 36:24	emailed 123:11	11:25 12:3
54:4,8,9 55:1	123:17,17 124:3	embarked 102:5	epsdt 7:6,9
56:2	124:3,3	emergency	22:22 23:2,3,14
dub 37:16	earlier 31:10	13:13	23:17,20 47:3
due 99:6	36:17 53:11	emerging 12:13	47:16,22 74:10
duly 5:7 121:11	54:15 91:2	employee	eq 22:14 66:22
dunn 2:6 4:18	early 7:7,7	122:12,13	equipment
4:18 56:20 69:1	89:19 91:13	enactment	13:12
69:3 70:13	93:22	77:19	errata 123:9,9
72:18	easier 70:10	enanthate 29:15	123:11
durable 13:12	97:7	encompassed	error 32:17 52:3
		28:14	

[errors - familiarize]

		1	
errors 51:25	everyone's 70:9	exhibit 3:9,9,10	expert 58:24
52:1	evidence 90:9	3:10,11,11,12	112:21
especially 47:1	90:25 91:8,15	3:12,13,13,14	expertise 71:10
65:17 117:15	91:24 92:3 95:5	3:14 5:24 6:1	80:22,24,25
esq 2:3,5,6,8,11	106:7 110:9	8:22 15:13,14	105:2 106:6
2:14,18,19	115:1,9,17,24	20:11 30:24	experts 58:20
123:1	118:16,23	31:1 33:6 55:12	98:11 104:22
establish 108:21	exact 10:11	56:14,19,21	107:2,2 109:17
estradiol 28:2,4	76:23 86:15	59:3,4,8 60:12	111:8 112:5
28:5,7 41:12,13	110:17	62:9 69:24	expires 121:21
41:14,19,23,24	exactly 8:7 57:3	70:13,15,21	122:22
42:5,17 43:5,8	57:6 77:2 95:8	72:13 73:2,8	extensive 67:18
43:25 48:8	examination 3:4	74:1,4,6,18 77:5	97:3
estrogen 28:8	5:12	79:8,10 82:7,8	extent 112:9
et 1:5,8 4:5,5	examined 5:9	82:10,13 83:12	extra 11:15 15:5
9:20 22:16 43:2	example 43:6	83:23 84:20,20	f
47:25 115:3	44:25 60:15,18	84:22 98:22,23	f64 84:7,8,9
123:5,5 124:1,1	except 57:8	98:24 99:2	f64.9 84:10
etiology 117:9	96:23	exhibits 3:6	f640 84:4,6
europe 96:19	excess 23:16	5:15,18,21	f649 82:24 83:2
european 53:15	exchange	68:25 79:4	83:5 84:4
96:14	106:23	81:23	fact 3:14 91:3,5
evaluate 86:21	excluded 116:6	existed 102:6	99:1 102:5
89:22	exclusion 6:25	existing 95:5	113:18,24
evaluated 31:25	7:1,4 66:1,11	expedited 64:11	facts 124:19
evaluating 35:9	67:6 68:12	expenses 40:12	fail 38:16
116:21	74:20 75:2,9,11	experience	123:13
evaluation	75:16 77:19	43:18 50:10	fairly 74:7
110:10 118:9	81:15 84:13,14	65:6,8 81:6 97:9	fall 9:19 58:18
evaluations	exclusions	110:9	71:17
100:17	27:12	experimental	familiar 9:16
eventually 87:2	excuse 9:13	17:6,20 18:3,17	15:1 22:11 23:4
everybody 58:7	89:10 120:8	19:2 48:4 89:23	72:1
everybody's	exhaustive	93:15,20 101:11	familiarize 9:15
96:17	45:22 46:2	115:15,19	

[family - formulary]

family 118:5	24:25 39:16,24	105:15	36:22 47:23
far 21:12,13	42:14,17 46:3,5	finding 104:17	56:1 66:2,3,15
30:12,16 34:15	66:23 67:4,5,10	findings 91:14	66:16,19 67:7
40:6 57:18 61:4	67:11 68:8,9	92:6,12 99:13	68:13 75:5
69:25 75:18	75:19,23 76:2,3	fine 5:17 7:24	77:16 81:16
76:21 86:18	76:17,22,24	8:8 35:22 48:22	82:21 84:16
88:3,4 95:24	81:18 83:12	57:13 72:21	90:14,18 91:2
98:1,15 104:16	101:6,10,14	85:2	93:16,20,25
109:6 110:12	felt 109:21	finish 11:16	99:20 121:5
farino 88:1	field 32:15	first 5:7 22:4	122:2 123:12,17
farrell 107:16	fields 105:2	33:9 42:5,18	fmmis 37:16
fashion 97:15	106:6	44:12 54:24	38:12 43:9 48:6
fault 69:6,6 79:5	figure 85:14,16	57:21 62:11,11	focused 115:21
fda 24:1,3,5,6,7	file 24:24	69:24 82:13	folks 93:22 94:1
24:9,13,14,15	filed 114:4	87:2,4,6,8 93:18	follow 39:13
24:18 27:4 31:9	fill 78:12	113:17	48:16 78:6,10
31:14,16,17,18	filled 58:19	fiscal 43:12	78:14 113:19
32:4 35:10 37:5	fills 24:24	fits 116:20	following 47:10
41:2 42:23	final 68:23	five 17:12 99:22	73:21 114:23
44:19 53:3,6,12	70:24,25 78:24	fl 123:10	follows 5:9 56:3
53:16,17,21,22	finalized 62:24	flag 39:12 48:16	foregoing 122:5
54:1,7,9 100:25	63:6,7,11 65:5	62:22	122:8 124:19
102:12	65:13,22,23,23	flexibility 18:8	forget 81:23
february 1:14	70:9	21:10 42:15	forgot 37:22
4:8 121:14	financial 108:21	66:25	63:3
122:16 123:3,6	108:23	flip 20:19	form 3:14 25:14
124:2	financially	floor 2:12	27:10 47:11
federal 20:23	122:15	florida 1:1,17	51:21 58:4
34:10 35:17,21	finasteride 29:1	1:20 2:3,4,7,10	77:18 91:17
94:5 102:14	find 10:18 34:23	2:20 3:9 4:8	92:8,13 99:1
114:10,14,18	39:9,11 49:15	6:11 7:1 8:18	formal 81:5
123:12,17	62:5,19 76:9	11:12,14,19,24	85:5
feds 23:18	77:2,6 90:13	14:23,24 15:2	formula 100:14
fee 21:13 22:15	91:4 97:22	16:3 20:8,24	formulary
23:6,8,15,16	102:4 103:8	21:3,7 27:2,3	35:14

[formulate - go]

Γ			ļī
formulate 35:14	g	105:6,25 109:14	general's 33:5
formulated	g 6:12 7:2 15:3	114:9,9 115:13	generally 6:9
92:22,24	116:7	117:1 119:15,22	14:1 16:10
formulation	gain 86:16,17	gaps 23:10,11	17:23 24:23
42:5 49:7,23	gainesville 2:7	gary 2:19 4:24	26:2 31:22
50:1 51:15	gapms 3:10,11	123:1	32:14 33:8 40:8
52:13,19	3:11,12,14 6:9	gather 10:2	41:25,25 43:1
formulations	6:13,13 10:15	32:20 78:20	43:22 49:17
41:15 44:14,25	14:14,14 17:14	gathered 10:4	63:12 64:5,12
forth 35:7 37:10	17:15,20 18:11	90:1 107:23	71:16 84:7 87:8
37:17 75:13	18:20,22 19:7	gender 3:12	93:6 100:25
113:20 115:22	55:14,21 56:9	6:16,18,20,21	117:2
forward 65:17	56:12,15 58:16	6:25 41:20 43:9	gestures 8:4
found 17:5	58:18,19,22	44:21 49:24	getting 12:7
32:17 57:18	60:1 61:5,9	51:3 56:9,13	26:5 79:25
80:7,9 118:22	63:13,16 64:1,5	60:3 66:2,4,12	102:20
four 11:7 45:1	64:9,11,12,13	66:16,17 67:6,9	gg970595
franklin 2:14	64:22 65:2,4	67:24 68:13,14	121:21 122:22
fraud 26:10,11	68:18,19 69:13	68:19 74:20,23	give 7:21 56:25
26:19 32:24,25	69:16 71:3,22	75:3,6,12,14	57:5 97:23,23
33:4	71:25 73:5,22	76:18 77:18,23	given 11:4 30:14
fraud's 26:18	74:2,16 78:24	78:25,25 79:8	47:1 61:22
freedom 104:2	79:8 80:11 81:8	81:15,16,17	65:17 78:5
frequently	84:19,21 85:1,3	83:6 84:10,15	86:11 92:23
32:17,20	86:19,19,22	84:17,21 86:21	107:13,14 108:6
front 57:2 62:9	87:3,14 89:21	89:2,22 90:8,8,9	109:24
68:2 82:14	90:2 93:1,9,14	90:15,19 91:9	gn 33:16
full 8:16 71:25	93:18 94:18	91:16,21 94:18	gnrh 29:25 30:4
fully 21:8	95:2,19 96:5,8,9	104:18 113:18	30:19
function 18:14	97:2,11,18	116:6,23 117:10	go 5:23 6:8
fund 2:12	100:4,11,20,22	117:22 119:24	10:18 15:12
funds 34:12	101:15,17,19,23	general 27:23	22:7 23:13
further 122:11	101:13,17,19,23	84:11 86:25	24:10 32:8
	102:1710,13,18	87:9 88:13	33:10 34:15
	102.23 103.0,7	92:25 112:18	42:2,15 48:20
	103.14 104./		

[go - highlights]

Page 140

48:21 52:11	gotten 99:24	114:17,21,22,24	40:13 50:21
62:1 67:17	governed 45:9	114:25	66:22 71:15
69:11 75:18	government	guide 109:22	79:24 80:23
77:1,15 91:6	13:23	guideline 30:14	83:22 88:24
93:11 101:15	governor 92:5	guidelines 16:2	89:13 90:10
107:25 110:16	94:23 103:15	16:24 22:20	94:1 98:25
goes 21:14 22:3	governor's	23:1 27:5 33:13	99:12,18 103:23
22:8 30:12,16	87:20,21,24	33:17,20 42:3	105:17,19,21,23
45:7 61:4 69:25	88:5,7,19 90:3,5	99:18 119:3,5	106:9 107:7
75:19 86:18	90:12,13,17,20	119:13	108:13,20,24
95:25	91:20 94:2 95:3	guys 69:5	115:2,21 119:12
going 5:14,18	95:6 103:16,20	gynecologists	health's 91:3,5
5:23 6:8 12:25	gperko 123:1	118:25	healthcare 4:4
18:1 24:14	grad 11:17	h	hear 34:4
26:16 28:18,19	graduate 11:15		held 4:7
31:17 33:25	12:1	h 36:23,24 45:13 124:3	help 5:22 40:12
36:18 38:24	graduated	half 13:17	81:7 100:19,19
39:24 41:2,4	11:13	hand 5:4 8:4	104:16
44:5,6 51:18	grant 18:7	121:13	helped 100:15
56:18 64:4	21:10	handful 68:6	helpful 37:23
65:18 67:17	grantham 62:13		helping 109:22
70:10,21 73:2,9	great 18:7 70:11	handing 82:2,3 handle 40:10	hey 113:6
77:2,6 78:8,19	89:7		hhs 34:11 89:9
79:7 84:25	grossman 104:9	handy 55:13	89:10 90:6 91:3
98:23 100:20	104:17 109:3	happen 15:4 32:16 34:1	91:25 92:6,11
101:14 102:7	111:7	happens 34:3	92:17 93:23
106:7 115:19	gs 62:8,9,10	happy 28:2	94:7 99:21
116:1,2 117:14	guess 65:6 85:9	hard 21:18 80:5	100:1 103:25
gonadotropin	98:6	head 110:15	113:18,19 114:2
29:23,24 74:21	guessing 65:4	health 1:16 2:3	114:17,21,22,24
gonzalez 2:11	guidance 30:15	8:18 12:4,8,11	114:24 115:10
4:23	30:18,21 31:6	12:12,17,20,25	highlighted
good 120:14	33:24 89:4,8,11	12:12,17,20,23	72:16,22
gosh 79:2	94:22,24 95:10	19:3 22:14	highlights 72:13
	100:1 109:22	26:15 31:24	72:23
		20.13 31.27	

Veritext Legal Solutions

[highly - information]

highly 114:8	huh 3:19 46:20	immerse 97:3	50:17 51:19
hill 2:15	56:4 61:6 82:25	impact 8:13	52:5,16,22 54:8
hire 112:10	94:13 101:24	implemented	54:10,19 55:9
113:6	105:10 110:14	75:16	66:9,24 101:1
historical 11:19	human 52:3	importantly	101:12 102:12
63:1	hundred 21:14	23:11	indications
history 11:12,14	54:2	importation	41:22 44:16,19
11:24,25 12:3,4	hypothetical	12:22 13:5	45:5,17 53:7
12:8 59:22 63:1	43:6	39:19	indicators 85:9
104:18 117:6	hypothetically	impressive 20:6	85:12
hold 65:20	47:25	inadequate	individual
holes 78:12	i	115:9	28:24 29:4,7,13
holtzman 2:19	icd 37:25 44:3,4	include 77:12	29:20,25 31:11
holtzmanvoge	44:9 48:7,7,9	109:7	35:24 54:24
123:1	51:12 84:8	including 44:25	60:24 71:7
hormonal 42:1	idea 111:19	117:10	83:24 106:12
hormone 3:10	identical 57:8	inclusion	individual's
19:7 29:23	identification	111:24	75:3
33:21 55:14,18	6:2 15:15 20:12	incorporated	individualized
56:16 57:16	31:2 56:22 59:5	15:1	31:21,22 55:4
65:3 66:4,17	70:16 79:11	independent	individually
67:8 68:14	82:11 84:23	18:2,15,19	76:4
69:18 74:22	99:3 111:22	109:10 113:23	individuals
76:16	identify 110:5	114:23	71:22 105:3
hormones 33:24	112:4	independently	106:5 112:15,19
66:8,8	identity 6:19	18:14	113:15 117:7
hospice 13:14	12:18	index 3:1,6 35:2	infancy 12:11
hospital 35:13	ii 13:23	indicate 41:17	info 93:23
hot 19:19	imagine 46:1	indicates 41:14	inform 81:7
hotline 26:10	imbalances 42:1	44:12,13 49:10	informal 85:7,9
hour 45:1	immediate	50:3	85:12
house 22:13	81:12	indicating 84:2	information
33:13	immediately	indication 41:16	10:2,4 22:23
https 36:22	35:3	41:16 44:15	34:18,19,21
45:12		49:11,12 50:16	35:6,12,13

[information - know]

37:15 39:10	interdisciplina	65:13 77:18	101:22 105:5
49:15,19 51:22	11:20	114:4	109:13
62:7 67:12 74:1	interested	jason 1:8 4:5	justice 2:3 90:6
76:19 77:1 78:1	122:15	107:3,6,19	k
78:2,3,10,13,21	internal 100:11	113:5 123:5	katie 87:25
89:25 91:6,15	internet 96:14	124:1	katy 2:3 4:14
92:23 106:15	interpreted 30:8	jazil 2:18 4:20	20:4
107:6 109:6	intimately 14:25	4:20 6:3 10:24	kidder 60:15
110:17,22 111:3	22:11	15:4,7,11 19:25	kind 9:20 12:11
113:7,13	introduce 4:11	20:4,6 25:14	15:22 18:13
initial 18:24	investigation	47:11 57:8,19	27:5,10 28:8
88:4 89:16	26:8 32:24,25	58:5 69:7 70:3	48:13 54:10
91:12 92:16	91:3,4 112:14	72:12,21 74:4	80:2 84:9 97:7
93:22 103:16	investigational	78:16 91:17	100:12,17,19
112:6	18:17 19:2 48:4	92:8,13 112:2	100:12,17,19
initially 63:5	101:11	112:17,23 113:4	110:15
95:6 113:25	involve 32:5	jeffrey 100:15	knew 115:5
initials 62:10	involved 9:25	jill 113:4,5	knew 7:9,20,25
initiate 85:3	10:6 22:9 26:5	job 9:17 14:11	8:8 10:22 15:9
initiated 22:1,2	47:20 51:24	58:22	20:8,9 21:17
69:14	87:25 88:2 94:2	john 8:16	22:23 31:8
inpatient 71:13	97:16 98:16	johnson 71:8,9	32:14 34:7,8,24
71:13	102:19 107:4	72:8	35:11 36:16,17
input 33:11	issue 69:8,12	joined 5:1	37:7,14 38:22
inside 98:9	issues 26:2	josefiak 2:19	40:7 41:6,7,16
instance 1:13	it'd 32:7 54:3	josephina 87:11	43:12 44:16
34:8 67:7	item 82:20	87:12	48:12 49:9
instances 46:16	items 103:3	journal 11:21	53:15 54:12
66:3,13 76:12	iterated 117:1	july 65:14 79:9	56:16 60:9
76:17 81:20	j	june 3:11,14	61:13,14 62:14
instruct 90:12	jacket 19:18	47:2 56:17,18	63:9,10,18
90:13	jacksonville 2:4	57:22,24 59:2	65:15 67:1 76:5
integrity 26:5,8	jane 113:5,5	60:2 61:5 84:19	76:16 77:9
32:23 33:3	january 13:24	84:20 85:1 87:3	79:19 80:11
	14:11,14 58:19	96:9 97:18	83:7,15 85:10

[know - looking]

85:11 89:18	larger 34:15	124:10,13,16	llp 2:9
91:7 99:20	late 12:10	link 4:22,25	loaded 51:10
100:4,7,24	laude 11:13	36:19 46:16	location 1:16
101:22 105:20	law 40:8	51:12	long 11:2 13:16
107:1 108:19	leaders 107:12	list 9:16 13:15	22:12,12 47:19
111:18,25 113:4	leadership	23:7 26:25 27:6	51:13 70:10
113:14 115:16	85:18 86:2,17	27:9,16 28:18	76:10 117:2
117:5,14	leads 104:16	36:19,25 37:4,7	longer 48:19
knowing 36:12	109:4,5	39:20,21,21	longitudinal
knowledge	lean 15:7	42:5 43:23	117:6
33:23 60:25	leave 80:19	45:22,25 46:2	look 14:23
62:25 75:22	led 105:1	49:6,6 54:16	24:21 32:8,16
81:19 85:23	left 60:8 80:20	77:7,16 79:5	41:10 42:4
86:5,7,8,9,16,17	101:21 115:23	listed 9:5 15:21	46:24 54:24
93:13,17,21	legal 2:6,11	23:17,21 35:4	55:8,12 57:21
95:13,16,18	86:20 123:16	35:16,21 39:23	71:19 76:13,23
97:6,13 106:22	legislative 65:18	41:15 42:5	77:5 81:22
knowledgeable	80:2	44:14 45:12	82:19 90:24,24
62:1 111:17	lend 118:12	46:15 47:18	95:4 103:3
known 64:16	lengthy 13:14	49:17 54:20	104:14 108:9
knows 113:2,3	119:14	55:9 58:1 59:14	looked 10:13
1	leon 121:6 122:2	71:7 101:5,9,13	looking 8:21
label 24:8 35:10	letter 85:6,15	listing 68:25	12:7,17 18:21
47:21,22 53:4,8	86:12 92:20	lists 27:15	20:16,19 26:6,6
53:22 54:4	94:10,14,17,21	literature 54:14	26:16 42:7
55:24 56:2	level 22:3,4,6,8	55:11 91:1,7	44:11 45:15
labeled 59:3,8	levels 65:16	93:11 97:4,17	49:6 50:1,16,18
82:5	liberty 104:4	97:21 115:4	51:19 52:12,18
laid 75:4	licensure 26:17	116:23 117:8	54:17,19 57:15
lambda 2:11	life 43:6 70:9	litigation 114:8	59:2 60:11
lappert 111:24	likely 74:14	little 10:4 11:8	61:18 70:7
large 1:20 35:5	110:24 114:8	39:5 48:12	77:14 78:24
44:18 93:12	limited 117:11	52:11 54:22	82:13 83:23
95:25	line 5:20 60:16	58:12	98:22 111:21
	82:20 124:4,7		
	1	1	

[looks - medicaid]

		1	1
looks 10:8 44:24	make 10:25	maps 96:12,13	maureen 88:1
60:18 74:7	16:22,25 18:2	96:18,19,21,23	maximum 37:13
83:14	18:15 25:24	march 121:21	mckee 2:14 4:23
lot 21:10 58:16	37:24 42:15	122:22	mcmaster 110:8
58:17 112:8	43:12 70:4,9	mark 5:14,23	mean 6:14 7:9
117:3	90:17 93:12	15:12 19:21	9:5 11:6 22:25
lots 26:9 63:15	99:25 119:21	30:24 56:18	24:10,13 26:9
63:15,15 117:9	makes 97:14	70:12 79:7 82:6	28:7,21 30:8
loud 5:21 8:3	making 31:10	82:8 98:23	31:15,15,16,17
low 63:22 64:5	35:24 92:1	marked 3:8 6:1	39:15 42:2,8,21
64:12 65:1,5	94:22 95:5	15:14 20:11,20	43:22 44:18
lower 40:12	100:16 110:7	31:1 56:14,21	45:24,25 47:22
lunch 79:6	115:10	59:4 70:15,21	47:22,23,25
120:13	managed 9:25	79:10 82:10	49:18,20 52:8
m	16:20 17:7,21	84:22 99:2	53:3,13 57:12
m 36:23	18:7 21:9 40:2	market 53:19	63:7 64:17,20
made 32:1 59:9	41:7 42:14 46:6	markups 79:13	67:2 73:7 81:4,5
59:15 60:21,21	46:7,10 64:9	79:14	82:6,20,22
61:12,13,14,17	66:22,25 68:9	marstiller 94:11	83:19 89:5
62:4,18 64:16	76:22,25 81:19	marstiller's	95:23 96:9
65:12 85:4,5	81:20 83:11,14	94:21	100:4 101:10
87:21 103:17,18	83:20,22 84:13	mastectomy	102:13 106:5,21
103:19,22 105:3	management	82:24 83:2	107:10,12 109:6
114:23,23	37:15	master 11:13	111:25 112:4
maf 1:3 4:6	manager 40:22	master's 97:10	114:12 117:7,13
magellan 30:15	63:2,4	match 41:4	118:11 119:1,1
30:19 31:6	managers 40:8	materials 9:22	120:6
40:18 76:1,1,3,5	40:10	22:17 80:11	means 36:9 42:9
76:12 77:2	mandating	matt 5:16	42:12 50:6 65:2
magna 11:13	102:22	matter 4:4	73:19 83:1
mahan 1:17 4:7	manual 52:24	58:20,23 71:10	meant 15:23
main 98:17,19	manufactured	80:21,24	medicaid 3:9
maintained	53:14	matthew 1:12	10:13,18 14:9
80:11	manufacturers	3:3 5:6 8:16	14:16,24 16:3,5
00.11	40:11	123:6 124:2,23	16:11 17:5,19

[medicaid - myflorida.com]

23:19 25:1,19	108:7		
20:9 22:16	member 83:16	minute 120:13	45:13
17:9,13,21,23	47:19,21,21	4:10	myflorida.com
16:15,18,23	meets 17:8	minnich 2:23	119:14
15:20,24 16:1,9	meetings 95:8	minimum 37:13	68:22 70:5
13:12 14:1,24	103:16	19:20	multiple 26:18
medical 6:10	93:22 94:3	mine 15:10	multi 87:23 88:5
medicaid's 88:3	91:13 92:16,21	mind 107:11	33:1,25
96:24 113:20	89:20 90:4	million 34:12	mpi 32:15,22
94:16 96:13,21	88:11,15 89:17	milliliters 50:3	20:23
91:21 93:16,20	87:23 88:6,10	45:1 50:2	moving 19:5
89:14 90:14,18	meeting 34:14	milligrams 42:6	moves 54:11
85:21 87:17,18	meet 17:12	28:13	move 59:7 65:16
83:25,25 84:16	28:9	micronized	moot 102:15,25
82:21 83:23,24	medroxyprog	12:14	99:23
80:1,1 81:16	89:4 106:6	microbiology	65:22 67:19
76:20 77:7,17	medicine 12:8	105:4,8,9,9	months 65:11
73:11 75:5	8:12	michelle 104:25	monroe 2:20
67:8 68:13	medications	mic 19:12	monique 71:8
66:16,19,21	102:16,18,20	miami 2:10 34:8	34:6
63:14 66:2,3,15	89:7 101:4	115:21	money 23:9
56:1,13 58:15	medicare 80:1	methods 10:17	moment 39:8
47:23 54:25	114:25	113:11,11	109:3 111:7
43:12 45:13	32:19 47:8,18	meter 111:23	104:10,13,21,22
41:7 42:21	25:7,13,16 26:4	met 25:21 75:4	mol 98:23
39:4 40:13 41:1	22:6 23:12,14	116:22	2:18 4:20
36:23 37:15	medically 16:9	69:8 103:14	mohammad
35:17,21 36:10	116:21 120:4	36:17 54:15	model 116:20
33:2,2,4 34:3	116:15,16,17,18	mentioned	74:6 112:13
31:10,12 32:23	93:7 108:6,10	115:21	19:24 72:25
26:13,19 27:2,3	89:6 90:25 93:4	102:7,11 115:2	mo 10:22 15:9
24:16 26:3,4,5,8	83:9,21 86:21	mental 100:17	mistake 68:24
23:25 24:4,11	45:7 47:19 48:2	15:10 20:1	mirror 46:8
21:3,7,21 23:23	34:14 41:3 42:3	memory 8:13	miriam 104:9
17:20 20:8,24	25:20 27:4 32:1	memo 112:3	minutes 48:18

[myriad - office]

Page 146

myriad 97:9	25:16 26:4	81:3	nw 2:7
n	32:19 46:1 47:9	new 2:13 43:20	ny 2:13
	47:18 115:1	43:21 53:17	0
n 4:1	necessity 14:24	newman 88:1	
nai 61:10 96:13	15:20,24 16:1,9	nine 55:23	o 2:18 4:1,1
97:22	16:15,19,24	non 13:13 24:7	oath 121:1
name 4:10 8:15	17:9,13,22 20:9	27:13 42:23	object 25:14
8:16 28:8,17	23:20 25:2,20	53:7	47:11 91:17
60:16 62:11,11	27:4 32:1 34:14	normally 32:5	92:8,13
69:4 81:24,25	41:3 42:3 45:8	northern 1:1	objection 78:19
88:17 104:24	47:19 48:3	nos 82:10	objections
105:16 106:11	86:21 93:5	notary 1:19	78:17
106:14,16,17,18	need 7:21 8:7	121:20 122:21	obstetricians
107:11,13,14	18:25 19:1	note 12:25	118:25
110:8,11,13,17 named 28:16	24:10 28:3	37:24 123:9	obtain 36:10 37:9 78:3
88:16 121:10	30:24 40:6 46:7	notes 122:7	obtained 49:20
names 35:3,3	46:8 48:15,19	notice 3:9 5:23	obtaining 23:22
107:24 108:4	48:21 62:7 63:2	6:8 8:21,22	obviously 8:2
national 39:1	78:15 94:9 99:6	55:18 77:15	34:3 66:24
101:3 102:16,17	99:8 103:8	111:16 119:2	occasional
native 3:13,13	106:18 111:14	november 13:24	97:24
native 9.13,13 natives 82:3,9	120:9	14:11,15,19	occasionally
nature 18:4	needed 31:8	number 44:18	97:22
93:15	needs 23:1	67:23 72:3	occur 34:23
nc 2:15	41:24	77:16 100:19	62:12
ncd 102:20,22	negative 3:19	117:2	occurrences
ncd's 102:19,20	neglect 117:11	numbered	99:5
ndc's 38:25	negotiate 40:16	122:9	october 75:1,10
necessarily 18:6	40:18	numbers 5:19	offered 104:13
32:18 37:8 38:2	negotiating	5:20 34:2,15	offhand 35:4
53:9 67:1,12	40:11	76:7,8,10,14,23	67:15 89:18
101:7,10 116:20	neither 52:21	numerous 11:18	office 14:7 33:5
necessary 16:10	never 44:20	11:18	74:13 80:7,10
22:6,22 23:12	49:22 53:3,6,9,9	nurse 22:5	80:10 87:20,21
23:15 25:7,13	63:11 65:4 67:7		87:24 88:5,8,19
,			, , , ,

Veritext Legal Solutions

[office - page]

90:3,5,12,13,17	44:4,8,11,20	90:3,17 91:2,12	oral 112:9,25
90:20 91:20	45:9,22 46:3,15	92:21 93:13	order 99:7
94:2 95:3,6	47:3,15 48:23	95:1,12 96:2,16	ordering 123:11
103:16,20	49:22 50:16	96:20,22 97:1	organizations
112:18	51:2,15 52:4,11	97:16,20 98:3,3	118:17
official 121:13	53:11,14,20,20	98:17,22 99:25	outline 23:9
offs 26:9	53:24 54:5 55:3	100:3,8,25	98:20 103:9
oh 28:4 69:10	55:5,12,25 56:5	101:2,5,22,25	outlining 97:17
79:2 120:10	56:8,10 57:21	103:1,8,13	outpatient
okay 5:15 6:7	57:23 58:4,9,23	104:6,11 105:8	26:22,24 82:19
7:13,17,18,23	59:1,19,24 60:6	105:18,22 106:9	82:21 83:1
7:25 8:11,17,21	60:9,14,23	106:24 107:5	outset 104:24
9:10,23 10:7,22	61:11,21 62:3,7	108:9,22 109:1	outside 9:8 98:9
11:8 12:19	62:15,19,19	109:3,12 110:2	106:2
13:19 14:23	63:10,25 64:11	110:19 111:12	outsourced
15:19 16:4,8,16	64:19,22 65:3,8	111:15 113:17	22:14
17:1,11,15 18:2	65:21 67:4	114:3,8,14	outstanding
18:15 19:5	68:11,18 69:16	115:13 116:4,10	115:25
20:16,19,21	69:20,22,25	118:24 120:15	override 38:9
21:1,17 22:9,25	70:2,2,11,14	old 80:10	oversaw 13:10
23:19,19,22	71:2,9 72:5,11	omar 2:11 4:23	71:12
24:5,15,20 25:1	73:2,17,25 74:9	once 17:24	overseen 83:21
25:5 27:15,23	74:18,25 75:10	28:21 75:25,25	own 9:22 61:19
28:9,13,16 29:1	76:5,8,15 77:5	78:7,13 95:10	93:24 97:8
29:11,19 30:3,6	78:4,16,22 79:7	97:3,12,12	100:12,17
30:18 31:8,20	79:17,22 80:7	ones 40:18 86:8	116:18
32:2,7,22 33:6	80:12,17,21	operating 9:18	р
33:15,21,25	81:6,14,22 82:2	operations	p 4:1 36:23
35:11,19,22	82:23 83:5,15	43:12 74:14	p&t 27:8
36:17 37:21,21	83:18 84:2,6,19	opinions 92:19	p.m. 120:16
38:18,21 39:2,9	85:16 86:2,6,9	92:22	pa 42:7 45:4
39:12,23 40:2	86:13,16,24	opportunity	pagan 2:11 4:23
40:20,23 41:4,7	87:1,12,21 88:2	93:11	page 3:3 5:20,22
41:13,19 42:17	88:9,15,18	option 109:24	20:20,25 55:23
42:21 43:5,7,23	89:12,16,20		58:2 60:19 62:9
			50.2 00.17 02.9

[page - plan]

	1		
70:23 124:4,7	pays 24:24	permanent	40:8,9,22 48:12
124:10,13,16	pbm 33:14	117:20	63:2,4 72:8
pages 82:14	40:17,20 76:1	person 58:21	phase 54:12
122:9	pbm's 40:13,15	59:11 64:23	55:6,7
paid 32:17,18	40:23	100:11 105:4,23	phd 11:16 12:5
108:15	pdf 36:24	107:17 112:7	12:7
paper 63:19	pdl 37:3 39:15	person's 6:18,19	phrase 6:24 7:2
papers 11:17	39:22,23 40:2	personally 95:7	physically 46:24
part 17:1,3	40:24 41:5,8,13	108:22 121:10	95:7
50:19 59:25	41:17 44:14,15	perspective	physician 51:23
101:17 106:24	45:3 49:10,13	100:12	105:11 110:23
participants	pdl.pdf. 36:24	pertinent 10:10	110:25 112:6
77:17	pdm 102:4	51:22	physicians
particular 7:3	pediatric 119:7	petersen 110:6	109:19 111:1,4
36:11 38:13	pediatrics	110:18,21	118:6
51:13 78:19	105:13 118:8	111:23 112:11	pickle 10:1,5,14
87:15 108:10	peer 54:14	113:6	61:10 96:12,20
parties 122:12	55:11 91:1	peterson 62:3	pillsbury 2:9
122:13 123:11	penalties 124:19	peterson's	pipeline 85:13
party 87:23	people 4:21	60:16	pittman 2:9
88:5	32:15 88:16,23	pgs 1:11	place 37:6 38:25
pass 54:16	113:18 117:16	pharm 36:23	50:20 54:4
103:5 110:11	percent 21:14	pharmaceutical	103:9 122:6
passed 105:16	54:2	27:7 37:6 53:15	placed 19:13
110:8	percentage 34:5	53:16	places 78:6
password 61:25	perimeter 23:10	pharmacist 72:6	plaintiff 2:2
past 20:13 56:8	period 13:24	72:8	plaintiff's 4:22
67:21 79:3	54:7 61:4 75:17	pharmacists	5:2 56:11
81:12	75.00 7(.10	21:19 48:15	plaintiffs 1:6,13
01.12	75:22 76:10	21.17 40.15	plaintins 1.0,13
patch 42:6 45:1	periodic 7:7,8	58:25	4:15,17,19
			_ ▲ · ·
patch 42:6 45:1	periodic 7:7,8	58:25	4:15,17,19
patch42:645:1pause7:22	periodic 7:7,8 periods 117:19	58:25 pharmacopoeia	4:15,17,19 72:23 82:4
patch42:645:1pause7:22pay23:1034:6	periodic7:7,8periods117:19perjury124:19	58:25 pharmacopoeia 35:13	4:15,17,19 72:23 82:4 plan 17:7,21
patch42:645:1pause7:22pay23:1034:634:1151:14,23	periodic7:7,8periods117:19perjury124:19perko2:192:19	58:25 pharmacopoeia 35:13 pharmacy 21:24	4:15,17,19 72:23 82:4 plan 17:7,21 18:1,2,15,23

[plan - prior]

	1		
81:20	73:11 74:18,25	prepared 9:1	preventive
plans 16:21 18:1	75:4,13,24,25	63:5 96:12,13	71:17
18:7,14 19:4	85:21 93:4	112:3	previous 28:22
21:9 40:13 41:8	portion 7:3 17:8	prescribe 33:16	68:18 93:14
42:15 46:7	17:16,21 74:11	42:9,10	97:11
66:22,25	portrayal 21:2	prescribed 25:7	previously 39:3
plastic 109:20	position 12:19	25:13,18 26:22	59:23 76:15
please 4:11,12	12:21 13:17	27:1,1,10 28:15	93:15
5:4 19:13 30:23	58:16 92:5,11	28:23 29:3,9,14	pricing 39:19
58:13 69:11	positions 58:18	29:18,21 30:1	primarily 12:23
123:9	positive 3:19	31:13 32:4 36:1	41:3 44:5 71:13
plus 55:10,11	68:24	36:13,23 42:22	85:20 96:11
point 7:13 18:13	possible 43:15	43:8 45:13 47:4	primary 6:20
43:24 78:7 84:7	62:5,14 67:3	47:8,13 48:3	58:22 71:12,16
87:2,5,6,8 91:14	post 33:25	50:8,17 51:20	82:24 84:3
97:13 102:15	potential 26:25	52:6,17,23	96:18,22
115:6,18	85:23 115:5,7	54:18,20 55:9	principally 9:24
pointing 111:15	117:9	prescription	print 72:19 79:6
policies 9:21	potentially	21:4,6 24:24	printed 59:18
13:11 22:19	26:14 27:16	26:21 27:1	59:20 82:16
23:5,6,17 28:6	72:19	36:19 39:3 40:3	prior 13:4,19
28:11 30:6,10	practice 20:8	40:15,25 45:23	14:3 16:6,12,16
33:8,10 67:2	practitioners	prescriptive	16:21,23 17:1,3
policy 3:9 14:9	105:2	23:7	21:6,11,11,15
14:16,25 15:13	pre 56:12 77:3	presence 89:12	21:21,25 22:12
20:22 23:21	precedence	present 2:23	23:13,23 24:2
25:17 26:20,23	65:19	79:21 88:10,12	24:11,16,19,21
26:25 27:11	predates 73:10	88:14,15,24	25:4,10,25
28:2,15,23,24	preferred 27:6	95:7 103:17	30:15 31:23
29:4,5,7,10,13	36:25 37:4,7	presented 11:17	32:2 35:23 36:3
29:14,17,18,20	49:5,6	pretty 9:17,17	36:4,7,10,15
29:22,25 30:2,3	preliminary 6:7	12:14 18:14	38:5,6,6,8,8,19
30:4,8,12,13,16	prepare 9:14	20:6 43:18,19	40:10,14 42:12
1			
30:17 33:7 51:1	10:9 11:2	43:22 99:15	42:16 45:2,6,18
30:17 33:7 51:1 58:15 66:7	10:9 11:2	43:22 99:15 102:17	42:16 45:2,6,18 45:18 46:17

[prior - psychological]

47:5,17 50:3	16:12 17:2,4,20	program 10:18	prong 18:21
51:17 52:14,20	21:20 22:1,4	12:21,22 13:5,8	54:6,11 93:5
52:25 65:25,25	23:13,22 24:11	14:12 26:5	prongs 16:1
66:11 67:5,19	24:17,21 30:16	32:23 33:2,3	17:12,13
68:11 74:19,22	31:23 33:11	37:16,25 39:19	properly 34:13
75:8,16 76:2	38:7 39:20	43:15,16 51:9	pros 116:18
81:14 84:13,14	40:15 42:11	53:24 56:1	provera 28:10
85:7,24 86:3	43:22 47:6	68:16 71:11	provide 10:11
92:6,12 95:22	49:21 50:19	programmed	10:16 43:23
103:18 111:4	52:25,25 53:17	38:12 43:1,9	45:5 46:16
priority 63:22	54:3,5,6 55:22	48:8 50:22 51:4	51:21 58:12
64:5,12 65:1,5	60:1 63:8 64:2	51:6,8,18	73:18 78:2,21
80:2 99:14,15	65:12 73:22	programming	91:6 104:15,18
99:16,17	86:23 89:21	48:7	104:23 109:22
privy 60:20,21	90:2 93:1,2,10	programs 10:14	provided 9:7,8
probably 11:5,5	93:18 95:2	79:25 96:13,21	30:19 31:6
11:6 21:19	98:16 100:11	prohibiting	33:13 70:6
56:25 77:11	104:23,25 111:5	10:20	78:11,13,17
78:14 86:11	111:6 112:3,4,5	project 2:3	111:1,9
110:24 114:16	115:8	79:21,22,24	provider 21:23
probing 118:15	produce 58:7	80:3 85:12,24	22:2 26:11,13
problem 7:19	produced 10:23	86:8,10,18	42:9
7:20 8:1	30:14 68:3 82:4	87:13,14 88:20	providers 26:3
procedure	product 82:23	88:25 97:2,3	26:14 32:21
37:16 38:23	83:9	99:14,15,16,17	34:4,5 105:1
43:21 48:13,14	production	projects 11:6	provides 93:10
50:20 53:6,8,23	112:12	63:16 64:3	providing 25:3
81:21 116:12	professional	65:19 70:1	75:8 109:7
123:17,17	6:10 14:1 17:23	88:21 97:9	psych 109:18
procedures 9:18	93:7 119:11	100:14	psychiatric
71:15,16	122:4	prompted	119:19
proceedings	professionally	117:20	psychiatry
122:5,10	81:1,2	promulgated	117:23 118:2
process 6:11,13	progesterone	30:5,9,11 33:9	psychological
10:6,13,15	28:13	33:18	120:1

[psychologist - recommendations]

psychologist	putting 79:5	randomized	124:12,15,18
109:18	q	116:8,12	reasonable
pubertal 73:2	quality 14:8	ranged 11:23	123:12
74:22 75:6	26:15	12:3	reasons 72:4
76:19 77:22	quantify 34:1	rate's 39:24	rebates 37:9
puberty 68:19	quarterly 11:20	rates 39:21	40:11,16,19
69:21,22 70:19	question 7:14	rather 15:7	rebecca 79:16
71:19 73:5 74:2	7:16 8:9 10:10	94:23	80:9,17
74:15	10:12,16 21:18	reach 93:23	recall 35:3
public 1:19 12:4	39:13,13 47:10	94:7 97:12	118:3
12:8,11,12,16	48:17 62:20	reaching 107:2	receipt 123:12
33:11 34:17,20	66:10,10 89:7	react 114:2	receive 113:21
34:22 49:21	92:14 94:9 96:4	reaction 113:23	received 11:4,10
121:20 122:21	108:19 112:1,20	114:1	11:11,13 34:10
publications	116:14 118:18	read 5:19 63:20	67:25 68:22
113:20	questions 7:22	112:3 115:20	75:20,20 107:6
publicly 34:17	9:25 10:5 11:4	123:8 124:19	receiving 68:6
37:11 114:2	35:20 59:22,24	reading 5:21	recess 49:1
published 11:19	59:25 78:6,8,10	99:5	recipient 21:21
94:25 95:10	78:14 82:6	reads 17:22	22:1 26:12 27:2
99:12 104:23	91:24 115:23,25	real 43:6	36:10 54:25
pull 45:10 62:2	116:22 117:3,13	realize 30:7	83:11,25
67:18,21,22	quick 100:1	115:6,18	recipients 24:16
79:6	quickly 33:6	realized 115:9	31:12,24 67:24
pulled 59:18,19	48:6 64:10 77:5	115:11,22 116:1	68:6 75:20 77:8
purchase 99:7	99:7,9	realizing 100:21	77:17 83:24
purpose 15:20	quite 6:9 13:14	really 19:25	recognize 36:25
15:23 35:10	66:10	26:17 30:12	37:2
42:19	r	36:7 40:14 49:9	recommend
purposes 56:2		53:18 64:17	110:20
put 19:12 31:23	r 36:23,24 124:3	93:10 100:14,22	recommendati
34:20,22 37:10	124:3	111:7	105:23 108:12
60:16 65:20	raise 5:4	reason 8:8 65:4	recommendati
82:16	raising 64:23	70:20,22 99:5	71:3 95:5
		123:9 124:6,9	107:18,21,24

[recommendations - request]

111:1 118:4,16	referring 31:5	relationship	92:17 98:18,19
118:18 119:3,6	35:20 45:11	105:18	100:9 109:7,25
recommended	55:23 66:19	relative 122:11	110:1,3 111:6
106:9 107:22,25	67:10 69:17,18	122:13	111:10 114:9
111:12,14	89:6 94:10	release 92:18	115:14 117:1
112:20 113:11	100:5,7	released 76:1	119:15,22
113:14	refers 6:11 7:1,3	99:19,21 101:4	reported 1:18
recommends	refine 100:19	114:17	reporter 1:19
112:7,8	regard 89:11	releases 94:4,5	4:9,12 5:3,11
record 8:15	123:13	releasing 29:23	8:5 12:24 122:1
40:20 59:2	regarding 30:10	74:21	122:5
68:21 69:24	30:19 56:9,12	relevant 115:14	reporter's 6:3,5
72:21 112:24,25	66:7 68:18	relied 93:23	reporting 26:19
122:10	88:25 89:1 90:7	105:5 117:22	reports 14:2
record's 72:12	regardless 23:4	rely 41:8 81:10	56:12 58:19
78:16	23:15 38:4	118:10	61:1 63:13,16
recorded 4:2	regards 88:20	remember	65:11,21,23
records 22:16	regional 12:2	86:15 114:11	97:12 104:23
25:19 34:20,22	regulations	remind 103:10	109:13 111:9,11
49:21 112:10,13	20:23	reminding	repository 62:1
recoupment	reimburse	65:15	represent 4:15
34:4	39:22 50:7	render 102:15	4:16,18
recoupments	reimbursed	renders 102:24	representative
32:20 34:23	21:7	repeat 25:9	4:3 9:11 60:24
reeves 1:18 4:10	related 60:3	117:24	61:2 68:4 95:14
121:20 122:4,21	73:17,18 74:2	rephrase 7:15	96:4 111:17
refer 6:12 12:25	78:24 79:24	92:14	represented
84:25	84:21 87:2 89:3	report 19:7	12:2
reference 15:2	89:13 90:19	26:11 57:25	representing
18:13 36:18	94:18 96:5 98:6	59:9 60:1 62:24	2:2,17 8:18
119:21	107:7 116:5	63:5 70:24,25	reproduce
referenced 31:9	119:23	71:5,7 73:5 74:2	27:10
91:2 123:7	relation 61:8	78:24 79:15,16	request 3:14
referencing	65:6 99:17,18	80:5,8,9 81:11	31:23 34:20,22
	-		
64:19	105:21	81:12 86:19	41:4 49:21 60:1

[request - ryan]

64:15 85:3,5	research 10:17	76:4 87:17,18	94:19 101:23
87:22 88:4 90:4	11:17 80:13	88:3 89:1 90:21	109:15 113:16
90:5 94:22,23	97:3,9 100:13	90:22 91:21	118:18
95:2,4 99:1,10	102:14,21,23	92:2,7,12 93:1,8	rise 26:7
103:17,18,19,22	104:14,16 106:2	93:10,24 95:9	risk 102:19
requested 52:10	109:23	117:8 118:19	risks 116:19
requesting	reserve 78:9,15	119:8,12 123:7	rivaux 2:8 5:1
87:17,18	118:17	reviewed 9:21	rl 2:23 4:10
requests 17:25	resources	10:8 22:10 23:1	rn 22:5 72:10
19:3 58:17	104:17	55:11 65:13,23	role 6:20 9:17
63:15 64:9 77:3	respective 106:6	91:1 97:25	10:6,15 13:4,7,8
85:7 90:18	respond 99:20	114:7 118:20	13:22,25 14:15
100:20,21	response 3:19	reviewing 41:2	65:7,9,10 98:5
require 21:6,11	3:19 74:15 90:6	54:4 97:17	101:21
21:15 24:20	91:23 94:22	116:23	roles 61:10
25:5,10 32:2	99:11,24 100:1	reviews 18:20	96:17
35:23 36:3,4,6,7	responses 117:5	34:1 90:11	roll 83:9
36:9 38:19	restrictive 46:11	104:19	romina 110:5
47:24 61:24	46:14,14	revisions 59:9	112:11
116:10,11	result 26:12,14	60:13 61:1,12	route 86:20 90:1
required 23:24	results 67:22	61:13,14,16,17	routed 73:23
24:19 33:3	resumes 120:17	62:4	routing 58:4
37:13 42:7,13	retrospective	rh 1:3 4:6	rule 6:12 7:2,4
45:2,4 50:4	32:6 52:8	richmond 2:4	15:2,2 17:9 30:5
51:17 52:14,20	returned 123:11	right 5:3,4,14	30:9,11 33:9,18
118:15	review 16:13,17	8:7 13:5 19:5,13	123:17,17
requirement	17:7 18:11	19:15 20:13	rulemaking
24:3 48:2 52:5	20:25 22:3,8,10	27:18 41:10	33:10
requirements	22:16 25:1 26:1	42:20 48:6 49:5	rules 9:22 26:17
23:18 48:1	32:6,16 42:11	51:7 52:24	123:12
51:23	46:18 47:17,24	53:13 56:8 57:9	run 28:18 70:10
requires 38:5	48:3 52:6,8,16	57:16 59:1	96:17
50:20 54:12	52:22,24 53:16	61:11 69:24	ryan 87:25
requiring 36:15	54:14 63:7,20	70:18 72:16	
61:15	64:2 65:12,16	78:11 89:15	

[s - sheet]

S	second 22:8	september	83:21 89:6
	48:19 54:11	70:20	93:15,19 115:14
s 2:20 4:1	55:5 62:11 77:6	sequence 95:9	115:19 116:4,6
123:13 124:3	99:6	seriously 118:17	116:7,24
safe 38:16	secondary 6:20	service 16:3,5	serving 86:4
sail 97:7	secretary 14:8	16:11,14,14,18	session 65:18
sale 53:19	63:8 86:4,5	16:22 17:5,8,19	set 35:20 48:12
sample 117:18	88:12 94:11,16	18:9,16,22,23	49:19 51:12
sarah 58:3,23	94:21 107:13	21:13 22:15	64:11 75:13
59:12 60:6,8	112:19	23:10,10,11	78:18 116:16
save 104:16	secretary's 85:6	27:13 35:14	setting 50:24,25
saw 5:24 10:7	85:15	38:13 42:14,17	seven 20:9,13
saying 59:7	section 15:1	44:7 46:3,5	65:22 99:23
64:25 93:5	20:24 27:12	50:21 51:13,14	several 67:18
114:11	see 32:8 36:20	66:23 67:5,10	sex 3:10 6:19,20
says 23:5 42:7	55:8 82:16 88:9	67:11 68:8,9	19:7 33:21,24
45:16 62:9 91:1	91:1 92:2 95:24	75:19,23 76:2,3	55:14,18 56:15
112:2	102:8 108:9	76:17,22,24	57:16 65:3 66:4
scale 93:12	seek 106:3	81:18 82:19	66:7,17 67:8
95:25	seeking 21:21	83:12 93:6	68:14 69:18
schedule 23:15	seems 54:3	102:23 116:15	76:16
23:16 39:16,24	73:21 82:15	116:16,17,18,21	shani 2:8 5:1
101:6,10,14	107:11 112:1	services 7:3,7,8	shapes 12:18
schedules 23:6,9	seen 9:4,6 31:3	13:9,14 18:3,8	sharepoint 58:2
scholarly 11:19	45:24	23:7,8 25:15	61:24 71:6
63:19 97:10	selected 71:23	26:3,23 27:11	shaw 2:9
school 11:15,17	72:4	28:15,23 29:4,9	sheena 62:13
13:13 34:9	seminar 63:19	29:14,18,22	sheeran 9:24
sciences 12:13	sending 98:5	30:2 32:18	86:25 87:1
scientific 104:19	senior 70:23	34:13 38:24	88:13 107:3,5
scratch 52:17	107:12	39:2,4 50:22	107:19
screen 45:16	sense 97:14	58:17 67:1,23	sheet 91:4,5
screening 7:8	sent 106:13,21	68:7 71:12,14	113:18,24 123:9
seal 121:13	sentence 99:6	71:14 73:3,25	123:10
search 95:24		74:14 80:1 83:9	

[shifted - start]

shifted 14:15	situation 64:8	space 7:22	spent 11:5
short 120:9	64:24	speak 5:8 8:1,3	spilling 36:21
shorthand	six 67:19 73:4	9:23 21:8 39:8	spiro 28:18
122:7	73:13,14 99:23	41:9,25 48:15	spironolactone
shortly 19:19	size 116:20	54:2 61:2 70:8	28:20,21
shoulder 15:8	sizes 117:18	72:1 81:9 95:8	split 19:23
show 67:22 68:4	sm's 22:12	speaking 7:19	spoke 107:17,20
68:5	small 117:18	7:23 43:1 47:25	107:20 112:15
showing 36:24	smc 40:13,23	76:20 93:3 97:8	112:19
84:12	snapshots 91:7	special 65:18	spreadsheet
side 4:22 5:2	society 119:5,7	73:3,25 74:14	10:14
40:16 62:8	119:7	specialized 13:9	staff 21:19 88:7
sign 123:9	solely 64:3	38:24	88:8,9 107:14
signature 70:7	solitary 97:2,15	specific 27:20	107:15 113:20
121:18 122:19	solutions 22:15	28:6,7,11,25	staffers 87:24
signed 63:8	123:16	29:17 30:17	stakeholder
65:14 69:1	somebody 26:10	31:25 35:6 38:2	64:16
70:23,25 114:13	somebody's	41:10 90:18	stamped 19:6
123:13	63:21	92:5 102:23	72:20 82:3
significant	somewhat 20:3	116:17	stamps 73:24
99:22	soon 120:9	specifically	82:9
significantly	sorry 19:24	13:25 27:19	standard 9:18
47:24	37:22 52:17	28:16,17 33:1	15:21,25 16:4
similar 119:3	69:5,11 74:5	61:9 88:20	17:22 21:3
simone 2:5 4:16	79:3 82:7,8	111:22 112:10	91:10
15:4 30:20	94:15 99:16	112:20	standards 6:10
55:13 77:7	103:8 109:1	specificity 88:17	14:2 17:23 93:7
simple 43:19	113:11 119:10	specifics 32:14	114:10,14,18
single 21:13,16	sought 77:17	speculate 71:22	116:16 119:17
65:1,2 116:16	sounds 7:25	speculation	stands 6:9 7:7
116:17	35:15	63:24	32:22 40:21
sir 5:3	south 11:21	spell 28:3	start 26:5 96:6
site 26:12 61:24	12:16	spelled 36:22	99:7,9 103:13
sitting 77:20	southern 2:6	spend 11:15	120:11
	11:20 12:18		

[started - systems]

started 11:10	studies 11:20	summer 79:18	surface 26:7
95:21 96:5	117:3	sunshine 83:22	surgeon 81:4
100:20,21	stuff 6:7 22:13	supervision	surgeries 57:14
115:16	subcategory	122:8	71:13 84:3
starting 20:22	84:11	supervisor 10:1	surgery 3:12
starts 55:25	subcontract	81:13	77:10 79:1,9
state 1:20 8:15	40:9	supervisors	80:25 81:7,17
10:18 27:19	subcontractor	65:15	82:20,21 83:1
33:1 79:24	33:14	supplement	84:16 109:20
94:16 95:4	subcontractors	112:11	surgical 71:14
96:12,21,23	16:20 17:7	support 54:16	surprising 64:1
99:20 114:25	subject 58:20,23	55:11 91:8,15	survey 26:12
121:5 122:2	59:23 60:16	115:9	117:14,17
stated 114:3	71:10 80:21,24	supported 36:2	surveys 26:14
124:19	subjected 16:23	36:13 91:24	26:15 117:4
statement 10:20	86:22	92:4 116:7,12	swear 4:12
10:21	submit 21:25	supporting	sworn 5:7
states 1:1 10:13	52:5	61:10 91:9 92:3	121:11
35:12 91:25	submitted 22:17	102:22 115:1	symposiums
92:1	52:15,15,21	suppose 49:20	12:1
stating 91:8	substances 8:13	supposed 27:11	symptoms 115:3
status 82:20	substantial	117:4,13	system 21:13
statute 123:12	102:21	suppression	22:15 35:12
step 54:6,14	substantiating	68:20 69:21,23	37:15,20,25
55:5,8	102:13	70:19 71:19	38:1,7,11,16
stop 7:15	successful 54:10	73:3,5 74:3,16	39:7 42:24,25
stops 22:7	sufficient 94:6	74:23 75:6	43:3,13,15,19
straightforward	sufficiently 92:4	76:19 77:23	48:8,11 49:19
43:22 119:4	suggested	sure 14:25	50:10,14,23
street 2:4,12,14	123:11	16:22,25 18:10	51:8,10,18
2:20	suggestions	19:25 21:24	53:24 59:14
strickland 87:25	104:13	31:9 43:12 70:4	71:6,7 76:24
strike 33:16	suit 19:17	70:8 99:25	systems 115:2
91:18	suite 2:9,14,20	105:13	
			1

[t - times]

t	telling 77:20	therapy 3:10	118:2 119:21
t 4:1 36:24	ten 65:11,21	19:7 33:22	third 54:13 55:8
124:3,3	term 6:16 7:6	55:14,19 56:16	thought 53:11
take 8:7,9 11:2	83:19 117:2	57:16 65:3 66:4	69:10
48:18,22 76:23	terms 68:24	66:17 68:14,20	thoughtful
77:6 82:7 90:24	testified 5:9	69:19 70:20	118:15
98:4 106:7	testify 9:1	71:20 73:5 74:3	thousands 34:3
115:17 118:16	testifying 95:14	74:16 76:16	three 10:12 11:7
120:9,12,12,13	testimony 123:8	77:23	13:17 34:25
taken 21:23	123:12	theses 97:10	35:1,11,16,21
117:16 122:6	testosterone	thing 23:25	50:22 54:6,12
takes 63:20	29:11,15,19	things 39:18	54:15 55:6,7
talk 69:22 111:4	44:11,13,19,21	49:18 71:15	56:12 57:17
talked 111:7	45:16,17 46:16	101:4 117:7,12	60:19 87:24
113:1,4,5,5	46:17 47:13	think 10:11	96:15
talking 24:7,8	49:7,11,22,23	11:24,25 16:7	time 1:15 4:9
28:4 93:25	50:1,2 51:15	19:23 21:25	11:15 13:24
111:10 114:5	52:13,18	22:7,17 24:23	14:3,9 22:12,13
117:19	tests 103:6	29:2 30:14 34:8	32:7 48:25 49:3
talks 35:6	text 35:12 60:18	34:12 37:8 38:8	52:10 61:4 63:2
tallahassee 1:17	thank 5:11	40:5,5 44:1	63:4,20 71:21
2:20 4:7 11:11	15:11 19:15	45:24 59:21	71:24,25 73:10
tamayo 87:11	28:5 30:23	60:8 62:7 65:11	73:24 74:25
87:12 88:10	41:13 48:23	67:21 68:9,9	75:1,10,17,22
task 61:9	57:19 72:25	69:8 71:14	76:10 78:9,15
tasked 13:25	74:6 94:17	72:10 78:5,17	79:20 85:8,22
taxonomy 84:9	113:8	80:13 87:4,25	86:4 87:9 91:12
team 33:3 71:12	thanks 20:5	88:11,11,12,13	93:14,18 96:17
teams 9:20	that'd 50:13	88:23 89:19,24	99:22 102:1
13:10 32:25	theirs 118:7,9	100:15,15,16	104:17 117:14
tech 72:8	thera 36:24	102:3 105:11,12	120:16 122:6
techniques	therapeutics	105:13 107:1,3	times 31:3 68:11
104:20	27:8 37:6	107:10,19,19	75:12 76:5 77:3
tell 16:8 22:25	therapies 67:8	109:17 112:8,17	77:21 84:15
34:5,7,7 83:7,11		114:15,20 116:5	95:12
ייייייייייייייייייייייייייייי			

[tip - understanding]

tip 26:9	transplant 97:6	trigger 50:14	u
title 83:18	transportation	triggering 26:8	uh 3:19,19,19
today 8:13 9:14	13:13	trouble 47:10	46:20 56:4 61:6
10:8 11:3 77:20	trauma 117:11	true 57:11 122:9	82:25 94:13
98:24	treat 41:20	124:20	101:24 105:10
today's 4:8	44:21 66:4,17	truth 5:8,8,9	110:14
together 12:16	67:8 76:18	try 7:16,21	ultimately
37:10 82:16	84:16	70:10 76:9,9	119:16,18
tom 94:14	treating 74:23	trying 65:15	umbrella 27:5
tonight 19:18	treatment 6:25	85:10,10,14,16	unanswered
took 65:22	7:8 43:8 49:24	97:5 98:6	115:23 116:22
top 20:25	51:2 56:13 60:3	tuberculosis	117:3,13
topic 12:9 78:19	66:1,12,15 67:6	12:10,15,17	undecanoate
111:15,21 112:2	67:25 68:12,14	turn 15:17	29:19
topics 8:21,23	74:20 75:2,6,11	36:20 70:22	under 3:14 9:19
9:2,4,16 11:18	75:13 77:23	84:19 108:1,2	17:16 20:22
12:2 77:16	78:25 81:15,17	109:1	25:2 27:1,14
78:18	84:15,21 89:22	turned 112:24	28:14 42:14
total 82:14	90:14,19 91:9	turning 33:6	47:4,14,22 48:2
totally 8:8	91:10,15 94:18	47:3 48:6 49:5	56:1 66:14,23
track 5:22 62:15	102:22 116:5,11	56:8	67:4 81:18
62:17	116:23 117:22	two 22:3 29:19	82:19 83:9
tracking 58:2	119:24	32:25 35:2	97:12 99:1
traditional	treatments	48:18 49:3	116:6 122:8
64:12,13	86:21 89:2 90:8	55:15 56:16	123:12 124:19
transcript 123:7	91:21 104:19	58:18 65:12,12	undersigned
123:13	115:1 117:20	65:21 73:17	121:9
transcripts 8:6	tree 100:3,8,10	82:13 83:10,11	understand
123:10	110:15	86:7 103:3,6	6:13 7:2,14,17
transgender	trial 54:7	117:19 120:15	8:4
61:8 119:12	trials 31:18	type 52:2 82:19	understanding
translated	54:12 55:7	90:22	8:17 46:10 50:9
122:8	116:8,13		74:13 76:11
transparent	tried 54:8 55:1		80:4 97:13
39:20			

[undertake - weak]

	26.12 42 5 44 2	112.10.11	
undertake	36:12 43:5 44:3	113:10,11	vouching 106:4
24:16 25:12	44:8 47:9,21	vast 27:9	vs 1:7 4:5 123:5
90:10,21,23	48:4 50:7 53:4,8	vendors 22:24	124:1
93:1,10 94:18	53:25 54:4	verbal 7:25	W
95:2,9	55:24 66:16	98:12,13,14	w 1:18 121:20
undertakes	89:21 105:24	104:9 106:22,23	122:4,21
21:21	107:3 118:7	verify 40:6	waits 63:23
undertaking	used 10:17,17	123:8	walk 5:18
47:5 52:6	16:5 22:12 42:1	veritext 123:10	wall 2:12
undertook	42:19 44:21	123:16	wallace 94:14
95:10 102:1	54:9 55:22	veritext.com	95:1
uniform 116:15	74:19 80:14	123:10	want 7:14,15,16
unique 83:25	93:14,19 100:16	version 56:15	15:17 19:24
100:12,13	104:6 123:13	57:24 59:10	37:23 48:18
116:15	uses 35:7 41:22	61:12 70:7	64:25 67:17
unit 33:4	42:23 45:5	versions 55:16	68:21 69:7,23
united 1:1 35:12	53:21,22	56:17 57:16,17	70:13 72:21
91:25 92:1	using 6:8,22,24	68:22 70:5	78:7 82:5 90:22
96:12	7:6 17:20 35:19	versus 76:24	91:20 99:22
university 11:12	40:23 44:2,2	77:3 116:19	106:5 120:12,13
11:14 110:9	48:14 118:3	viagra 27:21	wanted 70:22
update 43:19	usually 17:25	video 4:2 48:24	90:20,24 92:2
updated 43:13	21:23,23 22:2,4	49:2 120:11,15	99:20,25 100:18
45:16 47:2	23:12 26:4 35:5	videographer	wants 42:9
updates 113:21	42:1 49:21	2:23 4:2,11 8:2	waters 97:8
updating 13:11	62:10 63:16,20	19:12,15 48:24	waters 97.8 way 27:11 36:16
uploading 43:20	64:10,10 103:3	49:2 120:8,11	39:9 40:7 75:18
43:21	119:4	120:15	84:8 93:7
url 36:21	utilize 35:8	videotaped 1:12	102:10 115:23
usage 24:8	utilized 56:1	violation 25:17	we've 24:19
use 6:16 15:9,24	v	vogel 2:19	44:12 51:16
17:21 19:1 25:7	v 2:19 123:1	voice 64:16	52:19 56:14
25:13 27:21		volume 1:11	57:18 89:25
31:13 32:4		120:17	
33:15 35:9 36:1	104:10,13,21,22		weak 91:9,16
	109:3 111:7,23		118:22

[website - zoom]

Page 160

website 34:22	95:19,21,25	54:24 55:2 56:8
36:19 37:11	96:6 97:21 99:7	56:23 57:2,10
49:17	99:9	57:11 62:17
week 11:5	worked 14:7	69:2,10 70:11
weida 1:8 4:5	39:18 59:11	70:13 72:17
86:4 88:12	81:3 96:8,18,19	73:15 77:9,9
107:4,6 112:19	working 11:7,16	82:15 83:13
123:5 124:1	14:14 39:3,18	84:5 86:14
weird 81:24,24	61:5 79:23	92:16 98:15
went 58:20 60:9	115:16	105:7 109:6
63:7 97:24	works 40:7	114:12,12
98:15 103:6,7	50:10 93:4	118:14,14
108:12	97:11,11	120:14
western 96:19	world 119:11	year 65:14
whatsoever	worn 19:17	67:22 117:19
10:21	wpath 119:5,10	years 11:15,17
winthrop 2:9	write 98:17,19	13:18 20:9,14
wish 18:9	109:12 110:1,2	67:18
witness 3:1 4:13	writing 58:1	yep 25:10 73:3
5:7,10 6:4 19:19	99:11 109:18,24	york 2:13
25:15 31:3	written 111:24	young 113:18
48:21 56:23	112:10,13,24	Z
57:12 58:6	114:12	zoom 4:22,25
61:15 69:13	wrong 28:19	200111 1122,20
72:24 74:7,10	52:2 77:11	
92:9,14 120:14	98:24	
121:10,13 123:8	wrote 96:22	
123:8,9,13	y	
wondering 57:3	yeah 10:11,11	
worded 27:11	13:6 16:24	
words 81:3	29:24,24 32:13	
work 12:22	34:25 38:15	
38:11 59:23	39:11 40:1	
60:6 61:4,7	44:18 45:3	
78:20 84:8	52:12,12,12	
	,,	

Veritext Legal Solutions

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
(A) to review the transcript or recording; and
(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY. THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION. VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.

Page 125 UNITED STATES DISTRICT COURT 1 NORTHERN DISTRICT OF FLORIDA 2 3 CASE NO. 4:22-cv-00325-RH-MAF 4 5 AUGUST DEKKER, et al., Plaintiffs, 6 7 vs. JASON WEIDA, et al., 8 Defendants 9 10 Volume 2, Pgs. 125 - 261 11 12 VIDEOTAPED DEPOSITION OF: MATTHEW BRACKETT 13 AT THE INSTANCE OF: THE PLAINTIFFS 14 FEBRUARY 8, 2023 DATE: 15 TIME: COMMENCED: 1:30 P.M. 16 LOCATION: AGENCY FOR HEALTH CARE ADMINISTRATION 17 2727 MAHAN DRIVE TALLAHASSEE, FLORIDA 32308 18 REPORTED BY: DANA W. REEVES 19 Court Reporter and Notary Public in and for State of Florida at Large 20 21 22 23 24 25

	Page	126
1	APPEARANCES:	
2	REPRESENTING THE PLAINTIFF:	
3	KATY DEBRIERE, ESQ.	
	Florida Health Justice Project	
4	3900 Richmond Street	
	Jacksonville, Florida 32205	
5		
	SIMONE CHRISS, ESQ.	
6	CHELSEA DUNN, ESQ.	
-	Southern Legal Counsel, Inc.	
7	1229 NW 12th Avenue	
,	Gainesville, Florida 32601	
8		
Ũ	SHANI RIVAUX, ESQ.	
9	Pillsbury, Winthrop, Shaw, Pittman, LLP	
2	600 Brickell Avenue, Suite 3100	
10	Miami, Florida 33131	
11	OMAR GONZALEZ-PAGAN, ESQ.	
	Lambda Legal Defense and Education	
12	Fund, Inc.	
	120 Wall Street, 19th Floor	
13	New York, NY 10005	
 14	CATHERINE MCKEE, ESQ.	
	1512 E. Franklin Street, Suite 110	
15	Chapel Hill, NC 27514	
16		
17		
- /	REPRESENTING THE DEFENDANT:	
18		
	MOHAMMAD O. JAZIL, ESQ.	
19	GARY V. PERKO, ESQ.	
	Holtzman, Vogel, Barantorchinsky & Josef:	iak
20	119 S. Monroe Street, Suite 500	Lan
20	Tallahassee, Florida 32301	
21		
22		
23	ALSO PRESENT:	
	RL Minnich, Videographer	
24		
25		

	Page 1	27
1	INDEX TO WITNESS	
2		
3	MATTHEW BRACKETT PAG	Е
4	Examination by Ms. DeBriere 128	
5	Examination by Mr. Jazil 253	
6	Further Examination by Ms. DeBriere 255	
7		
8	INDEX TO EXHIBITS	
9		
10	NO. DESCRIPTION MARKED	
11	Exhibit 13 Medicaid coverage for children	153
10	state list	1.00
12	Exhibit 14 Medicaid policy Routing and Tracking Form	163
13	Exhibit 15 Molina Health Care Notice of	202
тЭ	Adverse Benefits	202
14	Exhibit 16 August 22, 2022 email	215
	Exhibit 17 August 22, 2022 SMMC policy	215
15	transmittal	
	Exhibit 18 Florida Medicaid health care alert	222
16	sign off form	
	Exhibit 19 June 3rd, 2022 series of emails	227
17	Exhibit 20 Florida Statute 120.542	234
	Exhibit 21 GAPMS queue	249
18	Exhibit 22 Health and Human Services document	253
	Exhibit 23 Treatment of gender dysphoria for	253
19	children and adolescents	
20		
21		
22		
23	*Uh-uh is a negative response	
~ 4	*Uh-huh is a positive response	
24 25		
25		

Page 128 DEPOSITION 1 2 Whereupon, 3 MATTHEW BRACKETT was called as a witness, having been previously duly 4 sworn to speak the truth, the whole truth, and nothing 5 but the truth, was examined and testified as follows: 6 7 VIDEOGRAPHER: This is beginning of video three. The time is 1:30 p.m. We're on the record. 8 9 EXAMINATION 10 BY MS. DEBRIERE:: 11 So prior to break, we were talking a little 0 12 bit about Dr. Van Mol and Dr. Grossman's involvement in 13 the 2022 GAPMS. How did AHCA identify them to participate in the July 8th rule hearing that was 14 related to? 15 16 So the -- are we talking about the rule Α 17 hearing? 18 Yes, related to the June 2022 GAPMS. 0 19 So since we had already been working with them Α 20 in relation to the GAPMS project, because Dr. Grossman 21 is a psychiatrist, and Dr. Van Mol is a family -- family 2.2 practice practitioner, that's based on their backgrounds 23 and their knowledge of the existing evidence, that was 24 our basis for selecting them to be on the panel for the July 8th hearing. 25

1	Q And turning back to the individuals who wrote
2	reports for the June 2022 GAPMS, who made the decision
3	to contract with them to prepare those reports?
4	A So after establishing each one, we wanted
5	to their backgrounds and their suitability to provide
6	reports, that decision was made by, I think, now
7	Secretary Weida.
8	Q And who was involved in determining whether
9	they had the appropriate backgrounds to write the
10	reports?
11	A So I think those individuals who were working
12	with the experts, I think that was, of course, now
13	Secretary Weida, I think at our time, General Counsel
14	Josephina Tamayo.
15	Q Okay. Anybody else?
16	A I don't
17	Q Were you involved?
18	A I was not.
19	Q Was Nai Chen involved?
20	A He was not.
21	Q Was Dede Pickle involved?
22	A She was not.
23	Q Okay. So now Secretary Weida and Josephina
24	Tamayo were the two people who decided whether the
25	consultants who read the reports were qualified to do

Page 130 1 so? 2 MR. JAZIL: Object to form. 3 THE WITNESS: So are you asking that whether or not those two only assessed their credentials? 4 BY MS. DEBRIERE:: 5 6 0 Yes. 7 I mean, yeah. I mean, they assessed their Α credentials and looked at their background and 8 9 experience and knowledge. 10 Were those the only two people that assessed Ο 11 their credentials before deciding whether to engage 12 them? 13 Α In regarding the Agency, I mean, the -- Andrew Sheeran may have been involved. So it's possible a 14 15 couple others with the principal decision to rely on 16 those experts was theirs. 17 Okay. And so just to be clear, you were not Q involved in that decision? 18 I was not involved in that decision. 19 Α 20 And Nai Chen was not involved in that 0 21 decision? 2.2 А That's correct. And Dede Pickle was not involved in that 23 0 decision? 24 25 А Correct.

1	Q When making that decision, did AHCA
2	investigate whether any of the consultants had a stance
3	related to the treatment of gender dysphoria?
4	A We, of course, were looking for those that
5	had were knowledgeable about the existing literature
6	of gender dysphoria, and those who would, for the
7	supplemental reports, would take an evidence-based
8	approach.
9	Q Did it so those were the only two criteria
10	that you used to determine which consultants you would
11	engage with?
12	A Correct.
13	Q And so opposition to gender-affirming care was
14	not a factor in who you chose?
15	A We were specifically looking I think we
16	might be talking semantics on what we consider
17	opposition, but we were looking for individuals who were
18	going to make reports and recommendations based on the
19	existing evidence.
20	Q Okay. Was whether the vendor had experienced
21	treating I'm sorry. Was whether the consultant had
22	experienced treating gender dysphoria a factor?
23	A Not so much a factor that would outweigh the
24	knowledge of the existing literature and the evidence,
25	since this was going to be a the GAPMS process really

1 takes into account peer-reviewed literature. It takes 2 into account evidence-based clinical guidelines, et 3 cetera, so those are our primary -- our primary factors 4 in evaluating the experts and their ability to 5 contribute to this report. 6 Q Would people who actually provide treatment in

g would people who actually provide cleatment in
gender dysphoria be most familiar with peer-reviewed
literature as it relates to their practice?

A Well, that is a complicated question. They
don't necessarily have to be. It's possible to -- I
mean, it is possible -- I mean, it is hypothetically
speaking, someone could engage in treatment of these
individuals and run and follow anecdotes.

14 Q So it's not important to AHCA that the 15 consultants with whom you engaged had actual experience 16 treating gender dysphoria?

A So based on how the GAPMS rule is written, the needs of the report, we really -- the primary ask was for individuals who were steeped in the evidence.

20 Q But didn't necessarily have actual real life 21 experience treating gender dysphoria?

A Right, that wasn't a primary consideration. Q Okay. For -- was AHCA aware that all the consultants with which you engaged took a stance to oppose mainstream medical organizations' stance on

	Page 133
1	gender-affirming care?
2	MR. JAZIL: Object to form.
3	THE WITNESS: So are you talking about in
4	opposition or in contradiction?
5	BY MS. DEBRIERE::
6	Q Contradiction.
7	A We whether contradiction or alignment
8	really was irrelevant, it really was taking a look and
9	making evidence-based conclusions.
10	Q Speaking to Dr. Brignardello-Petersen I'm
11	sorry. I'll start here actually. In deciding on
12	whether to use these consultants, was any input provided
13	from the Alliance Defending Freedom?
14	A No.
15	Q What about the Heritage Foundation?
16	A No.
17	Q Liberty Council?
18	A No.
19	Q Society for Evidence-Based Gender Medicine?
20	A We may have gotten Romina's name from that
21	organization.
22	Q Okay. And what about the Family Christian
23	Coalition?
24	A No.
25	Q Did you get anybody else's name from the

	Page 134
1	Society for Evidence-Based Gender Medicine?
2	A Because the because it was verbal
3	conversations, so don't don't think so, but the kind
4	of details because there's a lot of verbal
5	conversations and no written record, so
6	Q Maybe?
7	A It could be a maybe at best.
8	Q And did the Family Christian Coalition
9	recommend any of or play any role in the
10	recommendation of the consultants
11	A No.
12	Q with AHCA engaged? What about the Florida
13	Citizens Alliance?
14	A No.
15	Q The Florida Department of Health?
16	A Well, the Florida Department of Health passed
17	along to the name of Dr. Michelle Cretella. So, yes.
18	Q What about the Governor's office?
19	A No.
20	Q The Surgeon General Ladapo?
21	A Well, he would be acting in his capacity as,
22	of course, the agency head for the Department of Health.
23	So the Department of Health, cumulatively, gave us that
24	name.
25	Q Did he personally?

Г

There was a conversation, like, once with our Α 1 2 general counsel Tamayo at the time with Dr. Ladapo, but 3 we don't recall whether or not the name was given during that conversation. 4 5 I think you touched on this a bit earlier, so Ο I apologize for circling back around, but did AHCA 6 7 consider using any other consultants in the development of the June 2022 GAPMS? 8 9 Α By any other --10 Other than those that wrote the reports or Ο 11 Grossman or Dr. Van Mol? 12 Α There were those who were contacted. Of 13 course, there was -- it was all verbal conversations, but not necessarily -- not necessarily considered to 14 15 write a report either. 16 0 And do you remember who you were -- who you 17 contacted? 18 Α Since it was all through verbal conversations, it was eight months ago, it wasn't through written 19 20 correspondence, the -- we're not really aware of all 21 those details. And who was the one who did the contacting? 2.2 0 23 The contacting was done, I think -- I think by Α Andrew Sheeran. He's now our General Counsel. 24 I think 25 Josephina Tamayo -- Tamayo. Sorry. I think she also

Page 136 was involved in contacting them. 1 2 Q Okay. And those were all phone calls? These were verbal conversations, yes. 3 А So no communication by email? 0 4 А No. 5 6 0 Did you use the folks who ended up not 7 offering the reports -- aside from Dr. Van Mol and Dr. Grossman and the individuals who authored the reports, 8 9 did you use the people that you contacted in any other 10 capacity? 11 Α No. 12 0 And what was the scope of the agreement 13 between AHCA and each consultant? So each consultant, of course, they provide us 14 А 15 their hourly rate. We wrote up purchase agreements that 16 those amounts cannot exceed \$35,000 because of the 17 nature of the procurement. 18 Can you speak a little bit more to that? Ο I'm 19 not -- I'm unfamiliar with the way that -- the 20 regulations that govern that. 21 So if it were to exceed \$35,000, it would have А 2.2 to be a competitive procurement, and that's why -- so 23 the -- so we, of course, we enter in agreements with 24 each of these experts. The amounts paid to them cannot 25 exceed 35,000.

Okay. What was each vendor -- in procurement 1 0 2 of consultants, was this the usual procedure? I'm 3 sorry. In contracting. Yeah, this is the procedure that we can 4 Α follow. 5 That you can follow, but is it the usual 6 0 7 procedure? Well, I mean, what is defined by a usual 8 Α 9 procedure? I mean --10 How many times in prior GAPMS have you 0 11 contracted with a consultant to develop the GAPMS? Well, we haven't, but then there are 12 Α 13 instances -- I know with coverage determinations, et 14 cetera, that sometimes we will actually send stuff for a 15 physician review, like over at EQ Health Solutions. So 16 it's not unusual for us to ask for medical experts or 17 clinical expertise on a prospectus. 18 Had you ever previously contracted and paid Ο 19 the person for that clinical expertise? 20 Α No, we had not. 21 What was the total budget allocated to the Ο 2.2 development of the GAPMS? You know, 35,000 times seven. That'd be 23 Α 210 -- 245,000. 24 So each consultant is capped at --25 Q

Page 138 That was the cap of the budget. 1 А 2 Q And is that 34,999, or 35 straight? I'm leaning towards 34,999, so we can subtract 3 Α \$7 from that amount. 4 Has each consultant been paid in full 5 Ο Okay. for that work? 6 7 Α Each consultant has been paid in full for the work they completed. 8 9 0 Okay. Some of those consultants now, though, 10 are acting as experts in this case and being reimbursed for that, as well? 11 12 Α Those would be under separate agreements. 13 Q Okay. In the example you just gave about using outside physician consultants for the other GAPMS, 14 15 did AHCA pay those other consultants? 16 For other GAPMS? Those consultants are Α 17 usually salaried or have hourly rates from our 18 subcontractors. 19 Okay. Okay. But you didn't enter into any Q 20 kind of vendor agreement with them? 21 No, they're already employed by one of our Α 2.2 subcontractors. Okay. Did all of the \$35,000 paid to the 23 0 24 vendor -- paid to the consultants come directly from 25 AHCA?

1 A Yes.

4

2 Q Was AHCA reimbursed by anyone else for those 3 consultant payments?

A No.

5 Q Other than through its subcontractors, has 6 AHCA ever previously retained outside consultants to 7 undertake a review of the evidence-based clinical 8 practice guidelines for GAPMS?

9 Α Well, previously, we did actually have -- of 10 course, we discontinued it, but we did have PAYS, which 11 was back -- and we had it throughout 2017 -- which was a 12 course and evidence review guide program that I had to 13 subscribed to. We did have that and often referenced that in the early days, but after the amount of time, 14 15 and because it was an expensive subscription, we 16 discontinue it.

Q So that was a subscription service. Do you -can you recall any time that you engaged with an outside consultant, other than those employed by your subcontractors?

A No.

22 Q What about to undertake a review of 23 professional literature?

24 A No.

25 Q To actively participate by making a

21

- 1 recommendation or assessment as to the experimental or 2 investigational nature of the service?
 - A No.

Q Why didn't you use the subcontractors -- AHCA subcontractors, why didn't you rely on their expertise in developing the June 2022 GAPMS?

7 Because of this GAPMS and because of the Α nature of the subject. We did anticipate litigation 8 9 after -- once the report was done and once we were 10 working on it. So because of that anticipation, we 11 needed to have experts that were -- that did have a 12 degree of expertise in this field. Our subcontractors, 13 their practices are more like general practitioners, or may be specialized in other areas, and they wouldn't be 14 15 able to adapt quickly enough to the learning curve to 16 provide a valuable assessment.

Q So you were concerned about attacks litigation
might have on the integrity of that report itself?

19

3

A Can you repeat that?

Q Well, you said that because you anticipated litigation, that's why you engaged with consultants who had expertise, in particular --

A The Agency needed as robust a report as possible. So because we needed such a robust report, and because of the HHS guidance, the Department of

Health, so the fact that there were published documents out there, the Agency did need to come up with a response that we needed to disseminate as robust as possible, and that's why we engaged with the outside experts.

Q Why is gender-affirming care different fromany other Medicaid service?

Well, I'm going to defer to GAPMS process and 8 Α 9 our GAPMS report. For -- for the response to that is 10 that gender-affirming care, of course, we are looking 11 at, like, a treatment model that has very weak and 12 low-quality evidence supporting it. And because we did 13 a review and assessment of the literature, because there are a lot of claims made, especially by HHS, in 14 15 particular, about its efficacy, because of its nature, 16 because of -- and because of the low-quality evidence, 17 that's how we deemed it. I mean, it is a different sort 18 of care than we can consider traditional.

Q The GAPMS process is used to determine whethera Medicaid service is experimental, right?

A

21

2.2

Q So then that question is presented in any

Yes.

23 Medicaid service you're evaluating under GAPMS?

24 A That's right.

25 Q So why is gender-affirming care different?

I'm going to defer to the conclusions we drew 1 А 2 in the GAPMS report. 3 Why did you anticipate litigation before you 0 even reached a decision? 4 Well, I think that's because, I mean, this is 5 Α 6 often a very touchy subject. It's something that's 7 frequently seen in the mainstream media. And, of course -- of course, the documents from HHS. It is a 8 9 high-profile issue. It's considered by many to be 10 controversial. So that should -- that's kind of why we 11 did anticipate potential litigation resulting from 12 whatever determination we made. 13 Q Why didn't you need gender dysphoria experts from the prior gender dysphoria GAPMS? 14 15 Α For the prior ones? 16 Uh-huh. Ο 17 So for the prior ones, I think at the time --Α 18 I mean, we have to take it in context at the time, and, 19 of course, these were done piecemeal, these were all 20 separate reports, not one large one. So in the course -- at the time because this wasn't viewed as far 21 2.2 as a potential hot topic, there wasn't the HHS guidance 23 at the time, that's -- I think the best explanation as 24 far as to why we decided not to engage with consultants. HHS releases guidance all the time, though, 25 Q

	Pac	ſe	1	43
--	-----	----	---	----

1	about	coverage?

2	A Uh-huh. That's correct. It does.
3	Q Did you anticipate litigation for the 2016
4	GAPMS memo on puberty suppression therapy?
5	A The staff of the Agency who were present for
6	that determination are no longer with the Agency, so we,
7	in our current capacity, can't speak to that.
8	Q Did you undertake any research to derive an
9	answer for that question?
10	A No, we didn't.
11	Q Did you look at any past memos related to
12	whether or not the GAPMS might have litigation
13	initiated?
14	A It's always a concern with every coverage
15	determination and every GAPMS we do because inevitably,
16	if we do say no to a service, there's going to be
17	disappointed party. So it is a consideration we always
18	have in place that there might be litigation.
19	Q Well, then that brings me back to the question
20	as to why gender-affirming why this GAPMS is
21	different?
22	A Well, this brings us back to the present
23	circumstances behind how much attention the subject's
24	been drawing in the media. The and it goes back also
25	to the HHS guidance, which was making claims based on

evidence that we determined was insufficient. 1 2 Q So I only listen to NPR, I'll be honest. Ι 3 don't watch any news. What media? Where's this a hot topic in the media? 4 Oh, I mean, let's see here. I mean, we can 5 Α name a lot of sources. I also -- I do listen to NPR 6 7 myself. So NPR actually does periodically have an article on it. Then, of course, let's see here, there's 8 9 quite a few other sources of things listed here. CNN, 10 MSNBC, ABC, NBC. Your major outlets. New York Times. 11 The Guardian. 12 Q How long has the media coverage been going on 13 for? So as far as media coverage goes, well, the 14 А 15 media coverage, there's always been smatterings of it 16 here and there, but I think when -- as far as it 17 becoming a consistent theme probably the past year. But 18 that's not me speaking on behalf of the Agency, that's 19 me speaking from personal observation. 20 Okay. Fair enough. Did AHCA share any of the 0 21 draft consultant reports with external entities? 2.2 А We did not. The Governor's office? 23 0 We did not. 24 А 25 Q Department of Health?

Page 145 We did not. Α 1 2 Q No one? 3 Α No, they stayed internal. Did AHCA provide any material to the 0 4 consultants to review in drafting their reports? 5 6 Α No, we did not. 7 0 Did AHCA edit the reports of the consultants? There was some copy editing for style and 8 Α 9 Other than that, no, we did not make edits to grammar. 10 the content. 11 So no substantive edits? 0 12 Α No substantive edits. 13 Q And that includes Lappert's report? That includes Dr. Lappert's report. 14 Α 15 0 And Dr. Donovan's report? 16 And that's for Dr. Donovan. Α 17 And did any of the consultants provide edits Q 18 to the AHCA GAPMS report? So after we finished the draft, we did send 19 Α 20 drafts to Doctors Grossman and Dr. Van Wol and they 21 provided some feedback, but none of the feedback met --2.2 were made -- resulted in drastic changes. I think -- I 23 think Dr. Van Mol suggested we -- there's one more article we could discuss, and we added some content in 24 there regarding that. They did help us correct some 25

terminology errors. There are some -- so there are some technical edits that were made. But as far as anything substantive, my first draft, I mean, was largely intact by -- from the first draft process to when we had the final draft.

6 Q Okay. And you were the only person involved 7 in making the first draft?

I can articulate a little bit more on how that 8 Α 9 went. So while the experts -- while the experts were 10 composing their reports, I was composing mine. And once 11 we had their reports, then that was -- then we did 12 add -- we added some snippets from their reports in our 13 report to make it more, I quess you could say, cumulative. 14

Q Okay. So only after the consultants who wrote a report, those reports were done, then you pulled some of that information into your --

18 A Correct. So my section was complete when we
19 started receiving their reports.

20 Q Okay. Okay. What was the date of your first 21 draft?

A I think the date of my first draft -- let's
see here -- want to say early to mid May.
Q Okay. So, like, second week of May-ish?

25 A Somewhere around there, yeah.

Going back to the edits that the consultants 1 0 2 provided to your report, what terminology had to be 3 corrected? What was it? I mean, it was some medical 4 Α terminology. I don't remember the specifics. 5 I mean, 6 it was very, like, miniscule changes. 7 Where they red lines in, like, a Word 0 document? 8 9 Α No, the edits were given to me verbally and I 10 made them -- sometimes I made them right there when we 11 were talking to them. 12 Okay. You stated in your declaration filed 0 13 with the court on January 25th, 2023, that the only sources you relied on for the June 2022 GAPMS, were 14 15 those cited in the works cited section of the report; is 16 that a correct statement? 17 А That's correct. 18 So that means that the only sources that you 0 consulted or considered -- or cited in the June 2022 19 20 GAPMS report? 21 During the -- yeah, during the writing of the Α 2.2 GAPMS, those were the sources consulted. 23 Nothing else? 0 During the drafting of the report, nothing 24 А 25 else.

Page 148 What about after? 1 0 2 Α Afterwards, more out of intellectual curiosity, I did want to try to see what else was out 3 there, but that was more for personal intellectual 4 curiosity than it was for professional purposes. 5 6 0 Okay. What were those things that you 7 reviewed? Articles by Jack Turban. 8 Α 9 0 Can you spell his last name? 10 А T-U-R-B-A-N. 11 I'm not familiar. 0 12 Well, it's -- he is cited in our report, but Α 13 he also is -- he's frequently quoted a lot, so I was curious to see what other in print articles he had 14 15 produced. 16 Ouoted in what? Q 17 Α He's often cited in, like, news stories, media. 18 19 MS. DEBRIERE: Simone just got a note that 20 folks are having trouble hearing me. 21 BY MS. DEBRIERE:: 2.2 All right. When you were considering whether Q 23 the services listed at 59-G-1.050(7) were experimental, 24 did you evaluate whether excluding those services would 25 be budget neutral?

1

2

3

A No, we did not.

Q Did you consider whether private insurance covers the services excluded by 59-G-1.050(7)?

For this one we didn't, but primarily when we 4 Α do GAPMS, we really aren't interested in public and 5 6 private insurers. We're primarily interested in state 7 Medicaid programs and Medicare since, like, Florida Medicaid, they're public payers. So primarily, we 8 9 really want to know what the public payers say. 10 Usually, our lowest priority for GAPMS is to provide 11 analyses of what private payers pay. And generally, 12 often we need those to supplement if we're unable to get 13 that many policies from Medicaid programs across the 14 nation, but since it's -- for this GAPMS, we actually 15 surveyed all 50 states, then we had adequate information 16 from that. Most GAPMS reports, usually we get maybe 10 or 12 when it comes down to coverage policies, it's --17 18 it's pretty much what we can find in a certain amount of But for this one, we've -- since Dede Pickle was 19 time. 20 working on it independent, she was able to survey all 21 50.

Q And why is it covered under private insurance informative of whether or not a service is experimental? A Can you repeat that? Q Uh-huh. Why don't you rely on -- why don't

you consider private insurance coverage to be
 something -- I'm having trouble formulating what should
 be a simple question.

Why don't you look at private insurance coverage when you're determining whether or not a service is experimental?

7 Α Well, private insurance works differently. Ι mean, Florida Medicaid, like Medicare, is a 8 9 taxpayer-funded health care system. Private insurers, 10 since they're privately funded, there's a great deal 11 more latitude, what they can cover and what they don't 12 have to cover, and they're more subject to the 13 competition of the market, as opposed to Medicaid programs. So we -- while we do -- some often will look, 14 15 but often it's -- we often try to find what private 16 payers pay for following what we get from Medicare and 17 Medicaid. So, I mean, when it comes down to it, we can, 18 but it's not an absolute requirement, and we really do 19 want to find out what the Medicaid programs are paying 20 for. That's our first and foremost criteria for looking 21 at the coverage of -- other payers coverage.

Q So it's not apples to apples, because in Medicaid and Medicare, you've got state taxpayer dollars to consider, correct?

25

A That's correct.

Okay. But when you undertook the June 2022 1 0 2 GAPMS, you did not evaluate whether or not excluding those services would be budget neutral? 3 No, we didn't for this one, but we -- but 4 Α that's also not necessarily unique to this, as well. 5 So in other GAPMS, you've not evaluated the 6 0 7 budget neutrality of the service, whether or not you're going to cover it? 8 9 Α That's correct. In the GAPMS I did in 2017, 10 for, I think, like the nitrous oxide of -- pretty much 11 like an adjuvant to this, kind of jumped-up asthma test, 12 we didn't do a cost budget analysis because, like, we 13 weren't going to cover, it's not going to affect anything. 14 15 0 So then you did evaluate whether it was budget 16 neutral. You won't be covering it, so, therefore, it 17 was neutral? 18 Α Well, we just -- we just don't -- we just don't do one, because, I mean, we're not covering it. 19 20 So it comes down to if we were going to make a coverage determination, that's when you do a fiscal analysis. 21 So 2.2 a coverage determination is definitely turned into a 23 fiscal -- it needs -- it needs a fiscal analysis, because we're -- need to find out whether or not we're 24 going to be able to stay within our budget. 25

I see. I see. So in this instance, because 1 0 2 we are talking about the only GAPMS that excluded a service previously covered, did you do anything to 3 determine whether or not that would cost or save the 4 state money? 5 6 Α No. 7 I think you have -- you brought information 0 with you today about this. How did you collect state 8 9 Medicaid program coverage data? 10 So on that spreadsheet, so Dede Pickle, she Α 11 went across the -- yeah. So she --12 MR. JAZIL: Do you want to mark it as an 13 exhibit? (Whereupon, Exhibit No. 13 was marked for 14 identification.) 15 THE WITNESS: She surveyed 50 states and I 16 17 think territories -- even up in the territories --18 and was looking to see what their stances were on 19 gender-affirming care, to see whether or not they 20 had statements saying that they will cover it or policy saying that they wouldn't. And then 21 2.2 there -- those that just didn't have a policy 23 available, or had no policy in place. BY MS. DEBRIERE:: 24 25 Ο So Dede Pickle was the one who put together

1 the spreadsheet?

2

A Yes.

Q Okay. And where did she look to find this4 information in each state?

Well, she went to their state Medicaid web 5 Α 6 pages, looked at their -- like, their coverage guides or 7 materials in each state Medicaid -- Medicaid programs. There can likely be idiosyncrasies. I mean, some 8 9 have -- some are like ours, have a ton of coverage 10 policies, others are like Texas, Texas has one gigantic 11 coverage policy, which actually does -- despite the fact 12 it's huge, it's actually kind of more efficient. 13 It's -- you can get everything from there. But 14 that's -- that's what they do in Texas. Everything's 15 bigger in Texas. But she went and looked at all of the 16 different state -- various state Medicaid programs and 17 saw what their policies were and saw what was available. 18 And, of course, put the findings in the GAPMS report. Did she only do an online search? 19 Q 20 Α Yeah, it was only an online search. Did she contact any of the Medicaid programs? 21 0 2.2 А No. 23 Did she look at any of the policy reporters? 0 24 Α No, we -- no, we didn't use policy reporter for this GAPMS. 25

Q So just looking at the state's Medicaid Agency websites?

3 Α For the Medicaid, yes. But, generally, without having worked in Medicaid, one of our research 4 criteria for across all kinds of reports and projects is 5 6 that we do want to see what other states do. And so 7 that gives us a great deal of familiarity of how to navigate other states' programs. And one of our side 8 9 projects is the statewide Medicaid managed care program. 10 And, of course, we're always looking to see what other 11 states are doing. So we get a great deal familiar with 12 how to navigate the web pages of other states.

Q So at least half the states' Medicaid programs explicitly cover pubertal suppression treatment for gender dysphoria, is that correct?

16 A Based on -- based on the findings of the map.
17 So what -- so I will defer to the findings on the map.
18 Q Only ten exclude?

Defer to the findings as stated in the map. 19 Α 20 Okay. How about we do this: Based on the 0 21 findings in the map, only 10 states explicitly exclude 2.2 pubertal suppression therapy. How did you take that 23 into account when you reached the conclusions that you did about the services being experimental, that 24 particular service being experimental? 25

As far as that goes, it's informational, but 1 А 2 there was -- there was a divide between states that do 3 cover and states that don't. Primarily when making the determination we focus -- we really focused on the 4 evidence and what the evidence said about treatments for 5 6 gender dysphoria since the Medicaid program -- since 7 there is -- seems like there's an absence of policies for a lot of states. There are some states that come 8 9 out and say yes, and then there are some states that say 10 There is a -- there's a divide and you can even no. 11 potentially say like there could be a debate between 12 amongst the 50 states plus territories of whether or not 13 coverage is appropriate.

Q But you did say earlier on that you -- whether a service is covered under the other state Medicaid programs is usually a factor that you weigh heavily in determining whether a service is experimental.

MR. JAZIL: Object to form.

19THE WITNESS: So when it comes down to it --20it's like, so often, it's not just other Medicaid21programs, but also Medicaid programs are similar to22Florida. There are some Medicaid programs -- I'll23name two -- New York and California that are --24that cover things very, very liberally, as far as25services. Like, these added everything in their

18

1	fee schedules, where Florida Medicaid and
2	Florida Medicaid prides itself on being a very
3	fiscally responsible Medicaid program. So often we
4	try to see what states that are similar to our
5	Medicaid program, what they do. But we also do
6	see, we see overwhelming amounts of coverage from
7	states like us and states across the union, then
8	that does factor in our decision, but for in this
9	circumstance, because there is a split, if we were
10	going to have to more rely more so on the
11	evidence, than the notion that all these states
12	cover services, there it's not it's not
13	unanimous at all.
14	BY MS. DEBRIERE::
15	Q Did you ever contact the states that
16	explicitly exclude and ask them why they explicitly
17	exclude?
18	A We did not.
19	Q Did you ever call those states that have no
20	coverage statement one way or another and ask them?
21	A We didn't reach out to states. I mean, their
22	policy's online. I mean, that I mean, their
23	published policy is sufficient to give us the responses
24	we need to look at to look at it. Even for other
25	GAPMS, we don't contact other states.

Did you analyze how much Florida Medicaid 1 0 2 spends on -- spent on treatment for gender dysphoria prior to the categorical exclusion? 3 No, we did not. 4 Α Do you have any plans to reevaluate your 5 Ο 6 findings in the GAPMS report based on the September 2022 7 release of the WPS standards of care version eight? So in the immediate term, well, we don't, 8 Α 9 so -- but, I mean, we can reopen the GAPMS later on, 10 there is -- there is a process for that. But generally, 11 I mean, these standards of care, I mean, based on the 12 release of one set of new standards of care, I mean, for 13 the time being we don't have any immediate plans, not based on the release of one new update. 14 15 Ο Okay. How long did you personally work on 16 that initial draft of the June 2022 GAPMS report? 17 Oh, I was working on it pretty much until the Α 18 day it came out. 19 And you started that second week in May? Q 20 Α Well, no, that was after I had the very first 21 initial draft done. 2.2 0 Okay. So tell me when you first started 23 working on it. 24 А April 20th. Okay. So from April 20th until when it came 25 Q

Case 4:22-cv-00325-RH-MAF Document 120-6 Filed 04/07/23 Page 196 of 346

Page 158 Published on what -- well, we know that it was 1 out. 2 first reviewed by your higher-ups on June 1st. So April 20th to June 1st? 3 Yeah, that's sufficient. 4 Α Ο Okay. And you worked with Nai Chen and Dede 5 Pickle. 6 7 А Uh-huh. Did you read all of the articles in the 8 Q work-cited section? 9 10 I read every single document in that works Α cited section. 11 12 0 88 articles? 13 А All of them. Okay. Were you able to read everything, 14 0 understand it, and draft a report in --15 16 Α Yes. 17 How often during that time period did you Q communicate with the consultants? 18 Oh, I think between four and five times. 19 Α 20 And four or five times over that entire time Q 21 period? 2.2 А Yeah, during those time periods, yes, we have -- periodically have, like, a one-hour discussion 23 with them. 24 So you talked to them about five hours total 25 Q

Page 159 over that time period? 1 2 Α I think that's a valid estimate, yes. 3 Okay. Do you think it's more than that, like 0 more like 10 hours? 4 Α No. 5 Okay. Turning back really quickly to the 6 0 7 amount of -- the cost of treatment for gender dysphoria. How much was spent on the coverage of gender dysphoria 8 9 versus how much was spent -- strike that. 10 Do you know how much, prior to the adoption of 11 the categorical exclusion, how much annually AHCA spent 12 on the coverage of gender dysphoria? 13 Α We did not. 14 Are you able to obtain that information? Ο 15 Α Our data analytics between managed care plans paid per claim, and anything in fee-for-service, our 16 17 data bureau could probably muster that up. 18 Is there a way that we should ask for that Q 19 information to make the guestion clearer? 20 Α You'd want to -- you would -- to put in a 21 request we would need diagnosis code, we'd need NDC, and 2.2 we would need CPT codes. And what's NDC? 23 0 24 Α National Drug Code. Okay. And then for surgery, what would you 25 Q

1	need?
2	A You would need the corresponding CPT code.
3	Q Okay. So you need the diagnostic code, the
4	NDC for drug coverage, and the CPT code?
5	A And the time the date ranges.
6	Q And the date ranges. Okay. And then you
7	could tell us how much AHCA or the Florida Medicaid
8	program paid in coverage of treatment for gender
9	dysphoria over a given period of time. Okay. When you
10	were communicating with the consultants about drafting
11	the June 2022 GAPMS report, what kinds of questions did
12	you ask?
13	A Generally, questions about mostly just
14	questions about, like, articles, like studies, making
15	sure we have our bases covered, things like that. We
16	wanted to make sure we didn't miss anything, or there's
17	anything glaring we because it isn't a piece of
18	academic work it is, it is mainly it's like a thesis
19	or a dissertation, because we make a case, we have to
20	support that case. So we want to make sure we have our
21	bases covered.
22	Q What were the consultants' positions on WPATH?
23	A Their positions were that I think they
24	identified all they did was identified it as an
25	advocacy group, like a combination of clinical

professionals, plus advocates, community activists can 1 join it. So that -- it's kind of a hybrid organization, 2 3 that they explained that to us. So that was pretty much all the information they gave. 4 And you felt like that was an adequate 5 0 6 explanation of what WPATH was? 7 Α Yes. What about the Endocrine Society? What was 8 Q 9 their position on? 10 Their position was the Endocrine Society. I Α 11 mean, it is an established clinical organization. They 12 felt like the other guidelines, they had released 13 quidelines, but the Endocrine Society was transparent in releasing their guidelines. They did clarify that their 14 15 recommendations were based on weak or very weak 16 evidence. They also clarified that their guidelines 17 were not a standard of care, that they were just 18 quidelines. 19 And that's the Endocrine Society. Who does 0 20 that -- or your consultancy, who did that? 21 The Endocrine Society. So the Endocrine А 2.2 Society, in the text of their guidelines, they do 23 identify each line of the treatment model, like the 24 puberty suppression, the cross-sex hormones and 25 surgeries. Primarily the hormones is the Endocrine

1	Society, but they are very clear that it's either low-
2	or very-low-quality evidence that supports it, and they
3	also do put that disclaimer on there, this is not a
4	standard of care.
5	Q What was your what was the consultants'
6	position on the American Psychiatric Association's
7	recommendations for gender-affirming care?
8	A It didn't come up in the conversations.
9	Q Okay. How about the AAP?
10	A The AAP was that the evidence available to
11	support the AAP's positions wasn't sufficient.
12	Q Okay. What about the AMA?
13	A We didn't talk about the AMA.
14	MS. DEBRIERE: Okay. So I would like to do
15	you have the exhibit of the Medicaid policy routing
16	and tracking form for the June 2002 GAPMS?
17	MR. JAZIL: Can you re-mark on this
18	MS. DEBRIERE: Yes, please. I think I need
19	a bigger one.
20	(Whereupon, Exhibit No. 14 was marked for
21	identification.)
22	THE WITNESS: Yeah, that new formulation makes
23	it taste just like the real thing.
24	VIDEOGRAPHER: It's pretty good.
25	MR. JAZIL: See, we're finding common ground.

THE WITNESS: Wasn't, like, Coca-Cola and all 1 2 their peace commercials, they were holding hands around the world? That was from the '70s, I think. 3 BY MS. DEBRIERE:: 4 5 Okay. So I'm handing you what's been marked Ο as Plaintiff's Exhibit 14. It's the Medicaid policy 6 7 Routing and Tracking Form for the June 2022 GAPMS. There's a start date column there. What's that mean? 8 9 Α That's a start with the routing process. So 10 generally, for this, usually -- usually they try to 11 provide like a window. We always have, like, a window 12 of review. So for this, we enter the dates in the 13 The GAPMS is routed to first -- well, actually, system. since my supervisor Dede was out, I was her delegate, so 14 15 I did sign on her behalf. Then it went to Ann Dalton 16 who signed. And, of course, Secretary Weida, of course, 17 signed in his role, and then went to Deputy Secretary Wallace. 18 19 Okay. So start date's when the document hits Q 20 their desk? 21 Α Yes. 2.2 Q Okay. And then end date's when they've 23 reviewed it and passed it on? 24 Α Yes. Date received is going to measure the 25 Q Okay.

1	date that it hit their desk, but they didn't necessarily
2	pick it up and start reviewing it? I'm trying to
3	understand what's the difference between
4	A Date received should be when they got it.
5	Q Okay. And the start date's when they start
6	reviewing it? What's the difference there?
7	A Start date, end date yeah, that should be.
8	Q And the approval column means that the GAPMS
9	was approved by each person that checked the box and
10	initial by it?
11	A That's correct.
12	Q Okay. So the June 2022 GAPMS report, which is
13	46-pages long and contains five separate reports from
14	AHCA consultants, it was reviewed and approved by each
15	person on this list in one day?
16	A Yes.
17	Q And all four people on this list reviewed and
18	approved the June 2022 GAPMS report in the span of two
19	days?
20	A Uh-huh, that's correct.
21	Q Oh, I see there MB for DVP.
22	A Yeah.
23	Q Why choose to adopt the 2022 GAPMS report into
24	rule?
25	A Because so since we had determined it to be

experimental and investigational, so we decided that we 1 2 didn't need to make the -- based on the evidence, based 3 on what the GAPMS said, the categorical exclusion promulgating the rule is necessary. 4 Okay. So you adopted into rule because it was 5 Ο 6 a categorical exclusion? 7 Α It was going to be, yes. When was that decision made? 8 Ο 9 Α The decision that was made -- the decision to 10 make -- to make a new categorical exclusion, of course, 11 that was not going to be made until after we had 12 completed the GAPMS report and signed off on, because 13 obviously, had either the experts had they disagreed 14 with one another, or if I'd come up with a different 15 conclusion, can't make a categorical exclusion unless 16 everyone was in sync. So it was one of those things 17 where had -- had the expert opinions disagreed with each 18 other, had I come up with a contradictory conclusion, 19 there -- you had -- we had to wait until after the 20 report was done before we'd sign whether or not to 21 proceed with the categorical exclusion. 2.2 And when was the decision made to adopt it Q 23 into rule? Was that at the same time that you decided to make it a categorical exclusion? 24 Α That was made after we had had the report

Veritext Legal Solutions

1 signed and done.

-	
2	Q Okay. Sorry. I need to be more specific.
3	What date was that decision made?
4	A Well, I think it was probably made June 2nd.
5	Q Okay. And who made that decision?
6	A That would have probably have come down from
7	Secretary Marstiller, that would have come down from
8	now-Secretary Weida, and it would have come from our
9	General Counsel, Josephina Tamayo?
10	Q Why would it have come from those people?
11	A So because, of course, with our General
12	Counsel, with our Secretary, I mean, they do make the
13	decisions for the Agency. It's not out of the I
14	mean, it is typical in their role to make a decision to
15	promulgate something into rule.
16	Q Would that generally, though, be handled by
17	the Bureau of Medicaid policy?
18	A Sometimes. It depends on depends on the
19	nature of the rule change. Depends on where where
20	it's originating from.
21	Q How often has that decision come from the
22	Medicaid Secretary?
23	A So let's so to talk about the rulemaking
24	process a little bit.
25	Q Yeah.

Page 167 So rule -- proposes for rule changes come from 1 А all different directions and --2 3 Let's back up. Instead of talking generally 0 about rule changes, let's talk about changes to coverage 4 policies. 5 Those can be made by our Deputy Secretary. 6 Α 7 Those can come from the Secretary. I mean, anyone who --8 9 0 How often does that happen? 10 Α We can't speak to how often it happens. Ι 11 mean, it does happen. 12 Had it happened more with the Bureau of Ο 13 Medicaid policy? 14 You mean, those in Medicaid policy who Α 15 initiated these changes? 16 More often than not? Ο 17 I actually would probably say not. Α 18 Oh, okay. I'm just -- I'm surprised because Ο we learned from Ms. Dalton that the -- both the 19 20 rulemaking process and the coverage policy units are 21 housed within the Bureau of Medicaid policy. 2.2 Α Well, that's correct, they are, but often 23 they're responding to directives given to them from either senior leadership or legislative changes. 24 25 Q Okay.

Page 168 So, yeah, while they are the ones that 1 А 2 implement and write and craft the new policies or update the policies, they're often not the ones that are 3 piloting these new policies. 4 5 Or initiating the decision as to whether or Ο 6 not --7 Α Precisely. -- or adopt them into rule? 8 Q 9 Α Correct. 10 So you said that it was the decision to adopt 0 11 into rule was made on June 2nd, is that correct? 12 Α That's correct. 13 Q Okay. And the notice of rule development, that was issued on June 3rd, correct? 14 15 Α Yeah. 16 Q I swear. 17 Α Yeah, I'm deferring to the record on that. 18 Q Sure. The rulemaking process is highly documents, so 19 Α 20 I'm going to be deferring to the documentation for the 21 rulemaking process. 2.2 0 Okay. So it took less than 24 hours for AHCA 23 to decide to adopt the conclusion in the 2022 GAPMS report into a rule? And even less than that, because 24 you made it the same day that the report was released, 25

Paq	re	1(69

1	correct?
2	A Yes.
3	Q And at that time, you also knew which section
4	of 59-G it was going to go into?
5	A Yes, we did.
6	Q And who had to sign off on that decision?
7	A So all of our so whenever we adopt a rule,
8	it does go through a lengthy routing process. So it
9	does start the process starts in the Bureau of
10	Medicaid Policy, starts with the rules we have a
11	rules unit. That gets signed off on, then it goes to
12	the AHCA administrator authorities section, they have to
13	sign off. Then after that it goes to the Bureau Chief
14	of Medicaid Policy. Of course, likewise, they have to
15	review and sign off. Then it goes to the Assistant
16	Deputy Secretary of Policy and Quality. They have to
17	sign. Then, of course, the Deputy Secretary for
18	Medicaid has to sign. General Counsel's Office has to
19	sign. And then the Secretary is privy to all the
20	changes. And if Secretary decides like, wait, wait, we
21	can't do this or, no, there's a problem, yeah, that
22	sometimes can result in a frustrating headache, because
23	it takes a lot of work to get something that far.
24	Q Well, so the decision to adopt a categorical
25	exclusion to rule was made on June 2nd and the Notice of

Pac	яe	1	7(С

1	Proposed Rule was made on June 3rd. So it was routed
2	through that entire process in less than 24 hours?
3	A Are we talking about the GAPMS or the rule?
4	Q The rule?
5	A Yes. And that and that's not unusual
6	sometimes for for the process to move very quickly.
7	Q Okay. Because you just made it sound like it
8	was a very lengthy process.
9	A It is with the number of people, but it's
10	the rule content is very it's a very small addition.
11	It's not like a brand new coverage policy, because
12	often it depends on the nature of the rules. Like
13	one addition, that can move fast. Sometimes with
14	like, for instance, in my experience as a program
15	administrator, we completely overhauled the community
16	behavioral health policies. That was five new coverage
17	policies. So that, of course, is going to require a
18	much lengthier review process rather than a quick
19	amendment to a rule. So it really depends on the nature
20	of the rule. If it's a very lengthy coverage policy,
21	yeah, that can take some more time if it's but if
22	it's like adding a few bullets or amending a line, that
23	can that can move along much faster because the
24	review time's just not a lengthy review process is
25	not necessary.

Or deciding to eliminate three types of 1 0 2 services that were previously covered by Florida Medicaid? 3 Α Correct. And, of course, but -- and, of 4 course, we have the GAPMS memo to substantiate that. 5 6 0 Okay. Okay. So speaking to the rule, it bans 7 Medicaid coverage for -- puberty blockers or cross-sex hormone therapy and surgery if done so to treat gender 8 9 dysphoria, correct? 10 Α That's correct. 11 But not to treat other diagnoses? Ο 12 Not to treat other diagnoses. Only for the Α 13 diagnosis of gender dysphoria. Okay. Is this the only time that GAPMS has 14 0 15 been used to categorically eliminate coverage of treatment for a particular diagnosis? 16 17 For the one -- I think pretty much since the Α institution of the GAPMS process, I think this was a 18 first. 19 20 Once the decision was made to adopt the 0 21 conclusions of the 2022 GAPMS report into rule, who was 2.2 in charge of that process? 23 Α So our rule promulgation process, Cole 24 Gerring, he oversees the rule promulgation process for our coverage policies and administrative rules for 25

Page 172 Medicaid. 1 Does he head the Rules Unit under the Bureau 2 Q 3 of Medicaid policy? Yes, he does. 4 Α 5 Who drafted the actual language for the rule? 0 I believe -- I believe he drafted the 6 Α 7 lanquage. Did anybody revise it or have any input 8 Q 9 that --10 There was input. So I mean, there were some А discussions. I remember we did have a meeting with 11 12 everyone to -- between, I think, like, Sheena Grantham, 13 myself, I think Dede Pickle, I think Secretary Weida, I think like Sheena Grantham from General Counsel's 14 15 office, since rules are her area. I think there were 16 there was a -- there was a discussion on making sure 17 this was the finalized content we wanted. And how long did that discussion take? 18 Q About an hour. 19 Α 20 Okay. And what kinds of topics were discussed 0 21 during that? 2.2 А Just determining how granular we should get, 23 mostly. Okay. Okay. Was there any conversation about 24 Q whether adopting this categorical exclusion might 25

Page 173 violate comparability under the Federal Medicaid Act? 1 2 Α No. 3 0 What about EPSDT? No, because since we already have the -- we've 4 А already had the GAPMS report to substantiate the 5 overriding EPSDT guideline -- guidance and requirements. 6 7 Because Florida Medicaid does not have to 0 cover a service under EPSDT if it's experimental? 8 9 Α That's correct. 10 I had another question. Talking about how 0 11 granular to get with the language, was there any 12 conversation about what the Federal Medicaid Act 13 requires in terms of prescription drug coverage? I don't think so. Not during that 14 А 15 conversation. 16 Any other conversations had about that? 0 17 Α As far as the federal requirements for 18 prescription drug coverage? No, I don't think we had any conversations like that. 19 20 Okay. Any other conversations about 0 21 comparability under the Federal Medicaid Act? 2.2 А No. So comparability under the Federal Medicaid 23 0 Act was not taken into consideration when adopting the 24 categorical exclusion? 25

1

A No.

2

3

13

2.2

23

Q Who planned the public hearing regarding the proposed language in 59G-1.050(7)?

Α So for the public hearing, since we did 4 anticipate a larger than normal crowd, we -- so I think 5 that was a joint effort between Cole Gerring I think, 6 7 Chief -- now Chief of Staff Brock Juarez, then Chief of Staff Cody Farrell, and I think -- I think Secretary 8 9 Weida also had a little bit of input when it came down 10 to selecting the venue and making sure that we had 11 adequate staff and then also arranging for security as 12 well.

Q Why did you feel a need for security?

Because of this -- the controversial nature of 14 Α 15 the change and how those with opinions on it -- those 16 with feelings about it, I mean, they are deep-seated. Т 17 mean, there's -- so because of the sensitivities 18 involved, we just felt that it would be best in the 19 event -- and we did think it was unlikely, but in the 20 event that someone might get upset or unruly, to have 21 security.

Q Why did you pick the venue you picked?A Size and location.

24 Q What factors did you take into consideration 25 for size and location?

1	A That we would have adequate seating. That, of
2	course of course, location where it was, being
3	downtown, so
4	Q Downtown being an easier location to get to?
5	A Yes.
6	Q Why did the location need to be easy to get
7	to?
8	A Because, I mean, since I mean, you know, we
9	do government in the Sunshine, we wanted the hearing to
10	be accessible to as many people as possible, so we
11	wanted to be able to fill as many seats as we could.
12	The facilities here at AHCA weren't going to be
13	sufficient for that. The Department of Transportation
14	auditorium was a very, very good venue, not just not
15	just to be able to provide those of us who were on the
16	panel visibility to the audience, but also just because
17	of the seating capacity. So it just was an ideal venue
18	compared to what we had available at the Agency.
19	Q Where do you normally hold rule hearings?
20	A We usually hold them here.
21	Q Why were you concerned about adequacy of
22	seating?
23	A Because we did expect a large turnout.
24	Q Why did you expect a large turnout?
25	A Because of the amount of coverage that the

1	GAPMS report had received, because of everything that
2	we'd been seeing, as far as per previous news stories
3	prior to the release, we just knew that this was a
4	sensitive subject. A lot of people have a deep-seated
5	conviction about it one way or the other, and we just
6	anticipated a large turnout.
7	Q In the planning of the public hearing, did
8	AHCA communicate with the Governor's office at all?
9	A No.
10	Q Did AHCA communicate with Department of Health
11	at all?
12	A No.
13	Q Who participated in the public hearing from
14	AHCA?
15	A So the participants from AHCA were myself,
16	Sheena Grantham, whose General Counsel's office,
17	Secretary Weida. Those are the those are the three
18	of us who were on the panel for AHCA. And, of course, I
19	think Cole Gerring handled the administrative procedures
20	and then I think to help help with crowd control, we
21	had, I think, Brock Juarez and some of the staff from
22	communications also helped arrange in making sure that
23	there's adequate seating, and just kind of serve just
24	helping out in any way, or any capacity that was
25	necessary, as needed.

Did anybody at AHCA help facilitate the 1 0 2 attendance at the hearing? 3 There -- I think there's a speaker sign-in А sheet at the entrance. I think that -- like, I think 4 one of the Agency staff under Brock at the time was --5 6 was allowing people to sign in. 7 Ο Were there any particular people that were encouraged to be at the hearing? 8 9 Α No. Are you aware of the Governor's office 10 Ο 11 encouraging anybody to attend the hearing, anybody in 12 particular? 13 А No. No. Did anybody pay someone to attend the hearing? 14 Ο 15 Α So for our -- for our experts, Dr. Grossman, 16 Dr. Van Meter and Dr. Van Mol, they were compensated for 17 their time spent at the hearing, or their time 18 traveling -- for Dr. Van Mol and Dr. Van Meter, their 19 time traveling and their travel expenses. So we did 20 reimburse them, but that was it. 21 Did that include the same agreement with the Ο 2.2 \$35,000 cap or was that a separate agreement? 23 Α I don't think it was a separate agreement, 24 because the three of them had not come anywhere close to 25 exhausting their caps.

Did AHCA provide any materials to those 1 0 2 consultants prior to the hearing to review for the 3 hearing? On the day of the hearing we gave -- we gave 4 А them each bound copies of the report, but those 5 materials were already available online, so -- but we 6 7 just -- we just gave him paper copies or to reference but nothing -- no other additional materials. 8 9 Ο You didn't provide them any other materials 10 other than the GAPMS -- the June 2022 GAPMS? 11 That's correct. Δ 12 Q To review prior to the hearing? 13 Α Correct. Did you have any meetings with the consultants 14 0 15 prior to the hearing to prepare for the hearing? 16 Α We had a couple -- there were a couple Zoom 17 calls. 18 How long did those last? Q About an hour? 19 А 20 What kind of things were discussed during 0 21 those meetings? 2.2 Α Mostly the format. You know, we were talking 23 about, like, of course, Dr. Grossman, who was not going 24 to be able to travel. So we were talking about technological arrangements. I think with Doctors Van 25

1	Meter and Van Mol, we were mostly talking about travel
2	arrangements and, like, where they'd sit and so forth,
3	so I mean
4	Q Did you offer any questions that they might
5	anticipate from the audience and how they should
6	respond?
7	A To our experts? We didn't.
8	Q And why was it necessary to have the
9	consultants there?
10	A So well, since because we were actually
11	anticipating a crowd that was going to be largely
12	opposed to the challenge exclusion, we wanted to be able
13	to respond promptly and articulately to any comments
14	that were provided.
15	Q If you wanted to respond promptly and
16	articulately to any comments that were provided, what
17	was the purpose of having a public hearing?
18	A So the public hearing is to, of course, gather
19	feedback, but we also knew that we were likely going to
20	have either some type maybe medical professionals or
21	advocacy groups, or other advocates, and we did want to
22	be able to provide them with a little bit of engagement
23	to show that we do take their comments into
24	consideration, that we do think about them, that we do
25	engage with them.

Page 180 Did the consultants respond to any comments by 1 0 2 a supporter of the rule? I don't think they did, actually. 3 Α How about those that were opposed to the rule? 4 0 There was really -- I think Dr. Van Meter 5 Α 6 responded once. I think Dr. Van Mol responded once. 7 And Dr. Grossman didn't respond to anything. And that was -- both of those responses were 8 Q 9 in response to individuals who were speaking in 10 opposition to the rule? 11 Α Yes. 12 Have you ever participated in another rule Ο 13 hearing where there is direct and prompt response to public comment? 14 15 Α Yes. Yeah, we do. Yeah, I mean, I've participated in numerous rule hearings here at the 16 17 Agency. We do respond to comments. 18 When you say we, do you mean the office staff? Q 19 Α Office staff, yes. 20 What about consultants with which AHCA has 0 21 contracted? We -- we generally don't -- we generally 2.2 Α It's a -- it was a unique experience for this 23 don't. case, but we generally don't have contracted consultants 24 25 at our hearings.

Page 181 And where did the slogan, Let Kids Be Kids 1 0 2 come from? So that came from within, I think, our own 3 А Agency, our Communications Department or the Chief of 4 Staff's office. 5 Was there any input in developing that from 6 0 7 outside entities? 8 Α No. 9 So AHCA is wholly responsible for that slogan? 0 10 Α Yes. 11 Was AHCA responsible for the printing off of Ο 12 the stickers that had the slogan contained on it that 13 were being passed out at the hearing? Α No. 14 15 0 Do you know who was responsible for that? 16 We do not know where those came from. Α 17 Is it normal to have slogans of an Agency Q 18 passed out at a rule hearing? Have you ever seen that before? 19 20 Α I have not seen that before, so -- but we --21 that was not something that the Agency had anticipated, and we certainly were not responsible for the passing 2.2 23 out of stickers with a slogan on it. 24 Q Did outside counsel appear at the public 25 hearing? Did AHCA outside counsel appear at the --

1	A Yes, they did.
2	Q Why?
3	A Because, of course, sensitive nature. I mean,
4	there were there were attorneys also there was
5	because there was counsel that you know, who are
6	representing the plaintiffs who were also there. We do
7	anticipate litigation, so it was we did see to it
8	that we had outside counsel there to gather information
9	and be able to observe the procedures.
10	Q So AHCA had at the point of the public
11	hearing, AHCA had retained outside counsel to defend
12	against any potential litigation that the rule invited?
13	A Yes.
14	Q What was outside counsel's role at the
15	hearing?
16	A Outside counsel's role, I think I think
17	just calling up the speakers as they came. I think they
18	actually we had them helping out with the with the
19	hearing process and procedures.
20	Q What kind of well, okay. Did AHCA give the
21	consultants any instructions to prepare for the hearing?
22	A Basic ones. Most of I think, you know,
23	like to when responding that, you know, we would prompt
24	them to respond. Basic very basic instructions.
25	Q And so the instruction was that when AHCA

Veritext Legal Solutions

wanted someone to -- one of the consultants to respond, 1 2 you would prompt them to? So, yes. And during the hearing, Secretary 3 Α Weida would defer either to Dr. Van Meter or he would 4 defer to Dr. Van Mol when he needed -- when a response 5 was needed from one of them. 6 7 Ο Okay. Just going back to the slogan really quick, who in AHCA came up with that Let Kids Be Kids 8 9 slogan? I think -- I think it was a -- I think it was 10 Α 11 a team effort. I think, like, it was Cody Farrell and, 12 I think, Brock Juarez. I think they worked on the Let 13 Kids be Kids slogan. 14 Anybody else? 0 15 Α No, it would have been primarily them. 16 Who directed them to develop the slogan, or 0 17 was it their idea? 18 So the orders would have been given verbally. Α We don't know, like, exactly how they were told to do 19 20 that specific slogan. 21 0 When was the -- when was the slogan developed? It was developed, I think, in the days 2.2 Α 23 preceding the release of the report. When was the final draft of your report done? 24 Q So the final draft -- so the final draft as 25 Α

1	far as so the very, very final draft, like the last
2	finishing touches, as much as copy edits, was done that
3	week of the 2nd, but as far as the substantive
4	components of the report, that was done probably a few
5	weeks prior to the release.
6	Q So when was the slogan developed?
7	A Slogan was developed I think they did
8	were working on it, like, the week before the release.
9	Q Is it normal for AHCA to develop a slogan for
10	the conclusions found in a GAPMS report?
11	A No, this is this was a first.
12	Q Why develop a slogan?
13	A Well, we do develop slogans for whenever we do
14	have do releases, or whenever we have new programs.
15	For instance, Canadian Prescription Drug Importation, we
16	do have a slogan for that. We do have a web page
17	dedicated to prescription drug transparency pricing. So
18	we do have often to correspond with our press
19	releases, we often will do a logo.
20	Q But you just said it's not normal for a slogan
21	to be developed for GAPMS. So why do it in this
22	instance?
23	A So because HHS had already had made
24	announcements with the publication of their documents,
25	Department of Health had done theirs, we, of course,

1	likewise, because we were publishing this document, was
2	to, of course, create the website and to, of course,
3	create some graphics along with that website.
4	Q So was the slogan meant to draw attention to a
5	particular message that the Agency was trying to send?
6	A No, I mean, other than that, we did the report
7	and we did was evidence-based and concluded these
8	treatments were experimental and investigational.
9	Q For children and adults, right?
10	A For children and adults.
11	Q And why was it Let Kids be Kids?
12	A Because so for adults with when it comes
13	to Medicaid, states because you don't have the EPSDT
14	consideration, states can be much more have much more
15	discretion in denying coverage. They have a lot more
16	latitude to be able to deny coverage, so but for
17	services that are intended for pediatrics, or are under
18	EPSDT considerations, that's partially partially why
19	not like one of the services that we evaluated was
20	puberty suppression, adults aren't going to use that.
21	Q But the conclusion of the GAPMS report was
22	that all treatment for gender dysphoria was experimental
23	for kids and adults?
24	A That's correct.
25	Q The slogan's just targeted at kids?

Yes, that's correct. 1 Α 2 Q Why? So it comes back down to the EPSDT 3 А considerations. Because like -- well, for starters, I 4 mean, when it comes to adult coverage, that's a totally 5 6 different category. But for kids, especially with 7 puberty suppression and especially with the cross-sex hormones, because of the experimental and 8 9 investigational nature, that's probably why we -- why 10 the Agency embarked on a, I guess, child-based kind of 11 graphic for its web page. 12 What does it mean Let Kids be Kids? 0 13 Α I think, well, as far as semantics go, I think that could mean something different to everybody. 14 15 Ο What did AHCA by it? 16 Let kids be free to explore their own Α 17 identities and figure out who they are. 18 What are some examples of other slogans AHCA's Q used for its programs? 19 20 Α Well, lower prescription drug costs. 21 0 That's a slogan that we can find? I mean, that's one we've been using for 2.2 Α Yeah. 23 a while. I was using as -- under my signature on my 24 email, so things -- yeah, but, I mean, there are I think like prescription drug transparency. 25 sloqans.

I mean, that's part of, you know, the state's mission is 1 2 when it's coming up with new programs -- and obviously 3 it's not isolated to AHCA, I mean, every agency's going to have slogans and graphics for their new programs. 4 Ι 5 mean, if you look at the Department of Children and 6 Families, they're promoting Hope Florida in a big 7 capacity. So for a lot of these -- so for a lot of these programs that they want to have -- they want them 8 9 to be now such high profile, of course there's going to 10 be graphics and slogans.

11 Q Prescription Drug Transparency is not very 12 catchy, I'll say. Why create a web page dedicated to 13 supposedly fact-checking Health and Human Services? Is 14 that normal?

15 Α No, it's not, but following -- but the thing 16 is following the review of the evidence and how our 17 findings really did contradict what was in HHS 18 documents, because we really wanted to demonstrate -because we do understand, it's a GAPMS report, it's 46 19 20 Not many people are going to take the time to paqes. read it. So we wanted to kind of put it -- we wanted to 21 put the case in more simplistic layman's terms and make 2.2 23 it accessible to the audience to show that, hey, yeah, 24 this is a sensitive report. Yeah, if you got an hour and a half and you understand medical terminology and 25

Page 188 literature, you might have fun reading it, but for guick information, we wanted to provide a resource, because HHS had made all these claims regarding gender dysphoria treatment, we want to make it accessible to everybody that they could look at it and five minutes later understand the gist of what we were saying in the GAPMS report. Prior to the July 8th public hearing, did AHCA Q communicate with anyone from the Christian Family Coalition? No. Α Anyone from Florida Citizens Alliance? Q А No. Including Pastor Rick Stevens? 0 Α No. Anyone from Warriors of Faith, the Florida 0 Chapter? Α No. Including Troy Peterson? Q Α No. Anyone from Protect our Children Project? 0 А No. That includes Pastor Ernie Rivera? 0 That's correct. А

Q Okay. Anyone from Florida Prayer Network?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

25

Page 189 Α No. 1 And that includes Pam Olsen? 2 Q 3 Α Correct. Anyone from Partners for Ethical Care? 4 Ο Α No. 5 What about Chloe Cole? 6 Ο 7 Α No. Sophia Galvin. 8 Q 9 Α No. 10 Anyone from the Rainbow Redemption Project? Ο 11 Α No. 12 Q How many comments did AHCA receive in response 13 to the proposed changes to 59G-1.050? 600 or so. 14 Α Oh, that's all? Did AHCA read them all? 15 0 16 We did. А 17 Q Who at AHCA reviewed them? It was a combination. So, like, I think Cole 18 Α Gerring, Nai Chen, myself, I remember we did sit down 19 20 once and we started going through all the emails. Most 21 of them were very brief, maybe like one or two lines, 2.2 not substantive whatsoever. For the more substantive 23 ones, those I did careful reviews of. So it's three people. You, Nai Chen and Cole 24 Q 25 Gerring?

1	A Uh-huh.
2	Q Okay. And you split them up amongst each
3	other?
4	A We read them together.
5	Q What process did you use to decide whether or
6	not to incorporate the input into the final rule?
7	A We wanted to look at the we looked at the
8	content of every of every single comment. A lot of
9	the comments were just saying don't do this, or
10	something or something very sensationalist. So a lot
11	of the comments we really couldn't take into
12	consideration because there wasn't there wasn't
13	there was no substance behind them. So there were some
14	comments that were we did receive some feedback
15	from I think we got something we got we got a
16	lengthy comment from American Academy of Pediatrics. We
17	got a very lengthy one from Yale University. We got
18	feedback from the Endocrine Society. I think one of
19	UF's gender clinic physicians wrote us up, not a
20	terribly long comment, but wrote us a comment. So we
21	did want to take a look at the substantive onces. But
22	we did them into we did take into consideration every
23	comment submitted to us.
24	Q Did you receive any comments from the people

25 who had Medicaid coverage for treatment of gender

1 dysphoria?

2 Α During the comment review, there wasn't any -we didn't -- we didn't notice any comments from those 3 offhand, but, of course, that was over six months ago. 4 So we -- because of the volume of comments, we did have 5 6 to read them fairly quickly. 7 Had you received a comment from anyone who was Ο receiving Medicaid coverage for treatment of gender 8 9 dysphoria, how would you have factored that into your 10 ultimate determination? 11 Well, we would -- we would have looked at it. Δ 12 We would look at the content. We were wondering, like, 13 what kind of services they were receiving and so forth, but it depends on what the comment was. If they 14 15 provided a case for why they were getting it, you know, 16 but we didn't -- we didn't receive anything like that.

Q For those people who lost Medicaid coverage for treatment of gender dysphoria, or were going -stood to lose based on the categorical exclusion, during any of this process, was there any consideration given to the inability to access that care?

A There was. We did have questions. We wanted to make sure that if we were to discontinue individuals who were receiving, particularly cross-sex hormones, we wanted to -- we did have questions like, would there be

1	withdrawal? What would would they need some would
2	they be weaned off the medication? How would how
3	would the Agency take that into consideration? And we
4	actually kind of realized that if, say, if they do need
5	to discontinue testosterone because of the categorical
6	exclusion and their doctor deems, well, they're going to
7	need some small doses to wean themselves off, but we
8	also realized that necessarily wouldn't be for gender
9	dysphoria, that would be because of withdrawal symptoms,
10	and that would be a different diagnosis.
11	Q Did you give that guidance to any treating
12	professionals or Medicaid recipients?
13	A No, we didn't.
14	Q Okay. Why was it necessary to review the
15	comments quickly?
16	A It wasn't necessary to; it was just I mean,
17	most of the comments were because the nature, they
18	were most of them were sensationalist, a lot of them
19	just hurled insults at us, a lot of them ad hominem
20	attacks, things like that. We just kind of went through
21	a lot of them very fast.
22	Q So that wasn't quite my question. It sounds
23	like you were able to review them quickly.
24	A I think I want to rephrase as we were able to.
25	We weren't really in a hurry. Because, obviously, like,

we got a 47-page comment from Yale University. 1 That was 2 not a five-minute skim, obviously. So there were those 3 we deemed to be substantive comments that warranted in-depth attention, and then there were those we deemed 4 non-substantive comments and just read. They're like --5 6 yeah, we received some ones that were using, I will say, 7 the colorful metaphors. And then we don't -- I mean, obviously, not going to pay attention to those, so --8 9 but the substantive ones that where they're putting 10 together, like, an argument or making points, being 11 something that we have to take back and think over, we 12 did invest time in those, yes.

Q Were there any discussions about the commentsbetween you and Cole and Mr. Chen?

A As far as the discussions go, no, most of discussions were like, okay, let's move on to that one, that one's just insulting us or that one's -- that one's expletive-laden, let's move on. So when we got the substantive ones, of course, those were -- those were handled differently.

21

Q How were they handled differently?

A So those, because they were going to take in-depth review is not something that's going to be a group activity. Of course, we printed those out and started reviewing with a fine-tooth comb.

Did AHCA review the underlying cases and 1 0 2 studies cited in those substantive comments? 3 Α Yeah. Okay. How did they factor those in to the 4 0 ultimate determination? 5 So we did take a look. So we checked to see 6 Α 7 what studies that Yale University and the AAP brought into it. And we looked at two responses from the Yale 8 9 University, not just the response that they made to us, 10 because Yale University frequently cited their response 11 to Texas and Arkansas, we pulled that up as well and 12 did -- and analyzed that. So we looked to see what 13 articles they were citing and we were -- so we checked 14 to see whether our GAPMS report or any of the expert 15 reports also did evaluations of those studies to see 16 that -- make sure that we were in alignment. 17 Okay. Do you remember any particular Q 18 underlying cases or studies? There's -- I think there's one by Jack Turban 19 Α 20 that they cited. I think there was one that we did cite 21 in GAPMS review. We didn't discuss it at length, this 2.2 was by Tordoff, et al. And we looked at that. And, of 23 course, but we also captured those in Dr. 24 Brignardello-Petersen's piece that they were evaluated as, like, being very low-quality or in a critical risk 25

1 of bias.

4

2 Q Okay. How did you determine whether -- okay. 3 Turning to the implementation. Sorry.

A Okay.

5 Q Hold on. One second. Something breaking is 6 coming in. Did you review any comments that reference 7 court cases?

We did see some comments that referenced, I 8 Α 9 think, like Bostock v. Clayton. I mean, there were some 10 cases referenced in the comments, but, of course, I 11 mean, we were primarily interested in -- we were looking 12 for comments that were providing -- that were either 13 providing examples of literature or anything that was going to contradict the GAPMS report. In other words, 14 15 we were looking -- we were looking for anything that, I 16 guess you could say, delivered, like, a mortal wound or 17 something like that, something that would foreseeably 18 cause us to have to go back and make revisions or cause us to have to retract the rule, or something that -- or 19 20 a comment that we couldn't just dismiss or a comment that we couldn't explain. So those were what we were 21 2.2 looking for.

Q What types of information provided by the
public would have mortally wounded your conclusion?
A So a mortal wound would have come from a

quality study, or a number of quality studies. 1 2 Q And define a quality study. 3 So something that -- well, a quality study, Α well, I mean, that -- that's a pretty broad definition 4 of what you're asking for, and there are different ways 5 6 a quality study can come about, but something that, of 7 course, lengthy longitudinal histories on participants, either has adequate control groups. And this is not an 8 9 all-inclusive list. These are just examples. Also 10 follows participants for a lengthy period. 11 Well, what's the difference between that and a 0 12 lengthy longitudinal study? 13 Α Long -- when it comes to a longitudinal 14 history, what we mean by longitudinal history, and this 15 is often for behavioral health, is that longitudinal 16 history is necessary to really ascertain the full 17 impacts of somebody's mental health conditions. Because 18 it's -- because mental health, it's not necessarily like an acute illness or a chronic condition diagnosis. So, 19 20 like there's treatment histories, medications and --21 like, in other words, and, of course, like activities of 2.2 daily living, how that all is affected. So it's usually 23 something that has to be obtained over a number of 24 years. So, mental health longitudinal histories, but 25

we also were finding in the studies that we evaluate for 1 2 the GAPMS process that they lacked participants' longitudinal histories. If they even -- if they even 3 did -- provided any histories or any -- identified the 4 recipients or the participants at all. I mean, there 5 6 were so many studies where they were -- I think there 7 was one that we came across, and this was during the comment period, that was just a massive survey and they 8 9 were trying to give gift cards to participants. And, of 10 course, people were just completing it, but it was like 11 a one-time snapshot, and it's subjective self-reports. 12 So I mean, there are a myriad examples that we can say 13 for high-quality evidence, and not to mention RCT's, as well. So --14 15 Ο What does that stand for? 16 Randomized control trials. So there -- so, Α 17 yeah, so that was what we were looking for, evidence 18 that -- evidence that would hold up to questioning, and 19 that's not what we were finding. 20 So in undertaking the review of the comments, 0 21 the only thing you were looking for is anything that 2.2 would, in your definition, cause a mortal wound to your conclusion in the GAPMS? 23 24 Α That was among one of the things we were 25 looking for.

1	Q What else were you looking for?
2	A I mean, we were looking we were looking
3	for I mean, we, of course, we were looking to see if
4	there's anything that would directly conflict with the
5	GAPMS report. That was one thing, because the rule's
6	foundation was the GAPMS report. So that's the big
7	reason why we were looking for contradictory evidence or
8	evidence that would be like, well, wait a second, we say
9	it's all you know, because our primary argument is
10	it's low-quality evidence and therefore experimental,
11	experimental investigational. That basis doesn't
12	sustain itself if all of a sudden there's modern,
13	high-quality evidence out there. So we want to make
14	sure that we had not left any stones unturned. But we
15	were just you know, I mean, we this things we
16	weren't that was the primary thing we were looking
17	for.
18	Other things I mean, we also, I mean,
19	anything that spoke to the legality of it, but I mean,
20	of course, we wouldn't necessarily evaluate that. We'd
21	turn that over to legal, but anything that was
22	looking that was looking at the legality of what we
23	were doing. So I mean so, I mean, there were
24	different angles. I think when I was looking at it
25	through my personal lens, that was what I was looking

Veritext Legal Solutions

800-726-7007

305-376-8800

Page 199 for. 1 Are you aware that similar exclusions have 2 Q been found unconstitutional in other federal districts? 3 I am aware at the district level that there 4 Α have been some -- some exclusions that have been tossed, 5 6 yes. 7 All right. Turning to the implementation --0 MR. JAZIL: We've been going for an hour and a 8 half. Could we do a five-minute break? 9 10 MS. DEBRIERE: Sure. VIDEOGRAPHER: This concludes video three. 11 The 12 time is 3:00 p.m. 13 (Brief recess.) VIDEOGRAPHER: This is beginning of video four. 14 15 The time is 3:08 p.m. we're on the record. 16 BY MS. DEBRIERE:: 17 Just after that break, and I should have asked Ο 18 this earlier, just after that break, did you have any 19 conversations with anyone during that break? 20 Α During --21 Just this recent break? Did you have Ο 2.2 conversations with anyone? I mean, talked about, like, personality types 23 А on 16 personalities, just had a conversation, but as far 24 25 as the case goes, no.

Page 200 Okay. What about at lunch? 1 Q 2 А Just a quick touch-base with our attorneys. 3 Okay. How long did you talk? 0 Α 15 minutes. 4 Okay. All right. Turning to implementation 5 0 of the rule with managed care plans. Did Florida 6 7 Medicaid managed care plans -- well, we've already answered that. What's the purpose of Inter-Qual? 8 9 Α Inter-Oual? 10 0 Uh-huh. I don't have the answer to that. 11 А 12 Okay. Are you familiar with it at all? Q 13 А I'm not familiar with Inter-Qual. Did AHCA develop, or help develop language for 14 0 notices of adverse benefit determinations in order to 15 16 incorporate the categorical exclusion of treatment for 17 gender dysphoria? 18 Α No. 19 AHCA didn't assist at all in developing the Q 20 language for those denials for terminations? No, managed care plans were -- handled those 21 Α 2.2 themselves. 23 Okay. Did AHCA review any of the language 0 that managed care plans submitted to AHCA for review? 24 25 Α No.

Same question for notices of outcome relied on 1 0 2 by EQ Health? 3 Α No, AHCA wasn't directly involved in those. Did they review the notices of outcome 4 0 language? 5 Α 6 No. 7 Okay. What about Magellan? Q 8 А Magellan? No. 9 0 Did AHCA develop or help develop language for 10 any other types of notices used to notify a Medicaid 11 recipient of a denial or termination of treatment for 12 qender dysphoria? 13 А No. 14 All right. Can I have the notice of adverse Ο 15 benefit determination, and that's Bates-stamped 16 Defendant 000292335, I think. We'll check? Did I get it right? I don't think I did. I'll read the correct 17 18 Bates-stamp on -- so this is going to be the Molina Health Care Notice of Adverse Benefit Determination. 19 20 I'm not going to name the Medicaid recipient. And the 21 date stamp appears to be cut off, but it is dated 2.2 October 26th, 2022, and the initials for the recipient 23 are AS. (Whereupon, Exhibit No. 15 was marked for 24 identification.) 25

MR. JAZIL: Counsel, can we agree that this 1 2 should be confidential, attorney's eyes only? MS. DEBRIERE: Absolutely. 3 MR. JAZIL: Do you mind if I write that on top 4 of the --5 MS. DEBRIERE: Not at all. Not at all. 6 So the 7 previous Bates stamp I gave was not correct, but the Bates stamp on this exhibit is cut off, so I 8 9 can't provide the actual number, but I think I've 10 sufficiently described it. And, of course, it will 11 be Exhibit 15. 12 BY MS. DEBRIERE:: 13 Q All right. This particular notice of adverse benefit determination is from Molina. In that second 14 15 page there, it runs through AHCA's medical necessity definition, correct? 16 17 Α Yes, that's consistent. And that's consistent across notices of 18 Ο adverse benefit determinations? 19 20 So each health plan is a little idiosyncratic Α in how they do NABD's. We'd have -- we'd have to verify 21 2.2 with managed care plans. I mean, the contracts does 23 provide specific requirements when it comes down NABD's 24 and sending them. MS. DEBRIERE: Mo, do you know if you guys have 25

Case 4:22-cv-00325-RH-MAF Document 120-6 Filed 04/07/23 Page 241 of 346

Page 203 produced an NABD template to us? 1 MR. JAZIL: We've never --2 MS. DEBRIERE: I know they exist. They should 3 be pretty easy to --4 MR. JAZIL: I'll check. What's that stand for, 5 6 aqain? 7 THE WITNESS: Notice of Adverse Benefit Determination. It's a long phrase for a denial. 8 BY MS. DEBRIERE:: 9 Or termination or reduction? 10 0 11 Or termination, or reduction. А 12 Or partial reduction. Q 13 Α It's --Okay. So this particular notice of adverse 14 0 benefit determination is to an actual Medicaid 15 recipient, correct? 16 17 А Yes. 18 And it looks like it's been it's denying a 0 19 request for coverage of testosterone cypionate. 20 Α That's correct. 21 Okay. And what is the reason for the denial? 0 2.2 Α The box for other authority non-covered benefits is checked off. 23 Why isn't the, request service is not a 24 Q covered benefit, checked off? 25

1	A We would have to ask that question of the
2	plans.
3	Q Okay. So you don't require some kind of
4	uniform response to not that plans must provide when
5	there's a non-covered benefit?
6	A We're not aware of one. There I don't
7	think there's one mentioned in the contract.
8	Q Okay, but I guess my other question is, would
9	it be equally sufficient, had they checked off, must
10	meet accepted medical standards and not be experimental?
11	A They could have checked that box. They could
12	have checked, the requested service is not a covered
13	benefit. They could have checked other boxes, as well.
14	Q Okay, but it is accurate to say that it is not
15	a covered benefit?
16	A Yeah, that is accurate.
17	Q Is any plan allowed to currently cover
18	treatment for gender dysphoria of the services listed
19	and 59G-1.050(7)?
20	A For any plan right now currently?
21	Q Yes.
22	A No. No plan can cover them.
23	Q Since the adoption of the categorical
24	exclusion of treatment for gender dysphoria, how many
25	notices of adverse benefit determination have been sent

to Medicaid beneficiaries that denied coverage for
 services on the basis of --

3 So for MMA plans, so we did a little looking А into this -- so for managed medical assistance, which 4 most of these recipients, given their ages, are going to 5 6 be on MMA, we do not actually require the MMA plans to 7 submit reports regarding how many NABD's that they actually mail out to their enrollees. Long-term care, 8 9 that process is different. We do require them for 10 long-term care to mail those to report to the Agency how 11 many NABD's they are sending out, but for MMA we 12 currently don't have that as a requirement.

Q Okay. So is that -- does the same hold true
for notice of appeal plan -- plan appeal resolutions?

15 A As far as that goes, I don't think -- I don't 16 think we're collecting information from the plans on 17 those.

18 Q Okay. So generally, not just as related to19 treatment of gender dysphoria?

A Generally.

Q What about notice of outcomes?
A Notice of outcomes, I don't think we're
collecting them from those informations either.
Q Okay. Just generally, do any of those notices

25 include reference to the variance in waiver process

20

described at Florida Statute 120.542? 1 No. 2 Α I mean, we definitely -- I mean, so 3 looking at this, this is in compliance with what we do, we require them to have, which is an appeals process. 4 So, no, we don't -- we do not require the plans to 5 6 include the procedures for variances. 7 0 Okay. So those procedures are not listed in notices of denial? 8 9 Α That would be correct. 10 Okay. How many grievances have been submitted 0 11 to AHCA regarding a claim related to AHCA's adoption of 12 the categorical exclusion of treatment for gender 13 dysphoria? 14 So that information, we do have a complaint А 15 hub for recipients and providers who'd like to submit 16 complaints, be given the -- when the questions came in, 17 we, of course, have to reach out because our complaint hub is actually down in Fort Myers, so it's not -- it's 18 not here locally, so that's information we're still in 19 20 the process of obtaining. 21 And once you obtain that, you'll provide it to Ο 2.2 us? MR. JAZIL: Yes. 23 24 MS. DEBRIERE: Can you put that as a follow-up? 25 BY MS. DEBRIERE::

Page 207 How many -- how many appeals of Notice of 1 0 Adverse Benefit Determination denying care on the basis 2 of the exclusion have there been? 3 As far as appeals going up to the fair hearing 4 Α level, I think that's zero. 5 Okay. What about -- yeah, so that would 6 0 7 include both notice of plan appeal resolutions as well as notice of outcome? 8 9 Α Yeah. 10 Okay. Prior to August 21st, 2022, did AHCA Ο 11 ever reverse a decision made by AHCA or by a plan to 12 deny pubertal suppression therapy for the treatment of 13 gender dysphoria? We did not. 14 Α 15 0 You never reversed a decision to deny? 16 To deny? А 17 0 Yeah. No, we never did. Sorry. I misunderstood the 18 Α 19 question. 20 Okay. I just want to make sure you're 0 21 understanding. So prior to the adoption of the 2.2 categorical exclusion, did AHCA ever reverse a decision to deny puberty suppression therapy for the treatment of 23 qender dysphoria? 24 So if a plan reviewed for medical necessity 25 Α

Page 208 criteria decided, no, it didn't meet the criteria and 1 2 issued denial, no, we never reversed it. What about upon a fair hearing review? 3 0 Are we talking about, like, since 2015? 4 Α Well, I'm asking ever, but if 2015 is a 5 Ο 6 helpful marker. 7 Α I don't have that information offhand. Is that information you can obtain? 8 Q 9 Α I think we can. 10 Prior to August 21st, 2022, did AHCA ever 0 11 reverse a decision to deny cross-sex hormone therapy for 12 the treatment of gender dysphoria? And by reverse I 13 include at the fair hearing level. That's information that we would have to 14 Α 15 obtain. 16 Same question for surgery in furtherance of 0 17 the treatment for gender dysphoria. At the fair hearing level, we would have to 18 Α obtain that. 19 20 So you will tell us the number of times, if 0 21 ever, that AHCA reversed a decision at the fair hearing 2.2 level to provide treatment in furtherance of -- services 23 and treatment for gender dysphoria? 24 Α We can confirm it. It's probably zero. 25 Q Okay.

1	A As far as overturning a decision that was
2	already a denial, it's probably going to be zero, but we
3	just want to confirm.
4	Q Okay. I'll tell you, we have different
5	information.
6	A Okay.
7	Q How many AHCA fair hearings have been provided
8	where the categorical exclusion of treatment for gender
9	dysphoria was an issue?
10	A Well, can you repeat that?
11	Q How many AHCA fair hearings have occurred
12	where the subject at issue was the categorical exclusion
13	of treatment for gender dysphoria? So where the rule
14	exclusion
15	A We'll have to obtain those numbers.
16	Q Did any do final orders in general
17	reference the variance and waiver process described at
18	Florida Statute 120.542?
19	A You'll have to slow down and ask the question
20	a little bit
21	Q Sure. Sure. The final orders that are issued
22	at the end of any AHCA Medicaid fair hearing, do those
23	written final orders contain any reference to the
24	variance and waiver process at Florida Statute 120.542?
25	A I don't think the final orders do. I don't

	Page 210
1	think they do.
2	Q Okay. Is there any way you can get
3	confirmation of that answer?
4	A I mean, we could obviously pull up a copy of
5	the final order and see if that information is included.
6	Q If we had a copy of an AHCA final order, would
7	that be sufficient to determine, and it did not list it,
8	would that
9	A I'll defer to our attorneys, if that's
10	sufficient.
11	MR. JAZIL: That'd be sufficient. If you have
12	one, you can show it to him.
13	MS. DEBRIERE: Well, we can pull one up, can't
14	we?
15	MS. CHRISS: Just one?
16	MS. DEBRIERE: Yeah. Yeah. Why not. Yeah, as
17	long as their name's blocked out, which really
18	shouldn't matter here because we're dealing with an
19	AHCA employee.
20	THE WITNESS: Yeah. I mean, I'm cleared to
21	review PHI and recipient information. It shouldn't
22	be a problem.
23	MS. DEBRIERE: Do you want another one? I can
24	send you another one. Bear with me one second.
25	I'm going to forward you this email. And

Г

Page 211 it's -- I can tell you what the name of the 1 2 document is. It's the last document, 23. That should be the last one. Chelsea's copied on that 3 one, too. 4 5 THE WITNESS: Okay. MS. DEBRIERE: Okay. Okay. So feel free to 6 7 just scroll through it and see if you see any reference -- oh I'm sorry, it isn't a touchscreen? 8 9 THE WITNESS: I don't know where the scroll bar. 10 MS. CHRISS: It's just -- just use two fingers 11 12 and just go like that. 13 MS. DEBRIERE: Oh, it's a Mac. 14 MS. CHRISS: I'm sorry. 15 THE WITNESS: Okay. There it goes. Yeah. Ipads and iPhones I'm good with, Mac's I never got 16 17 comfortable with. MS. DEBRIERE: The next exhibit I'm going to do 18 19 is emails related to the policy transmittal and the 20 policy transmittal itself, if that helps. 21 MS. DUNN: Yep. 2.2 THE WITNESS: So are we talking about the -that last paragraph on the final page that's, like, 23 notice of judicial review? 24 25 BY MS. DEBRIERE::

So does that relate to the variance 1 0 Yes. 2 waiver process? I mean, it doesn't point out the variance 3 Α processes as described in section -- or Chapter 120. 4 Ι think that's more if they want to appeal to the next 5 level -- next court level. I don't think that's in 6 7 response to the variance process. That's a different 8 process. 9 0 Okav. Thank you. So it does not mention the variance waiver process --10 MR. JAZIL: Would it be possible just to read 11 12 off the --13 MS. DEBRIERE: Yes, absolutely. So it says at the bottom: Notice of a right to judicial review. 14 15 A party who is adversely affected by this final order is entitled to judicial review, shall be 16 17 instituted by filing the original notice of appeal with the Agency clerk of AHCA, and a copy along 18 with the filing fee prescribed by law with the 19 20 District Court of Appeal and appellate district 21 where the Agency maintains its headquarters or 2.2 where a party resides. Review proceedings shall be 23 conducted in accordance with the Florida appellate 24 rules. The Notice of Appeal must be filed within 30 days at the rendition of the order to be 25

1 reviewed.

THE WITNESS: Our various processes doesn't involve appellate courts, so it would not be an appellate case, so it's a different affair. BY MS. DEBRIERE:: Q Thank you. Okay. Did AHCA work with Florida

Medicaid managed care plans to implement the exclusion
set forth in 59G-1.050(7) in any way?

9 A No. I mean, the publication's in the Florida 10 Administrative Register, that was to provide ample 11 notice -- public notice that the rule's changing, the 12 managed care plans are responsible for keeping up with 13 changes to manage -- to AHCA's coverage policies and 14 administrative policies.

Q What about plan transmittal? Are you maybeforgetting those?

17 A We do not do a plan transmittal for this. Are18 you referring to a policy transmittal?

Q Yes.

19

20

A We did not send out a policy transmittal.

Q Okay. Okay. So we have what's marked as Exhibit 16 and Exhibit 17. Exhibit 16 is some emails from Dede Pickle to Jason Weida, cc'ing Ann Dalton. And those are dated August 22, 2022. I believe that's where they start. Also involved are you, Matt, and Ashley

1	Peterson. Also, I just want to note that Exhibit 17 is
2	an SMMC policy transmittal dated August 22nd, 2022.
3	(Whereupon, Exhibit Nos. 16 - 17 were marked
4	for identification.)
5	BY MS. DEBRIERE::
6	Q Getting back to the list of questions. So did
7	AHCA not send the plan policy transmittal out, Exhibit
8	17?
9	A We did not send them out.
10	Q Why?
11	A Pretty much because all it's doing is
12	reproducing what was already stated in the rule. The
13	rules the rule the policy changes already in rule,
14	that was announced through the FAR. Policy
15	transmittal's a little superfluous at this point.
16	Q Why draft an entire plan transmittal and then
17	not send it out?
18	A Which this happens frequently. Sometimes we
19	will draft something and later decide not to not to
20	use it, or not to utilize that content in favor of
21	different strategy. So, in this case, since the rule
22	since the rule change itself was pretty self-explanatory
23	and pretty direct, just we later deemed wasn't
24	necessary.
25	Q Who made the decision not to send out the

1
÷.

policy transmittal?

A I think that would have been -- that would
have been Secretary Weida.

4

Q Only Secretary Weida? Is it Weida or Weida?

A Weida. I mean, as Assistant Deputy Secretary, he would be within his purview to decide whether or not to send something out -- or to send something out, but given that the rule itself was self-explanatory, and we just decided that a policy transmittal wasn't necessary.

Q All right. In the email exchanges -- I think it's on the second page -- oh, and Jason Weida, at this time that he made this decision, was not the Secretary -- AHCA's Secretary, correct? At the time this was sent, Mr. Weida was not the AHCA Secretary, correct?

16 A Right, he was Assistant Deputy Secretary for
17 Policy and Quality.

Q On the last page, it looks like you were the person who drafted the first policy transmittal, is that correct?

A Yes. Yeah, I mean, Dede and I, it was a collaborative effort between the two of us. We were, of course, working on each other's language.

24 Q Why did you think Dede -- why did you and Dede 25 think it was important to draft a policy transmittal?

Page 216 Α We were asked to. 1 2 Q By who? I think Ann Dalton asked Dede to work on it. 3 А Okay. And later -- well, let's look to --4 0 Ashley Peterson says on August 22, 2022 at 10:35 a.m.: 5 I added one thing to help clarify that these drugs will 6 7 still be provided, just not for gender dysphoria. Please let me know if you think this is unnecessary or 8 9 adds confusion. 10 So at least Ashley thought there was some 11 clarity that could be provided to plans on the 12 implementation of the exclusion. 13 MR. JAZIL: Object to form. THE WITNESS: Okay. There's several emails. 14 15 Which one are you --16 BY MS. DEBRIERE:: 17 This one is from Ashley to Dede, copying you. Q 18 August 22nd, 11:04 a.m. That's Dede --А 10:35 a.m. 19 Q 20 Α Okay. 21 0 It's DEF 0002587. 2.2 Α Okay. I think it was just a minor, minor 23 technical catch. I mean, when we worked on this, I 24 mean, we were just fine tuning the drafts. And further up Ann wants to include the 60-day 25 Q

language in the alert, which has been later included. 1 2 What is the 60-day language? 3 Α That would be the bottom paragraph of the policy transmittal. 4 5 Okay. And that you're referring to starts Ο To ensure the safe discontinuation of puberty 6 with: 7 blockers or hormone and hormone antagonists for the treatment of gender dysphoria? 8 9 Α Uh-huh. 10 Then the managed care plan must notify its Ο 11 subcontractors, providers, enrollees receiving active 12 treatment and changes in coverage, and they must honor 13 any current prior authorization of prescribed outpatient 14 drugs for the treatment of gender dysphoria through 60 15 days after the date of this policy transmittal. So that 16 means that under the 60-day rule for continuity of care, 17 the managed care plans were to continue coverage of the 18 prescribed outpatient drugs for the treatment of gender dysphoria, correct? 19 20 Only for those existing prior authorizations А 21 had already been approved. 2.2 0 Okay. So that meant that AHCA was -- or that Florida Medicaid was covering this drugs? 23 Yeah, just for the sake of honoring existing 24 Α

25 PA's.

Was it not important that the plans know that 1 0 2 they should maintain continuity of care? 3 It's actually in the contract. I mean, when Α you refer to continuity of care, can you clarify what 4 you mean by continuity of care? 5 In this instance, I'm talking about the 6 Ο 7 continued coverage for 60 days of those prescribed outpatient drugs for the treatment of gender dysphoria. 8 9 Α As far as the continuity of care went, I mean, 10 there -- as far as medically necessary services, 11 enrollees are always going to have access to those. So 12 when it comes to the continuity of care, whether or --13 Q They're not going to have access to services that have been previously covered, but now are excluded, 14 15 correct? That'd be correct. 16 Α 17 Okay. So the 60-day continuity of care Q 18 ensures that after that categorical exclusion is 19 adopted, those individuals continue to access that care 20 for 60 days? 21 Α This, of course, was a draft. It was never 2.2 sent out. 23 At some point, AHCA thought that the 60-day Ο period of continuity of care should apply in this 24 situation, correct? 25

Since this was a draft and it was not -- not Α 1 2 officially sent out, this is not -- since it is draft 3 language, it is not an official transmittal, we sent out to the health plan, so this does not formally represent 4 the views of the Agency. This is a -- this is a draft 5 6 that we created, deliberated upon and decided not to 7 send out. Who decided? 8 0 9 Α That would, of course, been leadership. That 10 would have been -- would have gone to Assistant Deputy 11 Secretary Weida. 12 Q And he was the only one who was involved in 13 that decision, correct? I mean, since he oversees the bureau policy, 14 Α 15 that's -- which means policy transmittal, yes, he had --16 is within his -- is within his job description and his 17 responsibilities and rights to veto sending out a policy transmittal. 18 19 Okay. Since the policy transmittal was not Q 20 sent out, then is it AHCA's position that those who had a current prior authorization at the time that 21 2.2 categorical exclusion was adopted, was not entitled to 23 the 60-day continuity of care period -- were not

24 entitled?

25

A So once the rule went into effect, that was,

Page 220 of course, the notice of the plans that the coverage for 1 2 these services has to stop. 3 Immediately? 0 Well, I mean, that's based on what the rules 4 Α say, yeah. 5 Okay. So they -- that means that the plans 6 0 7 were not to implement this 60-day period of continuity of care as described in this transmittal? 8 9 Α Right, we didn't provide notice of -- them of 10 this. 11 Okay. And it was AHCA's position that Ο 12 Medicaid beneficiaries were not entitled to that? 13 А That's correct. Okay. You previously noted how people on 14 Ο 15 hormones may go through withdrawal, there was something as part of your 2022 GAPMS request. Why wasn't that 16 17 important to communicate to the plans? 18 Α Well, because withdrawal is not gender It's a different -- that's a different --19 dysphoria. 20 it'd be a different diagnosis altogether. 21 But in the decision to no longer cover drugs Ο 2.2 that may cause withdrawal, was it important to communicate to the plans or providers that they may need 23 to help facilitate transition off those drugs that would 24 25 no longer be covered?

We were leaving that to the health plans to 1 А 2 manage independently, as well as the providers of these services. 3 MS. DEBRIERE: Do we have a document titled 4 Florida Medicaid health alert? You just -- under 5 DEF 000258815. I feel like I've had the same Bates 6 7 stamp number. So we're marking as Exhibit 18, the Florida Medicaid health care alert sign-off form. 8 9 (Whereupon, Exhibit No. 18 was marked for 10 identification.) THE WITNESS: I'm familiar with that. 11 Т 12 drafted it. 13 BY MS. DEBRIERE:: That would definitely have been one of my 14 Ο 15 questions. 16 No, I'm listed on there as the analyst who А 17 drafted it. And there's Dede and Ann. 18 0 Yeah. 19 А 20 Okay. Did this healthcare alert go out to all 0 21 providers? 2.2 А That provider alert did not go out. And the provider alert on the back, it lists 23 Ο that same language to ensure the safe discontinuation of 24 puberty blockers or hormones and hormone antagonists for 25

1	the treatment of gender dysphoria, or allow transition		
2	to payment to non-Medicaid funding sources. You		
3	incorporated the reference to the 60-day continuity of		
4	care period. You drafted that one. Did you include		
5	that 60-day language?		
6	A Yeah. I yeah, I did include that.		
7	Q Why did you think it was important to include?		
8	A Because at the time we were we were		
9	creating a provider alert in sync with in sync with		
10	the policy transmittal, so we wanted to make sure that		
11	they used the same language and addressed the same		
12	things.		
13	Q And why wasn't this sent out?		
14	A Because because, well, we've deemed that		
15	the notice of the rule is sufficient, and that once the		
16	rule had said that AHCA will no longer cover these		
17	services, we could no longer cover those services. I		
18	mean, the rule was clear-cut. It's very I mean,		
19	language is pretty pretty straight to the point and		
20	direct.		
21	Q Who made the decision not to send this out?		
22	A That would have come from Assistant Deputy		
23	Secretary Weida at the time.		
24	Q Did you agree with that decision?		
25	A I thought it was sufficient. I actually		

thought given that we put the rule out there, the rule 1 2 is very straightforward, noticing, like, we had the 3 providers, health plans, adequate notice was given. Did Ms. Dalton agree with the decision not to 4 0 send any of this out? 5 6 А I can't speak to Ms. Dalton. She and I didn't 7 confer on our opinions of whether to -- we didn't confer on how we felt about it. 8 9 Was there any stated opposition to not sending 0 10 these out? 11 Not that I'm aware of, no. Α 12 So in managing withdraw, how would a plan or Ο 13 provider know how to navigate that if AHCA wasn't -- if AHCA notified them that they weren't going to cover the 14 15 service that was needed to help titrate individuals off of their hormones or puberty suppression therapy? 16 17 So it comes back down to practitioners Α 18 delivering treatment to their -- to their patients. Once again, it comes down to how, like -- you know, when 19 20 they know that they can't treat for gender dysphoria 21 anymore, and they know that the individual might 2.2 suffer -- might suffer withdrawal symptoms from 23 testosterone. We, of course, did see some conflicting 24 information on that one, whether they would experience symptoms or not, or estrogen, or if there were 25

1	withdrawal symptoms, you'd be treating the withdrawal.	
2	And, of course practitioners, we do trust the medical	
3	professionals to know what condition they're treating,	
4	when the because they do so every day when their	
5	course when they're, of course, diagnoses. And, of	
6	course, when the medical coders come in there to do the	
7	billing, it's	

8 Q If transition involved smaller dosages of 9 hormones over time to treat gender dysphoria, how was 10 the provider and the plan to know that they could 11 continue to prescribe that?

A It would be coming through a different diagnosis code. And since we only said that for -- we only said in the rule only for the diagnosis of gender dysphoria. So if they're -- so if they're taking on some small doesn't testosterone because of withdrawal, that's a different -- that's a different diagnosis altogether.

19 Q How would they know what diagnosis code to 20 use?

A So, practitioners and providers often don't -aren't that familiar with the coding system. That's where their coders do to figure out. So their coders, of course, review the medical records and, of course, put in the CPT codes, they put in the ICD-10 codes, the

place of service. So usually the claims process is usually done either by often, like, a clearing house or individual coders that sometimes just rotate like a circuit through different physicians offices and so forth.

Q So when we're talking about the safe
discontinuation of a medication, wouldn't the prudent
thing to do would be to notify providers and plans of
the options they had to ensure that individuals who
could no longer access this treatment could at least
come off of it as safely as possible?

A Given that physicians deal with that kind of situation, for other diagnoses and medical services, we just didn't feel it was necessary. That's one area we were going to, like, leave it. Practitioner discretion was how to withdraw their patients from testosterone or estrogen, if it was even necessary at all.

18 Q Did any managed care plan ask questions about 19 how to implement the categorical exclusion of 20 gender-affirming care?

A I don't think we received any questions formanaged care plans.

23 Q What about from providers?

A I don't think we received any providerquestions either.

Page 226 Did any plan communicate that they will 1 0 2 continue coverage in spite of the categorical exclusion? Definitely no. 3 Α Could a plan do that? 0 4 Α Well, they hypothetically can --5 Would Florida Medicaid allow them to do that? 6 0 7 А No, we would not. I'm showing you what's marked as -- well, I 8 Q 9 will be in a second -- what is marked as DEF_ 000169125. 10 It's the template member handbook -- actually, let's 11 skip that one. I'm sorry. I'm sorry. 12 MS. DUNN: Oh, I'm sorry, we have numbers that 13 aren't lining up with --MS. DEBRIERE: Yeah, let's actually -- let's 14 move to the emails from Susan Williams between her 15 and Magellan. I'm not sure what the Bates stamp 16 17 is. Okay. Thank you. 18 (Whereupon, Exhibit No. 19 was marked for identification.) 19 20 BY MS. DEBRIERE:: 21 And that's marked as 19 and it's a series of Ο 2.2 emails between Susan Williams, Jessica Forbes at AHCA, 23 Ashley Peterson, and the first date on the document is 24 June 3rd, 2022. The subject is for treatment of gender dysphoria for children and adolescents. 25

1	A Well, this was well, we received this prior
2	to the promulgation of the challenge exclusion.
3	Q You did. So, Stephanie McGriff over at
4	Magellan says, Hi, Ashley and Susan, attached are the
5	internal criteria not publicly posted. CCM that the
6	implemented all meds with the gender code equals B, both
7	in the subsequent updated denial letter that includes
8	the non-discriminatory verbiage. What are the internal
9	criteria she's referring to?
10	A So it looks like the email chain started on
11	April 20th, following the release of the Department of
12	Health's guidelines. So there were 14 impressions to
13	AHCA at that time. We had just initiated the GAPMS
14	process for these treatments.
15	Q Yeah. In fact so looking at the email from
16	Alicia King Wilson dated April 20th so that would be
17	the day that the Florida Department of Health released
18	its guidance, right?
19	A Yes.
20	Q And Secretary Marstiller directed Tom Wallace
21	just to start the GAPMS process.
22	A Yes.
23	Q It says: Leslie noted MMA does have an
24	internal gender dysphoria criteria, which is attached.
25	This internal document serves for a GnRH analog used to

delay puberty in adolescence with gender dysphoria, but 1 2 it does not speak to use of hormone therapy. This 3 document was provided by the Agency due to a fear of hearing requests received from Lupron for recipient with 4 this diagnosis. All requests for use of the drug at 5 that time to delay puberty were to be vetted by AHCA 6 7 before a final determination is made. Can you explain that a little bit more? What does it mean that AHCA had 8 9 to vet all determinations? What determinations was AHCA 10 vetting?

A I don't -- I mean, it's tough to fully understand the context of this email. I mean, the context level is light throughout the chain, because I mean, Magellan does handle the prior authorization of clinical reviews for drugs in the fee-for-service system.

17 Okay, but it says that this document was Q 18 provided the Agency due to a fair hearing request received from Lupron first, recipient with this 19 20 diagnosis, all requests required vetting by AHCA before a final determination was made. So, I mean, I interpret 21 2.2 that to mean that anytime Magellan received a request 23 for Lupron to treat gender dysphoria, AHCA had to vet it 24 before a decision as to coverage would be reached. Am I 25 wronq?

1	A No, that's what it sounds like. The		
2	pharmacy the pharmacy processes may involve as far		
3	as like the pharmacist job descriptions go I mean, as		
4	far as like vetting, that's the kind of the questions		
5	like, are they because we don't do in-house prior		
6	authorizations or clinical determinations anymore. We		
7	haven't done those since SMC went into a fact.		
8	Q Was a special exception made for the coverage		
9	of hormone therapy to treat gender I'm sorry for		
10	the treatment of puberty suppressant?		
11	A No. No. Yeah.		
12	Q So not to your knowledge		
13	A I'm just trying to figure out what they mean		
14	by vetting. Like, in other words, does this mean		
15	like, is Magellan sending the determination back to AHCA		
16	for yes or no approval?		
17	Q Yeah.		
18	A So they could be doing that.		
19	Q But you don't know?		
20	A Don't know.		
21	Q Can we find that information out?		
22	A We might be able to, because like because		
23	it's only a few emails, and we're trying to go over the		
24	process. I mean, it is possible that we could ask		
25	people who do oversee this area. I mean, they might		

	Page 230	
1	give us some information, but they may not be able to	
2	describe the exact context of the email because, I mean,	
3	sometimes things get lost in translation.	
4	Q Does Susan Williams still work here?	
5	A Yes, she does.	
6	Q Does Ashley Peterson still work here?	
7	A Ashley Peterson recently left us.	
8	Q What's recent?	
9	A Last week.	
10	Q Find another opportunity?	
11	A Yeah.	
12	Q How about Kelly Reuben?	
13	A Kelly Reuben's still here.	
14	Q Jessica Forbes.	
15	A Jessica Forbes is still with the Agency.	
16	Q Shantice Green.	
17	A No, she's not here anymore.	
18	Q She find another opportunity?	
19	A I believe so, yes.	
20	Q All right. So, as a reminder, all gender	
21	codes were removed from programming as directed by the	
22	Agency in 2017. What does that mean?	
23	A I'm not sure because I'm not sure what they	
24	mean by CCM. Generally, when we do when we make	
25	systems updates, it's either done through a file	

Paqe	231

maintenance or a customer service request to Gainwell 1 2 Technologies oversees the FMMIS, so --3 You were familiar with the programming of the 0 ICD-10 codes, but you're not familiar with programming 4 of the gender codes? 5 Well, no, I'm familiar with the -- how 6 А 7 diagnosis codes are programmed in the system, but this CCM acronym I'm not familiar with. 8 9 Ο What is a gender code? 10 You mean a gender code? Well, what they mean Α 11 by gender codes, I'm assuming that means the ICD-10 Code 12 That's -- that's assuming that's what that means. F64. 13 Q What's a B for both? Maybe that's written reference to male and 14 Α 15 female. 16 What is the significance of that? Why does it 0 17 matter if it's -- what are the options? B for both and 18 then, what, M for male, F for female? That could -- I mean, that's what I'm assuming 19 Α 20 based on -- based on this email chain. I mean, it's a 21 little difficult because -- I mean, there's a lot of 2.2 extrapolation and it's -- much of it's open to 23 interpretation, so --24 Q Sorry, I lost my place. Please prepare a CCM to remove gender code from all the NDC's. What are 25

NDC's? You said that? 1 2 А National drug codes. So that's almost like --3 kind of like a procedure code, because each drug has a corresponding NDC. So the system doesn't recognize drug 4 names or recognize national drug codes. 5 6 Ο Okay. And that was actually -- that 7 instruction was provided to someone -- Arlene Elliot sent that instruction to someone back in 2017, to remove 8 9 the gender code. Do you have any idea why Magellan and 10 AHCA were talking about this on June 3rd? 11 We hadn't announced that we were going to Δ No. 12 do a categorical exclusion yet. 13 Q Okay. I think this is just a place where we're going to need to reserve some time for deposition 14 15 after you're able to do some adequate research on what 16 the information this email contains, and then we can do 17 some follow-up questioning. Okay. 18 You mentioned earlier, were there any 19 communications from the plans about the exclusion prior 20 to its adoption? 21 Α What do you mean? Do the plans have any -- do 2.2 we discuss with the plans prior? No. 23 All right. Turning to waivers and variances 0 24 under Chapter 120, are you familiar with that process? 25 Α Oh, yes, I am.

1	Q Okay. I'm going to hand you a copy of the		
2	statute, Section 120.542. We'll mark that as Exhibit		
3	20.		
4	(Whereupon, Exhibit No. 20 was marked for		
5	identification.)		
6	BY MS. DEBRIERE::		
7	Q Are you familiar with the statute?		
8	A Yes, I'm familiar with it.		
9	Q Based on your understanding, what is the		
10	purpose?		
11	A So the purpose of this is because, of course,		
12	agencies are granted rulemaking authority. And because		
13	agencies now and, of course, the rulemaking process,		
14	I mean, it's public, transparent, but there are times		
15	that there may be an exception that's required, so it's		
16	kind of like the check and balances that if a variance		
17	is required on a rule that like a party could apply		
18	to that agency that administers that rule for		
19	consideration of a variance.		
20	Q Does the purpose of the underlying rule have		
21	to the spirit of it have to be met in granting the		
22	variance or waiver?		
23	A What's meant by the spirit?		
24	Q I'm trying to look for the specific language.		
25	So under subpart two, variance and waiver shall be		

1 granted when the person subject to this rule 2 demonstrates the purpose of the underlying statute -- I 3 guess in this case it would be a rule -- or what statute 4 will we be referencing?

Well, in legal terminology, I mean, 5 Α 6 differences between rule and statute, I mean, statutes, 7 of course, are approved by the legislature, goes to the Governor, and the rules are done under the authority of 8 9 the statutes. So, I mean, like agencies are authorized 10 to grant variances and waivers to requirements of the 11 rules consistent with the section and with rules adopted 12 under the authority of the section. So, I mean, they do 13 call out rules, specific. Then, of course, this applies to all state agencies, so --14

Q Who makes a determination at AHCA whether a petitioner has established a substantial hardship under the statute?

18 A Those come through our General Counsel's
19 office. So if somebody wants to request a variance,
20 they do so through our agency clerk.

21

Q And how is the determination itself made?

A So the agency clerk will reach out to individuals to, of course, who have pertinent knowledge about the -- about the circumstances of the request of the variance, will ask for input. And, of course, the

determination's made. It rides up to the Secretary.
 The Secretary has to do the final approval for a
 variance.

Q So same question as to determining whether principle -- principles of fairness are violated, who makes that determination?

A So when it comes to waivers and variances,
that's same process. Goes to the agency clerk. Then,
of course, does an investigation, consults with
individuals who are knowledgeable about the pertinent
subject, and then it goes up to the Secretary.

12 Q Has AHCA developed any criteria to guide its 13 determination of whether to grant a variance or waiver 14 from the categorical exclusion of gender-affirming care?

A No. No, we haven't. Variances are determined
on a very individualized basis.

So, again, turning back to the -- ensuring the 17 Q 18 purpose of the underlying statute, 120.542 specifically 19 states that variance and waivers shall be granted when 20 the person subject to the rule demonstrates that the 21 purpose of the underlying statute will be or has been 2.2 achieved by other means for the person. So that means the granting of the variance or waiver shows that the 23 24 purpose of the underlying statute will be or has been achieved by granting it. What statute -- in reviewing 25

1 2

3

any request for a variance or waiver from 159G-1.050(7), how would you demonstrate that the purpose -- well, what statute will be at issue, first of all?

A Well, for the statute -- I mean, would be Chapter 409. Those are the Florida Medicaid -- that consists of the Florida Medicaid statute, so --

Q What specific -- what specific provision of
409 would you be looking at?

9 A I mean, we'd be looking at -- well, for the
10 variance, we'd probably be looking at, like, I mean,
11 somewhere under 409.9, probably under covered services
12 or optional services.

Q Okay. So how -- if someone requested a waiver or variance from 59G-1.050(7), under what circumstances would AHCA authorize coverage of the services listed in that rule?

17 Α Well, we can't speak to those because I don't 18 think -- we haven't gotten a request for variances on 19 this yet. So like it says, a highly individualized 20 process. We will be looking at in-depth at the 21 recipient, looking at all the records available, and, of 2.2 course, discussing things with various experts and so 23 forth. But each request is individualized. So because each request is individualized and focuses on the 24 specific individual, we can't project on what grounds we 25

1 would grant a variance under.

2 Q Well, so the June -- the categorical exclusion 3 of treatment for gender dysphoria was adopted because the certain -- AHCA found that those services were 4 experimental, correct? And Florida Medicaid cannot 5 cover services that are experimental? 6 7 That's correct. Α So in what situation could AHCA grant a waiver 8 Ο 9 or variance covering services that AHCA has found to be 10 experimental? 11 Α Well, I mean, based on the rule we wouldn't. 12 I mean, based on the rule, we would deny the variance, 13 but because each variance, it's individualized requests, 14 we would have to go through and evaluate each one 15 individually. 16 Would the person have to establish that the 0 17 service they're requesting is not experimental? 18 Α We will not be placing the burden on the 19 recipient. 20 0 Who would the burden be on? 21 Α Well, that would be on -- it'd be an 2.2 individualized process, evaluating all the -- all -whatever medical records that we can get a hold of. 23 24 That's -- that's process that we use in the past, but based on the rule, I mean, yeah, we say that these 25

1	would you have a categorical exclusion. While we	
2	while the variance process is available, but because we	
3	have a categorical exclusion, we do declare the services	
4	to be experimental, investigational due to	
5	very-low-quality evidence that yeah, I mean, we would	
6	deny variance, but because variance reviews are	
7	individualized, we don't want to speak in absolute terms	
8	on the variance process. But for because, I mean,	
9	there's all kinds of questions that could come up in the	
10	review of the medical records. Maybe it was a maybe	
11	it was a misdiagnosis. Maybe something else could come	
12	up. That's pretty much why. So	
13	Q Okay.	
14	A Everything is different and	
15	Q If a person sought a waiver of the application	
16	of 59G-1.050(7) so they can receive Medicaid coverage	
17	for a mastectomy that is specifically to treat their	
18	gender dysphoria, under what circumstances would that	
19	waiver be granted?	
20	A For under what circumstances?	
21	Q Yeah.	
22	A Well, I mean, we did declare this service to	
23	be experimental investigational.	
24	Q So they could not get a waiver, correct? The	
25	waiver would be denied?	

Page 239 Based on the very general, hypothetical Α 1 situation that you provided, straight out just for 2 gender dysphoria, they got denied by their insured so 3 they request a variance. 4 5 Yeah. Ο Based on our rule language, yeah, it'd be 6 Α 7 denial. And someone is entitled to a fair hearing when 8 Q 9 Medicaid coverage is denied, correct? 10 Α Yes, they are. Given that the Agency has found the services 11 Ο 12 in 1.057 -- 59G-1.050(7) to be experimental, and 13 therefore never medically necessary, correct? 14 А Correct. 15 0 Could someone ever prevail at a fair hearing where they sought coverage of the services for gender 16 17 dysphoria? 18 Α Well, based on our rule, based on our 19 findings, no. 20 Could someone use the variance or waiver 0 21 process to get around the final decision issued after 2.2 the fair hearing? Well, I mean, they can request a variance, but 23 Α then they would go through the process, but based on our 24 rule and our findings, no. 25

Q How often do Medicaid beneficiaries file
 variance requests?

A So in the research for this case, we found 10 requests, and that's since going back to about 2015, 2016.

6 Q Okay. So between 2015, 2016 to present, there 7 has been 10 requests?

8

A That's correct.

9 Okay. These variances -- and I have copies of Ο 10 all of them, if you'd like to reference them. They 11 request that a service that AHCA affirmatively covers. 12 So there's -- there's a few types of variances we found 13 in our review. There's situations in which AHCA affirmatively covers the service, but the individual 14 15 wants an amount greater -- in a greater amount or 16 duration.

17 Α Yeah, I'm familiar with that one. It's --18 there was a variance request -- and it was actually several various requests, because they were granted for 19 20 six months at a time. We're talking about our recipient 21 under our I-budget waiver. So, of course, our I-budget 2.2 waiver -- and no, it isn't, it's codified in rule. So, 23 of course, there was a service limit on these behavior assistance services at the time. They were requesting 24 additional behavior assistance services. So while -- so 25

1	because we already covered the service, and they're just		
2	looking for additional services, you know, and that		
3	that's that's flexibility that we can grant because		
4	we haven't actually gone through the service they are		
5	requesting, we have not codified as a categorical		
6	exclusion, and we've not deemed that service be		
7	experimental investigational.		
8	Q Okay. And that's true for all the services		
9	that are contained in the variances		
10	A Yeah, from what I could tell, they're pretty		
11	much all I-budget.		
12	Q Okay. And they none of the services that		
13	they were requesting some kind of variance on had been		
14	categorically excluded, correct?		
15	A Correct.		
16	Q Okay. And none of them have been determined		
17	experimental?		
18	A Right.		
19	Q Okay. Do you know of every Medicaid recipient		
20	who made a request for a variance, if they were		
21	represented by counsel?		
22	A No, we don't know if they were all represented		
23	by counsel or not.		
24	Q Because I did notice that the recipients were		
25	all listed.		

1	A Yeah, the recipients were listed. The	
2	information is referred to the agency clerk. Then the	
3	Agency does its internal processes.	
4	Q Do you know what pro se means?	
5	A No.	
6	Q So, in any of the requests for variances to	
7	the Medicaid recipient, him or herself, do any of the	
8	direct request for the variance, or did they need	
9	assistance?	
10	A Given the complexities of request and	
11	legalities of it, I would I think it's safe to say	
12	that they had some assistance, although it's not	
13	required.	
14	Q Okay. Between April of 2022 and August 21st	
15	of 2022, did anyone at AHCA ever discuss the variance or	
16	waiver process for use in challenging a denial based on	
17	the categorical exclusion of treatment for gender	
18	dysphoria?	
19	A No.	
20	Q All right. Turning to our specific clients,	
21	at anytime prior to August 21st, 2022, did Florida	
22	Medicaid cover any of the services listed at	
23	59G-1.050(7) for the treatment of gender dysphoria and	
24	that actually	
25	A You're talking about	

		Page 243
1	Q	Everyone.
2	А	You're talking about after the hard date when
3	the ruling	took effect?
4	Q	Anytime prior to that, did Florida Medicaid
5	cover any	of the services listed at 59G-1.05
6	А	Prior to the effective date, yes.
7	Q	Okay. So they covered puberty blockers?
8	А	Yes. Well, for that small handful of
9	recipients	we pulled the data on, yes.
10	Q	They cover cross-sex hormone therapy for the
11	treatment	of gender dysphoria?
12	A	Yeah. I mean, as far as data showed.
13	Q	Did they cover surgery for the treatment of
14	gender dys	phoria?
15	A	From our data revealed, yes.
16	Q	At any time prior to August 21st, 2022, did
17	Florida Me	dicaid cover any of the services listed at
18	59G-1.050(7) for August Dekker?
19	A	We did go through our we did go through
20	there the	recipient's histories, yeah.
21	Q	Did Florida Medicaid cover puberty blockers
22	for August	Dekker to treat gender dysphoria?
23	A	For August Dekker?
24	Q	Yes.
25	A	Puberty blockers?

Paq	ГР	244	
гач		244	

1	Q Yes.
2	A I don't believe so, no.
3	Q Did Florida Medicaid cover hormone therapy for
4	August Dekker in treatment of gender dysphoria?
5	A For August Dekker, yes. I think I think
6	his managed care plan, Humana was providing him those.
7	Q And he's still currently eligible for Florida
8	Medicaid?
9	A Last time we checked he was still Medicaid
10	eligible.
11	Q Okay. And he's still enrolled in Humana, or
12	did he switch to another plan?
13	A Well, we haven't we haven't verified
14	since we did have an enrollment period and recipients
15	are eligible to switch plans during that enrollment
16	period.
17	Q In the coverage of hormones for treatment of
18	August Dekker's gender dysphoria, how long for how
19	long did AHCA authorize that treatment? For how long
20	did Florida Medicaid cover that treatment?
21	A I don't know the exact length. We would have
22	to go back and take a look at the records we received
23	from Humana on the case.
24	Q More than six months?
25	A I think it was more than six months.

Page 245 More than a year? 1 Q 2 Α That's where it gets hazy. Was coverage for hormones to treat gender 3 0 dysphoria terminated for August Dekker after August 4 5 21st? According to rule, yes, it would be 6 А 7 terminated. Did Florida Medicaid cover surgery for August 8 Q 9 Dekker and treatment of gender dysphoria? 10 Α Yes. 11 When? 0 12 So that would have been prior to the -- that Α 13 would have been prior to the challenge exclusion being Then to clarify, that was -- is -- the implemented. 14 15 managed care plan was covering that outside our state plan benefits. 16 17 How do you know that? Q 18 Because our state plan does not -- does not Α 19 specify the service as being -- as being mandated for 20 In other words, if Humana had denied the coverage. 21 service, well, it would have just been a denial because 2.2 it's not a -- Medicaid doesn't -- we don't have that in 23 our state plan. Managed care plans have to cover all 24 state plan services. Sex change operations are not a state plan covered service. 25

Surgery is a state plan covered service? 1 0 2 Α Surgery, yes, but for -- but not for this -necessarily this condition. 3 Does the state plan specify for what 4 Q conditions services are provided? 5 No, it doesn't break down the diagnosis codes, 6 Α 7 but this was one -- was the plan's discretion. The plan could have said yes. The plan could have said no. 8 Ιt 9 was up to the plan. 10 Were federal Medicaid match dollars used to Ο 11 pay for August Dekker's surgery? 12 Α So capitation rates that we pay to the plans 13 are per-member per-month rate. That is a combination of federal matching dollars and state revenue. 14 15 Ο Okay. At any time prior to August 21st, 2022, 16 did Florida Medicaid cover any of the services listed at 17 59G-1.050(7) for Brit Rothstein? Based on the -- based on the records that we 18 Α 19 pulled, based on the recipient's individual histories 20 that we were -- we were able to locate, looked like, 21 yes, we did. 2.2 Q Okay. Did Florida Medicaid ever cover puberty blockers for Mr. Rothstein? 23 So for Mr. Rothstein -- so for Mr. 24 Α 25 Rothstein -- I -- so. Sorry. I think he's one of the

Veritext Legal Solutions

Page 2	247
--------	-----

1	adult plaintiffs?
2	Q Yes. Yes. And you said that he I'm
3	sorry pulled in a lot of directions.
4	A We did cover services that we did determine to
5	be experimental investigational prior to the challenge
6	exclusion.
7	Q And no longer cover them, correct?
8	A Yes, because of the challenge exclusion.
9	Q Same question for KF.
10	A Since with KF, we did have a hard time
11	since for the minors we didn't have, like, their full
12	identification information. Trying to locate their
13	records in the system, I think there were encounters,
14	based on information we had, that did show they were
15	receiving GnRH.
16	Q Okay. For the treatment of gender dysphoria?
17	A Yeah.
18	Q Okay. And that includes Susan Doe, as well?
19	A Based on what we could find, looked like
20	they that there had been some coverage.
21	Q And they're KF is still currently eligible
22	for Florida Medicaid, is that correct?
23	A We would have I think I think they would
24	be, because we haven't been doing these determinations
25	because of COVID. So, yes, they would still be

Page 248 Medicaid-eligible. That would go for all the plaintiffs. MS. DEBRIERE: Okay. Let's -- can we take a five-minute break? MR. JAZIL: Sure. VIDEOGRAPHER: Okay. This concludes video four. The time is 4:15 p.m. (Brief recess.) VIDEOGRAPHER: This is the beginning of video five. The time is 4:30 p.m. We're on the record. BY MS. DEBRIERE:: All right. Turning back guickly to plaintiff Ο August Dekker, did Humana violate Florida Medicaid policy by covering his surgery for treatment of gender dysphoria? No, they did not at the time. Α Okay. And then I just want to talk about a Q few more exhibits. One labeled -- we've marked as Exhibit 21, and that is the GAPMS queue that was provided to us. (Whereupon, Exhibit No. 21 was marked for identification.) BY MS. DEBRIERE:: And it looks like the most recent date on that Q queue was maybe an update to one of the GAPMS in 2019.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

25

That's as far as it goes. Are all -- are these the only 1 2 GAPMS that are currently pending? 3 So the requests came in to pull the most А 4 recent GAPMS queue. 5 Yeah. Ο So at this -- when I went through our -- we 6 Α 7 have a GAPMS folder that's on our shared drive. I did look through to see what -- we have a folder for the 8 9 GAPMS queues. I did pull the most recent one. This was 10 the most recent one that had been updated that was in 11 there --12 Q I'm sorry. Go ahead. 13 Α This does -- this does consist of a lot of GAPMS reports, which I do remember drafting some of 14 15 those as well, but this was our most recent one. 16 0 And have there been GAPMS reports created 17 after 2018? 18 Α Yeah, I think there have been. 19 Why aren't they on this list? Q 20 I'm not -- I'm not sure why they wouldn't be А 21 included on this list. This list should be updated on 2.2 regular basis, so I'm not sure why they wouldn't be 23 included on this, or on the list on the share drive, because the GAPMS queue is really is not so much for the 24 GAPMS analyst, because GAPMS analysts generally have a 25

1	pretty good idea of what's outstanding, what's pending,
2	and what's been turned in. It's more for leadership
3	or their supervisor to pull and take a look at when
4	necessary, so I'm not sure why this hasn't been listed
5	to update in this current.
6	Q So whoever's working in GAPMS at the time has
7	a good understanding of which GAPMS are pending.
8	A When I was when I had the role, I could
9	tell you exactly where all my reports were, what their
10	status was and where they stood in the queue. So, yeah,
11	I kind of had all committed to memory.
12	Q Okay. Would that be true of anyone holding
13	that GAPMS position?
14	A As far as pulling it from memory, I couldn't
15	vouch for the other employees as to their memories, when
16	it came down to their reports that are outstanding.
17	Q But they should have a good sense?
18	A They should have a good sense of what's
19	pending and what's been turned in.
20	Q Can you provide us a list of what's pending
21	that's not listed on this queue?
22	A So I think so I think the ones that are
23	still pending aren't I think there were, like,
24	reopened reports. I think we had gotten requests from
25	the manufacturers of Atheno, was the asthma tests that I

1	discussed earlier. That was one I had to have
2	finalized. We've gotten a request for them to for us
3	to review it, provided that they don't send some more
4	evidence and more studies that have been done after our
5	original report. So I think that one was reopened.
6	That one should still be pending. Then there was
7	specially modified low-protein foods. That was another
8	one that I had written up. We had gotten requests to
9	reopen that one that, and to reevaluate that service. I
10	think there was another one, which was the which was
11	a bone growth stimulator called Exigent. I think that
12	one is still outstanding and pending. Now, those are
13	just some examples of ones I can think are still
14	pending.
15	Q Were there any new requests made after
16	December of 2018?
17	A Yeah. I mean, there have been some new
18	requests for either, like, expedited GAPMS or full
19	GAPMS. I mean, we do get the service requests in fairly
20	frequently, so
21	Q Because it would be odd if any new requests
22	hadn't come in almost five years
23	A Correct. Yeah.
24	Q Okay. But there's no way all right. And
25	then I just want to put into the record, because we've

1	been referring to it quite a bit, we'll Mark it as
2	Exhibit 22, and that is the document from Health and
3	Human Services that we've referenced multiple times
4	during the deposition. Is that the one you're referring
5	to?
6	A That's correct. This is it.
7	(Whereupon, Exhibit No. 22 was marked for
8	identification.)
9	BY MS. DEBRIERE::
10	Q Thank you. And then the guidance from the
11	Florida Department of Health regarding treatment of
12	gender dysphoria for children and adolescents dated
13	April 20th, 2022. That's Exhibit 23. Is that the
14	document that we've been referring to when we're talking
15	about DOH guidance?
16	A Yes, it is.
17	(Whereupon, Exhibit No. 23 was marked for
18	identification.)
19	MS. DEBRIERE: And then I think that's it
20	for my questions. The only thing I wanted to put
21	on the record, Mo, is we are at what time,
22	Videographer?
23	VIDEOGRAPHER: Do you mean the whole run time
24	or
25	MS. DEBRIERE: Just the questioning time.

Page 253 Yeah, the time that we've been live and active on 1 2 the record. VIDEOGRAPHER: Five hours, eight minutes plus 3 five and a half minutes. 4 MS. DEBRIERE: Okay. So want to just say that 5 we have an hour and 45 minutes of questioning --6 7 MR. JAZIL: Sure. MS. DEBRIERE: -- to reserve? 8 MR. JAZIL: And so the depo is open. I'd like 9 10 to ask questions at the end. So I'll just reserve 11 that until after our second session, is that okay, 12 or would you like for me to --13 MS. DEBRIERE: Can I confer with my team 14 quickly? Okay. VIDEOGRAPHER: We will remain on the record? 15 16 MS. DEBRIERE: We'll go off the record. 17 VIDEOGRAPHER: Okay. Off the record at 4:36 18 p.m. (Discussion off the record.) 19 20 VIDEOGRAPHER: We're back on the record. The 21 time is 4:37 p.m. 2.2 MS. DEBRIERE: And plaintiff's counsel is all 23 finished with their questioning. 24 EXAMINATION 25 BY MR. JAZIL::

1	Q This is Mohammed Jazil for the defense. I'll
2	try to be brief, recognizing we have time limitations
3	here. Mr. Brackett, I'd like to have you look at
4	Exhibit 3 again.
5	A Okay.
6	Q Exhibit 3 has a date on it, May 20th, 2022. I
7	want the record to be clear, why is that date not
8	accurate?
9	A This date isn't accurate because that date
10	is automatically sets to the date you print it out.
11	Q And what sets that date?
12	A The template is automatically set to enter in
13	this current date that you're viewing the document. So
14	it automatically updates the second you open it.
15	Q And that's the template in the AHCA document?
16	A That is our template, yeah.
17	Q And when was this GAPMS report created?
18	A This GAPMS was originally created in 2016.
19	Q Thank you. You discussed with my friend the
20	variance and waiver process. Do you recall that
21	testimony?
22	A Yes.
23	Q You testified that the variance and waiver
24	process is individualized. Do you recall that
25	testimony?

Page 255 Yes, I do. 1 Α 2 Q Once a variance and waiver request comes in, 3 it goes to the clerk is what you testified to, if my understanding is correct? 4 Α Yes. 5 And then the clerk routes it to whom? 6 0 7 The clerk gathers information and it has to be Α 8 routed up to the secretary. 9 Ο Is it routed directly to the Secretary or is 10 there any other office that it goes through first? I'd have to take a look at the variances 11 Δ 12 It might be -- I think it probably have to route aqain. 13 through General Counsel before it goes to the Secretary. Okay. And is the General Counsel's office 14 0 15 responsible for the formulating the Agency's position on 16 legal issues? 17 Α Yes. 18 Does that include the variance and waiver Q 19 process? 20 Α Yes. 21 MR. JAZIL: I have no further questions. 2.2 FURTHER EXAMINATION BY MS. DEBRIERE:: 23 Just one redirect. Very brief. On Exhibit 3, 24 Q which is the GAPMS memo dated May 20th, 2022, that was 25

Page 256 the date it was printed out. It also appears changes were made on that date, is that correct? Based on the comments in the edits, yeah, it А looks like somebody had made changes to that document on that date. 0 But you don't know who that person is? Α SG, I'm -- I can't speak to who SG is. But you will find that information out for us? Q А We can -- we can figure out who, but we would -- probably want to verify with IT. MS. DEBRIERE: Okay. That's all. MR. JAZIL: So, counsel, while we're still on the record, he's still under oath, so I'm not going to obviously talk to him about any issues that might come up, but with your consent, I'd like to at least work with him to gather the additional information that's being sought. Is that appropriate? MS. DEBRIERE: I mean, I would assume that would be your process. MR. JAZIL: He is under oath, and so I'm obviously not going to try to, you know --MS. DEBRIERE: I see. I see. MR. JAZIL: -- work with him while -- work with

him on his testimony, I say, as I try to gather

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

25

Page 257

additional information, so I'll make that clear on 1 2 the record. VIDEOGRAPHER: Anyone else? Anybody by Zoom? 3 MS. DEBRIERE: No. 4 VIDEOGRAPHER: Okay. This concludes the 5 February 8th, 2023 portion of the video-recorded 6 7 deposition of Corporate Representative for Agency for Health Care Administration. The time is 4:40 8 9 p.m. 10 COURT REPORTER: Are you going to be ordering 11 this? 12 MS. DEBRIERE: Yes. 13 COURT REPORTER: All right. And Mo has requested a rough draft. I told him I could get it 14 15 to him tomorrow. Do you guys -- would you guys 16 like one, as well? 17 MS. DEBRIERE: Yes, please. (Whereupon, the deposition was concluded at 18 19 4:40 p.m., and the witness did not waive reading 20 and signing.) 21 2.2 23 24 25

Page 258 CERTIFICATE OF OATH 1 2 3 4 5 STATE OF FLORIDA) 6 COUNTY OF LEON) 7 8 I, the undersigned authority, certify that the 9 above-named witness personally appeared before me and 10 11 was duly sworn. 12 13 WITNESS my hand and official seal this 21st 14 day of February, 2023. 15 16 17 Jana W. Veenes 18 19 20 DANA W. REEVES NOTARY PUBLIC COMMISSION #GG970595 21 EXPIRES MARCH 22, 2024 22 23 24 25

1	CERTIFICATE OF REPORTER
2	STATE OF FLORIDA)
	COUNTY OF LEON)
3	
4	I, DANA W. REEVES, Professional Court
5	Reporter, certify that the foregoing proceedings were
6	taken before me at the time and place therein
7	designated; that my shorthand notes were thereafter
8	translated under my supervision; and the foregoing
9	pages, numbered 128 through 257, are a true and correct
10	record of the aforesaid proceedings.
11	I further certify that I am not a relative,
12	employee, attorney or counsel of any of the parties, nor
13	am I a relative or employee of any of the parties'
14	attorney or counsel connected with the action, nor am I
15	financially interested in the action.
16	DATED this 21st day of February, 2023.
17	
18	
19	Jana W. Veenres
20	Nor -
21	DANA W. REEVES
	NOTARY PUBLIC
22	COMMISSION #GG970595
	EXPIRES MARCH 22, 2024
23	
24	
25	

1	Gary V. Perko, Esq.
-	gperko@holtzmanvogel.com
2	
3	February 21, 2023
4 5	RE: August Dekker, et al. vs. Jason Weida, et al.
6	February 8, 2023/Matthew Brackett/5696545
7	repractly 0, 2025/Matchew Brackett, 5050345
,	The above-referenced transcript is available for review.
8	The witness should read the testimony to verify its
	accuracy. If there are any changes, the witness should
9	note those with the reason on the attached Errata Sheet.
	The witness should, please, date and sign the Errata
10	Sheet and email to the deposing attorney as well as to
	Veritext at Transcripts-fl@veritext.com and copies will
11	be emailed to all ordering parties. It is suggested
	that the completed errata be returned 30 days from
12	receipt of testimony, as considered reasonable under
10	Federal rules*, however, there is no Florida statute to
13	this regard. If the witness fail(s) to do so, the
14	transcript may be used as if signed.
14 15	Yours,
16	Veritext Legal Solutions
17	*Federal Civil Procedure Rule 30(e)/Florida Civil
	Procedure Rule 1.310(e).
18	
19	
20	
21	
22	
23	
24	
25	

Case 4:22-cv-00325-RH-MAF Document 120-6 Filed 04/07/23 Page 299 of 346

Page	26
August Dekker, et al. vs. Jason Weida, et al.	
February 8, 2023/Matthew Brackett	
ERRATA SHEET	
PAGE LINE CHANGE	
REASON	
PAGE LINE CHANGE	
REASON	
PAGE LINE CHANGE	
REASON	
PAGE LINE CHANGE	
REASON	
PAGE LINE CHANGE	
REASON	
Under penalties of perjury, I declare that I have re	ea
the foregoing document and that the facts stated in	i
are true.	
Matthew Brackett DATE	

[& - 257]

Page 262

&	120.542 127:17	2	258:14 259:16
& 126:19	206:1 209:18,24	2 125:11	260:3,6 261:2
	235:18	20 127:17 233:3	2024 258:21
0	120.542. 233:2	233:4	259:22
000169125	1229 126:7	2002 162:16	20th 157:24,25
226:9	125 125:11	2002 102:10 2015 208:4,5	158:3 227:11,16
0002587 216:21	128 127:4 259:9	240:4,6	252:13 254:6
000258815	12th 126:7	2016 143:3	255:25
221:6	13 127:11	240:5,6 254:18	21 127:17
000292335	152:14	2017 139:11	248:19,21 260:3
201:16	14 127:12	151:9 230:22	210 137:24
00325 125:3	162:20 163:6	232:8	215 127:14,14
1	227:12	2018 249:17	21st 207:10
1.05 243:5	15 127:13 200:4	251:16	208:10 242:14
1.050 148:23	201:24 202:11	2019 248:25	242:21 243:16
149:3 174:3	1512 126:14	201 2 10:20 202 127:13	245:5 246:15
189:13 204:19	153 127:11	2022 127:14,14	258:13 259:16
213:8 236:1,14	159g 236:1	127:16 128:13	22 127:14,14,18
238:16 239:12	16 127:14	128:18 129:2	213:24 216:5
242:23 243:18	199:24 213:22	135:8 140:6	252:2,7 258:21
246:17	213:22 214:3	147:14,19 151:1	259:22
1.057 239:12	163 127:12	157:6,16 160:11	222 127:15
1.310 260:17	17 127:14	163:7 164:12,18	227 127:16
10 149:16	213:22 214:1,3	164:23 168:23	22nd 214:2
154:21 159:4	214:8	171:21 178:10	216:18
224:25 231:4,11	18 127:15 221:7	201:22 207:10	23 127:18 211:2
240:3,7	221:9	208:10 213:24	252:13,17
10005 126:13	19 127:16	214:2 216:5	234 127:17
10:35 216:5,19	226:18,21	220:16 226:24	24 168:22 170:2
110 126:14	19th 126:12	242:14,15,21	245,000 137:24
119 126:20	1:30 125:15	243:16 246:15	249 127:17
11:04 216:18	128:8	252:13 254:6	253 127:5,18,18
12 149:17	1st 158:2,3	255:25	255 127:6
120 126:12		2023 125:14	25 7 259:9
212:4 232:24		147:13 257:6	

Veritext Legal Solutions

[25th - actively]

25th 147:13 261 125:11 26th 201:22 2727 125:17 27514 126:15 29229 258:18 259:19 2nd 166:4 168:11 169:25 184:3 3 254:4,6 255:24 30 212:25 260:11,17 3100 126:9 32205 126:4 32301 126:20 32308 125:17 32601 126:7 33131 126:10 34,999 138:2,3 35 138:2 35,000 136:16 136:21,25 137:23 138:23 177:22 3900 126:4 3:00 199:12 3:08 199:15 3rd 127:16	4 409 236:5,8 409.9 236:11 45 253:6 46 164:13 187:19 47 193:1 4:15 248:7 4:22 125:3 4:30 248:10 4:37 253:21 50 149:15,21 152:16 155:12 500 126:20 5696545 260:6 59 148:23 149:3 169:4 59g 174:3 189:13 204:19 213:8 236:14 238:16 239:12 242:23 243:5,18 246:17 6 60 216:25 217:2 217:14,16 218:7 218:17,20,23 219:23 220:7	7 7 138:4 148:23 149:3 174:3 204:19 213:8 236:1,14 238:16 239:12 242:23 243:18 246:17 70s 163:3 8 8 125:14 260:6 261:2 88 158:12 8th 128:14,25 188:8 257:6 a a.m. 216:5,18,19 aap 162:9,10 194:7 aap's 162:11 abc 144:10 ability 132:4 able 140:15 149:20 151:25 158:14 159:14 175:11,15 178:24 179:12 179:22 182:9 185:16 192:23 192:24 229:22	absence 155:7 absolute 150:18 238:7 absolutely 202:3 212:13 academic 160:18 academy 190:16 accepted 204:10 access 191:21 218:11,13,19 225:10 accessible 175:10 187:23 188:4 accordance 212:23 account 132:1,2 154:23 accuracy 260:8 accurate 204:14 204:16 254:8,9 achieved 235:22 235:25 acronym 231:8 act 173:1,12,21 173:24 acting 134:21 138:10 action 259:14 250:15
3900 126:4 3:00 199:12 3:08 199:15	60 216:25 217:2	178:24 179:12	173:24
	217:14,16 218:7	179:22 182:9	acting 134:21
	218:17,20,23	185:16 192:23	138:10

[activists - ahca]

Page 264

	1	1	
activists 161:1	adds 216:9	207:21 232:20	143:5,6 144:18
activities 196:21	adequacy	adult 186:5	154:1 166:13
activity 193:24	175:21	247:1	175:18 177:5
actual 132:15	adequate	adults 185:9,10	180:17 181:4,17
132:20 172:5	149:15 161:5	185:12,20,23	181:21 185:5
202:9 203:15	174:11 175:1	adverse 127:13	186:10 192:3
actually 132:6	176:23 196:8	200:15 201:14	205:10 212:18
133:11 137:14	223:3 232:15	201:19 202:13	212:21 219:5
139:9 144:7	adjuvant	202:19 203:7,14	228:3,18 230:15
149:14 153:11	151:11	204:25 207:2	230:22 233:18
153:12 163:13	administers	adversely	234:20,22 235:8
167:17 179:10	233:18	212:15	239:11 242:2,3
180:3 182:18	administration	advocacy	257:7
192:4 205:6,8	125:16 257:8	160:25 179:21	agency's 187:3
206:18 218:3	administrative	advocates 161:1	255:15
222:25 226:10	171:25 176:19	179:21	ages 205:5
226:14 232:6	213:10,14	affair 213:4	ago 135:19
240:18 241:4	administrator	affect 151:13	191:4
242:24	169:12 170:15	affected 196:22	agree 202:1
acute 196:19	adolescence	212:15	222:24 223:4
ad 192:19	228:1	affirmatively	agreement
adapt 140:15	adolescents	240:11,14	136:12 138:20
add 146:12	127:19 226:25	affirming	177:21,22,23
added 145:24	252:12	131:13 133:1	agreements
146:12 155:25	adopt 164:23	141:6,10,25	136:15,23
216:6	165:22 168:8,10	143:20 152:19	138:12
adding 170:22	168:23 169:7,24	162:7 225:20	ahca 128:13
addition 170:10	171:20	235:14	131:1 132:14,23
170:13	adopted 165:5	aforesaid	134:12 135:6
additional	218:19 219:22	259:10	136:13 138:15
178:8 240:25	234:11 237:3	agencies 233:12	138:25 139:2,6
241:2 256:16	adopting 172:25	233:13 234:9,14	140:4 144:20
257:1	173:24	agency 125:16	145:4,7,18
addressed	adoption 159:10	130:13 134:22	159:11 160:7
222:11	204:23 206:11	140:23 141:2	164:14 168:22
		1	

Veritext Legal Solutions

800-726-7007

[ahca - apply]

160.12 175.12	261.1 1	analysis 151.10	antiaination
169:12 175:12	261:1,1	analysis 151:12	anticipation
176:8,10,14,15	alert 127:15	151:21,23	140:10
176:18 177:1	217:1 221:5,8	analyst 221:16	anybody 129:15
178:1 180:20	221:20,22,23	249:25	133:25 172:8
181:9,11,25	222:9	analysts 249:25	177:1,11,11,14
182:10,11,20,25	alicia 227:16	analytics 159:15	183:14 257:3
183:8 184:9	alignment 133:7	analyze 157:1	anymore 223:21
186:15 187:3	194:16	analyzed 194:12	229:6 230:17
188:8 189:12,15	alliance 133:13	andrew 130:13	anytime 228:22
189:17 194:1	134:13 188:12	135:24	242:21 243:4
200:14,19,23,24	allocated	anecdotes	apologize 135:6
201:3,9 206:11	137:21	132:13	appeal 205:14
207:10,11,22	allow 222:1	angles 198:24	205:14 207:7
208:10,21 209:7	226:6	ann 163:15	212:5,17,20,24
209:11,22 210:6	allowed 204:17	213:23 216:3,25	appeals 206:4
210:19 212:18	allowing 177:6	221:18	207:1,4
213:6 214:7	altogether	announced	appear 181:24
215:14 217:22	220:20 224:18	214:14 232:11	181:25
218:23 222:16	ama 162:12,13	announcements	appearances
223:13,14	amending	184:24	126:1
226:22 227:13	170:22	annually 159:11	appeared
228:6,8,9,20,23	amendment	answer 143:9	258:10
229:15 232:10	170:19	200:11 210:3	appears 201:21
234:15 235:12	american 162:6	answered 200:8	256:1
236:15 237:4,8	190:16	antagonists	appellate
237:9 240:11,13	amount 138:4	217:7 221:25	212:20,23 213:3
242:15 244:19	139:14 149:18	anticipate 140:8	213:4
254:15	159:7 175:25	142:3,11 143:3	apples 150:22
ahca's 186:18	240:15,15	174:5 179:5	150:22
202:15 206:11	amounts 136:16	182:7	application
213:13 215:13	136:24 156:6	anticipated	238:15
219:20 220:11	ample 213:10	140:20 176:6	applies 234:13
ahead 249:12	analog 227:25	181:21	apply 218:24
al 125:5,8	analyses 149:11	anticipating	233:17
194:22 260:5,5		179:11	
7-			

[approach - background]

approach 131:8	ashley 213:25	attendance	authorizations
appropriate	216:5,10,17	177:2	217:20 229:6
129:9 155:13	226:23 227:4	attention	authorize
256:18	230:6,7	143:23 185:4	236:15 244:19
approval 164:8	aside 136:7	193:4,8	authorized
229:16 235:2	asked 199:17	attorney 259:12	234:9
approved 164:9	216:1,3	259:14 260:10	automatically
164:14,18	asking 130:3	attorney's 202:2	254:10,12,14
217:21 234:7	196:5 208:5	attorneys 182:4	available
april 157:24,25	assessed 130:4,7	200:2 210:9	152:23 153:17
158:2 227:11,16	130:10	audience 175:16	162:10 175:18
242:14 252:13	assessment	179:5 187:23	178:6 236:21
area 172:15	140:1,16 141:13	auditorium	238:2 260:7
225:14 229:25	assist 200:19	175:14	avenue 126:7,9
areas 140:14	assistance 205:4	august 125:5	aware 132:23
argument	240:24,25 242:9	127:14,14	135:20 177:10
193:10 198:9	242:12	207:10 208:10	199:2,4 204:6
arkansas	assistant 169:15	213:24 214:2	223:11
194:11	215:5,16 219:10	216:5,18 242:14	b
arlene 232:7	222:22	242:21 243:16	b 148:10 227:6
arrange 176:22	association's	243:18,22,23	231:13,17
arrangements	162:6	244:4,5,18	back 129:1
178:25 179:2	assume 256:19	245:4,4,8	135:6 139:11
arranging	assuming	246:11,15	143:19,22,24
174:11	231:11,12,19	248:13 260:5	147:1 159:6
article 144:8	asthma 151:11	261:1	167:3 183:7
145:24	250:25	authored 136:8	186:3 193:11
articles 148:8	atheno 250:25	authorities	195:18 214:6
148:14 158:8,12	attached 227:4	169:12	221:23 223:17
160:14 194:13	227:24 260:9	authority	229:15 232:8
articulate 146:8	attacks 140:17	203:22 233:12	235:17 240:4
articulately	192:20	234:8,12 258:9	244:22 248:12
179:13,16	attend 177:11	authorization	253:20
ascertain	177:14	217:13 219:21	background
196:16		228:14	130:8

[backgrounds - capacity]

backgrounds	bear 210:24	179:22 209:20	broad 196:4
128:22 129:5,9	becoming	228:8 252:1	brock 174:7
balances 233:16	144:17	blocked 210:17	176:21 177:5
bans 171:6	beginning 128:7	blockers 171:7	183:12
bar 211:10	199:14 248:9	217:7 221:25	brought 152:7
barantorchinsky	behalf 144:18	243:7,21,25	194:7
126:19	163:15	246:23	budget 137:21
base 200:2	behavior 240:23	bone 251:11	138:1 148:25
based 128:22	240:25	bostock 195:9	151:3,7,12,15
131:7,18 132:2	behavioral	bottom 212:14	151:25 240:21
132:17 133:9,19	170:16 196:15	217:3	240:21 241:11
134:1 139:7	believe 172:6,6	bound 178:5	bullets 170:22
143:25 154:16	213:24 230:19	box 164:9	burden 237:18
154:16,20 157:6	244:2	203:22 204:11	237:20
157:11,14	beneficiaries	boxes 204:13	bureau 159:17
161:15 165:2,2	205:1 220:12	brackett 125:12	166:17 167:12
185:7 186:10	240:1	127:3 128:3	167:21 169:9,13
191:19 220:4	benefit 200:15	254:3 260:6	172:2 219:14
231:20,20 233:9	201:15,19	261:2,23	c
237:11,12,25	202:14,19 203:7	brand 170:11	california
239:1,6,18,18	203:15,25 204:5	break 128:11	155:23
239:24 242:16	204:13,15,25	199:9,17,18,19	call 156:19
246:18,18,19	207:2	199:21 246:6	234:13
247:14,19 256:3	benefits 127:13	248:4	called 128:4
bases 160:15,21	203:23 245:16	breaking 195:5	251:11
basic 182:22,24	best 134:7	brickell 126:9	calling 182:17
182:24	142:23 174:18	brief 189:21	calls 136:2
basis 128:24	bias 195:1	199:13 248:8	178:17
198:11 205:2	big 187:6 198:6	254:2 255:24	canadian
207:2 235:16	bigger 153:15	brignardello	184:15
249:22	162:19	133:10 194:24	cap 138:1
bates 201:15,18	billing 224:7	brings 143:19	177:22
202:7,8 221:6	bit 128:12 135:5	143:22	capacity 134:21
226:16	136:18 146:8	brit 246:17	136:10 143:7
	166:24 174:9		175:17 176:24
			1/3.1/ 1/0.27

[capacity - cited]

187:7	214:21 234:3	certify 258:9	checking 187:13
capitation	240:3 244:23	259:5,11	chelsea 126:6
246:12	cases 194:1,18	cetera 132:3	chelsea's 211:3
capped 137:25	195:7,10	137:14	chen 129:19
caps 177:25	catch 216:23	chain 227:10	130:20 158:5
captured	catchy 187:12	228:13 231:20	189:19,24
194:23	categorical	challenge	193:14
cards 197:9	157:3 159:11	179:12 227:2	chief 169:13
care 125:16	165:3,6,10,15	245:13 247:5,8	174:7,7,7 181:4
127:13,15	165:21,24	challenging	child 186:10
131:13 133:1	169:24 172:25	242:16	children 127:11
141:6,10,18,25	173:25 191:19	change 166:19	127:19 185:9,10
150:9 152:19	192:5 200:16	174:15 214:22	187:5 188:21
154:9 157:7,11	204:23 206:12	245:24 261:4,7	226:25 252:12
157:12 159:15	207:22 209:8,12	261:10,13,16	chloe 189:6
161:17 162:4,7	218:18 219:22	changes 145:22	choose 164:23
189:4 191:21	225:19 226:2	147:6 167:1,4,4	chose 131:14
200:6,7,21,24	232:12 235:14	167:15,24	chriss 126:5
201:19 202:22	237:2 238:1,3	169:20 189:13	210:15 211:11
205:8,10 207:2	241:5 242:17	213:13 214:13	211:14
213:7,12 217:10	categorically	217:12 256:1,4	christian 133:22
217:16,17 218:2	171:15 241:14	260:8	134:8 188:9
218:4,5,9,12,17	category 186:6	changing	chronic 196:19
218:19,24	catherine	213:11	circling 135:6
219:23 220:8	126:14	chapel 126:15	circuit 225:4
221:8 222:4	cause 195:18,18	chapter 188:17	circumstance
225:18,20,22	197:22 220:22	212:4 232:24	156:9
235:14 244:6	cc'ing 213:23	236:5	circumstances
245:15,23 257:8	ccm 227:5	charge 171:22	143:23 234:24
careful 189:23	230:24 231:8,24	check 201:16	236:14 238:18
case 125:3	certain 149:18	203:5 233:16	238:20
138:10 160:19	237:4	checked 164:9	cite 194:20
160:20 180:24	certainly 181:22	194:6,13 203:23	cited 147:15,15
187:22 191:15	certificate 258:1	203:25 204:9,11	147:19 148:12
199:25 213:4	259:1	204:12,13 244:9	148:17 158:9,11

[cited - complaint]

194:2,10,20	coca 163:1	come 138:24	193:13 194:2
citing 194:13	code 159:21,24	141:2 155:8	195:6,8,10,12
citizens 134:13	160:2,3,4	162:8 165:14,18	197:20 256:3
188:12	224:13,19 227:6	166:6,7,8,10,21	commercials
civil 260:17,17	231:9,10,11,25	167:1,7 177:24	163:2
claim 159:16	232:3,9	181:2 195:25	commission
206:11	coders 224:6,23	196:6 222:22	258:21 259:22
claims 141:14	224:23 225:3	224:6 225:11	committed
143:25 188:3	codes 159:22	234:18 238:9,11	250:11
225:1	224:25,25	251:22 256:15	common 162:25
clarified 161:16	230:21 231:4,5	comes 149:17	communicate
clarify 161:14	231:7,11 232:2	150:17 151:20	158:18 176:8,10
216:6 218:4	232:5 246:6	155:19 185:12	188:9 220:17,23
245:14	codified 240:22	186:3,5 196:13	226:1
clarity 216:11	241:5	202:23 218:12	communicating
clayton 195:9	coding 224:22	223:17,19 235:7	160:10
clear 130:17	cody 174:8	255:2	communication
162:1 222:18	183:11	comfortable	136:4
254:7 257:1	cola 163:1	211:17	communicatio
cleared 210:20	cole 171:23	coming 187:2	176:22 181:4
clearer 159:19	174:6 176:19	195:6 224:12	232:19
clearing 225:2	189:6,18,24	commenced	community
clerk 212:18	193:14	125:15	161:1 170:15
234:20,22 235:8	collaborative	comment	comparability
242:2 255:3,6,7	215:22	180:14 190:8,16	
clients 242:20	collect 152:8	190:20,20,23	compared
clinic 190:19	collecting	191:2,7,14	175:18
clinical 132:2	205:16,23	193:1 195:20,20	compensated
137:17,19 139:7	colorful 193:7	197:8	177:16
160:25 161:11	column 163:8	comments	competition
228:15 229:6	164:8	179:13,16,23	150:13
close 177:24	comb 193:25	180:1,17 189:12	competitive
cnn 144:9	combination	190:9,11,14,24	136:22
coalition 133:23	160:25 189:18	191:3,5 192:15	complaint
134:8 188:10	246:13	192:17 193:3,5	206:14,17
			· · · · · · · · · · · · · · · · · · ·

[complaints - contracting]

	10110	· · · ·	
complaints	184:10	considered	consults 235:9
206:16	condition	135:14 142:9	contact 153:21
complete 146:18	196:19 224:3	147:19 260:12	156:15,25
completed	246:3	considering	contacted
138:8 165:12	conditions	148:22	135:12,17 136:9
260:11	196:17 246:5	consist 249:13	contacting
completely	conducted	consistent	135:22,23 136:1
170:15	212:23	144:17 202:17	contain 209:23
completing	confer 223:7,7	202:18 234:11	contained
197:10	253:13	consists 236:6	181:12 241:9
complexities	confidential	consultancy	contains 164:13
242:10	202:2	161:20	232:16
compliance	confirm 208:24	consultant	content 145:10
206:3	209:3	131:21 136:13	145:24 170:10
complicated	confirmation	136:14 137:11	172:17 190:8
132:9	210:3	137:25 138:5,7	191:12 214:20
components	conflict 198:4	139:3,19 144:21	context 142:18
184:4	conflicting	consultants	228:12,13 230:2
composing	223:23	129:25 131:2,10	continue 217:17
146:10,10	confusion 216:9	132:15,24	218:19 224:11
concern 143:14	connected	133:12 134:10	226:2
concerned	259:14	135:7 137:2	continued 218:7
140:17 175:21	consent 256:15	138:9,14,15,16	continuity
concluded	consider 131:16	138:24 139:6	217:16 218:2,4
185:7 257:18	135:7 141:18	140:21 142:24	218:5,9,12,17
concludes	149:2 150:1,24	145:5,7,17	218:24 219:23
199:11 248:6	consideration	146:15 147:1	220:7 222:3
257:5	132:22 143:17	158:18 160:10	contract 129:3
conclusion	173:24 174:24	160:22 162:5	204:7 218:3
165:15,18	179:24 185:14	164:14 178:2,14	contracted
168:23 185:21	190:12,22	179:9 180:1,20	137:11,18
195:24 197:23	191:20 192:3	180:24 182:21	180:21,24
conclusions	233:19	183:1	contracting
133:9 142:1	considerations	consulted	137:3
154:23 171:21	185:18 186:4	147:19,22	

[contracts - coverage]

contracts	correct 130:22	costs 186:20	187:9 191:4
202:22	130:25 131:12	council 133:17	193:19,24
contradict	143:2 145:25	counsel 126:6	194:23 195:10
187:17 195:14	146:18 147:16	129:13 135:2,24	196:7,21 197:10
contradiction	147:17 150:24	166:9,12 181:24	198:3,20 202:10
133:4,6,7	150:25 151:9	181:25 182:5,8	206:17 215:23
contradictory	154:15 164:11	182:11 202:1	218:21 219:9
165:18 198:7	164:20 167:22	241:21,23	220:1 223:23
contribute	168:9,11,12,14	253:22 255:13	224:2,5,5,6,24
132:5	169:1 171:4,9	256:12 259:12	224:24 233:11
control 176:20	171:10 173:9	259:14	233:13 234:7,13
196:8 197:16	178:11,13	counsel's	234:23,25 235:9
controversial	185:24 186:1	169:18 172:14	236:22 240:21
142:10 174:14	188:24 189:3	176:16 182:14	240:23
conversation	201:17 202:7,16	182:16 234:18	court 125:1,19
135:1,4 172:24	203:16,20 206:9	255:14	147:13 195:7
173:12,15	215:13,15,20	county 258:6	212:6,20 257:10
199:24	217:19 218:15	259:2	257:13 259:4
conversations	218:16,25	couple 130:15	courts 213:3
134:3,5 135:13	219:13 220:13	178:16,16	cover 150:11,12
135:18 136:3	237:5,7 238:24	course 129:12	151:8,13 152:20
162:8 173:16,19	239:9,13,14	131:4 134:22	154:14 155:3,24
173:20 199:19	240:8 241:14,15	135:13 136:14	156:12 173:8
199:22	247:7,22 251:23	136:23 139:10	204:17,22
conviction	252:6 255:4	139:12 141:10	220:21 222:16
176:5	256:2 259:9	142:8,8,19,21	222:17 223:14
copied 211:3	corrected 147:3	144:8 153:18	237:6 242:22
copies 178:5,7	correspond	154:10 163:16	243:5,10,13,17
240:9 260:10	184:18	163:16 165:10	243:21 244:3,20
copy 145:8	correspondence	166:11 169:14	245:8,23 246:16
184:2 210:4,6	135:20	169:17 170:17	246:22 247:4,7
212:18 233:1	corresponding	171:4,5 175:2,2	coverage 127:11
copying 216:17	160:2 232:4	176:18 178:23	137:13 143:1,14
corporate 257:7	cost 151:12	179:18 182:3	144:12,14,15
	152:4 159:7	184:25 185:2,2	149:17 150:1,5

[coverage - debriere]

[1	· · · · · · · · · · · · · · · · · · ·
150:21,21	covid 247:25	currently	dated 201:21
151:20,22 152:9	cpt 159:22	204:17,20	213:24 214:2
153:6,9,11	160:2,4 224:25	205:12 244:7	227:16 252:12
155:13 156:6,20	craft 168:2	247:21 249:2	255:25 259:16
159:8,12 160:4	create 185:2,3	curve 140:15	dates 163:12
160:8 167:4,20	187:12	customer 231:1	day 157:18
170:11,16,20	created 219:6	cut 201:21	164:15 168:25
171:7,15,25	249:16 254:17	202:8 222:18	178:4 216:25
173:13,18	254:18	cv 125:3	217:2,16 218:17
175:25 185:15	creating 222:9	cypionate	218:23 219:23
185:16 186:5	credentials	203:19	220:7 222:3,5
190:25 191:8,17	130:4,8,11	d	224:4 227:17
203:19 205:1	cretella 134:17	d 128:1	258:14 259:16
213:13 217:12	criteria 131:9	daily 196:22	days 139:14
217:17 218:7	150:20 154:5	dalton 163:15	164:19 183:22
220:1 226:2	208:1,1 227:5,9	167:19 213:23	212:25 217:15
228:24 229:8	227:24 235:12	216:3 223:4,6	218:7,20 260:11
236:15 238:16	critical 194:25	dana 125:18	deal 150:10
239:9,16 244:17	cross 161:24	258:20 259:4,21	154:7,11 225:12
245:3,20 247:20	171:7 186:7	data 152:9	dealing 210:18
covered 149:22	191:24 208:11	159:15,17 243:9	debate 155:11
152:3 155:15	243:10	243:12,15	debriere 126:3
160:15,21 171:2	crowd 174:5	date 125:14	127:4,6 128:10
203:22,25 204:5	176:20 179:11	146:20,22 160:5	130:5 133:5
204:12,15	cumulative	160:6 163:8,25	148:19,21
218:14 220:25	146:14	164:1,4,7,7	152:24 156:14
236:11 241:1	cumulatively	166:3 201:21	162:14,18 163:4
243:7 245:25	134:23	217:15 226:23	199:10,16 202:3
246:1	curiosity 148:3	243:2,6 248:24	202:6,12,25
covering 151:16	148:5	254:6,7,9,9,10	203:3,9 206:24
151:19 217:23	curious 148:14	254:11,13 256:1	206:25 210:13
237:9 245:15	current 143:7	256:2,5 260:9	210:16,23 211:6
248:14	217:13 219:21	261:23	211:13,18,25
covers 149:3	250:5 254:13	date's 163:19,22	212:13 213:5
240:11,14		164:5	214:5 216:16
		104.3	

[debriere - describe]

221:4,13 226:14	decisions	183:4,5 210:9	denials 200:20
226:20 233:6	166:13	deferring	denied 205:1
248:3,11,23	declaration	168:17,20	238:25 239:3,9
252:9,19,25	147:12	define 196:2	245:20
253:5,8,13,16	declare 238:3	defined 137:8	deny 185:16
253:22 255:23	238:22 261:19	definitely	207:12,15,16,23
256:11,19,23	dede 129:21	151:22 206:2	208:11 237:12
257:4,12,17	130:23 149:19	221:14 226:3	238:6
december	152:10,25 158:5	definition 196:4	denying 185:15
251:16	163:14 172:13	197:22 202:16	203:18 207:2
decide 168:23	213:23 215:21	degree 140:12	department
190:5 214:19	215:24,24 216:3	dekker 125:5	134:15,16,22,23
215:6	216:17,18	243:18,22,23	140:25 144:25
decided 129:24	221:18	244:4,5 245:4,9	175:13 176:10
142:24 165:1,23	dedicated	248:13 260:5	181:4 184:25
208:1 215:9	184:17 187:12	261:1	187:5 227:11,17
219:6,8	deemed 141:17	dekker's 244:18	252:11
decides 169:20	193:3,4 214:23	246:11	depends 166:18
deciding 130:11	222:14 241:6	delay 228:1,6	166:18,19
133:11 171:1	deems 192:6	delegate 163:14	170:12,19
decision 129:2,6	deep 174:16	deliberated	191:14
130:15,18,19,21	176:4	219:6	depo 253:9
130:24 131:1	def 216:21	delivered	deposing 260:10
142:4 156:8	221:6 226:9	195:16	deposition
165:8,9,9,22	defend 182:11	delivering	125:12 232:14
166:3,5,14,21	defendant	223:18	252:4 257:7,18
168:5,10 169:6	126:17 201:16	demonstrate	depth 193:4,23
169:24 171:20	defendants	187:18 236:2	236:20
207:11,15,22	125:9	demonstrates	deputy 163:17
208:11,21 209:1	defending	234:2 235:20	167:6 169:16,17
214:25 215:12	133:13	denial 201:11	215:5,16 219:10
219:13 220:21	defense 126:11	203:8,21 206:8	222:22
222:21,24 223:4	254:1	208:2 209:2	derive 143:8
228:24 239:21	defer 141:8	227:7 239:7	describe 230:2
	142:1 154:17,19	242:16 245:21	

[described - district]

described	determined	differences	discontinuation
202:10 206:1	144:1 164:25	234:6	217:6 221:24
209:17 212:4	235:15 241:16	different 141:6	225:7
220:8	determining	141:17,25	discontinue
description	129:8 150:5	143:21 153:16	139:16 191:23
127:10 219:16	155:17 172:22	165:14 167:2	192:5
descriptions	235:4	186:6,14 192:10	discontinued
229:3	develop 137:11	196:5 198:24	139:10
designated	183:16 184:9,12	205:9 209:4	discretion
259:7	184:13 200:14	212:7 213:4	185:15 225:15
desk 163:20	200:14 201:9,9	214:21 220:19	246:7
164:1	developed	220:19,20	discriminatory
despite 153:11	183:21,22 184:6	224:12,17,17	227:8
details 134:4	184:7,21 235:12	225:4 238:14	discuss 145:24
135:21	developing	differently	194:21 232:22
determination	140:6 181:6	150:7 193:20,21	242:15
142:12 143:6,15	200:19	difficult 231:21	discussed
151:21,22 155:4	development	direct 180:13	172:20 178:20
191:10 194:5	135:7 137:22	214:23 222:20	251:1 254:19
201:15,19	168:13	242:8	discussing
202:14 203:8,15	diagnoses	directed 183:16	236:22
204:25 207:2	171:11,12 224:5	227:20 230:21	discussion
228:7,21 229:15	225:13	directions 167:2	158:23 172:16
234:15,21 235:6	diagnosis	247:3	172:18 253:19
235:13	159:21 171:13	directives	discussions
determination's	171:16 192:10	167:23	172:11 193:13
235:1	196:19 220:20	directly 138:24	193:15,16
determinations	224:13,14,17,19	198:4 201:3	dismiss 195:20
137:13 200:15	228:5,20 231:7	255:9	disseminate
202:19 228:9,9	246:6	disagreed	141:3
229:6 247:24	diagnostic	165:13,17	dissertation
determine	160:3	disappointed	160:19
131:10 141:19	difference 164:3	143:17	district 125:1,1
152:4 195:2	164:6 196:11	disclaimer	199:4 212:20,20
210:7 247:4		162:3	

[districts - efficacy]

dollars 150:23 246:10,14	drafts 145:20 216:24	191:1,9,18 192:9 200:17	edits 145:9,11 145:12,17 146:2 147:1,9 184:2
198:23 214:11 229:18 247:24	147:24 160:10 249:14	160:9 171:9,13 185:22 188:3	editing 145:8
doing 154:11	drafting 145:5	159:7,8,12	203:4 edit 145:7
doe 247:18 doh 252:15	215:19 221:12 221:17 222:4	142:14 154:15 155:6 157:2	easy 175:6
187:18	drafted 172:5,6	132:21 142:13	easier 175:4
168:19 184:24	257:14	131:22 132:7,16	146:23
141:1 142:8	219:1,2,5	127:18 131:3,6	232:18 251:1 early 139:14
documents	215:25 218:21	dysphoria	155:14 199:18
168:20	214:16,19	dvp 164:21	earlier 135:5
documentation	183:25,25 184:1	duration 240:16	261:3,3
261:19	157:10,21	211:21 226:12	260:17,17 261:3
252:2,14 254:15	146:3,7,21,22	dunn 126:6	e 126:14 128:1
227:25 228:3,17 252:2,14 254:13	145:19 146:3,4 146:5,7,21,22	duly 128:4 258:11	e
221:4 226:23	draft 144:21	238:4	252:12
185:1 211:2,2	183:5 194:23	due 228:3,18	247:16 248:15
158:10 163:19	180:5,6,7 183:4	228:15	244:18 245:4,9
127:18 147:8	177:18 178:23	218:8 220:21,24	243:14,22 244:4
document	177:15,16,16,18	217:14,18,23	242:23 243:11
178:25	145:15,16,20,23	drugs 216:6	239:3,17 242:18
doctors 145:20	136:7,7 145:14	232:2,3,4,5	237:3 238:18
doctor 192:6	134:17 135:2,11	187:11 228:5	227:24 228:1,23
divide 155:2,10	128:21 133:10	186:20,25	224:9,15 226:25
districts 199:3	dr 128:12,12,20	184:15,17	222:1 223:20

[efficient - exact]

efficient 153:12	employed	ensures 218:18	et 125:5,8 132:2
effort 174:6	138:21 139:19	ensuring 235:17	137:13 194:22
183:11 215:22	employee	enter 136:23	260:5,5 261:1,1
eight 135:19	210:19 259:12	138:19 163:12	ethical 189:4
157:7 253:3	259:13	254:12	evaluate 148:24
either 135:15	employees	entire 158:20	151:2,15 197:1
162:1 165:13	250:15	170:2 214:16	198:20 237:14
167:24 179:20	encounters	entities 144:21	evaluated 151:6
183:4 195:12	247:13	181:7	185:19 194:24
196:8 205:23	encouraged	entitled 212:16	evaluating
225:2,25 230:25	177:8	219:22,24	132:4 141:23
251:18	encouraging	220:12 239:8	237:22
eligible 244:7,10	177:11	entrance 177:4	evaluations
244:15 247:21	ended 136:6	epsdt 173:3,6,8	194:15
248:1	endocrine 161:8	185:13,18 186:3	event 174:19,20
eliminate 171:1	161:10,13,19,21	eq 137:15 201:2	everybody
171:15	161:21,25	equally 204:9	186:14 188:4
elliot 232:7	190:18	equals 227:6	everything's
else's 133:25	engage 130:11	ernie 188:23	153:14
email 127:14	131:11 132:12	errata 260:9,9	evidence 128:23
136:4 186:24	142:24 179:25	260:11	131:7,19,24
210:25 215:10	engaged 132:15	errors 146:1	132:2,19 133:9
227:10,15	132:24 134:12	especially	133:19 134:1
228:12 230:2	139:18 140:21	141:14 186:6,7	139:7,12 141:12
231:20 232:16	141:4	esq 126:3,5,6,8	141:16 144:1
260:10	engagement	126:11,14,18,19	155:5,5 156:11
emailed 260:11	179:22	260:1	161:16 162:2,10
emails 127:16	enrolled 244:11	establish 237:16	165:2 185:7
189:20 211:19	enrollees 205:8	established	187:16 197:13
213:22 216:14	217:11 218:11	161:11 234:16	197:17,18 198:7
226:15,22	enrollment	establishing	198:8,10,13
229:23	244:14,15	129:4	238:5 251:4
embarked	ensure 217:6	estimate 159:2	exact 230:2
186:10	221:24 225:9	estrogen 223:25	244:21
		225:17	

[exactly - facts]

	1	1	1
exactly 183:19	218:18 219:22	expedited	expires 258:21
250:9	225:19 226:2	251:18	259:22
examination	227:2 232:12,19	expenses 177:19	explain 195:21
127:4,5,6 128:9	235:14 237:2	expensive	228:7
253:24 255:22	238:1,3 241:6	139:15	explained 161:3
examined 128:6	242:17 245:13	experience	explanation
example 138:13	247:6,8	130:9 132:15,21	142:23 161:6
examples	exclusions	170:14 180:23	explanatory
186:18 195:13	199:2,5	223:24	214:22 215:8
196:9 197:12	exhausting	experienced	expletive 193:18
251:13	177:25	131:20,22	explicitly
exceed 136:16	exhibit 127:11	experimental	154:14,21
136:21,25	127:12,13,14,14	140:1 141:20	156:16,16
exception 229:8	127:15,16,17,17	148:23 149:23	explore 186:16
233:15	127:18,18	150:6 154:24,25	external 144:21
exchanges	152:13,14	155:17 165:1	extrapolation
215:10	162:15,20 163:6	173:8 185:8,22	231:22
exclude 154:18	201:24 202:8,11	186:8 198:10,11	eyes 202:2
154:21 156:16	211:18 213:22	204:10 237:5,6	f
156:17	213:22,22 214:1	237:10,17 238:4	f 231:18
excluded 149:3	214:3,7 221:7,9	238:23 239:12	f64 231:12
152:2 218:14	226:18 233:2,4	241:7,17 247:5	facilitate 177:1
241:14	248:19,21 252:2	expert 165:17	220:24
excluding	252:7,13,17	194:14	facilities 175:12
148:24 151:2	254:4,6 255:24	expertise 137:17	fact 141:1
exclusion 157:3	exhibits 127:8	137:19 140:5,12	153:11 187:13
159:11 165:3,6	248:18	140:22	227:15 229:7
165:10,15,21,24	exigent 251:11	experts 129:12	factor 131:14,22
169:25 172:25	exist 203:3	130:16 132:4	131:23 155:16
173:25 179:12	existing 128:23	136:24 137:16	156:8 194:4
191:19 192:6	131:5,19,24	138:10 140:11	factored 191:9
200:16 204:24	217:20,24	141:5 142:13	factors 132:3
206:12 207:3,22	expect 175:23	146:9,9 165:13	174:24
209:8,12,14	175:24	177:15 179:7	facts 261:19
213:7 216:12		236:22	1aus 201.17

[fail - florida]

fail 260:13	farrell 174:8	filed 147:12	150:20 157:20
fair 144:20	183:11	212:24	157:22 158:2
207:4 208:3,13	fast 170:13	filing 212:17,19	163:13 171:19
208:18,21 209:7	192:21	fill 175:11	184:11 215:19
209:11,22	faster 170:23	final 146:5	226:23 228:19
228:18 239:8,15	favor 214:20	183:24,25,25	236:3 255:10
239:22	fear 228:3	184:1 190:6	fiscal 151:21,23
fairly 191:6	february 125:14	209:16,21,23,25	151:23
251:19	257:6 258:14	210:5,6 211:23	fiscally 156:3
fairness 235:5	259:16 260:3,6	212:15 228:7,21	five 158:19,20
faith 188:16	261:2	235:2 239:21	158:25 164:13
familiar 132:7	federal 173:1,12	finalized 172:17	170:16 188:5
148:11 154:11	173:17,21,23	251:2	193:2 199:9
200:12,13	199:3 246:10,14	financially	248:4,10 251:22
221:11 224:22	260:12,17	259:15	253:3,4
231:3,4,6,8	fee 156:1 159:16	find 149:18	fl 260:10
232:24 233:7,8	212:19 228:15	150:15,19	flexibility 241:3
240:17	feedback 145:21	151:24 153:3	floor 126:12
familiarity	145:21 179:19	186:21 229:21	florida 125:1,17
154:7	190:14,18	230:10,18	125:20 126:3,4
families 187:6	feel 174:13	247:19 256:8	126:7,10,20
family 128:21	211:6 221:6	finding 162:25	127:15,17
128:21 133:22	225:14	197:1,19	134:12,15,16
134:8 188:9	feelings 174:16	findings 153:18	149:7 150:8
far 142:21,24	felt 161:5,12	154:16,17,19,21	155:22 156:1,2
144:14,16 146:2	174:18 223:8	157:6 187:17	157:1 160:7
155:1,24 169:23	female 231:15	239:19,25	171:2 173:7
173:17 176:2	231:18	fine 193:25	187:6 188:12,16
184:1,3 186:13	field 140:12	216:24	188:25 200:6
193:15 199:24	figure 186:17	fingers 211:11	206:1 209:18,24
205:15 207:4	224:23 229:13	finished 145:19	212:23 213:6,9
209:1 214:14	256:9	253:23	217:23 221:5,8
218:9,10 229:2	file 230:25	finishing 184:2	226:6 227:17
229:4 243:12	240:1	first 146:3,4,7	236:5,6 237:5
249:1 250:14		146:20,22	242:21 243:4,17

[florida - gender]

Page 279

243:21 244:3,7	221:8	fully 228:11	164:8,12,18,23
244:20 245:8	formally 219:4	fun 188:1	165:3,12 168:23
246:16,22	format 178:22	fund 126:12	170:3 171:5,14
247:22 248:13	formulating	funded 150:9,10	171:18,21 173:5
252:11 258:5	150:2 255:15	funding 222:2	176:1 178:10,10
259:2 260:12,17	formulation	further 127:6	184:10,21
fmmis 231:2	162:22	216:25 255:21	185:21 187:19
focus 155:4	fort 206:18	255:22 259:11	188:6 194:14,21
focused 155:4	forth 179:2	furtherance	195:14 197:2,23
focuses 236:24	191:13 213:8	208:16,22	198:5,6 220:16
folder 249:7,8	225:5 236:23	g	227:13,21
folks 136:6	forward 210:25	g 148:23 149:3	248:19,25 249:2
148:20	found 184:10	169:4	249:4,7,9,14,16
follow 132:13	199:3 237:4,9	gainesville	249:24,25,25
137:5,6 206:24	239:11 240:3,12	126:7	250:6,7,13
232:17	foundation	gainwell 231:1	251:18,19
following	133:15 198:6	galvin 189:8	254:17,18
150:16 187:15	four 158:19,20	gapms 127:17	255:25
187:16 227:11	164:17 199:14	128:13,18,20	gary 126:19
follows 128:6	248:7	129:2 131:25	260:1
196:10	franklin 126:14	132:17 135:8	gather 179:18
foods 251:7	free 186:16	137:10,11,22	182:8 256:16,25
forbes 226:22	211:6	138:14,16 139:8	gathers 255:7
230:14,15	freedom 133:13	140:6,7 141:8,9	gender 127:18
foregoing 259:5	frequently	141:19,23 142:2	131:3,6,13,22
259:8 261:19	142:7 148:13	142:14 143:4,12	132:7,16,21
foremost 150:20	194:10 214:18	143:15,20	133:1,19 134:1
foreseeably	251:20	145:18 147:14	141:6,10,25
195:17	friend 254:19	147:20,22 149:5	142:13,14
forgetting	frustrating	149:10,14,16	143:20 152:19
213:16	169:22	151:2,6,9 152:2	154:15 155:6
form 127:12,16	full 138:5,7	151:2,0,9 152:2	157:2 159:7,8
130:2 133:2	196:16 247:11	156:25 157:6,9	159:12 160:8
155:18 162:16	251:18	157:16 160:11	162:7 171:8,13
163:7 216:13		162:16 163:7,13	185:22 188:3
		102.10 103.7,13	

Veritext Legal Solutions

[gender - green]

204:18,24	230:24 249:25 gerring 171:24	144:14 155:1 169:11 13 15	251:2,8 govern 136:20
205:19 206:12	gerring 171:24	169:11,13,15	govern 136:20
207:13,24	174:6 176:19	199:25 205:15	government
208:12,17,23	189:19,25	211:15 234:7	175:9
209:8,13 216:7	getting 191:15	235:8,11 249:1	governor 234:8
217:8,14,18	214:6	255:3,10,13	governor's
218:8 220:18	gg970595	going 131:18,25	134:18 144:23
222:1 223:20	258:21 259:22	141:8 142:1	176:8 177:10
224:9,14 225:20	gift 197:9	143:16 144:12	gperko 260:1
226:24 227:6,24	gigantic 153:10	147:1 151:8,13	grammar 145:9
228:1,23 229:9	gist 188:6	151:13,20,25	grant 234:10
230:20 231:5,9	give 156:23	156:10 163:25	235:13 237:1,8
231:10,11,25	182:20 192:11	165:7,11 168:20	241:3
232:9 235:14	197:9 230:1	169:4 170:17	granted 233:12
237:3 238:18	given 135:3	175:12 178:23	234:1 235:19
239:3,16 242:17	147:9 160:9	179:11,19 183:7	238:19 240:19
242:23 243:11	167:23 183:18	185:20 187:3,9	grantham
243:14,22 244:4	191:20 205:5	187:20 189:20	172:12,14
244:18 245:3,9	206:16 215:8	191:18 192:6	176:16
247:16 248:14	223:1,3 225:12	193:8,22,23	granting 233:21
252:12	239:11 242:10	195:14 199:8	235:23,25
general 129:13	gives 154:7	201:18,20 205:5	granular 172:22
134:20 135:2,24	glaring 160:17	207:4 209:2	173:11
140:13 166:9,11	gnrh 227:25	210:25 211:18	graphic 186:11
169:18 172:14	247:15	218:11,13	graphics 185:3
176:16 209:16	go 169:4,8	223:14 225:15	187:4,10
234:18 239:1	186:13 193:15	232:11,14 233:1	great 150:10
255:13,14	195:18 211:12	240:4 256:13,22	154:7,11
generally	220:15 221:20	257:10	greater 240:15
149:11 154:3	221:22 229:3,23	gonzalez 126:11	240:15
157:10 160:13	237:14 239:24	good 162:24	green 230:16
163:10 166:16	243:19,19	175:14 211:16	

[grievances - history]

grievances	guides 153:6	headquarters	hearings 175:19
206:10	guys 202:25	212:21	180:16,25 209:7
grossman	257:15,15	health 125:16	209:11
128:20 135:11	h	126:3 127:13,15	heavily 155:16
136:8 145:20	h 261:3	127:18 134:15	help 145:25
177:15 178:23	half 154:13	134:16,22,23	176:20,20 177:1
180:7	187:25 199:9	137:15 141:1	200:14 201:9
grossman's	253:4	144:25 150:9	216:6 220:24
128:12	hand 233:1	170:16 176:10	223:15
ground 162:25	258:13	184:25 187:13	helped 176:22
grounds 236:25	handbook	196:15,17,18,25	helpful 208:6
group 160:25	226:10	201:2,19 202:20	helping 176:24
193:24	handful 243:8	219:4 221:1,5,8	182:18
groups 179:21	handing 163:5	223:3 227:17	helps 211:20
196:8	handle 228:14	252:2,11 257:8	heritage 133:15
growth 251:11	handled 166:16	health's 227:12	hey 187:23
guardian	176:19 193:20	healthcare	hhs 140:25
144:11	193:21 200:21	221:20	141:14 142:8,22
guess 146:13	hands 163:2	hearing 128:14	142:25 143:25
186:10 195:16	happen 167:9	128:17,25	184:23 187:17
204:8 234:3	167:11	148:20 174:2,4	188:3
guidance	happened	175:9 176:7,13	hi 227:4
140:25 142:22	167:12	177:2,8,11,14	high 142:9
142:25 143:25	happens 167:10	177:17 178:2,3	187:9 197:13
173:6 192:11	214:18	178:4,12,15,15	198:13
227:18 252:10	hard 243:2	179:17,18	higher 158:2
252:15	247:10	180:13 181:13	highly 168:19
guide 139:12	hardship	181:18,25	236:19
235:12	234:16	182:11,15,19,21	hill 126:15
guideline 173:6	hazy 245:2	183:3 188:8	histories 196:7
guidelines 132:2	head 134:22	207:4 208:3,13	196:20,25 197:3
139:8 161:12,13	172:2	208:18,21	197:4 243:20
161:14,16,18,22	headache	209:22 228:4,18	246:19
227:12	169:22	239:8,15,22	history 196:14
	107.22		196:14,16

[hit - individualized]

hit 164:1	hourly 136:15	201:25 214:4	impressions
hits 163:19	138:17	221:10 226:19	227:12
hold 175:19,20	hours 158:25	233:5 247:12	inability 191:21
195:5 197:18	159:4 168:22	248:22 252:8,18	include 177:21
205:13 237:23	170:2 253:3	identified	205:25 206:6
holding 163:2	house 225:2	160:24,24 197:4	207:7 208:13
250:12	229:5	identify 128:13	216:25 222:4,6
holtzman	housed 167:21	161:23	222:7 255:18
126:19	hub 206:15,18	identities	included 210:5
holtzmanvoge	huge 153:12	186:17	217:1 249:21,23
260:1	huh 127:23	idiosyncrasies	includes 145:13
hominem	142:16 143:2	153:8	145:14 188:23
192:19	149:25 158:7	idiosyncratic	189:2 227:7
honest 144:2	164:20 190:1	202:20	247:18
honor 217:12	200:10 217:9	illness 196:19	including
honoring	human 127:18	immediate	188:14,19
217:24	187:13 252:3	157:8,13	inclusive 196:9
hope 187:6	humana 244:6	immediately	incorporate
hormone 171:8	244:11,23	220:3	190:6 200:16
208:11 217:7,7	245:20 248:13	impacts 196:17	incorporated
221:25 228:2	hurled 192:19	implement	222:3
229:9 243:10	hurry 192:25	168:2 213:7	independent
244:3	hybrid 161:2	220:7 225:19	149:20
hormones	hypothetical	implementation	independently
161:24,25 186:8	239:1	195:3 199:7	221:2
191:24 220:15	hypothetically	200:5 216:12	index 127:1,8
221:25 223:16	132:11 226:5	implemented	individual
224:9 244:17	i	227:6 245:14	223:21 225:3
245:3	icd 224:25 231:4	important	236:25 240:14
hot 142:22	231:11	132:14 215:25	246:19
144:3	idea 183:17	218:1 220:17,22	individualized
hour 158:23	232:9 250:1	222:7	235:16 236:19
172:19 178:19	ideal 175:17	importation	236:23,24
187:24 199:8	identification	184:15	237:13,22 238:7
253:6	152:15 162:21		254:24

[individually - jessica]

Page 283

	1	1	1
individually	initiating 168:5	interested 149:5	ish 146:24
237:15	input 133:12	149:6 195:11	isolated 187:3
individuals	172:8,10 174:9	259:15	issue 142:9
129:1,11 131:17	181:6 190:6	internal 145:3	209:9,12 236:3
132:13,19 136:8	234:25	227:5,8,24,25	issued 168:14
180:9 191:23	instance 125:13	242:3	208:2 209:21
218:19 223:15	152:1 170:14	interpret 228:21	239:21
225:9 234:23	184:15,22 218:6	interpretation	issues 255:16
235:10	instances	231:23	256:14
inevitably	137:13	invest 193:12	it'd 220:20
143:15	instituted	investigate	237:21 239:6
information	212:17	131:2	i
146:17 149:15	institution	investigation	jack 148:8
152:7 153:4	171:18	235:9	194:19
159:14,19 161:4	instruction	investigational	jacksonville
182:8 188:2	182:25 232:7,8	140:2 165:1	126:4
195:23 205:16	instructions	185:8 186:9	january 147:13
206:14,19 208:7	182:21,24	198:11 238:4,23	jason 125:8
208:8,14 209:5	insufficient	241:7 247:5	213:23 215:11
210:5,21 223:24	144:1	invited 182:12	260:5 261:1
229:21 230:1	insulting 193:17	involve 213:3	jazil 126:18
232:16 242:2	insults 192:19	229:2	127:5 130:2
247:12,14 255:7	insurance 149:2	involved 129:8	133:2 152:12
256:8,17 257:1	149:22 150:1,4	129:17,19,21	155:18 162:17
informational	150:7	130:14,18,19,20	162:25 199:8
155:1	insured 239:3	130:23 136:1	202:1,4 203:2,5
informations	insurers 149:6	146:6 174:18	202:1,4 203:2,3
205:23	150:9	201:3 213:25	212:11 216:13
informative	intact 146:3	219:12 224:8	248:5 253:7,9
149:23	integrity 140:18	involvement	253:25 254:1
initial 157:16,21	intellectual	128:12	255:21 256:12
164:10	148:2,4	ipads 211:16	256:21,24
initials 201:22	intended 185:17	iphones 211:16	jessica 226:22
initiated 143:13	inter 200:8,9,13	irrelevant 133:8	230:14,15
167:15 227:13			230.17,13

Veritext Legal Solutions

800-726-7007

[job - level]

	106 6 10 10 16	1 1 1	1 1 1 1
job 219:16	186:6,12,12,16	knowledge	leadership
229:3	kind 134:3	128:23 130:9	167:24 219:9
join 161:2	138:20 142:10	131:24 229:12	250:2
joint 174:6	151:11 153:12	234:23	leaning 138:3
josefiak 126:19	161:2 176:23	knowledgeable	learned 167:19
josephina	178:20 182:20	131:5 235:10	learning 140:15
129:14,23	186:10 187:21	1	leave 225:15
135:25 166:9	191:13 192:4,20	labeled 248:18	leaving 221:1
juarez 174:7	204:3 225:12	lacked 197:2	left 198:14
176:21 183:12	229:4 232:3	ladapo 134:20	230:7
judicial 211:24	233:16 241:13	135:2	legal 126:6,11
212:14,16	250:11	laden 193:18	198:21 234:5
july 128:14,25	kinds 154:5	lambda 126:11	255:16 260:16
188:8	160:11 172:20	language 172:5	legalities 242:11
jumped 151:11	238:9	172:7 173:11	legality 198:19
june 127:16	king 227:16	174:3 200:14,20	198:22
128:18 129:2	knew 169:3	200:23 201:5,9	legislative
135:8 140:6	176:3 179:19	215:23 217:1,2	167:24
147:14,19 151:1	know 137:13,23	219:3 221:24	legislature
157:16 158:2,3	149:9 158:1	219.3 221.24 222:5,11,19	234:7
160:11 162:16	159:10 175:8	233:24 239:6	length 194:21
163:7 164:12,18	178:22 181:15		244:21
166:4 168:11,14	181:16 182:5,22	lappert's 145:13 145:14	lengthier
169:25 170:1	182:23 183:19		170:18
178:10 226:24	187:1 191:15	large 125:20	lengthy 169:8
232:10 237:2	198:9,15 202:25	142:20 175:23 175:24 176:6	170:8,20,24
justice 126:3	203:3 211:9		190:16,17 196:7
k	216:8 218:1	largely 146:3 179:11	196:10,12
	223:13,19,20,21		lens 198:25
katy 126:3	224:3,10,19	larger 174:5	leon 258:6 259:2
keeping 213:12	229:19,20 241:2	latitude 150:11	leslie 227:23
kelly 230:12,13	241:19,22 242:4	185:16	letter 227:7
kf 247:9,10,21	244:21 245:17	law 212:19	level 199:4
kids 181:1,1	256:6,22	layman's	207:5 208:13,18
183:8,8,13,13	,	187:22	208:22 212:6,6
185:11,11,23,25			,

[level - made]

228:13	188:1 195:13	196:15,25 197:3	lot 134:4 141:14
liberally 155:24	litigation 140:8	look 133:8	144:6 148:13
liberty 133:17	140:17,21 142:3	143:11 150:4,14	155:8 169:23
life 132:20	142:11 143:3,12	153:3,23 156:24	176:4 185:15
light 228:13	143:18 182:7,12	156:24 187:5	187:7,7 190:8
likely 153:8	little 128:11	188:5 190:7,21	190:10 192:18
179:19	136:18 146:8	191:12 194:6	192:19,21
likewise 169:14	166:24 174:9	216:4 233:24	231:21 247:3
185:1	179:22 202:20	244:22 249:8	249:13
limit 240:23	205:3 209:20	250:3 254:3	low 141:12,16
limitations	214:15 228:8	255:11	162:1,2 194:25
254:2	231:21	looked 130:8	198:10 238:5
line 161:23	live 253:1	153:6,15 190:7	251:7
170:22 261:4,7	living 196:22	191:11 194:8,12	lower 186:20
261:10,13,16	llp 126:9	194:22 246:20	lowest 149:10
lines 147:7	locally 206:19	247:19	lunch 200:1
189:21	locate 246:20	looking 131:4	lupron 228:4,19
lining 226:13	247:12	131:15,17	228:23
111111g 220.15		131.13,17	220.23
list 127:11	location 125:16	141:10 150:20	m
0		· · · · · · · · · · · · · · · · · · ·	m
list 127:11	location 125:16	141:10 150:20	m m 231:18
list 127:11 164:15,17 196:9	location 125:16 174:23,25 175:2	141:10 150:20 152:18 154:1,10	m m 231:18 mac 211:13
list 127:11 164:15,17 196:9 210:7 214:6	location 125:16 174:23,25 175:2 175:4,6	141:10 150:20 152:18 154:1,10 195:11,15,15,22	m 231:18 mac 211:13 mac's 211:16
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23	location 125:16 174:23,25 175:2 175:4,6 logo 184:19	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25	m 231:18 mac 211:13 mac's 211:16 made 129:2,6
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16	m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25	m m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3	m m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2 147:10,10 165:8
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9	m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2 147:10,10 165:8 165:9,11,22,25
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21	m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2 147:10,10 165:8 165:9,11,22,25 166:3,4,5 167:6
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25 242:1,22 243:5	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8 205:8,10 210:17	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21 241:2	m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2 147:10,10 165:8 165:9,11,22,25 166:3,4,5 167:6 168:11,25
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25 242:1,22 243:5 243:17 246:16	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8 205:8,10 210:17 244:18,19,19	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21 241:2 looks 203:18	m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2 147:10,10 165:8 165:9,11,22,25 166:3,4,5 167:6 168:11,25 169:25 170:1,7
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25 242:1,22 243:5 243:17 246:16 250:4,21	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8 205:8,10 210:17 244:18,19,19 longer 143:6	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21 241:2 looks 203:18 215:18 227:10	mm231:18mac211:13mac's211:16made129:2,6141:14142:12145:22146:2147:10,10165:8165:9,11,22,25166:3,4,5167:6168:11,25169:25170:1,7171:20184:23
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25 242:1,22 243:5 243:17 246:16 250:4,21 listen 144:2,6	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8 205:8,10 210:17 244:18,19,19 longer 143:6 220:21,25	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21 241:2 looks 203:18 215:18 227:10 248:24 256:4	mm231:18mac211:13mac's211:16made129:2,6141:14142:12145:22146:2147:10,10165:8165:9,11,22,25166:3,4,5167:6168:11,25169:25170:1,7171:20184:23188:3194:9
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25 242:1,22 243:5 243:17 246:16 250:4,21 listen 144:2,6 lists 221:23	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8 205:8,10 210:17 244:18,19,19 longer 143:6 220:21,25 222:16,17	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21 241:2 looks 203:18 215:18 227:10 248:24 256:4 lose 191:19	mm231:18mac211:13mac's211:16made129:2,6141:14142:12145:22146:2147:10,10165:8165:9,11,22,25166:3,4,5167:6168:11,25169:25170:1,7171:20184:23188:3194:9207:11214:25
list 127:11 164:15,17 196:9 210:7 214:6 249:19,21,21,23 250:20 listed 144:9 148:23 204:18 206:7 221:16 236:15 241:25 242:1,22 243:5 243:17 246:16 250:4,21 listen 144:2,6 lists 221:23 literature 131:5	location 125:16 174:23,25 175:2 175:4,6 logo 184:19 long 144:12 157:15 164:13 172:18 178:18 190:20 196:13 200:3 203:8 205:8,10 210:17 244:18,19,19 longer 143:6 220:21,25 222:16,17 225:10 247:7	141:10 150:20 152:18 154:1,10 195:11,15,15,22 197:17,21,25 198:1,2,2,3,7,16 198:22,22,24,25 205:3 206:3 227:15 236:8,9 236:10,20,21 241:2 looks 203:18 215:18 227:10 248:24 256:4 lose 191:19 lost 191:17	m 231:18 mac 211:13 mac's 211:16 made 129:2,6 141:14 142:12 145:22 146:2 147:10,10 165:8 165:9,11,22,25 166:3,4,5 167:6 168:11,25 169:25 170:1,7 171:20 184:23 188:3 194:9

[made - mean]

234:21 235:1	155:3 160:14	marker 208:6	167:11,14
241:20 251:15	172:16 174:10	market 150:13	172:10 174:16
256:2,4	176:22 193:10	marking 221:7	174:17 175:8,8
maf 125:3	male 231:14,18	marstiller 166:7	179:3 180:15,18
magellan 201:7	manage 213:13	227:20	182:3 185:6
201:8 226:16	221:2	massive 197:8	186:5,12,14,22
227:4 228:14,22	managed 154:9	mastectomy	186:24 187:1,3
229:15 232:9	159:15 200:6,7	238:17	187:5 192:16
mahan 125:17	200:21,24	match 246:10	193:7 195:9,11
mail 205:8,10	202:22 205:4	matching	196:4,14 197:5
mainstream	213:7,12 217:10	246:14	197:12 198:2,3
132:25 142:7	217:17 225:18	material 145:4	198:15,18,18,19
maintain 218:2	225:22 244:6	materials 153:7	198:23,23
maintains	245:15,23	178:1,6,8,9	199:23 202:22
212:21	managing	matt 213:25	206:2,2 210:4
maintenance	223:12	matter 210:18	210:20 212:3
231:1	mandated	231:17	213:9 215:5,21
major 144:10	245:19	matthew 125:12	216:23,24 218:3
make 131:18	manufacturers	127:3 128:3	218:5,9 219:14
145:9 146:13	250:25	260:6 261:2,23	220:4 222:18,18
151:20 159:19	map 154:16,17	mb 164:21	228:8,11,12,14
160:16,19,20	154:19,21	mcgriff 227:3	228:21,22 229:3
165:2,10,10,15	march 258:21	mckee 126:14	229:13,14,24,25
165:24 166:12	259:22	mean 130:7,7,13	230:2,22,24
166:14 187:22	mark 152:12	132:11,11 137:8	231:10,10,19,20
188:4 191:23	162:17 233:2	137:9 141:17	231:21 232:21
194:16 195:18	252:1	142:5,18 144:5	233:14 234:5,6
198:13 207:20	marked 127:10	144:5 146:3	234:9,12 236:4
222:10 230:24	152:14 162:20	147:4,5 150:8	236:9,10 237:11
257:1	163:5 201:24	150:17 151:19	237:12,25 238:5
makes 162:22	213:21 214:3	153:8 156:21,22	238:8,22 239:23
234:15 235:6	221:9 226:8,9	156:22 157:9,11	243:12 251:17
making 131:1	226:18,21 233:4	157:11,12	251:19 252:23
133:9 139:25	248:18,21 252:7	161:11 163:8	256:19
143:25 146:7	252:17	166:12,14 167:7	

[means - mortal]

	1		1
means 147:18	217:23 220:12	member 226:10	minutes 188:5
164:8 217:16	221:5,8 222:2	246:13	200:4 253:3,4,6
219:15 220:6	226:6 236:5,6	memo 143:4	misdiagnosis
231:11,12	237:5 238:16	171:5 255:25	238:11
235:22,22 242:4	239:9 240:1	memories	mission 187:1
meant 185:4	241:19 242:7,22	250:15	misunderstood
217:22 233:23	243:4,17,21	memory 250:11	207:18
measure 163:25	244:3,8,9,20	250:14	mma 205:3,6,6
media 142:7	245:8,22 246:10	memos 143:11	205:11 227:23
143:24 144:3,4	246:16,22	mental 196:17	mo 202:25
144:12,14,15	247:22 248:1,13	196:18,25	252:21 257:13
148:18	medical 132:25	mention 197:13	model 141:11
medicaid	137:16 147:4	212:9	161:23
127:11,12,15	179:20 187:25	mentioned	modern 198:12
141:7,20,23	202:15 204:10	204:7 232:18	modified 251:7
149:7,8,13	205:4 207:25	message 185:5	mohammad
150:8,13,17,19	224:2,6,24	met 145:21	126:18
150:23 152:9	225:13 237:23	233:21	mohammed
150.25 152.7		200.21	
153:5,7,7,16,21	238:10	metaphors	254:1
153:5,7,7,16,21	238:10	metaphors	254:1
153:5,7,7,16,21 154:1,3,4,9,13	238:10 medically	metaphors 193:7	254:1 mol 128:12,21
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21	238:10 medically 218:10 239:13	metaphors 193:7 meter 177:16,18	254:1 mol 128:12,21 135:11 136:7
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2	238:10 medically 218:10 239:13 medicare 149:7	metaphors 193:7 meter 177:16,18 179:1 180:5	254:1 mol 128:12,21 135:11 136:7 145:23 177:16
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21 169:10,14,18	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20	<pre>metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4</pre>	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21 169:10,14,18 171:3,7 172:1,3	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20 medicine 133:19	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4 mine 146:10	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5 monroe 126:20
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21 169:10,14,18 171:3,7 172:1,3 173:1,7,12,21	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20 medicine 133:19 134:1	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4 mine 146:10 miniscule 147:6	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5 monroe 126:20 month 246:13
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21 169:10,14,18 171:3,7 172:1,3 173:1,7,12,21 173:23 185:13	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20 medicine 133:19 134:1 meds 227:6	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4 mine 146:10 miniscule 147:6 minnich 126:23	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5 monroe 126:20 month 246:13 months 135:19
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21 169:10,14,18 171:3,7 172:1,3 173:1,7,12,21 173:23 185:13 190:25 191:8,17	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20 medicine 133:19 134:1 meds 227:6 meet 204:10	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4 mine 146:10 miniscule 147:6 minnich 126:23 minor 216:22	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5 monroe 126:20 month 246:13 months 135:19 191:4 240:20
153:5,7,7,16,21 154:1,3,4,9,13 155:6,15,20,21 155:22 156:1,2 156:3,5 157:1 160:7 162:15 163:6 166:17,22 167:13,14,21 169:10,14,18 171:3,7 172:1,3 173:1,7,12,21 173:23 185:13 190:25 191:8,17 192:12 200:7	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20 medicine 133:19 134:1 meds 227:6 meet 204:10 208:1	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4 mine 146:10 miniscule 147:6 minnich 126:23 minor 216:22 216:22	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5 monroe 126:20 month 246:13 months 135:19 191:4 240:20 244:24,25
$\begin{array}{c} 153:5,7,7,16,21\\ 154:1,3,4,9,13\\ 155:6,15,20,21\\ 155:22\ 156:1,2\\ 155:22\ 156:1,2\\ 156:3,5\ 157:1\\ 160:7\ 162:15\\ 163:6\ 166:17,22\\ 167:13,14,21\\ 169:10,14,18\\ 171:3,7\ 172:1,3\\ 173:1,7,12,21\\ 173:23\ 185:13\\ 190:25\ 191:8,17\\ 192:12\ 200:7\\ 201:10,20\\ \end{array}$	238:10 medically 218:10 239:13 medicare 149:7 150:8,16,23 medication 192:2 225:7 medications 196:20 medicine 133:19 134:1 meds 227:6 meet 204:10 208:1 meeting 172:11	metaphors 193:7 meter 177:16,18 179:1 180:5 183:4 miami 126:10 michelle 134:17 mid 146:23 mind 202:4 mine 146:10 miniscule 147:6 minnich 126:23 minor 216:22 216:22 minors 247:11	254:1 mol 128:12,21 135:11 136:7 145:23 177:16 177:18 179:1 180:6 183:5 molina 127:13 201:18 202:14 money 152:5 monroe 126:20 month 246:13 months 135:19 191:4 240:20 244:24,25 mortal 195:16

[mortally - numbers]

mortally 195:24	navigate 154:8	176:25 183:5,6	notary 125:19
move 170:6,13	154:12 223:13	223:15	258:20 259:21
170:23 193:16	nbc 144:10	needs 132:18	note 148:19
193:18 226:15	nc 126:15	151:23,23	214:1 260:9
msnbc 144:10	ndc 159:21,23	negative 127:23	noted 220:14
multiple 252:3	160:4 232:4	network 188:25	227:23
muster 159:17	ndc's 231:25	neutral 148:25	notes 259:7
myers 206:18	232:1	151:3,16,17	notice 127:13
myriad 197:12	necessarily	neutrality 151:7	168:13 169:25
n	132:10,20	never 203:2	191:3 201:14,19
n 128:1 148:10	135:14,14 151:5	207:15,18 208:2	202:13 203:7,14
nabd 203:1	164:1 192:8	211:16 218:21	205:14,21,22
nabd' 203.1 nabd's 202:21	196:18 198:20	239:13	207:1,7,8
202:23 205:7,11	246:3	new 126:13	211:24 212:14
nai 129:19	necessary 165:4	144:10 155:23	212:17,24
130:20 158:5	170:25 176:25	157:12,14	213:11,11 220:1
189:19,24	179:8 192:14,16	162:22 165:10	220:9 222:15
name 133:20,25	196:16 214:24	168:2,4 170:11	223:3 241:24
134:17,24 135:3	215:9 218:10	170:16 184:14	notices 200:15
144:6 148:9	225:14,17	187:2,4 251:15	201:1,4,10
155:23 201:20	239:13 250:4	251:17,21	202:18 204:25
211:1	necessity 202:15	news 144:3	205:24 206:8
name's 210:17	207:25	148:17 176:2	noticing 223:2
named 258:10	need 141:2	nitrous 151:10	notified 223:14
names 232:5	142:13 149:12	non 193:5	notify 201:10
nation 149:14	151:24 156:24	203:22 204:5	217:10 225:8
national 159:24	159:21,21,22	222:2 227:8	notion 156:11
232:2,5	160:1,2,3	normal 174:5	npr 144:2,6,7
nature 136:17	162:18 165:2	181:17 184:9,20	number 170:9
140:2,8 141:15	166:2 174:13	187:14	196:1,23 202:9
166:19 170:12	175:6 192:1,4,7	normally	208:20 221:7
170:19 174:14	220:23 232:14	175:19	numbered
182:3 186:9	242:8	northern 125:1	259:9
192:17	needed 140:11	nos 214:3	numbers 209:15
1/2.1/	140:23,24 141:3		226:12

[numerous - options]

numerous	180:19 181:5	173:20 182:20	omar 126:11
180:16	234:19 255:10	183:7 188:25	once 135:1
nw 126:7	255:14	190:2 192:14	140:9,9 146:10
	offices 225:4	190.2 192.14	171:20 180:6,6
	official 219:3	195:2,2,4 200:1	189:20 206:21
0	258:13	200:3,5,12,23	219:25 222:15
o 126:18 128:1,1			
oath 256:13,21	officially 219:2	201:7 203:14,21	223:19 255:2
258:1	oh 144:5 157:17	204:3,8,14	onces 190:21
object 130:2	158:19 164:21	205:13,18,24	one's 193:17,17
133:2 155:18	167:18 189:15	206:7,10 207:6	193:17
216:13	211:8,13 215:11	207:10,20	ones 142:15,17
observation	226:12 232:25	208:25 209:4,6	168:1,3 182:22
144:19	okay 129:15,23	210:2 211:5,6,6	189:23 193:6,9
observe 182:9	130:17 131:20	211:15 212:9	193:19 250:22
obtain 159:14	132:23 133:22	213:6,21,21	251:13
206:21 208:8,15	136:2 137:1	216:4,14,20,22	online 153:19
208:19 209:15	138:5,9,13,19	217:5,22 218:17	153:20 156:22
obtained 196:23	138:19,23	219:19 220:6,11	178:6
obtaining	144:20 146:6,15	220:14 221:20	open 231:22
206:20	146:20,20,24	226:17 228:17	253:9 254:14
obviously	147:12 148:6	232:6,13,17	operations
165:13 187:2	151:1 153:3	233:1 236:13	245:24
192:25 193:2,8	154:20 157:15	238:13 240:6,9	opinions 165:17
210:4 256:14,22	157:22,25 158:5	241:8,12,16,19	174:15 223:7
occurred 209:11	158:14 159:3,6	242:14 243:7	opportunity
october 201:22	159:25 160:3,6	244:11 246:15	230:10,18
odd 251:21	160:9 162:9,12	246:22 247:16	oppose 132:25
offer 179:4	162:14 163:5,19	247:18 248:3,6	opposed 150:13
offering 136:7	163:22,25 164:5	248:17 250:12	179:12 180:4
offhand 191:4	164:12 165:5	251:24 253:5,11	opposition
208:7	166:2,5 167:18	253:14,17 254:5	131:13,17 133:4
office 134:18	167:25 168:13	255:14 256:11	180:10 223:9
144:23 169:18	168:22 170:7	257:5	optional 236:12
172:15 176:8,16	171:6,6,14	olsen 189:2	options 225:9
177:10 180:18	172:20,24,24		231:17
1//.10 100.10			

[order - people]

	1		
order 200:15	overriding	panel 128:24	passing 181:22
210:5,6 212:16	173:6	175:16 176:18	past 143:11
212:25	oversee 229:25	paper 178:7	144:17 237:24
ordering 257:10	oversees 171:24	paragraph	pastor 188:14
260:11	219:14 231:2	211:23 217:3	188:23
orders 183:18	overturning	part 187:1	patients 223:18
209:16,21,23,25	209:1	220:16	225:16
organization	overwhelming	partial 203:12	pay 138:15
133:21 161:2,11	156:6	partially 185:18	149:11 150:16
organizations	own 181:3	185:18	177:14 193:8
132:25	186:16	participants	246:11,12
original 212:17	oxide 151:10	176:15 196:7,10	payers 149:8,9
251:5	р	197:2,5,9	149:11 150:16
originally	p 128:1	participate	150:21
254:18	p.m. 125:15	128:14 139:25	paying 150:19
originating	128:8 199:12,15	participated	payment 222:2
166:20	248:7,10 253:18	176:13 180:12	payments 139:3
outcome 201:1	253:21 257:9,19	180:16	pays 139:10
201:4 207:8	pa's 217:25	particular	peace 163:2
outcomes	pagan 126:11	140:22 141:15	pediatrics
205:21,22	page 127:3	154:25 171:16	185:17 190:16
outlets 144:10	184:16 186:11	177:7,12 185:5	peer 132:1,7
outpatient	187:12 193:1	194:17 202:13	penalties 261:19
217:13,18 218:8	202:15 211:23	203:14	pending 249:2
outside 138:14	215:11,18 261:4	particularly	250:1,7,19,20
139:6,18 141:4	261:7,10,13,16	191:24	250:23 251:6,12
181:7,24,25	pages 153:6	parties 259:12	251:14
182:8,11,14,16	154:12 164:13	259:13 260:11	people 129:24
245:15	187:20 259:9	partners 189:4	130:10 132:6
outstanding	paid 136:24	party 143:17	136:9 164:17
250:1,16 251:12	137:18 138:5,7	212:15,22	166:10 170:9
outweigh	138:23,24	233:17	175:10 176:4
131:23	159:16 160:8	passed 134:16	177:6,7 187:20
overhauled	pam 189:2	163:23 181:13	189:24 190:24
170:15	Pam 107.2	181:18	191:17 197:10

[people - policy's]

220:14 229:25	226:23 230:6,7	plaintiff 126:2	246:12
period 158:17	petitioner	248:12	play 134:9
158:21 159:1	234:16	plaintiff's 163:6	please 162:18
160:9 196:10	pgs 125:11	253:22	216:8 231:24
197:8 218:24	pharmacist	plaintiffs 125:6	257:17 260:9
219:23 220:7	229:3	125:13 182:6	plus 155:12
222:4 244:14,16	pharmacy 229:2	247:1 248:2	161:1 253:3
periodically	229:2	plan 202:20	point 182:10
144:7 158:23	phi 210:21	204:17,20,22	212:3 214:15
periods 158:22	phone 136:2	205:14,14 207:7	218:23 222:19
perjury 261:19	phrase 203:8	207:11,25	points 193:10
perko 126:19	physician	213:15,17 214:7	policies 149:13
260:1	137:15 138:14	214:16 217:10	149:17 153:10
person 137:19	physicians	219:4 223:12	153:17 155:7
146:6 164:9,15	190:19 225:4,12	224:10 225:18	167:5 168:2,3,4
215:19 234:1	pick 164:2	226:1,4 244:6	170:16,17
235:20,22	174:22	244:12 245:15	171:25 213:13
237:16 238:15	picked 174:22	245:16,18,23,24	213:14
256:6	pickle 129:21	245:25 246:1,4	policy 127:12,14
personal 144:19	130:23 149:19	246:7,8,9	152:21,22,23
148:4 198:25	152:10,25 158:6	plan's 246:7	153:11,23,24
personalities	172:13 213:23	planned 174:2	156:23 162:15
199:24	piece 160:17	planning 176:7	163:6 166:17
personality	194:24	plans 157:5,13	167:13,14,20,21
199:23	piecemeal	159:15 200:6,7	169:10,14,16
personally	142:19	200:21,24	170:11,20 172:3
134:25 157:15	pillsbury 126:9	202:22 204:2,4	211:19,20
258:10	piloting 168:4	205:3,6,16	213:18,20 214:2
pertinent	pittman 126:9	206:5 213:7,12	214:7,13,14
234:23 235:10	place 143:18	216:11 217:17	215:1,9,17,19
petersen 133:10	152:23 225:1	218:1 220:1,6	215:25 217:4,15
petersen's	231:24 232:13	220:17,23 221:1	219:14,15,17,19
194:24	259:6	223:3 225:8,22	222:10 248:14
peterson 188:19	placing 237:18	232:19,21,22	policy's 156:22
214:1 216:5		244:15 245:23	

[portion - process]

	•1 1	• 122.2.2	2.42.4
portion 257:6	prescribed	primary 132:3,3	pro 242:4
position 161:9	212:19 217:13	132:18,22 198:9	probably
161:10 162:6	217:18 218:7	198:16	144:17 159:17
219:20 220:11	prescription	principal	166:4,6 167:17
250:13 255:15	173:13,18	130:15	184:4 186:9
positions 160:22	184:15,17	principle 235:5	208:24 209:2
160:23 162:11	186:20,25	principles 235:5	236:10,11
positive 127:23	187:11	print 148:14	255:12 256:10
possible 130:14	present 126:23	254:10	problem 169:21
132:10,11	143:5,22 240:6	printed 193:24	210:22
140:24 141:4	presented	256:1	procedure
175:10 212:11	141:22	printing 181:11	137:2,4,7,9
225:11 229:24	press 184:18	prior 128:11	232:3 260:17,17
posted 227:5	pretty 149:18	137:10 142:14	procedures
potential 142:11	151:10 157:17	142:15,17 157:3	176:19 182:9,19
142:22 182:12	161:3 162:24	159:10 176:3	206:6,7
potentially	171:17 196:4	178:2,12,15	proceed 165:21
155:11	203:4 214:11,22	184:5 188:8	proceedings
practice 128:22	214:23 222:19	207:10,21	212:22 259:5,10
132:8 139:8	222:19 238:12	208:10 217:13	process 131:25
practices 140:13	241:10 250:1	217:20 219:21	141:8,19 146:4
practitioner	prevail 239:15	227:1 228:14	157:10 163:9
128:22 225:15	previous 176:2	229:5 232:19,22	166:24 167:20
practitioners	202:7	242:21 243:4,6	168:19,21 169:8
140:13 223:17	previously	243:16 245:12	169:9 170:2,6,8
224:2,21	128:4 137:18	245:13 246:15	170:18,24
prayer 188:25	139:6,9 152:3	247:5	171:18,22,23,24
preceding	171:2 218:14	priority 149:10	182:19 190:5
183:23	220:14	private 149:2,6	191:20 197:2
precisely 168:7	pricing 184:17	149:11,22 150:1	205:9,25 206:4
prepare 129:3	prides 156:2	150:4,7,9,15	206:20 209:17
178:15 182:21	primarily 149:4	privately	209:24 212:2,7
231:24	149:6,8 155:3	150:10	212:8,10 225:1
prescribe	161:25 183:15	privy 169:19	227:14,21
224:11	195:11	· ·	229:24 232:24

[process - purview]

233:13 235:8	184:14 186:19	provided	246:22
236:20 237:22	187:2,4,8	133:12 145:21	public 125:19
237:24 238:2,8	project 126:3	147:2 179:14,16	149:5,8,9 174:2
239:21,24	128:20 188:21	191:15 195:23	174:4 176:7,13
242:16 254:20	189:10 236:25	197:4 209:7	179:17,18
254:24 255:19	projects 154:5,9	216:7,11 228:3	180:14 181:24
256:20	promoting	228:18 232:7	182:10 188:8
processes 212:4	187:6	239:2 246:5	195:24 213:11
213:2 229:2	prompt 180:13	248:20 251:3	233:14 258:20
242:3	182:23 183:2	provider 221:22	259:21
procurement	promptly	221:23 222:9	publication
136:17,22 137:1	179:13,15	223:13 224:10	184:24
produced	promulgate	225:24	publication's
148:15 203:1	166:15	providers	213:9
professional	promulgating	206:15 217:11	publicly 227:5
139:23 148:5	165:4	220:23 221:2,21	published 141:1
259:4	promulgation	223:3 224:21	156:23 158:1
professionals	171:23,24 227:2	225:8,23	publishing
161:1 179:20	proposed 170:1	providing	185:1
192:12 224:3	174:3 189:13	195:12,13 244:6	pull 210:4,13
profile 142:9	proposes 167:1	provision 236:7	249:3,9 250:3
187:9	prospectus	prudent 225:7	pulled 146:16
program 139:12	137:17	psychiatric	194:11 243:9
152:9 154:9	protect 188:21	162:6	246:19 247:3
155:6 156:3,5	protein 251:7	psychiatrist	pulling 250:14
160:8 170:14	provide 129:5	128:21	purchase
programmed	132:6 136:14	pubertal 154:14	136:15
231:7	140:16 145:4,17	154:22 207:12	purpose 179:17
programming	149:10 163:11	puberty 143:4	200:8 233:10,11
230:21 231:3,4	175:15 178:1,9	161:24 171:7	233:20 234:2
programs 149:7	179:22 188:2	185:20 186:7	235:18,21,24
149:13 150:14	202:9,23 204:4	207:23 217:6	236:2
150:19 153:7,16	206:21 208:22	221:25 223:16	purposes 148:5
153:21 154:8,13	213:10 220:9	228:1,6 229:10	purview 215:6
155:16,21,21,22	250:20	243:7,21,25	

[put - recommendation]

Page 294

put 152:25	253:10 255:21	187:21 189:15	191:7 193:6
153:18 159:20	queue 127:17	190:4 191:6	225:21,24 227:1
162:3 187:21,22	248:19,25 249:4	193:5 201:17	228:4,19,22
206:24 223:1	249:24 250:10	212:11 260:8	244:22
224:25,25	250:21	261:19	receiving
251:25 252:20	queues 249:9	reading 188:1	146:19 191:8,13
putting 193:9	quick 170:18	257:19	191:24 217:11
q	183:8 188:1	real 132:20	247:15
qual 200:8,9,13	200:2	162:23	recent 199:21
qualified 129:25	quickly 140:15	realized 192:4,8	230:8 248:24
quality 141:12	159:6 170:6	really 131:25	249:4,9,10,15
141:16 162:2	191:6 192:15,23	132:18 133:8,8	recently 230:7
169:16 194:25	248:12 253:14	135:20 149:5,9	recess 199:13
	quite 144:9	150:18 155:4	248:8
196:1,1,2,3,6 197:13 198:10	192:22 252:1	159:6 170:19	recipient 201:11
197:13 198:10	quoted 148:13	180:5 183:7	201:20,22
238:5	148:16	187:17,18	203:16 210:21
question 132:9	r	190:11 192:25	228:4,19 236:21
141:22 143:9,19	r 148:10 261:3,3	196:16 210:17	237:19 240:20
150:3 159:19	rainbow 189:10	249:24	241:19 242:7
173:10 192:22	randomized	reason 198:7	recipient's
201:1 204:1,8	197:16	203:21 260:9	243:20 246:19
207:19 208:16	ranges 160:5,6	261:6,9,12,15	recipients
209:19 235:4	rate 136:15	261:18	192:12 197:5
247:9	246:13	reasonable	205:5 206:15
questioning	rates 138:17	260:12	241:24 242:1
197:18 232:17	246:12	recall 135:3	243:9 244:14
252:25 253:6,23	rather 170:18	139:18 254:20	recognize 232:4
questions	rct's 197:13	254:24	232:5
160:11,13,14	reach 156:21	receipt 260:12	recognizing
179:4 191:22,25	206:17 234:22	receive 189:12	254:2
206:16 214:6	reached 142:4	190:14,24	recommend
		191:16 238:16	134:9
$-221 \cdot 15225 \cdot 18$	154.73 778.74	191110 200110	10,
221:15 225:18	154:23 228:24 read 129:25	received 163:25	recommendati
221:15 225:18 225:21,25 229:4 238:9 252:20	154:23 228:24 read 129:25 158:8,10,14		

Veritext Legal Solutions

[recommendations - represent]

Page 295

recommendati	referencing	released 161:12	146:13,16 147:2
131:18 161:15	234:4	168:25 227:17	147:15,20,24
162:7	referred 242:2	releases 142:25	148:12 153:18
record 128:8	referring	184:14,19	157:6,16 158:15
134:5 168:17	213:18 217:5	releasing	160:11 164:12
199:15 248:10	227:9 252:1,4	161:14	164:18,23
251:25 252:21	252:14	relied 147:14	165:12,20,25
253:2,15,16,17	regard 260:13	201:1	168:24,25
253:19,20 254:7	regarding	rely 130:15	171:21 173:5
256:13 257:2	130:13 145:25	140:5 149:25	176:1 178:5
259:10	174:2 188:3	156:10	183:23,24 184:4
recorded 257:6	205:7 206:11	remain 253:15	184:10 185:6,21
records 224:24	252:11	remember	187:19,24 188:7
236:21 237:23	register 213:10	135:16 147:5	194:14 195:14
238:10 244:22	regular 249:22	172:11 189:19	198:5,6 205:10
246:18 247:13	regulations	194:17 249:14	251:5 254:17
red 147:7	136:20	reminder	reported 125:18
redemption	reimburse	230:20	reporter 125:19
reactingtion	i chinoui șe	200120	
189:10	177:20	remove 231:25	153:24 257:10
-			-
189:10	177:20	remove 231:25	153:24 257:10
189:10 redirect 255:24	177:20 reimbursed	remove 231:25 232:8	153:24 257:10 257:13 259:1,5
189:10 redirect 255:24 reduction	177:20 reimbursed 138:10 139:2	remove 231:25 232:8 removed 230:21	153:24 257:10 257:13 259:1,5 reporters
189:10 redirect 255:24 reduction 203:10,11,12	177:20 reimbursed 138:10 139:2 relate 212:1	remove 231:25 232:8 removed 230:21 rendition	153:24 257:10 257:13 259:1,5 reporters 153:23
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15	remove 231:25 232:8 removed 230:21 rendition 212:25	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4 reference 178:7	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8 relation 128:20	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5 repeat 140:19	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7 146:10,11,12,16
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4 reference 178:7 195:6 205:25	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8 relation 128:20 relative 259:11	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5 repeat 140:19 149:24 209:10	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7 146:10,11,12,16 146:19 149:16
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4 reference 178:7 195:6 205:25 209:17,23 211:8	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8 relation 128:20 relative 259:11 259:13	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5 repeat 140:19 149:24 209:10 rephrase 192:24	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7 146:10,11,12,16 146:19 149:16 154:5 164:13
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4 reference 178:7 195:6 205:25 209:17,23 211:8 222:3 231:14	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8 relation 128:20 relative 259:11 259:13 release 157:7,12	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5 repeat 140:19 149:24 209:10 rephrase 192:24 report 132:5,18	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7 146:10,11,12,16 146:19 149:16 154:5 164:13 194:15 197:11
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4 reference 178:7 195:6 205:25 209:17,23 211:8 222:3 231:14 240:10	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8 relation 128:20 relative 259:11 259:13 release 157:7,12 157:14 176:3	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5 repeat 140:19 149:24 209:10 rephrase 192:24 report 132:5,18 135:15 140:9,18	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7 146:10,11,12,16 146:19 149:16 154:5 164:13 194:15 197:11 205:7 249:14,16
189:10 redirect 255:24 reduction 203:10,11,12 reevaluate 157:5 251:9 reeves 125:18 258:20 259:4,21 refer 218:4 reference 178:7 195:6 205:25 209:17,23 211:8 222:3 231:14 240:10 referenced	177:20 reimbursed 138:10 139:2 relate 212:1 related 128:15 128:18 131:3 143:11 205:18 206:11 211:19 relates 132:8 relation 128:20 relative 259:11 259:13 release 157:7,12 157:14 176:3 183:23 184:5,8	remove 231:25 232:8 removed 230:21 rendition 212:25 reopen 157:9 251:9 reopened 250:24 251:5 repeat 140:19 149:24 209:10 rephrase 192:24 report 132:5,18 135:15 140:9,18 140:23,24 141:9	153:24 257:10 257:13 259:1,5 reporters 153:23 reports 129:2,3 129:6,10,25 131:7,18 135:10 136:7,8 142:20 144:21 145:5,7 146:10,11,12,16 146:19 149:16 154:5 164:13 194:15 197:11 205:7 249:14,16 250:9,16,24

Veritext Legal Solutions

[representative - rivera]

[
representative	242:13	responsible	260:7
257:7	requirement	156:3 181:9,11	reviewed 132:1
represented	150:18 205:12	181:15,22	132:7 148:7
241:21,22	requirements	213:12 255:15	158:2 163:23
representing	173:6,17 202:23	result 169:22	164:14,17
126:2,17 182:6	234:10	resulted 145:22	189:17 207:25
reproducing	requires 173:13	resulting 142:11	213:1
214:12	research 143:8	retained 139:6	reviewing 164:2
request 159:21	154:4 232:15	182:11	164:6 193:25
203:19,24	240:3	retract 195:19	235:25
220:16 228:18	reserve 232:14	returned 260:11	reviews 189:23
228:22 231:1	253:8,10	reuben 230:12	228:15 238:6
234:19,24 236:1	resides 212:22	reuben's 230:13	revise 172:8
236:18,23,24	resolutions	revealed 243:15	revisions 195:18
239:4,23 240:11	205:14 207:7	revenue 246:14	rh 125:3
240:18 241:20	resource 188:2	reverse 207:11	richmond 126:4
242:8,10 251:2	respond 179:6	207:22 208:11	rick 188:14
255:2	179:13,15 180:1	208:12	rides 235:1
requested	180:7,17 182:24	reversed 207:15	right 132:22
204:12 236:13	183:1	208:2,21	141:20,24
257:14	responded	review 137:15	147:10 148:22
requesting	180:6,6	139:7,12,22	185:9 199:7
237:17 240:24	responding	141:13 145:5	200:5 201:14,17
241:5,13	167:23 182:23	163:12 169:15	202:13 204:20
requests 228:4,5	response 127:23	170:18,24,24	212:14 215:10
228:20 237:13	127:23 141:3,9	178:2,12 187:16	215:16 220:9
240:2,4,7,19	180:9,13 183:5	191:2 192:14,23	227:18 230:20
242:6 249:3	189:12 194:9,10	193:23 194:1,21	232:23 241:18
250:24 251:8,15	204:4 212:7	195:6 197:20	242:20 248:12
251:18,19,21	responses	200:23,24 201:4	251:24 257:13
require 170:17	156:23 180:8	208:3 210:21	rights 219:17
204:3 205:6,9	194:8	211:24 212:14	risk 194:25
206:4,5	responsibilities	212:16,22	rivaux 126:8
required 228:20	219:17	224:24 238:10	rivera 188:23
233:15,17		240:13 251:3	

[rl - send]

rl 126:23	217:16 219:25	salaried 138:17	215:3,4,5,13,13
robust 140:23	222:15,16,18	save 152:4	215:14,16
140:24 141:3	223:1,1 224:14	saw 153:17,17	219:11 222:23
role 134:9	233:17,18,20	saying 152:20	227:20 235:1,2
163:17 166:14	234:1,3,6	152:21 188:6	235:11 255:8,9
182:14,16 250:8	235:20 236:16	190:9	255:13
romina's 133:20	237:11,12,25	says 212:13	section 146:18
rotate 225:3	239:6,18,25	216:5 227:4,23	147:15 158:9,11
rothstein	240:22 245:6	228:17 236:19	169:3,12 212:4
246:17,23,24,25	260:17,17	schedules 156:1	233:2 234:11,12
rough 257:14	rule's 198:5	scope 136:12	security 174:11
route 255:12	213:11	scroll 211:7,9	174:13,21
routed 163:13	rulemaking	se 242:4	see 144:5,8
170:1 255:8,9	166:23 167:20	seal 258:13	146:23 148:3,14
routes 255:6	168:19,21	search 153:19	152:1,1,18,19
routing 127:12	233:12,13	153:20	154:6,10 156:4
162:15 163:7,9	rules 169:10,11	seated 174:16	156:6,6 162:25
169:8	170:12 171:25	176:4	164:21 182:7
rule 128:14,16	172:2,15 212:24	seating 175:1,17	194:6,12,14,15
132:17 164:24	214:13 220:4	175:22 176:23	195:8 198:3
165:4,5,23	234:8,11,11,13	seats 175:11	210:5 211:7,7
166:15,19 167:1	260:12	second 146:24	223:23 249:8
167:1,4 168:8	ruling 243:3	157:19 195:5	256:23,23
168:11,13,24	run 132:13	198:8 202:14	seeing 176:2
169:7,25 170:1	252:23	210:24 215:11	seems 155:7
170:3,4,10,19	runs 202:15	226:9 253:11	seen 142:7
170:20 171:6,21	S	254:14	181:18,20
171:23,24 172:5	s 126:20 128:1	secretary 129:7	selecting 128:24
175:19 180:2,4	260:13 261:3	129:13,23	174:10
180:10,12,16	safe 217:6	163:16,17 166:7	self 197:11
181:18 182:12	221:24 225:6	166:8,12,22	214:22 215:8
190:6 195:19	242:11	167:6,7 169:16	semantics
200:6 209:13	safely 225:11	169:17,19,20	131:16 186:13
214:12,13,13,21	sake 217:24	172:13 174:8	send 137:14
214:22 215:8		176:17 183:3	145:19 185:5

[send - slogan]

210:24 213:20	155:17 159:16	several 216:14	signature
214:7,9,17,25	173:8 203:24	240:19	186:23 258:18
215:7,7 219:7	204:12 223:15	sex 161:24	259:19
222:21 223:5	225:1 228:15	171:7 186:7	signed 163:16
251:3	231:1 237:17	191:24 208:11	163:17 165:12
sending 202:24	238:22 240:11	243:10 245:24	166:1 169:11
205:11 219:17	240:14,23 241:1	sg 256:7,7	260:13
223:9 229:15	241:4,6 245:19	shani 126:8	significance
senior 167:24	245:21,25 246:1	shantice 230:16	231:16
sensationalist	251:9,19	share 144:20	signing 257:20
190:10 192:18	services 127:18	249:23	similar 155:21
sense 250:17,18	148:23,24 149:3	shared 249:7	156:4 199:2
sensitive 176:4	151:3 154:24	shaw 126:9	simone 126:5
182:3 187:24	155:25 156:12	sheena 172:12	148:19
sensitivities	171:2 185:17,19	172:14 176:16	simple 150:3
174:17	187:13 191:13	sheeran 130:14	simplistic
sent 204:25	204:18 205:2	135:24	187:22
215:14 218:22	208:22 218:10	sheet 177:4	single 158:10
219:2,3,20	218:13 220:2	260:9,10	190:8
222:13 232:8	221:3 222:17,17	shorthand	sit 179:2 189:19
separate 138:12	225:13 236:11	259:7	situation 218:25
142:20 164:13	236:12,15 237:4	show 179:23	225:13 237:8
177:22,23	237:6,9 238:3	187:23 210:12	239:2
september	239:11,16	247:14	situations
157:6	240:24,25 241:2	showed 243:12	240:13
series 127:16	241:8,12 242:22	showing 226:8	six 191:4 240:20
226:21	243:5,17 245:24	shows 235:23	244:24,25
serve 176:23	246:5,16 247:4	side 154:8	size 174:23,25
serves 227:25	252:3	sign 127:16	skim 193:2
service 139:17	session 253:11	163:15 165:20	skip 226:11
140:2 141:7,20	set 157:12 213:8	169:6,13,15,17	slogan 181:1,9
141:23 143:16	254:12	169:18,19 177:3	181:12,23 183:7
149:23 150:6	sets 254:10,11	177:6 221:8	183:9,13,16,20
151:7 152:3	seven 137:23	260:9	183:21 184:6,7
154:25 155:15			184:9,12,16,20

[slogan - states]

185:4 186:21	247:3 249:12	specifics 147:5	start 133:11
slogan's 185:25	sort 141:17	specify 245:19	163:8,9,19
slogans 181:17	sought 238:15	246:4	164:2,5,5,7
184:13 186:18	239:16 256:17	spell 148:9	169:9 213:25
186:25 187:4,10	sound 170:7	spends 157:2	227:21
slow 209:19	sounds 192:22	spent 157:2	started 146:19
small 170:10	229:1	159:8,9,11	157:19,22
192:7 224:16	sources 144:6,9	177:17	189:20 193:25
243:8	147:14,18,22	spirit 233:21,23	227:10
smaller 224:8	222:2	spite 226:2	starters 186:4
smatterings	southern 126:6	split 156:9	starts 169:9,10
144:15	span 164:18	190:2	217:5
smc 229:7	speak 128:5	spoke 198:19	state 125:20
smmc 127:14	136:18 143:7	spreadsheet	127:11 149:6
214:2	167:10 223:6	152:10 153:1	150:23 152:5,8
snapshot 197:11	228:2 236:17	staff 143:5	153:4,5,7,16,16
snippets 146:12	238:7 256:7	174:7,8,11	155:15 234:14
society 133:19	speaker 177:3	176:21 177:5	245:15,18,23,24
134:1 161:8,10	speakers 182:17	180:18,19	245:25 246:1,4
161:13,19,21,22	speaking 132:12	staff's 181:5	246:14 258:5
162:1 190:18	133:10 144:18	stamp 201:18	259:2
solutions 137:15	144:19 171:6	201:21 202:7,8	state's 154:1
260:16	180:9	221:7 226:16	187:1
somebody	special 229:8	stamped 201:15	stated 147:12
234:19 256:4	specialized	stance 131:2	154:19 214:12
somebody's	140:14	132:24,25	223:9 261:19
196:17	specially 251:7	stances 152:18	statement
sophia 189:8	specific 166:2	stand 197:15	147:16 156:20
sorry 131:21	183:20 202:23	203:5	statements
133:11 135:25	233:24 234:13	standard	152:20
137:3 166:2	236:7,7,25	161:17 162:4	states 125:1
195:3 207:18	242:20	standards 157:7	149:15 152:16
211:8,14 226:11	specifically	157:11,12	154:6,8,11,12
226:11,12 229:9	131:15 235:18	204:10	154:13,21 155:2
231:24 246:25	238:17		155:3,8,8,9,12

[states - surgery]

	1	1	
156:4,7,7,11,15	street 126:4,12	substance	supplement
156:19,21,25	126:14,20	190:13	149:12
185:13,14	strike 159:9	substantial	supplemental
235:19	studies 160:14	234:16	131:7
statewide 154:9	194:2,7,15,18	substantiate	support 160:20
status 250:10	196:1 197:1,6	171:5 173:5	162:11
statute 127:17	251:4	substantive	supporter 180:2
206:1 209:18,24	study 196:1,2,3	145:11,12 146:3	supporting
233:2,7 234:2,3	196:6,12	184:3 189:22,22	141:12
234:6,17 235:18	stuff 137:14	190:21 193:3,5	supports 162:2
235:21,24,25	style 145:8	193:9,19 194:2	supposedly
236:3,4,6	subcontractors	subtract 138:3	187:13
260:12	138:18,22 139:5	sudden 198:12	suppressant
statutes 234:6,9	139:20 140:4,5	suffer 223:22,22	229:10
stay 151:25	140:12 217:11	sufficient	suppression
stayed 145:3	subject 140:8	156:23 158:4	143:4 154:14,22
steeped 132:19	142:6 150:12	162:11 175:13	161:24 185:20
stephanie 227:3	176:4 209:12	204:9 210:7,10	186:7 207:12,23
stevens 188:14	226:24 234:1	210:11 222:15	223:16
stickers 181:12	235:11,20	222:25	sure 160:15,16
181:23	subject's 143:23	sufficiently	160:20 168:18
stimulator	subjective	202:10	172:16 174:10
251:11	197:11	suggested	176:22 191:23
stones 198:14	submit 205:7	145:23 260:11	194:16 198:14
stood 191:19	206:15	suitability 129:5	199:10 207:20
250:10	submitted	suite 126:9,14	209:21,21
stop 220:2	190:23 200:24	126:20	222:10 226:16
stories 148:17	206:10	sunshine 175:9	230:23,23 248:5
176:2	subpart 233:25	superfluous	249:20,22 250:4
straight 138:2	subscribed	214:15	253:7
222:19 239:2	139:13	supervision	surgeon 134:20
straightforward	subscription	259:8	surgeries
223:2	139:15,17	supervisor	161:25
strategy 214:21	subsequent	163:14 250:3	surgery 159:25
	227:7		171:8 208:16

[surgery - thing]

			
243:13 245:8	190:21,22 192:3	team 183:11	test 151:11
246:1,2,11	193:11,22 194:6	253:13	testified 128:6
248:14	244:22 248:3	technical 146:2	254:23 255:3
surprised	250:3 255:11	216:23	testimony
167:18	taken 173:24	technological	254:21,25
survey 149:20	259:6	178:25	256:25 260:8,12
197:8	takes 132:1,1	technologies	testosterone
surveyed	169:23	231:2	192:5 203:19
149:15 152:16	talk 162:13	tell 157:22	223:23 224:16
susan 226:15,22	166:23 167:4	160:7 208:20	225:16
227:4 230:4	200:3 248:17	209:4 211:1	tests 250:25
247:18	256:14	241:10 250:9	texas 153:10,10
sustain 198:12	talked 158:25	template 203:1	153:14,15
swear 168:16	199:23	226:10 254:12	194:11
switch 244:12	talking 128:11	254:15,16	text 161:22
244:15	128:16 131:16	ten 154:18	thank 212:9
sworn 128:5	133:3 147:11	term 157:8	213:6 226:17
258:11	152:2 167:3	205:8,10	252:10 254:19
symptoms 192:9	170:3 173:10	terminated	that'd 137:23
223:22,25 224:1	178:22,24 179:1	245:4,7	210:11 218:16
sync 165:16	208:4 211:22	termination	theirs 130:16
222:9,9	218:6 225:6	201:11 203:10	184:25
system 150:9	232:10 240:20	203:11	theme 144:17
163:13 224:22	242:25 243:2	terminations	therapy 143:4
228:16 231:7	252:14	200:20	154:22 171:8
232:4 247:13	tallahassee	terminology	207:12,23
systems 230:25	125:17 126:20	146:1 147:2,5	208:11 223:16
t	tamayo 129:14	187:25 234:5	228:2 229:9
t 128:1 148:10	129:24 135:2,25	terms 173:13	243:10 244:3
261:3,3	135:25 166:9	187:22 238:7	thesis 160:18
take 131:7	targeted 185:25	terribly 190:20	thing 162:23
142:18 154:22	taste 162:23	territories	187:15 197:21
142:18 134:22	taxpayer 150:9	152:17,17	198:5,16 216:6
170:21 172:18	150:23	155:12	225:8 252:20
187:20 190:11			

[things - transmittal]

things 144:9	194:19,20 195:9	177:17,19	top 202:4
148:6 155:24	197:6 198:24	187:20 193:12	topic 142:22
160:15 165:16	201:16,17 202:9	197:11 199:12	144:4
178:20 186:24	204:7 205:15,16	199:15 215:12	topics 172:20
192:20 197:24	205:22 207:5	215:13 219:21	tordoff 194:22
198:15,18	208:9 209:25	222:8,23 224:9	tossed 199:5
222:12 230:3	210:1 212:5,6	227:13 228:6	total 137:21
236:22	215:2,10,24,25	232:14 240:20	158:25
think 129:6,11	216:3,8,22	240:24 243:16	totally 186:5
129:12,13	222:7 225:21,24	244:9 246:15	touch 200:2
131:15 134:3	232:13 236:18	247:10 248:7,10	touched 135:5
135:5,23,23,24	242:11 244:5,5	248:16 250:6	touches 184:2
135:25 142:5,17	244:25 246:25	252:21,23,25	touchscreen
142:23 144:16	247:13,23,23	253:1,21 254:2	211:8
145:22,23	249:18 250:22	257:8 259:6	touchy 142:6
146:22 151:10	250:22,23,24	time's 170:24	tough 228:11
152:7,17 158:19	251:5,10,11,13	times 137:10,23	towards 138:3
159:2,3 160:23	252:19 255:12	144:10 158:19	tracking 127:12
162:18 163:3	thought 216:10	158:20 208:20	162:16 163:7
166:4 171:17,18	218:23 222:25	233:14 252:3	traditional
172:12,13,13,14	223:1	titled 221:4	141:18
172:15 173:14	three 128:8	titrate 223:15	transcript 260:7
173:18 174:5,6	171:1 176:17	today 152:8	260:13
174:8,8,19	177:24 189:24	together 152:25	transcripts
176:19,20,21	199:11	190:4 193:10	260:10
177:3,4,4,23	time 125:15	told 183:19	transition
178:25 179:24	128:8 129:13	257:14	220:24 222:1
180:3,5,6 181:3	135:2 139:14,18	tom 227:20	224:8
182:16,16,17,22	142:17,18,21,23	tomorrow	translated
183:10,10,10,11	142:25 149:19	257:15	259:8
183:12,12,22	157:13 158:17	ton 153:9	translation
184:7 186:13,13	158:20,22 159:1	took 132:24	230:3
186:25 189:18	160:5,9 165:23	168:22 243:3	transmittal
190:15,18	169:3 170:21	tooth 193:25	127:15 211:19
192:24 193:11	171:14 177:5,17		211:20 213:15

[transmittal - undertake]

213:17,18,20	190:25 191:8,18	233:24 247:12	unable 149:12
214:2,7,16	196:20 200:16	tuning 216:24	unanimous
215:1,9,19,25	201:11 204:18	turban 148:8	156:13
217:4,15 219:3	204:24 205:19	194:19	unconstitutional
219:15,18,19	206:12 207:12	turn 198:21	199:3
220:8 222:10	207:23 208:12	turned 151:22	under 138:12
transmittal's	208:17,22,23	250:2,19	141:23 149:22
214:15	209:8,13 217:8	turning 129:1	155:15 172:2
transparency	217:12,14,18	159:6 195:3	173:1,8,21,23
184:17 186:25	218:8 222:1	199:7 200:5	177:5 185:17
187:11	223:18 225:10	232:23 235:17	186:23 217:16
transparent	226:24 229:10	242:20 248:12	221:5 232:24
161:13 233:14	237:3 242:17,23	turnout 175:23	233:25 234:8,12
transportation	243:11,13 244:4	175:24 176:6	234:16 236:11
175:13	244:17,19,20	two 129:24	236:11,14 237:1
travel 177:19	245:9 247:16	130:4,10 131:9	238:18,20
178:24 179:1	248:14 252:11	155:23 164:18	240:21 256:13
traveling	treatments	189:21 194:8	256:21 259:8
177:18,19	155:5 185:8	211:11 215:22	260:12 261:19
treat 171:8,11	227:14	233:25	underlying
171:12 223:20	trials 197:16	type 179:20	194:1,18 233:20
224:9 228:23	trouble 148:20	types 171:1	234:2 235:18,21
229:9 238:17	150:2	195:23 199:23	235:24
243:22 245:3	troy 188:19	201:10 240:12	undersigned
treating 131:21	true 205:13	typical 166:14	258:9
131:22 132:16	241:8 250:12	u	understand
132:21 192:11	259:9 261:20	u 148:10	158:15 164:3
224:1,3	trust 224:2	uf's 190:19	187:19,25 188:6
treatment	truth 128:5,5,6	uh 127:23,23,23	228:12
127:18 131:3	try 148:3 150:15	142:16 143:2	understanding
132:6,12 141:11	156:4 163:10	149:25 158:7	207:21 233:9
154:14 157:2	254:2 256:22,25	164:20 190:1	250:7 255:4
159:7 160:8	trying 164:2	200:10 217:9	undertake
161:23 171:16	185:5 197:9	ultimate 191:10	139:7,22 143:8
185:22 188:4	229:13,23	194:5	

[undertaking - vs]

undertaking	153:24 185:20	234:19,25 235:3	version 157:7
197:20	190:5 211:11	235:13,19,23	versus 159:9
undertook	214:20 224:20	236:1,10,14	vet 228:9,23
151:1	228:2,5 237:24	237:1,9,12,13	veto 219:17
unfamiliar	239:20 242:16	238:2,6,6,8	vetted 228:6
136:19	used 131:10	239:4,20,23	vetting 228:10
uniform 204:4	141:19 171:15	240:2,18 241:13	228:20 229:4,14
union 156:7	186:19 201:10	241:20 242:8,15	video 128:7
unique 151:5	222:11 227:25	254:20,23 255:2	199:11,14 248:6
180:23	246:10 260:13	255:18	248:9 257:6
unit 169:11	using 135:7	variances 206:6	videographer
172:2	138:14 186:22	232:23 234:10	126:23 128:7
united 125:1	186:23 193:6	235:7,15 236:18	162:24 199:11
units 167:20	usual 137:2,6,8	240:9,12 241:9	199:14 248:6,9
university	usually 138:17	242:6 255:11	252:22,23 253:3
190:17 193:1	149:10,16	various 153:16	253:15,17,20
194:7,9,10	155:16 163:10	213:2 236:22	257:3,5
unnecessary	163:10 175:20	240:19	videotaped
216:8	196:22 225:1,2	vendor 131:20	125:12
unruly 174:20	utilize 214:20	137:1 138:20,24	viewed 142:21
unturned	V	venue 174:10,22	viewing 254:13
198:14	v 126:19 195:9	175:14,17	views 219:5
unusual 137:16	260:1	verbal 134:2,4	violate 173:1
170:5	valid 159:2	135:13,18 136:3	248:13
update 157:14	valuable 140:16	verbally 147:9	violated 235:5
168:2 248:25	varuable 140.10 van 128:12,21	183:18	visibility 175:16
250:5	135:11 136:7	verbiage 227:8	vogel 126:19
updated 227:7	145:20,23	verified 244:13	volume 125:11
249:10,21	177:16,16,18,18	verify 202:21	191:5
updates 230:25	178:25 179:1	256:10 260:8	vouch 250:15
254:14	180:5,6 183:4,5	veritext 260:10	vs 125:7 260:5
ups 158:2	variance 205:25	260:16	261:1
upset 174:20	209:17,24 212:1	veritext.com	
use 133:12	212:3,7,10	260:10	
136:6,9 140:4	233:16,19,22,25		
	233.10,19,22,23		

[w - working]

wwanted129:4websites154:2220:18,2w125:18258:20160:16172:17week146:24223:222259:4,21175:9,11179:12157:19184:3,8224:16wait165:19179:15183:1230:9witness1169:20,20198:8187:18,21,21weeks184:5128:413waive257:19188:2190:7weida125:8133:315	224:1,1 127:1 30:3 52:16 162:22
w123.18 238.20175:9,11 179:12157:19 184:3,8224:16259:4,21175:9,11 179:12157:19 184:3,8224:16wait165:19179:15 183:1230:9witness 1169:20,20 198:8187:18,21,21weeks 184:5128:4 13waive257:19188:2 190:7weida 125:8133:3 15	127:1 30:3 52:16 162:22
239.4,21179:15 183:1230:9witness 1wait 165:19187:18,21,21weeks 184:5128:4 13169:20,20 198:8188:2 190:7weida 125:8133:3 15	30:3 52:16 162:22
169:20,20 198:8187:18,21,21weeks184:5128:4 13waive257:19188:2 190:7weida125:8133:3 15	52:16 62:22
waive 257:19 188:2 190:7 weida 125:8 133:3 15	62:22
waive 237.19	
waiver 205:25 191:22,25 129:7,13,23 155:19 1)3:7
walver 203.23 209:17,24 212:2 222:10 252:20 163:16 166:8 163:1 20	
a 209.17,24 212.2 212:10 233:22 wants 216:25 172:13 174:9 210:20 2	211:5,9
233:25 235:13 234:19 240:15 176:17 183:4 211:15,2	22 213:2
235:23 236:1,13 warranted 213:23 215:3,4 216:14 2	21:11
237:8 238:15,19 193:3 215:4,4,5,11,14 257:19 2	258:10
238:24,25 warriors 188:16 219:11 222:23 258:13 2	260:8,8
watch 144:3 260:5 261:1 260:9,13	·
240:22 242:16 way 136:19 weigh 155:16 wol 145:2	20
254:20,23 255:2 156:20 159:18 went 146:9 wondering	g
255:18 176:5,24 210:2 152:11 153:5,15 191:12	
waivers 232:23 213:8 251:24 163:15,17 word 147	7:7
234:10 235:7,19 ways 196:5 192:20 218:9 words 19	95:14
wall 126:12 we've 149:19 219:25 229:7 196:21 2	29:14
wallace 163:18 173:4 186:22 249:6 245:20	
227:20 199:8 200:7 whatsoever work 138	· ·
want 146:23 203:2 222:14 189:22 157:15 1	
148:3 149:9 241:6 248:18 whoever's 250:6 160:18 1	
150:19 152:12 251:2,25 252:3 wholly 181:9 213:6 21	
154:6 159:20 252:14 253:1 williams 226:15 230:4,6 2	
160:20 179:21 weak 141:11 226:22 230:4 256:24,2	
187:8,8 188:4 161:15,15 wilson 227:16 worked 1	
190:21 192:24 wean 192:7 window 163:11 158:5 18	33:12
198:13 207:20 weaned 192:2 163:11 216:23	
209:3 210:23 web 153:5 winthrop 126:9 working	
212:5 214:1 154:12 184:16 withdraw 129:11 1	
238:7 248:17 186:11 187:12 223:12 225:16 149:20 1	
251:25 253:5 website 185:2,3 withdrawal 157:23 1	
254:7 256:10 192:1,9 220:15 215:23 2	250:6

[works - zoom]

works 147:15	180:15 186:22
150:7 158:10	186:24 187:23
world 163:3	187:24 193:6
wound 195:16	194:3 197:17
195:25 197:22	204:16 207:6,9
wounded	207:17 210:16
195:24	210:16,16,20
wpath 160:22	211:15 215:21
161:6	217:24 220:5
wps 157:7	221:19 222:6,6
write 129:9	226:14 227:15
135:15 168:2	229:11,17
202:4	230:11 237:25
writing 147:21	238:5,21 239:5
written 132:17	239:6 240:17
134:5 135:19	241:10 242:1
209:23 231:14	243:12,20
251:8	247:17 249:5,18
wrong 228:25	250:10 251:17
wrote 129:1	251:23 253:1
135:10 136:15	254:16 256:3
146:15 190:19	year 144:17
190:20	245:1
У	years 196:24
vale 190:17	251:22
193:1 194:7,8	yep 211:21
194:10	york 126:13
yeah 130:7	144:10 155:23
137:4 146:25	Z
147:21 152:11	zero 207:5
153:20 158:4,22	208:24 209:2
162:22 164:7,22	zoom 178:16
166:25 168:1,15	257:3
168:17 169:21	201.0
170:21 180:15	
170.21 100.13	

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
(A) to review the transcript or recording; and
(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY. THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION. VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.